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Abstract  
The purpose of this thesis was to increase the efficiency of the Positron Emission 
Tomography (PET) tracer development process. Since many neuroimaging agents fail due to 
undesirably high non-specific binding (NSB) to brain tissue, we aimed at estimating the 
extent of NSB as early as possible, preferably before radioactive labeling and extensive 
animal testing. To this purpose we have developed, optimized and evaluated several in vitro 
assays with respect to their ability to predict brain tissue binding and, in particular, NSB in 
PET. A major goal of this thesis was the implementation of a miniaturized assay for the 
prediction of NSB in order to meet the demand for maximal efficiency, i.e. high throughput 
and minimal consumption of reagents, samples and animal tissue. Since octanol/water 
distribution coefficients ( octDlog ) are routinely measured in almost every research 
organization, we investigated whether octDlog  is also useful for the prediction of brain tissue 
binding. In this context, we have developed a filter-based octDlog assay (Carrier Mediated 
Distribution System=CAMDIS) to overcome the drawbacks of the traditional shake flask 
technique, i.e. tedious phase separation and high consumption of reagents.  Strategies have 
been developed to correct for drug adsorption to the assay construct in order to warrant both 
high throughput and high quality of the data. Even though the CAMDIS octDlog values were 
in excellent agreement with literature shake flask data, our results indicated that octanol is 
only a poor surrogate for tissue binding, as shown by the poor correlation between octDlog  
and the unbound fraction of drug in brain ( brainuf , ) available through equilibrium dialysis. The 
latter is the current industrial standard method for the measurement of tissue binding, 
however the technique is hampered by high consumption of animal tissue and low 
throughput. Apart from octDlog , another, more complex membrane surrogate system, namely 
the Parallel Artificial Membrane Permeation Assay (PAMPA), has found entry into many 
laboratories. We investigated whether the fraction of drug retained by the PAMPA barrier 
proves useful for the prediction of tissue binding. Since the default PAMPA setup at Roche 
was inappropriate in this respect, we optimized PAMPA towards better predictive power and 
compatibility with mass spectrometric analysis. Provided that PAMPA was conducted under 
optimized conditions (pH 7.4, brain polar lipids, without solubilizers), the membrane fraction 
was in much better agreement with tissue binding as compared to octDlog . Nevertheless, the 
predictive power was still unsatisfactory reflecting the fact that reverse micelles rather than 
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lipid bilayers constitute the permeation barrier as revealed by NMR experiments. Since 
neither CAMDIS nor PAMPA yielded sufficiently reliable NSB - estimates, we developed a 
miniaturized label-free Lipid Membrane Binding Assay (LIMBA) allowing for the 
measurement of brain tissue/water distribution coefficients at minimal consumption of brain 
homogenate. LIMBA was highly predictive for the binding of drugs and molecular imaging 
probes to brain tissue and therefore provides a viable alternative to the equilibrium dialysis 
technique. LIMBA thus allows for more efficient optimization of potential PET tracers and 
should reduce the attrition rate in the late and particularly expensive stages in the PET tracer 
development process. 
 
Keywords: Tissue distribution, Non-specific binding, Equilibrium dialysis, PET tracer, 
Octanol/water distribution coefficient  
Table of Contents 
v 
 
Table of Contents 
 
1 Introduction ...................................................................................................................... 1 
1.1 The Traditional Drug Discovery Process ................................................................................ 1 
1.2 The FDA’s Critical Path Initiative .......................................................................................... 2 
1.3 Molecular Imaging with PET .................................................................................................. 2 
1.3.1 Principles of PET ............................................................................................................ 3 
1.3.2 The Value of PET in the Drug Discovery and Development Process............................. 6 
1.3.3 Shortcomings and Challenges of Developing New PET Tracers ................................. 11 
2 Rationale and Aims of Research ................................................................................... 17 
3 Capsules ........................................................................................................................... 28 
4 Manuscripts ..................................................................................................................... 35 
4.1 Carrier Mediated Distribution System (CAMDIS): A New Approach for the Measurement 
of Octanol/Water Distribution Coefficients ...................................................................................... 35 
4.2 The Impact of Drug Adsorption to Microtiter Plates on the Accuracy of LogDoct ............... 84 
4.3 Drug Adsorption to Teflon and Excipient-Aided Drug Recovery ...................................... 128 
4.4 Evaluation and Management of Excipient-Related Matrix Effects in HPLC-ESI/MS 
Analysis of PAMPA-Permeability .................................................................................................. 169 
4.5 
31
P and 
1
H-NMR Studies on the Molecular Organization of Lipids in the PAMPA 
Permeation Barrier .......................................................................................................................... 205 
4.6 Evaluation of a Novel Lipid Membrane Binding Assay (LIMBA) for the Assessment of 
Brain Tissue Binding ...................................................................................................................... 248 
4.7 Label-Free Assay for the Assessment of Non-specific Binding of Positron Emission 
Tomography Tracer Candidates ...................................................................................................... 293 
5 Summary ....................................................................................................................... 331 
6 Acknowledgements ....................................................................................................... 348 
7 Curriculum Vitae .......................................................................................................... 350 
List of Abbreviations 
vi 
 
List of Abbreviations 
AD Alzheimer's Disease 
ACN Acetonitrile 
DA  Cross sectional area 
ADME Absorption, Distributions, Metabolism, Elimination 
availB  Receptor density which is available for drug binding 
BBB Blood-brain barrier 
maxB  Total receptor density 
BLM Black lipid membrane 
BP  Binding potential  
BPL  Brain polar lipids  
BTL Brain total lipids 
C  Concentration 
NDC  Concentration of free plus non-specifically bound tracer 
SC  Concentration of tracer bound specifically to receptors 
pC  Concentration of unmetabolized tracer in plasma 
CAMDIS Carrier Mediated Distribution System 
CE Capillary electrophoresis 
CHAPS Na· 3-[(3-Cholamidopropyl) dimethylammonio]-1-
propanesulfonate 
CPI Critical Path Initiative 
CT Computer tomography 
CTAB Cetyltrimethylammonium bromide 
D2 receptor Dopamine D2 receptor 
DMPK Drug Metabolism and Pharmacokinetics 
DMSO Dimethyl sulfoxide 
ESI Electrospray ionization source 
FaSSIF Simulated gastrointestinal fluid in the fasted state 
FDA Food and Drug Administration 
FDG 2-(F-18)Fluoro-2-Deoxy-D-Glucose 
FeSSIF Simulated gastrointestinal fluid in the fed state 
List of Abbreviations 
vii 
 
NDf  Free fraction of drug in brain (PET nomenclature)  
pf  Free fraction of drug in plasma (PET nomenclature) 
brainuf ,  Unbound fraction of drug in brain 
GCA Glycocholic acid 
HP - β - CD Hydroxypropyl-β-cyclodextrine 
HPLC High performance liquid chromatography 
IND  Investigational new drug 
21,kK  Rate constants governing the transfer of a PET tracer from plasma 
into tissue and vice versa 
43,kk  Rate constants governing receptor association and receptor 
dissociation of a PET tracer  
uKp  Tissue/plasma water partition coefficient 
LIMBA Lipid Membrane Binding Assay 
LogBB  Brain/blood distribution coefficient 
brainLogD  Brain tissue/water distribution coefficient 
octLogD  Octanol/water distribution coefficient 
PAMPALogD  PAMPA-lipid/water distribution coefficient 
MRI Magnetic resonance imaging 
ms Manuscript 
MS Mass spectrometry 
NCE  New chemical entity 
NMP N-methyl-2-pyrrolidone 
NMR Nuclear magnetic resonance 
NSB Non-specific binding 
PAMPA Parallel Artificial Membrane Permeability Assay 
PBPK modeling Physiologically based pharmacokinetic modeling 
eP  Effective permeability 
PE Phosphatidylethanolamine 
PET Positron Emission Tomography 
PFGNMR Pulsed field gradient NMR 
PG Propylene glycol 
P-gp P-glycoprotein 
List of Abbreviations 
viii 
 
PK/PD Pharmacodynamic/pharmacokinetic 
apK  Negative logarithm of the acid dissociation constant 
POPC 1-Palmitoyl-2-oleoyl-phosphatidylcholine 
PTFE Polytetrafluorethylene = Teflon 
PVDF Polyvinylidendifluorid 
QSAR Quantitative structure/activity relationship  
R&D Research and Development 
RREF  Reference region in autoradiography or PET 
RO Receptor occupancy 
ROI Region of interest in autoradiography or PET 
RP Reversed phase 
SDS Sodium dodecyl sulfate  
TAC Time-activity curve 
TB  Total binding 
TC Taurocholic acid 
TCM Tissue compartment model 
NDV  Volume of distribution in the non-displaceable compartment  
SV  Volume of distribution (specific binding at the receptor site) 
octaq VV ,  Volume of the aqueous phase and volume of the octanol phase 
)(),( REFNDT RVROIV  Total volume of distribution as in the region of interest and in the 
reference region 
DK/1  Receptor affinity 
18F, 11C, 15O, 13N Fluorine-18, cabone-11, oxygen-15, nitrogen-13 
5-HT receptor Serotonin receptor 
 
 
 
 
 
1. Introduction 
 1 
 
1 Introduction 
1.1 The Traditional Drug Discovery Process 
Advances in genomics and systems biology [1] in addition to the evolutions in automation 
and information technology had been expected to result in a vast number of potential drug 
candidates that could be used in clinics for the treatment of human disease [2]. However, for 
the past two decades the pharmaceutical research and development is facing a crisis in 
productivity. The number of new chemical entities (NCE) approved by the FDA has neither 
met expectations nor the demand for potent and selective drug compounds acting at novel 
targets [3].  
The traditional process in drug discovery is a lengthy enterprise and traditionally proceeds 
linearly across the preclinical milestones and the clinical phases I-IV. Structural optimization 
of hit series is heavily based on in vitro models for the selection of promising lead candidates 
which are subsequently tested in animals prior to human subjects [4]. It takes on average 12-
15 years to bring a drug to the market and the cost for the process has reached the order of 
US$2 billion (2010 [5]). Only 1-2 compounds out of ten thousand enter the clinical phase and 
the success rate of those which have reached entry into human is only approximately 11% 
[6]. The vast majority of attrition occurs in the full development clinical phases (IIb and III) 
and it goes without saying that failing at this stage is costly. The major reasons for attrition, 
i.e. lack of efficacy and safety (each contributing to 30 % of the failures) [6], are even more 
prominent when novel targets are concerned for which biological mechanisms might be 
insufficiently explored [7, 8] and therapeutical needs are unmet [1].  
The development of drug compounds for the treatment of human mental disorders is 
exceptionally challenging and the chance that clinical candidates reach the market is as low 
as 8 % [6]. Neuropsychiatric diseases such as depression, bipolar disorder and schizophrenia 
are far from being entirely understood and animal models are at best approximations thereof 
[9]. In addition, drug molecules targeting the central nervous system (CNS) have to be 
delivered across the blood brain barrier (BBB) which essentially acts as a neuroprotective 
barrier and hinders large or hydrophilic compounds from entering the brain [10]. As a 
consequence, considerable discrepancies between plasma and biophase concentrations may 
arise and pharmacokinetic - pharmacodynamic (PK/PD) modeling approaches based on 
plasma pharmacokinetics likely become invalid [11].  
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1.2 The FDA’s Critical Path Initiative 
The limitations of developing drugs (particularly CNS-active drugs) along the milestones in 
the traditional discovery and development process are apparent and the realization has grown 
that the drug development process needs to be modernized in order to translate the advances 
of basic research into new marketed therapies. In 2004, the U.S. Food and Drug 
Administration (FDA) launched a Critical Path Initiative (CPI) diagnosing and addressing the 
reasons for the productivity decline in pharmaceutical research and development (R&D) [12]. 
The landmark 2004 report drew the conclusion that the technologies applied for the 
prediction of the clinical performance of promising drug candidates have not kept pace with 
the development of basic scientific innovation. While cutting edge technologies have found 
entry in drug discovery and lead optimization, pre-clinical and clinical trials in animals and 
humans appear to be based on trial and error rather than on evidenced-based research. A 
better product development toolkit is urgently needed to “get fundamentally better answers 
about how the safety and effectiveness of new products can be demonstrated, in faster time 
frames, with more certainty, and at lower costs” [12]. i) The development and utilization of 
biomarkers, i.e. surrogate markers for disease progression, drug effectiveness and drug safety 
and ii) the streamlining of clinical trials by using biomarkers have been uncovered as the 
most important areas for improving medical product development [13, 14]. 
1.3 Molecular Imaging with PET   
Modernizing the critical path according to the abovementioned strategies requires innovative 
technologies to support the claimed objectives. The FDA has stressed the great potential of 
imaging technologies, especially molecular imaging tools, in contributing to new biomarkers 
(imaging biomarkers) and providing valuable insights into the distribution, binding and 
pharmacological effect of new chemical entities (NCE) [13, 14]. However, it has also been 
recognized that the application of imaging tools within the drug development process requires 
efforts invested in developing them specifically for this purpose.  
The basic concept of molecular imaging may be summarized as the visualization, 
characterization and quantification of biological processes in living organisms at the cellular 
or molecular level [15, 16]. In contrast to primarily morphological imaging methods (e.g. 
magnetic resonance imaging, MRI), the primarily molecular imaging methods permit to study 
disease models and the effect of drug treatment prior to the manifestation of anatomical 
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changes (e.g. tumor growth) [15]. Owing to its high sensitivity
1
[17] and the large number of 
compounds to which the technique is applicable [18], particularly positron emission 
tomography (PET) holds much promise to bridge the gap between preclinical and clinical 
research, especially in the field of neurodegenerative and neuropsychiatric disorders [19]. 
The principles and applications of PET in addition to the requirements posed upon the 
molecular imaging probes are summarized in the following. 
1.3.1 Principles of PET 
PET is a non-invasive technique that provides three-dimensional images of physiological 
functions (e.g. cerebral blood flow, brain metabolism) and molecular targets (receptors, 
transporters or proteins) in intact living subjects (animals, humans). The technique exploits 
molecular imaging probes which are labeled with short-living positron - emitting 
radionuclides such as fluorine-18 (half-life, 2/1t  = 110 min), carbon-11 ( 2/1t  = 20 min), 
nitrogen-13 ( 2/1t  = 10 min) and oxygen-15 ( 2/1t  = 2 min) [18]. The radionuclides are 
produced by nuclear reactions (bombardment of stable isotopes with protons or deuterons) 
within a cyclotron before they are incorporated in the molecules of interest by radiosynthesis 
[20, 21]. Since many molecules of interest (drugs; biomolecules, e.g water and glucose) 
contain e.g. carbon, labeling is possible without considerably changing the biological activity 
of the probes (fluorine-18 may replace hydrogen in biomolecules) [18]. Tracer concentrations 
(picomolar amounts) of the radioligand are injected intravenously into the test organism in 
question and the temporal and spatial distribution of the radioligand is monitored by means of 
a PET camera (for details see Fig. 1). 
 
                                                          
1
 PET is 1-2 orders of magnitude more sensitive as compared to SPECT  
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Figure 1   Schematic representation of the principles of PET. A biologically active molecule labeled 
with a positron-emitting radionuclide (e.g. 2-(F-18) Fluoro-2-Deoxy-D-Glucose) is injected into a 
patient. The radionuclide decays by emission of a positron which collides with a nearby electron in 
the tissue. Positrons and electrons are matter and antimatter, and their collision produces two gamma 
rays (511 keV) that move in opposite direction throughout the body. These are detected by the PET 
camera comprised of scintillator units arranged in circuit around the test organism. Only photons 
which arrive simultaneously (in coincidence) at two detectors located opposite to each other are 
transformed into the image finally observed. The image reflects a three-dimensional map of the tracer 
distribution in a time and location-resolved manner. PET images are shown at the example of glucose 
metabolism to map a human brain’s response in performing different tasks (highest metabolic rates 
are in red); adapted from [22]. 
 
The PET scanner yields dynamic images of the tracer distribution (Fig. 2A) which need to be 
translated into truly quantitative biological outcome measures such as receptor density, ligand 
affinity, or the rate of transport through a molecular pathway [23]. Since the PET scanner 
cannot differentiate between the chemical forms or environments in which the radioactivity 
resides [24], the time activity curve (TAC) in a region of interest (ROI, e.g. the striatum, 
Fig. 2B) represents a composite of free and bound, parent and metabolized radioligand in 
plasma and in tissue. 
In order to isolate the signal emerging from the specific binding to the target site, a 
mathematical model is required which relates the radioactivity delivered by plasma (plasma 
input function) to the radioactivity accumulated at the target site in tissue (tissue response 
function). To this pursuit, the principles of compartmental modeling are frequently applied 
which characterize a radioligand’s fate in terms of rate constants governing the transfer 
between predefined compartments [25, 26]. Target binding and brain uptake, for example, 
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enter the model as a combination of rate constants which are to be estimated by fitting the 
model to the observed PET data.  
In many cases, a three-compartment model (Fig. 2C) is appropriate for describing the kinetics 
of radiotracer delivery from plasma (compartment 1) into the brain, where the tracer either 
binds non-specifically to tissue environment (brain compartment 1) or specifically to the 
target (brain compartment 2) [26]. However, the parameterization of the plasma input 
function requires continuous blood sampling including tedious HPLC-based determination of 
parent and metabolized tracer and the quantification of the unbound fraction in plasma. An 
alternative approach, which avoids blood sampling, relies on using a reference tissue 
essentially devoid of receptors as input function for the TAC observed in the ROI. In simple 
terms, the specific binding to the target corresponds to the difference between the 
radioactivity in the receptor-rich region (ROI) and the receptor - free reference region. The 
higher the specific binding and the lower the non-specific binding (NSB), the higher the 
sensitivity of PET to monitor radioligand interactions with the target site. Since the number 
of available binding sites ( availB ) and a radioligand’s affinity to that binding site ( DK/1 ) 
cannot be inferred separately, a PET scan seeks to derive the binding potential, ( BP ), 
corresponding to the product of receptor density and affinity
2
 [27]. Changes in the binding 
potential can be interpreted in terms of disease progression or drug-target interaction. For 
example, the reduction of the binding potential in the striatum may be related to the 
degeneration of dopaminergic neurons in Morbus Parkinson or to the percentage of dopamine 
receptors occupied after treatment with dopamine agonists [28]. 
                                                          
2
 If the reference tissue model is used for data analysis, the unbound fraction of tracer in the brain, NDf , is not 
accessible for quantification. Therefore, the binding capacity is expressed as DNDND KBfBP /max .  
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Figure 2   The time course of the uptake, binding and washout of [
18
F]-fallypride (dopamine D2/3 
receptor antagonist) in the brain of a healthy human subject. A: Examples of images from the 180 min 
scan and B: the associated time activity curves in the region of interest (striatum) rich in dopamine 
receptors and in the reference region (cerebellum) devoid of dopamine receptors (approximation), 
adapted from [29]. C: Three-compartment model (two-tissue compartment model) taking into account 
the tracer concentrations in plasma (free and non-specifically bound in plasma), the passage across the 
blood-brain barrier, the distribution into the non-displaceable compartment (free and non-specifically 
bound tracer in brain) and the binding to the target site (specifically bound). Free and non-specifically 
bound tracer concentrations are lumped together into one compartment, based on the assumption that 
equilibration between the two states is rapid as compared to receptor binding. The free fraction in 
brain, fND, denotes the fraction of tracer in the non-displaceable compartment in the unbound state. It 
is assumed that only the unbound concentration is available for receptor binding and similarly that 
only the free fraction in plasma (fp) can cross the blood brain barrier. The rate constants 1K , 2k , 3k  
and 4k describe the transport into and out of the brain and the association and dissociation at the target 
site, respectively. In the reference region, a two-compartment model is sufficient due to the assumed 
absence of dopamine receptors.  
 
1.3.2 The Value of PET in the Drug Discovery and Development Process   
As outlined above, PET is a powerful non-invasive tool, able to provide dynamic, 
quantifiable measures of e.g. brain uptake and drug-target interaction in healthy and diseased 
animals and humans [28]. Due to the high sensitivity of PET, picomolar concentrations of a 
radioligand can be determined with high accuracy and without disturbing the biological 
process of interest. The outcome measures of PET are of relevance in all preclinical and 
clinical stages (Fig. 3) including the following areas of application [30,31]: i) 
Pharmacokinetic studies with the labeled drug, to confirm that the drug reaches the target. ii) 
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RO studies with the cold drug and a target-specific radioligand, to answer the questions 
whether the drug binds to the target and how much receptors are occupied. iii) Proof-of-
mechanism studies with imaging biomarkers reflecting changes in metabolism (e.g. glucose 
consumption), physiology (e.g. blood perfusion) and/or biology (receptor density), to answer 
the question whether the application of the drug is related to a pharmacodynamic response. 
iv). Proof-of-concept studies with imaging biomarkers for pathophysiology, to answer the 
question whether the drug has a clinical benefit. The results from clinical studies on 
pathophysiology and response after treatment can also be back-translated to characterize the 
target expression in different species [8] and to assess the scope, limitations and possible 
refinements of preclinical animal models [32]. This advocates PET as a valuable translational 
tool to bridge the gap between pre-clinical research and clinical application [8].  
 
 
Figure 3   The drug discovery and development process and key aspects that can be studied with PET. 
(adapted from [9, 31] .  
 
1.3.2.1 Studying Disease Pathophysiology  
The FDA has particularly recognized the great potential of PET in providing imaging 
biomarkers for neurocognitive disorders and depression [1]. Much progress has been made, 
for example, in the development of PET tracers ( [
18
F]FDDNP, [
11
C]PIB ) that bind to 
amyloid plaques in Alzheimer’s disease (AD, Fig. 4) [33]. Apart from these target-specific 
radioligands, also functional imaging with 2-(18F)Fluoro-2-Deoxy-D-Glucose (FDG) as a 
measure of glucose metabolism has the capability to allow earlier diagnosis of subtle changes 
in pathophysiology [12]. Prevention trials and therapeutic intervention prior to the 
manifestation of clinical symptoms thus become feasible. Monitoring disease progression 
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after treatment with an investigational new drug (IND) could moreover provide a new, more 
precise way for demonstrating drug efficiency. It is also worth noting that diagnostic 
biomarkers hold promise to streamline clinical trials by identifying patient populations which 
would benefit most from drug treatment. Apart from Alzheimer’s disease, radioligands for 
the quantitative assessment of inflammatory response in multiple sclerosis [34], for the 
degeneration of dopaminergic neurons in Morbus Parkinson and for other disease-related 
changes in pathophysiology have also been developed [18].  
 
 
Figure 4   “Cerebral glucose metabolism (18F-
FDG) and 
11
C-PIB amyloid imaging in two 
AD patients and one healthy control. The PET 
scans show 
18
F-FDG and 
11
C-PIB at a saggital 
section. Red indicates high, yellow medium, 
blue low 
11
C-PIB retention. MMSE Mini-
Mental- State-Examination, ys. years. 
Courtesy of Uppsala PET centre/ Imanet and 
Karolinska University Hospital Huddinge” 
[33]. 
 
1.3.2.2 Pharmacokinetic Studies  
PET has evolved as a valuable tool to characterize the pharmacokinetic profile of 
radioactively labeled drug candidates by following their distribution throughout the body. 
The demonstration of drug entry into the target tissue confirms exposure for efficiency [16] 
and similarly the (unwanted) accumulation of drug candidates in other organs can be used for 
safety assessment. Biodistribution studies in living human subjects are of particular interest 
for drug candidates directing the brain where i) biopsies are not suitable to confirm passage 
across the highly restrictive BBB and ii) significant species differences in the expression of 
efflux transporters (e.g. P-glycoprotein, P-gp) may confound the extrapolation from animal 
models to humans [10]. 
The high sensitivity of PET allows conducting ‘microdosing’ studies early in phase I, 
initiated by the FDA/EMEA to accelerate the pace of first-entry-into-human studies [35]. 
Since microdosing is based on the application of sub-pharmacological doses (< 100
th
 of the 
dose required for a pharmacologic effect), the potential risk of toxic effects is relatively low 
and regulatory requirements accordingly moderate. The information which PET provides on 
drug availability, delivery, clearance, tissue binding and target interaction may help 
1. Introduction 
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concentrate resources for clinical studies on the most promising drug candidates while 
compounds with a high probability to fail could be eliminated prior to the enrollment of large 
numbers of patients.  
1.3.2.3 Receptor Occupancy Studies and Pharmacodynamics 
RO studies are aimed to relate the dose, plasma and/or tissue concentration of a drug 
candidate to the percentage of the target site occupied. To this pursuit, competition studies are 
conducted, based on the visualization of receptor densities with a target-specific radioligand 
(tracer doses), before and after application of the unlabeled drug candidate (pharmacological 
dose) [36].  
Dose-RO relationships have the capability i) to de-risk clinical trials by assisting in dosing 
selection [23] and ii) to differentiate between under-dosing (too low RO) and lack of 
efficiency (proof-of-concept) [31, 37]. Insight into mechanistic aspects of drug action can be 
gained by combining radioligand studies of drug occupancy with radiotracer studies of tissue 
markers expected to change after treatment, e.g. downstream cellular pathways, metabolism, 
glucose consumption, cell trafficking and gene expression. Radioligands acting at specific 
targets can also provide biomarkers for drug safety and efficiency as the following example 
shows: the treatment of schizophrenia requires 65-80% occupancy of dopamine D2-receptors 
while higher levels aggravate extrapyramidal side effects without additional therapeutic 
benefit [8]. The link between RO and clinical endpoint, however, still needs to be validated.  
1.3.2.4 Summary of Major Achievements in Brain PET 
As outlined above, PET has a tremendous potential for streamlining the drug discovery 
process and many imaging agents have found application in such relevant research areas like 
oncology (tumor diagnosis with e.g. FDG), cardiology (diagnosis of coronary heart disease) 
and neurology [11].  
PET is of particular value in CNS research due to the severely restricted accessibility of the 
tissue and possible discrepancies that may arise between plasma and tissue pharmacokinetics 
as to the presence of the BBB. Jones et al. summarized that “brain PET has made its greatest 
advances in quantifying metabolism and G-protein coupled receptors in various disease states 
and after treatment” [23]. Historically, many efforts for treating neurological disorders 
(schizophrenia, Parkinson’s disease) have been directed at dopamine and serotonine 
receptors, resulting in a large portfolio of drug candidates; some of which have become 
successful PET tracers. Notably, “improved tracers for subtypes of serotonin, cannabinoid, 
and metabotropic glutamate receptors, as well as noradrenaline transporters, amyloid-β and 
1. Introduction 
 10 
 
neuroinflammatory changes” [19] are important breakthroughs of the recent years which have 
expanded the scope of PET to new questions. Examples of successful PET tracers for 
imaging physiological processes and specific target sites are presented in Table 1, along with 
an example of a labeled drug, zolmitriptan, whose pharmacokinetic profile had been 
characterized with PET.  
 
Table 1   Radiotracers and ligands used in PET studies of neuropharmacology. Table adapted from 
[30].  
Physiological Process/Molecular Target Radiotracer/Ligand 
Metabolic or physiologic biomarkers 
Blood flow H2
15
O 
Oxygen consumption 
15
O2 
Oxidative metabolism 
18
F-FDG 
Radioligands for known targets and radiolabeled drugs
 
L-DOPA decarboxylase activity (Parkinson’s 
disease) 
18
F-6-fluorodopa (F-DOPA) 
Amyloid deposits (Alzheimer’s disease) 11C-PiB and 18F-FDDNP 
Dopamine transporter 
11
C- and 
18
F-CFT 
Dopamine D1 receptors 
11
C-SCH23390 
Dopamine D2 receptors 
11
C-raclopride 
Serotonin transporter 
11
C-DASB 
Serotonin 5-HT1A receptor 
11
C-WAY100635 
Serotonin 5-HT2A receptor 
18
F-altanserin 
Muscarinic acetylcholine receptors 
11
C-(+)3-MPB 
Nicotinic acetylcholine receptors 
11
C- and 
18
F-A-85380 
Opioid μ, κ, e, δ receptors 11C-diprenorphine, 11C-buprenorphine 
Opioid μ receptor 11C-carfentenil 
Opioid δ receptors N1’-(11C-methyl)naltrindole 
Central benzodiazepine receptor (GABA) 
11
C-flumazenil 
Substance P/NK1 receptor 
18
F-FE-SPA-RQ 
Radiolabeled drug 
Pharmacokinetics 
18
C-Zolmitriptan 
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1.3.2.5 Suggestions for Future Research in Brain PET  
The brain is the most studied and the most complex tissue, but also the one least understood 
[23]. In view of the burden of suffering due to the manifestation of mental disorders, and 
especially with the ever growing relevance of Alzheimer’s disease, Morbus Parkinson, cancer 
and stroke in an aging society, the conceivable future applications of PET are manifold. Jones 
et al. recently suggested the following relevant biological processes that require imaging 
agents (Table 2) [23]: 
 
Table 2   Suggested future 
research areas of brain PET.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3.3 Shortcomings and Challenges of Developing New PET Tracers 
Despite the wealth of information PET could provide for accelerating the development of 
novel CNS-active drugs, it appears that its full potential has not been exploited yet [23]. The 
lack of access to sophisticated methodologies (cyclotron) and the high cost of PET as 
compared to other imaging methodologies (e.g. MRI) have been identified as major 
hindrances for the further advancement of PET [23, 38]. 
 “Future suggestions of relevant biological processes that 
require robust imaging agents [...] include: 
i Downstream effector pathways coupled to neuroreceptors 
ii Neuroimmunity/inflammation as a factor in brain disease 
and the role of astrocytes and their associated chemokines 
iii Transient opening of the BBB as a factor in brain 
inflammation 
iv Enhancing the delivery of drugs across the BBB 
v Specific imaging markers of neuronal and glial 
subtypes 
vi Progenitor stem cell activity and their chemokines for 
repairing brain damage 
vii Glioma stem cell activity 
viii Brain viral and bacterial infections (e.g., herpes 
encephalitis and tuberculosis) 
ix Brain plasticity, e.g., in stroke recovery 
x The neurochemical components underlying 
memory, learning, maturation, ageing cognitive 
decline/enhancement, and personality”[23] 
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Moreover, the expansion of PET for use in basic research and clinical application is heavily 
dependent on the availability of innovative PET tracers [39]. Even though many target-
specific imaging radioligands are available (especially for D2/3 and 5 - HT receptors), the 
development of drug candidates binding to novel targets requires in-parallel development of 
novel PET tracers. The more imaging agents are developed, the more physiological processes 
and targets in healthy and diseased brain can be explored and the higher is the impact of PET 
for drug discovery. However, the lack of innovative PET tracers has contributed to the fact 
that PET has not evolved as extensively as expected [23].  
1.3.3.1 The PET Tracer Development Process 
The development of novel PET tracers poses a major challenge which is almost as time-and 
resource-intensive as the development of novel drugs (8-10 years for imaging agents, 10-15 
years for drugs [40]). In view of the fact that a radioligand’s success is directly dependent on 
the success of a drug candidate and vice versa, the synchronous development of both is 
particularly ambitious and potential pitfalls are numerous. Special technical facilities 
(cyclotron, PET camera, modeling and image reconstruction) and the expert knowledge of a 
radiotracer imaging team are required for developing PET tracers, however, there are many 
analogies to the drug development process (Fig.5). 
 
 
 
Figure 5   The PET tracer discovery and development process. The details for the timeframe of 
developing an imaging agent up to the Filing for microdosing studies are based on experience within 
Roche (personal communication, unpublished). The estimation of the timeframe for the whole 
development process (8-10 years) was obtained from literature [40].  
 
After selecting a target of interest, high affinity ligands with suitable physicochemical 
properties (see below) are tritium-labeled for further experiments in rodents. Labeling with 
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Tritium (long half - life) opens the possibility to measure radioligands at tracer concentrations 
without the need for sophisticated PET facilities (cyclotron). The long half-life is of practical 
importance since in vitro and ex vivo studies (in vivo is not possible) can be performed over a 
period of several month using the same batch [23]. Autoradiography performed as in vitro or 
ex vivo tissue binding study (incubation of the PET tracer with tissue slices) allows for 
quantification of tracer specific binding, non-specific binding and the regional distribution 
thereof in various tissue sections [41, 42]. In vivo autoradiography (injection of tracer and 
sacrifice of animal thereafter) provides additional information about pharmacokinetic aspects 
before the tracer is finally tested in living man. The last stage, the actual PET experiment, is 
the most elaborate since incorporation of a positron - emitting radionuclide is required.  
Predictive, less resource demanding assays are therefore of utmost importance in order to 
concentrate resources on the most promising candidates and to eliminate inappropriate 
molecules as early as possible. Notably, the requirements placed upon successful PET tracers 
and drugs are not necessarily the same and several aspects important for a good image quality 
in PET need to be considered. As will be outlined below, the list of requirements is long and 
balancing of physicochemical properties necessary [43] which might contribute to the current 
lack of innovate PET tracers. 
1.3.3.2 Relationships between PET Tracer Properties and Image Quality  
1.3.3.2.1 Target Density, Target Affinity, Selectivity and Specific Radioactivity  
First and foremost, the target needs to be identified and a measureable number of target sites 
should be present in the tissue of interest, e.g. the brain. Since the concentration of many 
neuroreceptors ( maxB ) is rather low (nano to femtomoles per mg tissue range), the affinity 
(1/ DK ) of the tracer candidates should be sufficiently high, i.e. in the nanomolar to sub-
nanomolar range [44, 45]. It goes without saying that a lower target density requires a higher 
affinity of the radioligand [43]. An ideal tracer should also be selective, although non-
selectivity is no criterion for exclusion provided that target and non-target sites are 
anatomically separated. To achieve high levels of sensitivity it is important to prepare tracer 
candidates with high specific radioactivity and with sufficient yield. A low specific activity 
would require higher doses which may lead to saturation of available binding sites making 
assumptions on tracer kinetic modeling invalid and undesired toxic and pharmacological 
effects probable. The radiosynthesis should be rapid and feasible in a few steps due to the 
short half - lives of the commonly used positron - emitting radioisotopes (fluorine-18: 
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2/1t  = 110 min, carbon-11, 2/1t  = 20 min) [18]. At a given specific radioactivity, the receptor 
concentration/affinity ratio ( maxB / DK ) displays the maximum possible specific signal which 
can be obtained from a radiotracer. However, it should be noted that optimizing compounds 
exclusively towards higher affinity may be misleading if other aspects like toxicity, scanning 
duration, radiotracer delivery (brain uptake), metabolism and non-specific binding are 
disregarded [43].  
1.3.3.2.2 Toxcicity 
A prerequisite for any application of radioligands in living human subjects is non-toxicity and 
the absence of adverse pharmacological effects [24]. The advantage of PET in this respect is 
certainly the fact that only tracer doses are applied, in a few patients and in a limited number 
of experiments. The safety requirements for FDA approval are therefore less stringent than 
for the entry of drug candidates into the clinical phase. Nevertheless a limited safety package 
is required based on single dose acute toxicology studies in two animal species [46]. 
1.3.3.2.3 Affinity and Tracer Kinetic Modeling 
A very high affinity may leads to a situation that obviates the interpretation of PET scans in 
terms of processes at the target site, namely when the distribution of the radiotracer becomes 
dependent on the blood flow rather than on the rate of target binding [43]. In addition, high 
affinity prolongs the time until specifically bound radioligand is equilibrated, i.e. when the 
rate of ligand-receptor association equals the rate of dissociation. This equilibrium state is 
succeeded by a washout phase as the radiotracer is being cleared from brain and plasma. 
Extracting the relevant outcome measures (related to maxB / DK ) from a series of PET scans 
requires capturing the washout phase which explains that high affinity also prolongs the 
scanning duration. In view of the short half - lives of commonly used PET tracers, it becomes 
clear that exceedingly long scanning times and very high affinity radioligands are 
incompatible with PET. Furthermore, it has been recognized that ligands with very high 
affinity are unsuited because the modeling approaches used for data analysis can only handle 
reversible and irreversible binding, but not the states in between [44].  
1.3.3.2.4 Plasma Protein Binding and Plasma Clearance 
A low plasma protein binding of the radiotracer is advantageous since only the unbound 
fraction of radioligand in plasma is available for entering the brain [43]. Moreover, a lower 
protein binding gives rise to a higher plasma clearance which in turn is associated with a 
shorter time to reach steady state. Accordingly, the minimal scan duration decreases for the 
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benefit of a higher sensitivity and the possibility to use higher affinity radioligands. 
Generally, a moderate-to-high clearance is desirable to improve the image quality and the 
likely development success of a PET tracer. In addition, lower protein binding assures more 
reliability of the image analysis since the unbound fraction can be quantified with higher 
accuracy. The consideration thereof is crucial for assuring that changes in the binding 
potential are related to changes at the target site rather than to intersubject differences in 
plasma protein binding.   
1.3.3.2.5 Blood - Brain Barrier Permeability 
The BBB functions to protect the CNS from natural xenobiotics and to maintain cerebral 
homeostasis. Unlike peripheral permeation barriers, the tight endothelium constituting the 
BBB lacks fenestrations and contains tight junctions which prevent paracellular diffusion 
[10]. The highly protective function of the membrane is reinforced by ABC transporters such 
as P-gp and multidrug resistance associated proteins [10]. The size and charge restrictions for 
entering the brain are therefore particularly conservative and only small (cross sectional area, 
DA < 70 Å
2
) and low-to moderately charged molecules are able to pass the BBB by passive 
diffusion [47]. Radiotracers targeting receptors in the CNS should readily cross the BBB and 
they should preferably be non-P-gp substrates [45].  
1.3.3.2.6 Metabolism  
An additional quality criterion is the resistance of the tracer to rapid metabolism including the 
absence of brain penetrant radiolabeled metabolites which would complicate the 
unambiguous interpretation of radioactivity-time curves. This requirement is an implication 
from the inability of a PET camera to distinguish between the parent radioligand and 
radiolabeled metabolites [45].  
1.3.3.2.7 Non-specific Brain Tissue Binding and the Role of Lipophilicity 
Provided that the unmetabolized radioligand reaches its target, the signal obtained is still 
lower than what is hoped for according to the receptor density/affinity ratio, maxB / DK . Apart 
from specific binding to the target site, radioligands also bind non-specifically to non-
saturable brain components (membrane structures) [18]. NSB can be understood in terms of a 
background noise from which the specific binding needs to be distinguished. A high NSB 
reduces the signal contrast in PET and thus the sensitivity to explore changes in the binding 
capacity due to physiological, pathophysiological or pharmaceutical processes. Undesirably 
high NSB is one of the main reasons why PET tracers undergo attrition in vivo. More 
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precisely it is an unsuitably low ratio between specific binding and non-specific binding 
which makes a radioligand likely to fail in vivo [28].  
As a rule of thumb it is assumed that higher lipophilicity goes along with higher NSB but also 
with higher affinity for the target site [43]. Balancing lipophilicity is therefore crucial, not 
only to ensure a good image quality, but also to warrant brain permeability. It has been 
recognized that successful PET tracers are characterized by octPlog  values < 3, most of them 
are in the range of octPlog = 2.5 [20]. However, there are exceptions to the rule which raise the 
question as to the ability of octanol to predict NSB of radioligands in brain tissue. 
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2 Rationale and Aims of Research 
As described in the introductory chapter, PET provides the unique opportunity to monitor 
disease progression and drug efficiency on a cellular, subcellular and molecular level in 
living subjects at an early stage in drug development. PET therefore holds great promise to 
aid the optimization of potential drug candidates and to reduce the attrition rate in the later 
and cost-intensive clinical phases. The expansion of PET for use in basic research and 
clinical application is heavily dependent on the availability of innovative PET tracers [39]. 
However, the number of approved radioligands considerably lags behind the number of 
receptors, especially neuroreceptors, which could potentially be visualized and targeted to 
treat human disease [48]. Many radioligands fail due to an unfavorably high NSB to lipid 
membranes and non-target proteins which attenuate the signal arising from specific binding at 
the target site [43]. In order to enhance the confidence in the likely development success of  a 
PET tracer it is desirable to estimate the extent of NSB as early as possible, preferably before 
labeling of the molecular probe. The unbound fraction of drug in brain ( brainuf , ) is considered 
a reliable NSB-surrogate for PET tracers targeting receptors in the CNS [49]. However, the 
measurement of brainuf ,  requires laborious equilibrium dialysis hampered by the requirement 
for large quantities of animal tissue [50].  
Therefore, the main purpose of this thesis was to devise and to evaluate a strategy for 
estimating the NSB of neuroimaging agents in an assay which works with unlabeled 
compounds and which requires fewer animals as compared to equilibrium dialysis. In a 
broader sense, we were interested whether an in vitro NSB-estimate can be used as decision 
criterion for the selection or rejection of potential PET tracers. This raised the question upon 
the existence of a NSB limit above which the failure of a PET tracer is more probable than its 
success. The expected benefit of an in vitro NSB - estimate for the PET tracer development 
process is obvious: Either tracer candidates with inappropriately high NSB can be rejected 
prior to labeling, or, more desirable, the optimization towards balanced lipophilicity can be 
accelerated. 
There are several possibilities conceivable for estimating the NSB of neuroimaging tracers in 
a manner that is consistent with our ambition to replace or reduce animal testing. For obvious 
ethical reasons, the use of artificial surrogate systems would be preferable. We considered i) 
octanol worth to evaluate since opinions about the quality of which as membrane-mimicking 
system diverge substantially. Previous comparisons between octDlog  and tissue binding in 
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general [51], and between octDlog  and NSB [43] in particular, relied on rather small datasets 
limiting the explanatory power of these studies. Moreover, correlations between NSB and 
chromatographically derived octDlog  values [52] are ambiguous: using a model (reversed 
phase in chromatography) of a model ( octDlog ) introduces scatter to the data and leaves 
questions unanswered as to the value of octanol itself. For the measurement of octDlog , we 
have developed a novel assay, referred to as CArrier-Mediated DIStribution System 
(CAMDIS, see below). Similar to octanol, it has recently become common practice within 
Roche (Basel) to use the membrane fraction in the Parallel Artificial Membrane Permeability 
Assay (PAMPA) as a primary indicator for NSB (in-house, unpublished results). Yet, a 
systematic comparison between tissue binding and PAMPA-membrane retention has been 
pending ever since the introduction of PAMPA in 1998 [53]. Hence, we addressed the 
question whether ii) the fraction of drug retained in the PAMPA membrane represents a 
meaningful surrogate for NSB. In addition, iii), we aimed to develop an in vitro assay for 
assessing the binding of drugs and drug-like molecules to brain homogenate and to predict 
the NSB of PET tracer candidates. The assay will in the following be referred to as LIpid 
Membrane Binding Assay (LIMBA). The decision to develop LIMBA in a miniaturized 
format was driven by the aim for accurate NSB-estimates at low expenses of animals. We 
were specifically interested whether LIMBA, in comparison with the artificial-membrane 
mimicking systems mentioned above, provides significant advantages that justify favoring 
animal tissue over artificial models for the prediction of NSB.  
A comparative evaluation of the different surrogate systems required first and foremost a 
thorough validation of the individual assays (CAMDIS, PAMPA, LIMBA) to ensure the 
accuracy of the respective assay read-outs. The first objective of this thesis was the 
development, optimization and implementation of the novel octDlog assay, CAMDIS, which is 
described in manuscript 1. What was the driving force for developing CAMDIS after 
thousands of octDlog values have been measured with the traditional shake flask technique? 
The question can be answered with i) the tedious and time-consuming phase separation 
encountered in the traditional shake flask method which on top of that is prone to error due to 
emulsification [54] and incomplete phase separation [55]; and ii) the lack of suitable 
alternatives with respect to direct lipophilicity assays. As a strategy to overcome the 
difficulties of the shake flask technique, a filter was used in CAMDIS as support for octanol, 
yet the basic concept of shaking, separating and then analyzing two immiscible solvents for 
the distributed solute (octanol/water) was maintained.  
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It is important to note that CAMDIS was developed as a miniaturized high-throughput assay 
in order to meet the demand for cost-effective profiling of a large number of compounds in a 
short time. However, miniaturization in general goes along with an increase in the relative 
proportion of boundary layers to which a solute could adsorb or penetrate. Nominal and 
actual drug concentrations may then not necessarily be the same and, as a result, experimental 
artifacts are likely to arise. This drawback of miniaturized screening assays is particularly 
important when measuring octDlog  since two interfaces need to be considered, i.e. the filter-
supported octanol/water interface and the interface formed between water and the well plate. 
However, neither have adsorption-related artifacts been estimated before in a quantitative 
manner, nor have methods been proposed to correct for erroneous octDlog  values. For the 
sake of more reliable octDlog  values, we addressed the question under which experimental 
conditions (e.g. solute concentration, phase volume ratio) adsorption does not significantly 
compromise the accuracy of octDlog . Aiming to predict and eventually prevent adsorption-
related artifacts, we also raised the question which physicochemical properties make 
compounds susceptible to adsorption. 
Within this scope, we first studied the adsorption to the filter-supported octanol/water 
interface (manuscript 1). Specifically we were interested whether interfacial drug adsorption 
actually manifests itself as an error in octDlog . Moreover we were interested whether this error 
must be attributed to the adsorption to the liquid/liquid interface, the adsorption to the filter 
support or both. To resolve this question, we compared the CAMDIS- octDlog  values with 
octDlog  values derived from a conventional, miniaturized shake flask experiment (no filter) 
using the example of a cationic, an anionic and a non-ionic drug. 
If and how adsorption to the well plate affects the accuracy of octDlog  was investigated 
separately in manuscript 2. We chose Teflon as the well plate material of interest since it is 
widely used and preliminary studies in our lab were not in line with the often supposed 
inertness to adsorption. First, we characterized the sorption profile of 24 structurally diverse 
drugs by means of HPLC-UV, and we then parameterized a model which incorporates both, 
Teflon adsorption and octanol/water distribution. The predictive power of the model was 
tested by comparing octDlog  values derived with a miniaturized (CAMDIS) assay and with a 
large-scaled (1L glass flask) shake flask experiment considering the latter the gold standard 
for the following reasons: i) both phases were accessible for concentration analysis and ii) the 
surface to volume ratio was much smaller as compared to a miniaturized assay.  
2. Rationale and Aims of Research 
 20 
 
During the course of our investigation it became clear that drug-well plate interactions 
significantly falsify octDlog values whenever sticky, hydrophilic or sparingly soluble 
compounds are concerned which likely precipitate.  For such instances, we aimed to correct 
erroneous octDlog  values by recovering adsorbent or aggregated drugs from the Teflon plate. 
Excipients such as detergents [56], cyclodextrines [57], organic solvents [58] and bovine 
serum albumin [59] have proven useful for the recovery from drug adsorption to 
polypropylene and polystyrol. Yet, studies on the minimization of drug loss to Teflon are 
missing due to the uncritical use of the polymer. In addition, most of the knowledge 
concerning excipient-aided drug recovery has been gained from case studies rather than from 
designed experiments on a structurally diverse data set. In screening assays such as CAMDIS 
it is however crucial to lean on excipients which work for a large variety of compounds and 
which moreover do not interfere with the detection method for the analyte. HPLC coupled 
with electrospray ionization/mass spectrometry (HPLC - ESI/MS) was used for concentration 
analysis in CAMDIS since the method is more sensitive and better selective as compared to 
UV spectroscopy. Hence, in manuscript 3 we not only tested the desorbing efficiency of 
various excipients (detergents, cyclodextrines, organic solvents) on a structurally diverse 
dataset (n=26) but also evaluated the excipients in terms of compatibility with 
HPLC - ESI/MS. In this regard, it is worth noting that excipients can disturb the 
concentration analysis with HPLC-MS by suppressing an analyte’s  ionization efficiency 
(matrix effect) [60]. Among the excipients tested, 2-propanol was the only agent which was 
both effective and compatible with MS. The question as to whether 2-propanol also proves 
useful for correcting erroneous octDlog  values was then addressed in manuscript 2 within the 
framework of the octDlog - adsorption study. 
Only after having shown how to avoid, identify and correct experimental artifacts, 
respectively, we were able to validate CAMDIS on an extended dataset in manuscript 1. To 
this purpose, the literature was searched for compounds with known shake flask 
octDlog values serving as gold standard for octDlog . Stringent quality criteria were applied for 
the inclusion of compounds in the validation dataset (n = 52) in order to enable an 
unambiguous comparison of the methods. 
Recall that our ultimate purpose was the comparative evaluation of various membrane-
mimicking systems (octanol, PAMPA lipid, brain homogenate) with respect to their 
predictive ability for NSB. Accordingly, the next major objective of this thesis was the 
alignment of PAMPA with the basic requirements for a sensitive, specific and predictive 
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assay which moreover can be interpreted on a molecular level. To the pursuit of our 
objective, we used the Roche PAMPA setup as starting point for our own optimization 
purposes. By default, a solubilizer (glycocholic acid) is used in the Roche setup to 
accomplish the detection of sparingly soluble compounds, however, also other excipients are 
frequently applied in PAMPA as model formulation agents (N-methyl-1-pyrrolidone [NMP], 
hydroxypropy-β-cyclodextrine [HP-β-CD], propylene glycol [PG], taurocholic acid [TC] as 
one component of the FaSSIF/FeSSIF media) [61]. Since matrix-related excipient effects may 
disturb the concentration analysis with ESI/MS (see above), we addressed the following 
questions in manuscript 4: i) which of the excipients used in PAMPA cause matrix effects ii) 
is it possible to predict the presence of matrix effects, iii) do matrix effects manifest 
themselves as erroneous assay read-outs (permeability, membrane retention) and if so, iii), 
how does the experimental setup need to be modified towards MS compatibility. There is a 
certain overlap between the dosing vehicles which have already been evaluated in terms of 
matrix effects [62, 63] and the excipients tested within the scope of this thesis. However, the 
literature lacks information on matrix effects in presence of the FaSSIF/FeSSIF media, GCA 
and NMP. In addition, the studies published on excipient-related matrix effects pertain to the 
excipients levels in plasma which are typically encountered in a Drug Metabolism and 
Pharmacokinetics (DMPK) study. In contrast, we studied excipient concentrations relevant in 
PAMPA and required for effective solubilization.  
Apart from these analytical objectives, we aimed at shedding light on the lipid organization in 
the PAMPA barrier by means of different NMR techniques. Although there are different 
speculative models [64], the structure of the PAMPA barrier has never been characterized 
before at the molecular level. For example, the wide - spread assumption that bilayers are 
formed was based on electrochemical experiments with a filter-lipid-solvent system different 
from that actually used in PAMPA [65]. It is far from clear whether the results can be applied 
to PAMPA and therefore we dedicated a chapter of this thesis (manuscript 5) to that question. 
Specifically we were interested whether or not the term bilayer membrane and PAMPA 
membrane can be used synonymously. Knowledge about the lipid organization in PAMPA is 
not only of academic interest, but also of utmost importance to assess the scope and limitation 
of the membrane-mimicking system [10, 66, 67]. Ultimately it is essential for understanding 
the relationship between the structure of a test compound and the extent of membrane 
retention, which is in turn fundamental for guiding the structural optimization of test 
compounds.  
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The next major objective of thesis was the development of LIMBA, a novel miniaturized in 
vitro assay for estimating the binding of drugs and drug-like molecules to brain homogenate. 
The concept of LIMBA was inspired by PAMPA and CAMDIS in terms of using a filter 
device as support for the membrane-mimicking system. In contrast to CAMDIS and PAMPA, 
brain homogenate instead of an artificial lipid-solvent mixture was coated on the filter in 
order to remain as close as possible to the in vivo situation. 
In manuscript 6 we aimed at evaluating all assays, CAMDIS, PAMPA and LIMBA, in a 
comparative way with respect to their predictive ability for NSB. The following strategy was 
pursued: The literature was searched for drugs which had been characterized with equilibrium 
dialysis. The corresponding brainuf , -estimates were considered the gold standards for tissue 
binding allowing for comparative evaluation with the various surrogate systems investigated. 
Even though the brainuf , -estimates themselves are only approximations of the NSB in vivo, for 
validation purposes we abstained from using in vivo data for the following reasons: i) the 
number of compounds characterized with PET was much smaller than that measured with 
equilibrium dialysis and ii) active transport processes may complicate the interpretation of the 
PET data. In manuscript 6 we aimed to identify the in vitro assay which was best to predict 
brainuf , . In manuscript 7, we finally tested whether that assay, i.e. LIMBA, is also useful for 
the prediction of NSB in autoradiography and in a PET study. The research plan is 
summarized in Fig. 6.  
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Figure 6   Research plan. 
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3  Capsules 
3.1 Carrier Mediated Distribution System (CAMDIS): A Novel Approach for the 
Measurement of Octanol/Water Distribution Coefficients 
 
Background:  
The octanol/water distribution coefficient, octDlog , has found ever growing interest in the 
drug development process as a key parameter for the prediction of a compound’s 
pharmacokinetic, toxicokinetic and pharmacodynamic profile. To overcome the difficulties of 
the traditional shake flask method, arising from time - consuming and possibly incomplete 
phase separation, we have developed and validated a novel filter-based octDlog assay 
(CAMDIS).  
 
Results:  
The use of a hydrophobic filter support for octanol enabled fast, convenient and complete 
phase separation. CAMDIS was applicable for compounds of all charge classes yielding 
highly reproducible octDlog values in excellent agreement with the literature shake flask data 
(valid octDlog range: -0.5 - maximal 4.2). The miniaturized assay requires correction for 
adsorption which will be discussed in our accompanying manuscripts 2 and 3.  
 
Conclusion:  
CAMDIS enables the precise measurement of octDlog at lower sample consumption and 
reduced net manpower hours as compared to the traditional shake flask technique.  
 
Significance:  
CAMDIS bridges the gap between the requirement for high quality AND rapid 
octDlog assessment and may thus aid the optimization of potential drug candidates in the 
earliest phase of the drug development process.   
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3.2 The Impact of Drug Adsorption to Microtiter Plates on the Accuracy of LogDoct 
 
Background:  
Miniaturization and automation of high - throughput screening assays, such as CAMDIS, 
have created a situation where compound aggregation and adsorption to the labware (e.g. 
Teflon well plate) may remain undetected, but likely lead to experimental artifacts. 
Therefore, the impact of drug loss to a Teflon microtiter plate on the accuracy of octDlog was 
studied. 
 
Results:  
Drug loss to Teflon manifests itself as underestimation in octDlog  i) for compounds with low 
affinity for octanol (hydrophilic) but a high affinity for Teflon (typical for planar drugs with 
many hydrogen bond donors, e.g. doxorubicin) and ii) for compounds precipitating during the 
time course of the distribution assay. Experimental errors could be minimized by increasing 
the drug concentration and/or the volume of octanol (applicable to the 1
st
 case) or by 
recovering adsorbed drug with 2-propanol (applicable to the 2
nd
 case). The validity of using 
2-propanol as a desorbing agent will be demonstrated in our accompanying manuscript 3. 
 
Conclusion:  
Although lipophilic compounds are prone to adsorption to Teflon, accurate octDlog values are 
obtained, provided that only one drug layer adsorbs to the Teflon surface. Then, the 
distribution equilibrium is shifted towards drug dissolved in the octanol phase and drug 
adsorption to the well plate can be neglected. In contrast, drug precipitation/aggregation in 
the well plate may lead to an underestimation of octDlog  , which is the more pronounced the 
lower the lipophilicity of a compound. 
 
Significance:  
The identification of compounds with a high propensity for erroneous octDlog  values and the 
possibility to correct them provides higher data reliability, avoids misinterpretations, and thus 
helps guiding lead compound optimization in a reasonable way.  
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3.3 Drug Adsorption to Teflon and Excipient-Aided Drug Recovery 
 
Background:  
Non-specific binding of potential drug candidates to microtiter plates has recently been 
recognized as the source of experimental artifacts, but only scarce information is available for 
how to correct for adsorption. The proper choice of excipients (i.e. surfactants, 
cyclodextrines, organic solvents) for drug recovery was investigated for a structurally diverse 
dataset and the compatibility of these excipients for data analysis with HPLC-ESI/MS was 
tested. 
 
Results:  
Micellar concentrations of SDS (anionic) enabled the recovery of all adsorbent drugs whereas 
Brij 35 (non-ionic) and CTAB (cationic) were less efficient for the bases chlorpromazine and 
doxorubicin. Almost complete recovery except for doxorubicin (required acidification) was 
achieved by addition of 2,6-di-O-methyl-β-cyclodextrin and organic solvents (acetonitrile, 
DMSO, 2-propanol). All excipients, except for 2-propanol, caused ion suppression in 
ESI - MS. 
 
Conclusions:  
The superior detergency of SDS for cationic drugs indicates that electrostatic repulsion 
between surfactant residing at the Teflon surface and mixed SDS-drug micelles free in 
solution plays an important role in excipient-aided drug recovery. We recommend using SDS 
if UV is the selected analytical technique while 2-propanol is preferable for ESI-MS. 
 
Significance:  
The proposed guideline for excipient-aided drug recovery may be applied for the correction 
of potentially erroneous results in high-throughput assays to avoid misinterpretations and 
achieve higher certainty in the data of interest. 
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3.4 Evaluation and Management of Excipient-Related Matrix Effects in 
HPLC - ESI/MS Analysis of PAMPA-Permeability 
 
Background:  
The presence of solubilizers and model formulation agents in the parallel artificial membrane 
permeability assay (PAMPA) may suppress the ionization efficiency in ESI-MS (matrix 
effect) resulting in reduced analyte sensitivity and possibly incorrect outcome measures. 
Therefore we tested whether the excipients commonly used in PAMPA cause matrix effects 
in HPLC - ESI/MS and if so, to what extent this affects the accuracy of observed 
permeabilities. In addition, we evaluated strategies to manage excipient-related matrix 
effects. 
 
Results:  
Pronounced matrix effects were observed for excipients favoring the air-water interface 
(glycocholic acid, FaSSIF/FeSSIF media), forming multiply-charged ions 
(hydroxypropyl--cyclodextrin) and/or carrying a proton acceptor in the form of nitrogen 
(1 - methyl - 2 - pyrrolidone). Propylene glycol showed the weakest matrix effect. The 
presence of ion-suppressing solubilizers (tested here: glycocholic acid) in the PAMPA donor 
invalidated mass balancing and disregard thereof resulted in overestimated permeability.  
 
Conclusion  
Excipients distributed non-uniformly in the PAMPA donor and acceptor during the 
permeation process should be adjusted to the same level before concentration analysis with 
HPLC-MS. If the use of excipients aims to increase compound solubility rather than to 
investigate a specific excipient-effect, replacement of the frequently used glycocholic acid by 
propylene glycol is suggested for the sake of better sensitivity. 
 
Significance  
Management of excipient-related matrix effects in PAMPA is crucial when using 
HPLC - ESI/MS as an alternative detection mode to UV. The proposed strategies may aid in 
the generation of accurate outcome measures, i.e. permeability and membrane retention. 
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3.5 31P and 1H-NMR Studies on the Molecular Organization of Lipids in the PAMPA 
Permeation Barrier  
 
Background:  
The structure forming the permeation barrier in PAMPA (lipid-dodecane-filter system) has 
never been characterized experimentally. To shed light in the black box we investigated the 
molecular organization of lipids in the PAMPA barrier by means different nuclear magnetic 
resonance (NMR) techniques. To deduce the relationship between barrier structure and 
function we also measured PAMPA-barrier/water distribution coefficient for structurally 
diverse drugs as a function of drug and lipid concentration.  
 
Results:  
Dodecane in large excess over lipid induced the lamellar-to-isotropic phase transition, 
irrespective of whether or not a filter (PVDF) support was used. The isotropic phase 
corresponded to lipid aggregates (diameter approximately 5 nm). The PAMPA-barrier/buffer 
distribution coefficients increased with a rise in the lipid content, a decrease of drug 
concentration (only for amphiphilic cationic drugs) and, roughly, a rise in the octanol/water 
partition coefficient.  
 
Conclusion:  
The data suggests that the binding to and, in turn, the permeation across the PAMPA barrier 
is facilitated by the presence of reversed egg lecithin micelles which act as carriers rather 
than as barriers for the transport of particularly cationic amphiphilic drugs. This distinguishes 
PAMPA from biological membranes. The size cutoff, arising from attenuated insertion into 
densely packed biological membranes, is not observed in PAMPA. 
 
Significance  
Knowledge about the organization of the PAMPA barrier may aid in the interpretation of the 
relevant assay read-outs, i.e. passive permeability and membrane retention. The scopes but 
also the limitations of using a non-bilayer system as a model for a biological bilayer 
membrane should always be kept in mind in order to allow for a rational optimization of 
potential drug candidates. 
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3.6 Evaluation of a Novel Lipid Membrane Binding Assay (LIMBA) for the 
Assessment of Brain Tissue Binding 
 
Background:  
Existing methods for estimating the unbound fraction of drug in brain ( brainuf , ) yield 
sufficiently accurate results but low throughput (brain slice uptake technique) and high tissue 
consumption (homogenate dialysis) hamper their application for earlyADME profiling. 
Therefore we have developed a miniaturized Lipid Membrane Binding Assay (LIMBA) 
based on the immobilization of minute amounts of brain homogenate (1.2 μL) on a filter 
support which allows for assessing brain tissue/water distribution coefficients ( brainDlog ) in a 
high-throughput manner. In particular, we were interested whether brainDlog is in better 
agreement with brainuf ,  as compared to octDlog , Plog  and the fraction of drug retained in the 
permeation barrier of the Parallel Artificial Membrane Permeability Assay ( PAMPADlog ).  
 
Results:  
The classical lipophilicity scales, octDlog and Plog , were inappropriate in describing brainuf ,  at 
a sufficient statistical certainty level (r
2 
( octDlog ) = 0.23, r
2
( Plog ) = 0.49). Provided that 
PAMPA was optimized in terms of lipid composition and nature of the buffer, the membrane 
fraction was satisfactorily predictive for brainuf ,  (r
2 
= 0.61). Using LIMBA the best agreement 
with brainuf ,  was obtained (r
2 
= 0.74). 
 
Conclusion:  
LIMBA allows estimating drug distribution into brain tissue with sufficient accuracy and at 
considerably reduced tissue consumption and at higher throughput as compared to the 
homogenate dialysis method. 
 
Significance 
LIMBA may aid in the selection of lead compounds with an appropriate pharmacokinetic 
profile and moreover it can be used to estimate unbound drug concentrations in brain. In 
addition there is great potential to estimate the non-specific binding or radioligands in 
Positron Emission Tomography (accompanying manuscript 7).  
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3.7 Label-Free Assay for the Assessment of Non-specific Binding of Positron Emission 
Tomography Tracer Candidates 
 
Background:  
High non-specific binding (NSB) of radiotracers to membranes and non-target proteins 
affects the accuracy with which receptor occupancy at the target site can be measured by 
means of positron emission tomography (PET). To enhance the confidence in the likely 
development success of a PET tracer it is desirable to estimate NSB as early as possible, 
preferably before labeling of the ligand. Since neither octDlog  nor Plog is predictive for NSB, 
and homogenate dialysis is hampered by low throughput and high tissue consumption, we 
validated the ability of the novel high-throughput tissue binding assay, LIMBA, to predict the 
NSB of potential PET tracers.  
 
Results:  
In summary, we could show that brain tissue / water distribution coefficients ( brainDlog ) 
measured with LIMBA are highly predictive for NSB observed by in vitro autoradiography. 
Moreover, brainDlog is a good surrogate for NSB in PET, provided that non - Pgp-substrates 
are concerned. 
 
Conclusion:  
Since LIMBA works without labeling and the tissue consumption per compound is very low 
(1.2 μL), estimates of NSB can be obtained with considerably higher throughput than with 
the homogenate dialysis technique or with autoradiography.  
 
Significance 
LIMBA may accelerate the selection of PET tracers with appropriate NSB characteristics and 
the rejection of compounds with undesirable high background noise. Ultimately, this may 
enhance the confidence in the likely development success of a PET tracer. 
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ABSTRACT 
We present an improved method for the fast and reliable measurement of octanol/water 
distribution coefficients ( octDlog  ). The new assay, referred to as carrier - mediated 
distribution system (CAMDIS), utilizes a filter support for octanol which facilitates the phase 
separation from water. This overcomes inconveniences of the traditional shake flask method, 
i.e. laborious phase separation and propensity to emulsion formation. A guideline for the best 
practice of CAMDIS is derived describing a strategy to manage drug adsorption at the filter-
supported octanol/buffer interface. We validated the assay on a set of 52 structurally diverse 
drugs with known shake flask octDlog  values. Excellent agreement with literature data 
(r
2
 = 0.996, standard error of estimate, SEE = 0.111), high reproducibility (standard 
deviation, SD < 0.1 octDlog  units), minimal sample consumption (10 μL of 100 μM DMSO 
stock solution) and a broad analytical range ( octDlog  range = - 0.5 - 4.2) make CAMDIS a 
valuable tool for the high - throughput assessment of octDlog .  
 
 
KEYWORDS 
Octanol/water distribution coefficient, Octanol/water partition coefficient, Filter support, CAMDIS, 
pH dependence, Concentration dependence, Drug Adsorption to Plastic. 
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1. Introduction 
Lipophilicity has emerged as one of the key physicochemical parameters in the drug 
development process to predict a compound’s ADME/Tox profile [1, 2] and its likely 
biological activity [1, 3-5]. The most frequently used lipophilicity parameter is the 
octanol/water distribution coefficient ( octDlog  ) or, when referring to non - ionized species, 
the octanol/water partition coefficient ( octPlog  ). This is mainly due to the vast amount of 
published octPlog  ( octDlog  ) data [6], the good interlaboratory reproducibility and, as a result, 
the availability of a growing number of octPlog prediction packages [7, 8]. In the light of the 
non - trivial task to cope with the presence of charges, ion - pairing, conformational changes 
and the lack of parameterization for certain fragments, it is not surprising that in silico 
predictions can only give an initial estimate of octDlog [9], and as a consequence, the 
requirement for accurately measured octDlog values is still high.  
The traditional approach to determine octDlog values using the shake flask technique is 
tedious, wasteful [10] and, in turn, cannot accomplish the demand for high - throughput 
screening. Although the concept of shaking and separating two immiscible solvents in order 
to analyze the concentration ratio of a distributed solute seems simple, phase separation is a 
time consuming step and, more importantly, is prone to artifacts. Amphiphilic compounds 
tend to enrich at the interface between two immiscible solvents and to form stable emulsions 
[6, 11] which sometimes cannot be dispersed by centrifugation. In addition, compounds with 
high lipophilicity will preferentially distribute into the octanol phase while leaving very small 
amounts in the aqueous phase. Even minimal contamination of the aqueous phase with 
octanol will then have a significant effect on the accuracy of octDlog [12]. 
Several strategies have been proposed to overcome the difficulties of phase separation and to 
translate the manual shake flask technique into an automated 96 - well plate format. One 
example is the frozen water phase method [12]. It involves freezing the aqueous phase in 
liquid nitrogen and removing liquid octanol from the top. Considering the similar freezing 
points of water and octanol (0 °C vs. -15 °C [13]), the possible time window for the 
incubation with liquid nitrogen is quite narrow. Moreover, high-throughput automation is 
impaired by additional washing steps required to remove octanol remaining on the frozen 
aqueous phase [12]. Another strategy is to directly inject the liquid into an LC or LC/MS 
system without separating the phases in advance [14]. Therefore specially developed HPLC 
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injection programs have been advocated based on the repellant effect of a water plug 
aspirated before piercing through the octanol layer. However, accumulation of sparingly 
soluble drugs at the capillary tip weakens the repellant effect and may falsify the results [15]. 
The inconveniences associated with the conventional or modified shake flask assays have 
resulted in the development of several other direct or indirect techniques for the assessment 
of lipophilicity. Despite distinct benefits, none of the alternative methods is without 
difficulties [16, 17] and the classical shake flask technique is still considered the gold 
standard. Alternative methods that make use of octanol as a bulk phase are not yet amenable 
to high - throughput (dialysis tubing [18]) and/or are only applicable to compounds with 
ionizable groups (filter probe [19], potentiometric method [20]). Concerning the widely used 
chromatographic methods, disadvantages such as the need for external calibration, restricted 
column lifetime, nonlinear co - solvent behavior and limited applicability range are well 
known [10, 16, 21, 22].  
An apparatus for the measurement of octanol/water distribution coefficients based on the 
immobilization of octanol on a filter probe has been proposed by Cantwell [23] and was later 
improved by Tomlinson [24]. Unfortunately, the apparatus was large scale, and therefore not 
meeting the demands for high - throughput analysis. In the framework of a permeability 
assessment across an artificial lipid - mimicking systems [25], Camenisch immobilized 
octanol on a filter (hydrophobic PVDF). A miniaturized adaptation of the system named 
PAMPA (Parallel Artificial Membrane Permeability Assay) was later used by Faller to derive 
octPlog by estimating the effect of membrane (octanol) retention on the apparent permeability 
of the neutral species aNPlog [26]. Unfortunately, the PAMPA - octanol assay suffers from 
reduced accuracy in the octPlog range 0 – 2 (the variation of aNPlog  with octPlog  flattens [26]) 
and requires knowledge of the apK . 
In the present study, we translated the idea of using a filter support for octanol into the 
development of a novel miniaturized high - throughput octDlog assay, which will in the 
following be referred to as CArrier Mediated DIstribution System (CAMDIS [27]). The 
design of the plate as well as the setup of the assay is described in Fig. 1.  
 
Fig. 1 
 
Rather than relying on variations of permeability with octPlog , the design of CAMDIS was 
intended to directly measure a solute’s concentration ratio in the octanol/water system. In this 
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sense, CAMDIS retains the straightforwardness of the traditional shake flask method as a 
direct lipophilicity measure while facilitating time intensive phase separation. As octanol 
support, we used a PVDF filter attached to the bottom of the customized and commercially 
available Diffusion - Filtration (DIFI) tubes (Fig. 1 A [28]). The filter surface and the core 
(PVDF fibers) may constitute an additional compartment, at which an amphiphilic compound 
may adsorb and to which it may penetrate, respectively. Therefore we investigated under 
which experimental conditions adsorption of drug at/into the filter becomes negligible 
compared to the distribution into octanol. To provide an assay yielding accurate data despite 
miniaturization we assessed the optimal equilibration time, phase volume ratios, drug 
concentrations and calibration procedure. 
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2. Theoretical Basis 
The octanol/water distribution coefficient is defined as the equilibrium ratio of the drug 
concentration in octanol, eqoctC  , and in the aqueous phase, 
eq
aqC  
, according to [21]: 
 
 eqaqeqoctoct CCD /loglog  .    (1) 
 
The most straightforward way to obtain the distribution ratio is the direct concentration 
analysis in both solvents. Unfortunately, very lipophilic compounds demand the use of 
minute amounts of octanol (e.g. 1 µL) which are inaccessible for direct analysis [11]. Even if 
sufficient octanol is recovered, possible shifts in the absorption spectra, ion suppression in 
mass spectrometry, difficulties in liquid handling and evaporative loss still complicate the 
analysis of both phases. Therefore, solute concentrations in octanol are usually obtained from 
mass balance, i.e. from the difference between initial, 0
aqC , and equilibrium aqueous drug 
concentrations, eq
aqC . In the following, mass - balance derived distribution coefficients are 
defined as 'log octD  whereas distribution coefficients relying on the analysis of both phases 
(eq.1) are indicated as octDlog . As a direct measure, octDlog is not affected by the presence of 
the PDVF filter used in CAMDIS and will therefore be considered the gold standard. If, 
however, only the aqueous phase is assayed, any amount of solute at the filter or at the 
filter - supported interface, eq
fin , would wrongly be attributed to the octanol phase. 
Overestimating the solute concentration in octanol by eq
fin  
may manifest itself as an 
erroneously high 'log octD , according to (for derivation of eq. 2 see Supporting Information): 
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where  
aqV and octV are the volumes of the aqueous and the octanol phase, respectively. In the 
ideal case, solute adsorption to filter becomes negligible compared to the distribution into 
octanol (   eqfiaqeqaqaq nVCC 0 ) and eq.2 simplifies to:  
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Experimental conditions where the adsorption to the filter can be neglected are highly 
desirable because in eq. 3 all parameters are either known (
aqV , octV ) or can easily be 
measured ( 0
aqC , 
eq
aqC  
). A viable option to increase the amount of drug in octanol in order to 
outcompete the filter - adsorbed drug is to increase the volume of octanol 
( eqaqaq CC 
0 increases). If saturable binding at the filter occurs, a rise of the total drug 
concentration, 0
aqC , will likewise diminish the influence of the filter and of 
eq
fin . 
An estimate of eq
fin  and the true octDlog  can be obtained by measuring the 
'log octD  - 
0
aqC profiles and fitting eq. 4 to the experimental data (see Supporting Information 
for derivation of eq. 4):  
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3. Materials and Methods 
3.1. Drugs and Chemicals  
Most of the drugs, chemicals and solutes were obtained from commercial sources (Acros, 
Aldrich, Alexis, Dayang, Fluka, Gardena, Merck, Molekula, Sigma, Sirius) and were used as 
received. Amitriptyline, chloramphenical, desipramine · HCl, dexamethasone, diazepam, 
fentanyl, meprobamate, mesoridazine, metronidazole, prednisolone and primidone were 
available through our in - house Compound Depository Group as proprietary compounds. 
Formic acid, water and acetonitril were supplied from Merck (Darmstadt, Germany) and were 
of HPLC - grade. 
3.2. Determination of Distribution Coefficients (n - Octanol/Buffer) with CAMDIS 
3.2.1. Assay Protocol (Validation Setup) 
Prior to the distribution experiment, octanol and phosphate buffer (25 mM) were mutually 
saturated at room temperature. Drug compounds were introduced into the pre - saturated 
phosphate buffer as DMSO stock solutions (10 mM) resulting in a 100 µM sample solution 
(1200 µL, DMSO content 1 %, v/v). The solutions were filtered (Millipore Multiscreen Filter 
Plate, MDRLN 0410) into a 96 - deep well receiver plate (Nunc, 278752) and diluted with 
pre - saturated phosphate buffer (200 µL). The secondary dilution was performed to minimize 
the risk of delayed drug precipitation during the distribution experiment. Aliquots of the 
filtrate ( aqV = 150 µL) were transferred into an in - house made Teflon plate and covered 
with the DIFI tubes (Weidmann Plastics Technology AG, Rapperswill, Switzerland, 23358) 
which were pre - coated with octanol ( octV  = 1µL and 15µL, respectively; n = 3 for each 
volume). Use of an automated liquid handling system (Beckmann Coulter, Bio RAPTER 
FRD, Microfluidic workstation) permitted fast, reproducible and accurate dispensing of 
octanol (SD < 3 %). The assay kit was sealed and allowed to shake at room temperature until 
distribution equilibrium was achieved (16 - 22 h). After disassembly of the DIFI tubes from 
top of the Teflon plate, the equilibrium drug concentrations in the aqueous phase, eq
aqC  , were 
analyzed with HPLC - UV/MS. In parallel, a reference experiment was carried out in the 
same plate but without octanol to obtain the initial aqueous drug concentrations, o
aqC . One of 
the reference wells contained 1 : 5 diluted filtrate to provide a calibration check. Unless 
otherwise stated, the equilibrium drug concentrations in octanol, eq
octC  , were not measured 
4. Manuscripts 
 43 
 
directly but obtained by mass balance. The apparent distribution coefficient, 'log octD  , was 
then calculated according to eq. 3. In some cases, octanol residing in the DIFI tubes was 
analyzed directly after centrifugation (1000 rpm, 5 min) of the octanol phase into a PCR 
receiver plate (Eppendorf, octDlog  ). Due to the fact, that all UV measurements were carried 
out under the same conditions, the concentration terms were replaced by the analyte 
responses in UV or MS. The commonly non - linear mass response was accounted for by 
performing an internal calibration series (see Section 3.6). 
3.2.2. Time- and Concentration Dependence of Distribution Coefficients 
The time- and concentration dependencies at pH 7.4 were performed in octanol - saturated 
buffer (50 mM Tris/114 mM NaCl, pH 7.4, we only decided after a perusal of the published 
shake flask data, preferentially obtained in phosphate buffer, to change the buffer system to 
phosphate for the final assay validation). The concentration dependent measurements at 
different pH values were performed in octanol - saturated sodium formiate (pH 3; 4), sodium 
acetate (pH 5), BisTris (pH 6;7), Tris (pH 8;9) and universal buffer (Sirius, pH 10), each at 
constant ionic strength (I = 0.05 M). The analyte - spiked aqueous solutions were manually 
prepared in glass vials by diluting a DMSO stock solution with octanol - saturated assay 
buffer to the desired solute concentration, thereby keeping the DMSO content constant 
(1 %, v/v). The time dependent measurements were performed at 100 µM rolipram. The 
concentration dependence at pH 7.4 was obtained at 5; 12.5; 25; 100; 200; 300 µM using 
rolipram, buspiron and propranolol as test analytes. The octDlog ( 
'log octD  ) - pH profiles of 
zolpidem were obtained at 12.5 µM and 100 µM, respectively. The time on the shaker was 
6 h for the 1 µL setup and min. 24 h for the 15 µL setup (achievement of equilibrium was 
verified). Only UV data was used for concentration analysis. At least 3 measurements were 
performed for each incubation time, concentration and pH and mean octDlog and 
'log octD values were reported.  
3.3. Determination of Distribution Coefficients with the Shake Flask Method 
Octanol (1 µL and 15 µL) was directly delivered into the assay plate (96 - well PCR plate) 
using the abovementioned Beckman dispenser. Afterwards, octanol - saturated assay buffer 
spiked with analyte was distributed on top of the octanol layer. Concentrations and phase 
volumes were matching the experimental conditions in CAMDIS. The PCR plate was sealed 
and inversed 100 times followed by overnight shaking at room temperature. After 
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centrifugation of the PCR plate (1500 rpm, 20 min, Eppendorf, Centrifuge 5810R), the 
aqueous phase was directly injected onto the HPLC. The injection needle was programmed to 
pierce through the octanol layer and aspire only the aqueous phase. A contamination of the 
aqueous phase by octanol cannot be excluded. However, the compounds analysed by the 
shake flask method were of intermediate lipophilicity for which contamination with octanol 
should play only a minor role.  
3.4. Detection of Precipitation and of Drug Adsorption to the Well Plate 
Test compounds (olanzapine, chlorpromazine, Ro - 1) were dissolved in DMSO (50 mM) and 
11 consecutive dilutions in DMSO were prepared (0.1 mM - 50 mM). An aliquot of each 
stock solution (1.5 µL) was transferred into an in - house made Teflon plate and diluted 
1 : 100 with octanol - saturated buffer (50 mM Tris, 114 mM NaCl, pH 7.4) resulting in 
1 - 500 µM analyte solutions. The Teflon plate was sealed and allowed to shake for 18 h at 
room temperature. Then, the sample solutions were injected onto an HPLC system and the 
peak areas were recorded at appropriate wavelength (n = 2). Deviation from a straight line 
when plotting the absorbance vs. initial aqueous drug concentrations was used to detect drug 
adsorption to the well plate and drug precipitation.  
3.5. Selection of the Validation Dataset 
A set of 52 drugs with known shake flask octDlog values was compiled from literature in 
order to validate CAMDIS. Starting from a search in the MedChem Database, all original 
references were carefully inspected and only values retrieved at ambient temperature 
(20 - 25°C)  with the traditional or a miniaturized shake flask method were included. Data 
from adapted shake flask procedures (interface extraction [29], three - phase titration [30]) 
was not considered. With respect to ionizable compounds, only octDlog values obtained at 
pH 7.4 were included, while no pH constraint was applied to neutral compounds. Generally, 
only distribution coefficients measured in the octanol - phosphate - buffer system were 
included. Even if not always stated, we assumed that the two phases were mutually saturated. 
However, for some compounds we encountered high variability among literature data and in 
these cases we gave preference to reports leaving no uncertainties about phase saturation. 
Entries in the MedChem Database of unpublished data (‘private communication’) were only 
included when confirmed to be of high quality ( octPlog   - star value). However, when 
violating one of the abovementioned criteria, the value was neglected. For validation, the 
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average literature value was taken and compared with the average 'log octD value derived from 
CAMDIS (n = 3).  
3.6. HPLC/MS Instrumentation and Chromatographic Conditions 
Drug concentrations were quantified using an Agilent 1200 HPLC - MS system (Agilent 
Technologies, CA, USA) equipped with a degasser, auto - sampler, column oven, binary 
pump, DAD detector and API single quadrupole mass spectrometer (Agilent 6140). If not 
otherwise mentioned, a 5 µL aliquot of each sample was injected onto a Kinetex 2.6 µm, 
2.1 x 50 mm analytical column (Phenomenex, Germany) operated at 60 °C. The mobile phase 
consisted of A (water) and B (acetonitril), both containing 0.1 % (V/V) formic acid. The 
gradient elution on the Agilent 1200 system was performed as follows: initial 40 % B 
(1.5 mL/min), 0.1 - 0.15 min 40 % B (linear decrease of the flow rate to 1 mL/min), 
0.15 - 0.35 min linear gradient from 40 % B to 95 % B (1 mL/min), 0.35 min - 0.9 min 95 % 
B (1 mL/min). After passing the DAD detector, the eluent was introduced into the 
electrospray interface maintaining the following source settings: capillary voltage + 4 kV, 
drying gas flow (N2)  13 L/min, drying gas temperature 350 °C, nebulizer pressure 60psi, 
dwell time 50 ms. Electrospray was initiated with a time delay of 0.4 min to prevent 
extensive entry of DMSO and buffer salts into the API source. The integral of the 
pseudo - molecular ion intensity, [M+H]
+
, was aquired in single reaction monitoring mode 
(SRM). Internal calibration for MS data analysis was accomplished by injection of 1, 3, and 
5 µL of the sample solution. If UV sensitivity was sufficient, peak areas at appropriate 
wavelength were used for the calculation of 'log octD .  
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4. Results  
4.1. Assay Development  
Assessment of the optimal assay conditions was an essential element for the successful 
validation of CAMDIS on an extended dataset. For the assay development we selected 
compounds with moderate lipophilicity (Fig. 2) to grant the accessibility of octDlog ( 
'log octD  ) 
values with two phase volume ratios ( aqV was kept constant; octV  = 1 µL and 15 µL). Each 
drug was measured well below its critical micellar concentration, DCMC  (assessed by surface 
activity measurements [31], data not shown).  
 
Fig. 2 
 
4.1.1. Equilibration Time  
For evaluating the optimal shaking time, rolipram (Fig. 2) was selected as a test compound of 
intermediate lipophilicity. We used an in - house shake flask 'log octD value obtained after 100 
inversions and overnight shaking to provide a reference. Fig. 3 shows that distribution 
equilibrium was achieved after 6 h in the 1 µL octanol setup and after 16 h in the 15 µL 
octanol setup. After this time, CAMDIS 'log octD values were comparable with the reference 
shake flask values. The slight decrease of 0.2 'log octD units after 16 h shaking in the 1 µL 
CAMDIS setup can be traced back to the preceding evaporation of octanol (approximately 
0.2 µL). From a practical point of view, overnight shaking (16 - 22 h) is most feasible in the 
laboratory routine because it allows for the assessment of CAMDIS 'log octD at sufficient 
accuracy for both phase volume ratios.  
 
Fig. 3 
 
4.1.2. Optimal Drug Concentrations and Phase Volume Ratios 
As indicated in the Theoretical Section, the validity of estimating distribution coefficients 
with the simplified mass balance equation (eq. 3) heavily depends on the experimental 
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conditions. In order to retrieve the boundary conditions at which a possible adsorption to the 
filter can be neglected and the ‘true’ octDlog is approximated (eq. 3), we varied two key 
parameters in CAMDIS: i) the phase volume ratio ( octV  = 15 µL and 1μL; aqV = 130 µL) and 
ii) the initial aqueous drug concentration ( 0
aqC = 12.5 µM and100 µM). As a reference, we 
used the traditional shake flask 'log octD values and attributed potential discrepancies between 
CAMDIS and shake flask data to the presence of the filter (all other parameters like buffer, 
drug concentrations, phase volume ratios etc. were identical). In addition, we conducted 
CAMDIS at octV  = 15 µL and both, the octanol and the buffer phase, were assayed for the 
distributed drug. We consider these octDlog values as the ‘true’ values (gold standard) 
because assumptions of mass balance were not necessary and adsorption of compounds to the 
filter can be neglected. Therefore, the octDlog values can be used as a reference to prove the 
accuracy of the 'log octD values (CAMDIS and shake flask) that were derived from analysis of 
the initial and the equilibrium aqueous concentrations. To render the study meaningful for a 
wide range of lipophilicity and different ionization states, we measured the distribution 
coefficients for a weak base, zolpidem, ( apK  = 6.47), a weak acid, phenytoin ( apK  = 8.18 ), 
and a neutral compound, rolipram, over a wide pH range (pH 3 - 10). The investigated 
lipophilicity range is determined by the intrinsic lipophilicity of the non-ionized drug, octPlog , 
reduced by the fraction of ionized drug at a particular pH (see eq. S8 and S9 [9], Supporting 
Information).  
Fig. 4 shows the fraction of the basic compound zolpidem in its non - ionized form (Fig. 4A) 
in association with the lipophilicity - pH profiles obtained from different setups:  i) the ‘true’ 
CAMDIS octDlog  - pH profile (Fig. 4B), ii) the CAMDIS 
'log octD - pH profile (Fig. 4C) and 
iii) the shake flask 'log octD - pH profile (Fig. 4D).  
 
Fig. 4 
 
Irrespective of which setup was used, the variation of distribution coefficients with 0
aqC or 
octV  
was minimal when the non - ionized species predominated (pH > apK ). However, with a 
decrease in pH, mass - balance derived CAMDIS 'log octD values showed the following trend 
(Fig. 4C): Low concentrations and, particularly, low volumes of octanol resulted in an 
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overestimation of 'log octD which reflects an additional drug adsorption to the filter. Ion pairing 
as a mechanism leading to higher 'log octD values can be excluded, because the gold 
standard octDlog  (Fig. 4B) was independent of variations in drug concentration (the same 
buffer was used). The overestimation in CAMDIS 'log octD (Fig. 4C) became the more 
pronounced the higher the ionization degree, paralleling the drop in lipophilicity. With 
respect to the shake flask profile, the same, but much less pronounced trend was observed at 
pH 3 (Fig. 4D). Because adsorption to the filter could be excluded, the erroneously high 
shake flask 'log octD (pH 3) must be traced back to an enrichment of amphiphilic zolpidem at 
the octanol/buffer interface (see Discussion). A comparison of the mass balanced 'log octD - pH 
profiles (CAMDIS, Fig. 4C; shake flask Fig. 4D) with the per - definition ‘true’ octDlog  - pH 
profiles (Fig. 4B) revealed agreement over the whole pH range when high drug 
concentrations (100 µM) in combination with high volumes of octanol ( octV  = 15 µL) were 
used. The example of 'log octD at pH 4 shows that, with this optimal setup, excellent agreement 
of CAMDIS and shake flask data was achieved (Table 1).  
 
Table 1 
 
The CAMDIS 'log octD   - pH profiles for the acid, phenytoin, and the neutral compound, 
rolipram, are shown in Fig. 5A and Fig. 5B, respectively. In contrast to zolpidem, neither for 
phenytoin nor for rolipram a variation of 'log octD with drug concentration was observed which 
indicates that no or only negligible adsorption to the filter occured. We confirmed this by 
comparing CAMDIS 'log octD  with shake flask
'log octD values, for which perfect agreement 
was found (data not shown). Because no discrepancy in CAMDIS 'log octD  at different 
concentrations was observed for the most critical case, i.e. at 1 µL octanol, we did not 
perform the experiment with 15 µL octanol. 
 
Fig. 5 
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4.1.3. Drug Adsorption to the Filter for Different Cationic Compounds 
In the next step we tested whether i) adsorption of drug to the filter is a general trend for 
cationic compounds, ii) the resulting overestimation in 'log octD relates to the degree of 
ionization, and iii) an increase of 0
aqC and/or octV  may be used as a general strategy for 
avoiding an overestimation in 'log octD . For these purposes, we measured the CAMDIS 
'log octD values (pH 7.4) for structurally unrelated compounds with different ionization degrees 
and covered a wide concentration range ( 0
aqC  =  5 - 300 µM) and two phase volume ratios 
( octV  = 1 µL and 15 µL, respectively).  
Fig. 6A-C shows the 0
aqC  - CAMDIS 
'log octD (pH 7.4) profiles for rolipram (non-charged, 
Fig. 6A), buspiron (61.9 % positive charge at pH 7.4, Fig. 6B) and propranolol (99.2 % 
positive charge at pH 7.4, Fig. 6C), given in the order of increasing positive ionization.  
 
Fig. 6 
 
As expected, the non - charged rolipram corresponded to the ideal case in which the 
'log octD was independent of variations in 
0
aqC and octV  (Fig. 6A). In contrast, the 
'log octD values 
of the bases, buspiron and propranolol, obtained with 1 µL octanol dropped exponentially 
with increasing drug concentration up to approximately 25 µM (buspiron, Fig. 6B) and 
100 µM (propranolol, Fig. 6C), respectively, where a plateau was reached. The difference 
between 'log octD at infinite dilution and infinite concentration (extrapolated) was higher for 
propranolol, which is also the compound with the higher ionization degree and the lower 
lipophilicity ( 'log octD 0.22 vs. 
'log octD 0.08 for buspiron). At propranolol concentrations 
exceeding 100 µM, the measured 'log octD obtained with 1 µL octanol approached the 
'log octD derived with the 15 µL setup (Fig. 6C). We compared the CAMDIS 
'log octD values for 
propranolol (Fig. 6 C) with the corresponding shake flask 'log octD values (Fig. 6 D) and an 
excellent agreement was observed at 15 µL octanol, and also at 1 µL octanol provided that 
0
aqC  > 100 µM. At lower drug concentrations, the CAMDIS 
'log octD values (1 µL setup) were 
overestimated with respect to the shake flask data corresponding to an enrichment of drug at 
the PVDF filter. Similarly, the shake flask data showed slight concentration dependence with 
the same trend towards overestimated 'log octD values at lower concentrations. This again 
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points to the fact that interfacial enrichment also takes place in shake flask. In summary, 
positively charged compounds tend to adsorb to the PVDF filter or the filter - supported 
boundary layer leading to an overestimation of 'log octD , which can be counteracted by a rise 
in 0
aqC and/or octV .  
4.1.4. Quantification of Drug Adsorption to the Filter 
Estimates for the amount of drug at the solvent boundary layer, eq
fin , (with filter in CAMDIS 
and without filter in shake flask) were obtained by fitting eq. 4 to the experimental data in 
Fig. 6B - D. The number of layers at the filter, layerN  , could be assessed from 
eq
fin  according 
to eq. S10 (Supporting Information). Table 2 shows a summary of the fitting parameters for 
each compound and setup including the correlation statistics as well as the estimates for the 
‘true’ octDlog , 
eq
fin  and layerN  .  
 
Table 2 
 
The fitted estimates for the ‘true’ octDlog were in excellent agreement with the apparent 
(observed) 'log octD values at high drug concentrations. We found approximately two layers of 
drug sticking to the filter, irrespective of which compound was used. A possible 
interpretation is that each side of the membrane, i.e. the side towards the aqueous and towards 
the octanol phase, respectively, was covered by one layer of drug. Assuming the same 
interfacial area, we gained a slightly smaller estimate for the number of layers ( layerN  = 1.7) in 
the 15 µL shake flask experiment. Only approx. 1/5
th 
of this estimate was found for the 1 µL 
shake flask setup. The simple reason therefore is that due to the small volume of octanol, 
which is not forced to spread throughout the filter area, the contact area with the buffer phase 
was only approx. 1/5
th
 of the filter area. The eq
fin estimates in shake flask assay were less 
precise than in CAMDIS due to less pronounced concentration dependence of 'log octD .  
4.1.5. Diagnosis and Handling of Precipitation and Drug Adsorption to the Well Plate 
A simple proof of whether precipitation or drug adsorption to the well plate occurs during the 
assay time can be gained from a calibration check. Fig. 7 shows the calibration curves for test 
solutions of olanzapine (Fig. 7A), chlorpromazine (Fig. 7B) and a Roche compound (Fig. 7C) 
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obtained after 18 h storage in a Teflon plate (the total drug concentration ranged from 
1 - 100 µM).  
 
Fig. 7 
 
Olanzapine is an example of the ideal case where a plot of UV response vs. drug 
concentration yielded a straight line indicating that neither drug adsorption to the well plate 
nor precipitation occurred (Fig. 7A). In contrast, the increase (chlorpromazine, Fig. 7B) and 
the decrease (Ro - 1, Fig. 7C) in analyte response at high drug concentrations were clear 
indicators of saturable plastic sorption and drug precipitation, respectively. Within the 
framework of a HT octDlog assay, it is impractical to obtain a complete calibration curve. 
However, a two - point check with the initial aqueous drug solution ( 0
aqC  = 100 µM, 
reference 1) and a 1 : 5 dilution thereof (reference 2) is feasible. Both should be treated in the 
same way as the aqueous solutions used for the distribution experiment, however, without 
addition of octanol. When the linearly extrapolated 1 : 5 dilution yields a predicted UV 
response above (below) that observed with the 100 µM reference, saturable drug adsorption 
to the well plate (precipitation) occurs (like in Fig. 7 B, C, respectively). Drug precipitation 
occurs most likely in the reference experiment because the concentration in the aqueous 
phase is not reduced by the presence of octanol. In contrast, adsorption to the well plate plays 
a major role in the distribution experiment (with octanol) because saturation of the Teflon 
surface in the reference might be achieved.  
4.1.6. Guideline for CAMDIS 
The implications drawn from the calibration check and the filter - related adsorption are 
summarized in the flow chart in Fig. 8. It is intended as guideline to avoid artifacts possibly 
arising when the calculation of distribution coefficients relies on mass balance (eq.3).  
 
Fig. 8 
 
For high-throughput purposes, we recommend performing measurements generally at high 
initial drug concentrations ( 0
aqC  
=100 µM) and at two phase volume ratios ( octV  = 15 µL and 
1 µL; 
aqV = 150 µL). To yield the initial aqueous drug concentration,
0
aqC  , two aqueous drug 
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solutions without octanol should be prepared, one at 0
aqC  
=100 µM (reference 1) and a 1:5 
dilution thereof ( 0 5:1,aqC  
=20 µM, reference 2).  
The actual analysis should start with i) the calibration check: If neither 
aggregation/precipitation nor sorption to the well plate occurs, reference 1(100 µM) and the 
extrapolated value of reference 2 (5*20 µM) should yield the same value, with the average of 
it reflecting 0
aqC . In case of precipitation (reference 1(100 µM) < 5*reference 2(20 µM) it is 
evident that the extrapolated UV response of the 20 µM reference should be used as a 
measure of 0
aqC . In contrast, when saturable adsorption to the well plate occurs (reference 
1(100 µM) > 5*reference 2(20 µM)), we recommend considering the undiluted 100 µM 
reference as 0
aqC  . Although the violation in the mass balance equation due to drug adsorption 
to the well plate cannot be corrected in this way, the error in 'log octD is in most cases 
negligible. Experimental evidence will be published (accompanying manuscript 2). 
 ii) After defining which reference to use, the 'log octD values obtained with 1 µL and 15 µL 
octanol should be compared. Anionic and electrically neutral compounds do not adsorb to 
Teflon and therefore the 'log octD   values obtained from the two setups should agree. For 
cationic compounds, overestimation in 'log octD  due to filter adsorption was observed 
( 'log octD (1μL) > 
'log octD (15μL). To correct for adsorption, it is not only essential to perform 
measurements at high initial drug concentrations (100 µM); in addition, the 'log octD  for 
hydrophilic ( octDlog  < 2.5), cationic compounds should be estimated from the 15 µL octanol 
setup. For very lipophilic compounds ( octDlog  > 2.5), low volumes of octanol (1 µL) are 
advisable because otherwise hardly any drug is left in the aqueous phase for concentration 
analysis.  The solute dissolved in octanol will in case of lipophilic drugs be much higher than 
the solute bound by the filter yielding still valid results for 'log octD (for exact range see 
Discussion).  
4.2. Assay Validation 
A set of 52 drugs with known shake flask octDlog (pH 7.4) values was compiled from 
literature in order to validate the novel CAMDIS assay. We applied stringent selection 
criteria to the literature reports (see Section 3.5) and entries in the Pomona College 
MedChem Database to ensure the highest possible consistency among the data. As an 
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additional quality parameter we calculated the standard deviation across the various literature 
reports. The standard deviation was still considerable for some compounds and not linked to 
the magnitude of octDlog . The final dataset was structurally diverse and covered a broad 
range of physicochemical properties (Table 3).  
 
Table 3 
 
All compounds along with their literature 'log octD values, corresponding original literature 
references and measured CAMDIS 'log octD values are listed in Table 4.  
 
Table 4 
 
We retrieved the CAMDIS 'log octD values by strictly following the flow chart in Fig. 8. 
Compounds which showed strong signs of precipitation (astemizole, felodipine, 
ketoconazole, loratadine) were excluded from the dataset. Three drugs, notably only 
phenothiazines (*values in Table 4), adsorbed to the Teflon well plate but were still 
considered in the correlation statistics. The standard deviation among the CAMDIS data was 
generally very low (SD < 0.1 'log octD units). Fig. 9A shows the correlation line of literature 
shake flask vs. the CAMDIS log Doct’ values yielding the following statistics: 
 
Shake flask octDlog (or 
'log octD ) = 0.960 * CAMDIS 
'log octD +0.025         (12) 
 
 r
2
=0.996, SEE 0.111, n=52 
 
The slope close to 1 and the intercept close to 0 indicate excellent correlation statistics which 
show that the classical shake flask method and the novel CAMDIS method are directly 
comparable. An inspection of the residuals plot (Fig. 9B) indicates a generally low error in 
'log octD (residual - 0.245 – 0.23). A slight trend towards underestimation of hydrophilic 
compounds ( 'log octD  < 0.5) and overestimation of lipophilic compounds ( 
'log octD  < 1.5) was 
observable (see Discussion). No such general trend in residuals is evident with respect to 
different charge classes. 
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5. Discussion 
To overcome difficulties of the traditional shake flask method arising from time - consuming 
and possibly incomplete phase separation, we have developed and validated a novel approach 
(CAMDIS) to measure octanol/water distribution coefficients in a high - throughput manner. 
The assay is based on the immobilization of octanol on a filter support which is fixed at the 
bottom of our in - house developed DIFI tubes [27]. A sandwich with the buffer plate can be 
easily assembled and disassembled, enabling concentration analysis of the distributed solute 
in one or both phases. The implications of using a filter support for throughput, accuracy and 
applicability range of CAMDIS are discussed in the following.  
5.1. Throughput 
The octanol/water distribution coefficient is a thermodynamic measure presuming 
equilibrium conditions in the solute - solvent system. Leo and Hansch found that in the 
classical shake flask method approximately 100 inversions in roughly 5 min are sufficient to 
achieve equilibrium [6]. Equilibration times in the new assay were longer (optimal: 16 - 22 h) 
because the filter device separates the bulk phases and precludes an intense interexchange of 
the solvents. The fact, however, that the filter prevents amphiphilic compounds from forming 
troublesome emulsions is of great advantage, making time - consuming waiting for the phases 
to separate or an additional centrifugation step [6] unnecessary. 
In response to the possible emulsification in shake flask, also slow stir modifications of the 
classical ‘shake’ method have been advocated which are in closer analogy with CAMDIS in 
terms of agitation procedure and equilibration time [32]. Even though reaching steady state in 
CAMDIS may take a certain time, the fact that the assay is fully automated in the 96 - well 
plate format and the removal of octanol is a matter of seconds reduces not only the net 
manpower hours, but also the overall assay time. Integration of CAMDIS into the laboratory 
routine is most efficiently achieved by running two phase volume ratios in parallel and 
analyzing the distributed solute after overnight incubation (16 - 22 h). This procedure allows 
measurement of approximately 200 compounds per week. 
5.2. Accuracy 
Incomplete and laborious phase separation is the Achilles heel of the classical shake flask 
method which has been challenged by several efforts (see Introduction). A filter support 
prevents contamination of the aqueous phase with octanol more efficiently than any other yet 
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published technique (water plug aspiration [14, 15], frozen water phase [12]). Moreover, and 
distinct from conventional filter plates, the geometry of the DIFI plates (Fig. 1) avoids 
experimental artifacts arising from capillary effects at the vessel wall. In addition, the small 
filter volume allows working with very small volumes of octanol, and thus even very 
lipophilic compounds can be measured. 
The drawback of using a filter is enhanced interfacial drug adsorption due to the spreading of 
octanol (if octV  = 1 μL) across an enlarged boundary layer. The slightly more pronounced 
adsorption in CAMDIS as compared to the shake flask technique even at similarly - sized 
boundary layers (if octV  = 15μL) suggests that the filter itself somewhat aggravates the 
interface effect. The surface potential of PVDF, used as the filter material, has been found to 
be negative (approximately - 22 mV [33]) giving rise to electrostatic attraction of oppositely 
charged drugs. This might explain the fact that only bases but neither negatively charged nor 
non - ionized compounds enriched at the interface. Since mass - balance derived apparent 
'log octD reflects both, adsorption to the filter and distribution into octanol, it will be naturally 
higher than the ‘true’ octDlog . However, overestimation due to drug adsorption to te filter was 
only significant in the rare case that several unfavourable conditions coincided, including i) 
presence of positive charge, ii) low volume of octanol, iii) drug concentrations below a 
certain limit, and iv) low lipophilicity. Under these conditions, less drug enters the octanol 
phase, and, in turn, drug adsorption to the filter cannot anymore be considered insignificant 
(eq. 2,   eqfiaqeqaqaq nVCC 0  is not fulfilled). Under these conditions, eq. 2 predicts, and our 
experimental data showed, an overestimation of the true octDlog . The convergence of 
'log octD and octDlog with a rise in concentration and volume of octanol points to surface 
saturation even at the lowest concentration investigated (5 µM, Fig. 5). This is in contrast to 
the nature of a simple distribution process into octanol where the amount of drug in octanol 
linearly increases with a rise in the initial drug concentration and the volume of octanol. In 
order to shift the balance towards drug dissolved in octanol, high drug concentrations 
(100 µM) and high volumes of octanol (15 µL) are preferable. Taking these precautions into 
account, an excellent agreement with the true octDlog was achieved. 
Provided that optimized experimental conditions were used, the comparability of CAMDIS 
'log octD with the literature shake flask data was excellent. Although RP - HPLC derived 
capacity factors are an attractive alternative from a throughput point of view [34], distribution 
into octanol and retention on reversed silica phases are not equivalent and direct lipophilicity 
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measures are clearly preferable. Distribution coefficients derived with CAMDIS are more 
reproducible (SD= 0.04 ± 0.02) than those from potentiometric titrations (typically expected 
SD = 0.4 ( octDlog  ) [16] and octanol - PAMPA (SD = 0.31 ( Plog ) [26]), despite the fact that 
each approach relies on solute distribution into bulk phase octanol. The variability introduced 
by the need for estimating ionization constants (potentiometry, octanol - PAMPA) or by 
using different column batches in RP - HPLC is not present in CAMDIS. Moreover, the fact 
that troublesome emulsification is prevented by introduction of a filter is beneficial not only 
from a throughput point of view but also for improved accuracy. The possibility to apply 
different volumes of octanol (up to 25 μL) guarantees high sensitivity over a wide 
'log octD range (see below). In contrast, octanol - PAMPA is restricted to the particular volume 
of octanol (3 μL) that is necessary to impregnate a filter and to form a permeation barrier. 
Because the variation of permeability with Plog flattens in the Plog  range 0 - 2, 
octanol - PAMPA leads to less accurate results in this case [26]. Finally, the integration of a 
calibration check in CAMDIS, able to detect possible artifacts arising from precipitation and 
drug adsorption to the well plate, provides a higher level of certainty. 
5.3. Applicability Domain 
5.3.1. Charge Class 
CAMDIS works with acids, bases, neutral and zwitter – ionic compounds which allows for 
the assessment of 'log octD for all classes of compounds with a single screening platform. This 
is a major benefit compared to RP - HPLC (no acids)[34], potentiometry (no neutrals) or 
octanol-PAMPA (no zwitter - ionic compounds)[26] where a backup capacity for the 
respective missing charge class must always be provided. Particularly neutral compounds 
constitute a major part in the portfolio of potential drug candidates and omitting the 
lipophilicity characterization of those is not a viable option. 
5.3.2. Lipophilicity Range 
If no adsorption at the filter - supported interface takes place (acids, neutral compounds), the 
accessible lipophilicity range is mainly determined by the selected phase volume as well as 
the precision and sensitivity of the analytical method. Use of HPLC - MS then allows the 
measurement of octDlog in the range - 0.5 - 4.2 (with octV  = 15 µL and 1 µL octanol, 
aqV  = 150 µL).  
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However, for the evaluation of the accessible lipophilicity range in case of interfacial drug 
adsorption (bases), the associated experimental error needs to be considered and can be 
simulated as described in Fig. 10.  
 
Fig. 10 
 
The parabolic shape of the error curve (experimental error as a function of octDlog ) can be 
understood as follows: At the extremely low and the extremely high end of the octDlog range, 
very low drug concentrations will be found in one of both solvents. This means that any 
enrichment at the interface will have a significant effect on the equilibrium aqueous drug 
concentration translating into the increasing error sensitivity of octDlog (see also eq.3). It was 
shown that the overestimation of 'log octD due to drug enrichment at the octanol/buffer 
interface is a general pattern which also occurs in shake flask. A quantitative assessment on 
the accuracy of octanol/water distribution coefficients has, however, not been delineated 
before. This was possible and necessary in CAMDIS because the area of common interface is 
increased when minute volumes of octanol (1 µL) are forced to spread throughout the filter. 
The opposite effect is of course true when larger volumes of octanol are framed by the DIFI 
tube. Combining the thresholds governed by the phase volume ratio and those dictated by 
interfacial drug adsorption, a reliable assessment of CAMDIS 'log octD at the desired accuracy 
level (max. error 0.1 'log octD units) is possible in the 
'log octD range - 0.3 - 2.5 (15 µL octanol) 
and 0.9 - 3.8 (1 µL octanol). Despite the fact that the applicability range is much smaller than 
with RP - HPLC [34] and the PAMPA-octanol assay [26] ( octDlog = - 1.5 - 6 and - 2 - 8, 
respectively), we consider the range as sufficiently wide and optimized for potential drug 
candidates. Compounds with higher or lower lipophilicity are in general terms also 
undesirable from a biopharmaceutical point of view [35]. More important than an extended 
measurement domain is the reliability of experimental data in the relevant octDlog range. 
5.4. Limitations and Future Perspectives 
We have shown that CAMDIS is a valuable tool for measurement of octDlog which is the 
most frequently used parameter for the prediction of a compound’s pharmaceutical, 
environmental and biological fate [10]. The use as of octanol as a membrane - mimicking 
system is justified by itsdielectric constant of r  = 10 [36] which reflects the dielectric 
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conditions in the head group region of a membrane. However, octanol lacks the anisotropy 
and asymmetry of a biological membrane[37]. To overcome this deficit we tested CAMDIS 
with other solvent systems than octanol, including phospholipid membranes and tissue 
homogenates from animal and human organs (e.g. brain homogenates). A proof has already 
been established in our lab (manuscript 6). 
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6. Conclusions 
We have demonstrated on a chemically diverse and broad set of compounds (n = 52) that the 
novel CAMDIS assay (i) produces accurate 'log octD values in excellent agreement with 
literature shake flask data, (ii) is applicable for all charge classes, (iii) is easily implemented 
on a screening platform as a 96 - well plate based high - throughput assay, (iv) reduces the 
net manpower hours required as compared to the classical shake flask technique by 
accelerating the phase separation process, (v) is more reproducible than RP - HPLC, 
potentiometry and octanol - PAMPA based techniques (SD < 0.1), and (iv) allows the 
assessment of octDlog values in a range matching the expected scope within a typical drug 
development process ( octDlog = - 0.5 - 3.8 [maximal 4.2]). We believe that CAMDIS thus 
bridges the gap between the requirement for high quality AND rapid octDlog assessment. In 
this light, CAMDIS can aid the optimization and prioritizing of potential drug candidates in 
the earliest phase of the drug development process.   
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TABLES 
Table 1   CAMDIS 
'log octD  (pH 4) values for zolpidem obtained with different octanol volumes and 
initial drug concentrations. The values correspond to the CAMDIS 
'log octD  
profile in Fig. 4C, at pH 4. 
The difference between CAMDIS 
'log octD and the shake flask 
'log octD  
is given along (
'log octD ).  
 octV [µL]
a
 
'log octD at pH 4
b
 
'log octD
c
 
12.5 µM 100 µM 12.5 µM 100 µM 
1 0.65±0.02 0.35±0.01 0.46 0.16 
15 0.28±0.04 0.20±0.10 0.09 0.00 
a
aqV = 130 µL,
 b
fraction ionized 99.7 %,  
c 
the shake flask value (
'log octD  = 0.20) obtained at 100 µM 
and 15 µL octanol is used as the reference.  
 
 
 
Table 2   Summary of model parameters and estimates of the number of drug layers, 
layersN , adsorbed at the octanol/buffer interface. 
Compound 
Method 
r2 
octDlog  
eq
fin  (µmol) layersN  
octV  1µL 15µL 1µL 15µL 1µL 15µL 1µL 15µL 
Buspiron CAMDIS 0.971 - 2.27 - 8 E-05 - 2.28 
 Propranolol
a
 CAMDIS 0.972 0.682 1.32 1.32 6 E-05 6 E-05 2.07 2.07 
Propranolol Shake flask 0.727 0.807 1.30 1.33 1 E-05 5 E-05 0.34 1.72 
a 
The octDlog - concentration profile for the 15μL setup was fitted by using the 
eq
fin - estimate from the 1μL 
setup (set as fixed parameter) while only allowing the true octDlog  to vary.  
 
 
 
 
 
 
 
4. Manuscripts 
 61 
 
Table 3   Key molecular properties of the validation dataset including neutral (n = 20), 
basic (n = 20), acidic (n = 11) and zwitter - ionic (n = 1) compounds. 
Parameter Range 
Molecular weight [g/mol] 147 - 734 
Highest basic apK - lowest acidic apK  10.18 - 4.2 
Pc log
a
 0.46 - 5.92 
octDlog  at pH 7.4 (shake flask)
b
 -0.43 - 4.18 
a
Pc log  v4.71 Daylight, 
b
 literature values, for references see Table 4. 
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Table 4   Properties of the 52 compounds used for validation of CAMDIS.  
ID Compound Charge 
class
a
 
octDlog (pH 7.4) ± SD Reference 
CAMDIS Shake flask 
(Literature) 
1 Albendazole N 3.35±0.03 3.29 [38] 
2 Alprenolol · HCl B 1.00±0.15 0.88±0.13 [39-43] 
 
3 Amitriptyline B 2.99±0.03 2.79±0.34 [39, 44, 45] 
4 Antipyrine N 0.28±0.06 0.24±0.01 [46-48] 
5 Buspirone · HCl B 2.28±0.02 2.14 b 
6 Caffeine N -0.01±0.01 -0.04±0.06 [39, 49-52] 
7 Carbamazepine N 1.75±0.01 1.65 [53, 54] 
8 Chloramphenicol N 1.15±0.06 1.12±0.04 [55, 56] 
9 Chlorpromazine · HCl* B 3.35±0.03 3.16±0.11 [39, 45, 57, 58] 
10 Chlorthalidone A 0.93±0.01 0.85 [59]
; c 
11 Cimetidine B 0.26±0.06 0.33 [60, 61] 
12 
 
Clomipramine · HCl* B 3.34±0.02 3.28±0.06 [45, 62] 
13 Clozapine B 3.09±0.02 2.99 [45] 
14 Coumarin N 1.43±0.08 1.42±0.04 [49, 63] 
15 Desipramine · HCl B 1.30±0.13 1.41±0.09 [45, 62, 64] 
16 Dexamethason N 1.97±0.03 1.82±0.11 [6, 65, 66] 
17 Diazepam N 2.93±0.02 2.74±0.10 [39, 67-69] 
18 Diclofenac · Na A 1.20±0.05 1.14±0.05 [70-74] 
19 Disopyramide B -0.55±0.08 -0.43±0.35 [42, 75] 
20 Erythromycin B 0.99±0.17 0.96±0.42 [76, 77] 
21 Fentanyl B 2.98±0.02 2.86 [78] 
22 Fluoxetine · HCl B 2.02±0.01 1.88±0.08 [39, 79] 
23 Flurbiprofen A 0.95±.07 0.91 [70] 
24 Glyburide A 2.23±0.04 2.19 [38] 
25 Griseofulvin N 2.33±0.02 2.18±0.00 [80] 
26 Hydrochlorothiazide A -0.11±0.05 -0.12 [81] 
27 Hydrocortisone N 1.54±0.05 1.57±0.06 [6, 82] 
28 Ibuprofen A 1.04±0.07 
 
1.27±0.34 [39, 70, 71] 
29 Imipramine · HCl B 2.49±0.05 2.51±0.02 [45, 62] 
30 Indomethacin A 1.00±0.10 0.76±0.22 [71, 74] 
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ID Compound Charge 
class
a
 
octDlog (pH 7.4) ± SD Reference 
CAMDIS Shake flask 
(Literature) 
31 Ketoprofen A -0.12±0.01 -0.23±0.04 [71, 83] 
32 Labetalol · HCl Z 1.05±0.11 1.09 [84] 
33 Lidocaine B 1.74±0.05 1.61±0.31 [39, 45, 85] 
34 Meprobamate N 0.88±0.02 0.70 [49] 
35 Mesoridazine B 1.79±0.07 1.81 [45] 
36 Metoclopramide · HCl B 0.44±0.01 0.53±0.10 [42, 86] 
37 Metoprolol · Tartrate B -0.35±0.01 -0.17±0.20 [40, 42, 43, 84, 87, 88] 
38 Metronidazole N -0.05±0.01 -0.07±0.06 [50, 89] 
39 Naproxen A 0.25±0.07 0.32±0.02 [71, 83] 
40 Nimodipine N 4.00±0.04 4.18 [90] 
41 Paracetamol N 0.30±0.05 0.30 [39] 
42 Phenytoin A 2.44±0.01 2.23±0.38 [47, 87] 
43 Prednisolone N 1.63±0.05 1.45±0.04 [6, 49] 
44 Primidone N 0.85±0.03 0.91 [91] 
45 Progesterone N 3.89±0.02 3.76±0.19 [6, 92, 93] 
46 Propranolol · HCl B 1.21±0.08 1.21±0.16 [40-42, 84, 87, 88, 94-98] 
47 Temazepam N 2.22±0.02 1.98±0.11 [39, 99] 
48 Testosterone N 3.38±0.01 3.23±0.16 [39, 92, 100, 101] 
49 Theophylline N -0.01±0.01 -0.02 [50] 
50 Triflupromazine · HCl* B 3.63±0.03 3.39 [58] 
51 Trimethoprim B 0.52±0.01 0.64 [102] 
52 Warfarin A 0.94±0.08 1.12±0.11 [103, 104] 
a
N: neutral (less than 3 % ionization at pH 7.4); A: acid apK  < 8.9; B: base apK > 6; Z: zwitterions with acid 
apK  < 8.9 and base apK  > 6 ( apK calculated with MoKa); 
b
in-house measured shake flask value obtained in 
Tris buffer (pH 7.4), 
c
measured with countercurrent chromatography, *evidence for drug adsorption to the well 
plate 
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FIGURES 
 
Figure 1   Design of the novel DIFI© tubes used as solid support for octanol (A). The lipophilic 
PVDF membrane (m) fixed on the bottom of the polypropylene tubes (t) is suited to be coated with 
commonly 1 µL or 15 µL octanol. Eight DIFI tubes are aligned in one stripe (B) conforming to the 
typical 8x12 well plate format. The coated DIFI tubes are dipped into an in - house made Teflon plate 
(C) prefilled with analyte - spiked aqueous phase as shown in (D). A 96 - well polypropylene plate (p) 
is used as a carrier for the DIFI tubes to enable convenient handling. The sandwich is put on a shaker 
to allow the solute to distribute in the octanol - buffer system. After distribution equilibrium is 
achieved, the two phases are separated by removal of the DIFI plate. 
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Figure 2   Structures, octDlog  (pH  7.4) and apK  values (in - house) of the test compounds used for 
assay development. 
a
literature value [105], 
b
 in - house shake flask value at pH 7.4 (Tris/NaCl), 
c
mean 
of literature shake flask data (see Table 4). 
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Figure 3   Kinetics of rolipram distribution in the octanol - filter - buffer system. Rolipram (100 µM) 
was introduced into 150 µL buffer (50 mM Tris, 114 mM NaCl, pH 7.4) and covered with the 
octanol - precoated DIFI tubes ( octV  = 1 µL () and 15 µL ()). Distribution coefficients were 
obtained after shaking the CAMDIS assembly for up to 38 h. Similar 
'log octD  
values with  both phase 
volume ratios were attained after 16 - 22 h (vertical ). This value is identical with the reference 
shake flask 
'log octD  
(horizontal  ).  
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Figure 4A   Ionization profile of zolpidem for the pH range 3 - 10. The fraction unionized was 
calculated from the pH and the measured apK  (basic apK  = 6.47) according to the 
Henderson - Hasselbalch equation. B-D: Distribution coefficient - pH profiles for zolpidem obtained 
with different methods (see below). The volume of octanol was 1 µL (black symbols) and 15 µL (grey 
symbols), respectively. The volume of the aqueous phase was 130 µL. The initial aqueous drug 
concentration was 12.5 µM (squares) and 100 µM (triangles), respectively. B: CAMDIS octDlog   - pH 
profile (gold standard) relying on the measurement of both phases (15 μL octanol necessary). The 
theoretical octDlog   - pH profile () was estimated from the measured octDlog at pH > 10 via the 
Henderson - Hasselbalch equation. C: CAMDIS 'log octD  - pH profile relying on mass balance (only 
the aqueous phase was measured). D: Shake flask 'log octD  - pH profile relying on mass balance. 
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Figure 5   pH - 
'log octD  
profile of A: phenytoin (acid, apK  = 8.18) and B: rolipram (neutral). 
Conditions and symbols were as in Fig. 4C, however, only 1 µL octanol was used.  
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Figure 6   
'
octDLog  - concentration (pH 7.4) profiles at two volumes of octanol ( octV  = 1 µL () and 
15 µL (), respectively) for the non - charged rolipram (A), the weak base buspirone (61.9 % 
ionized, B), and the strong base propranolol (99.2 % ionized C,D). 
'
octDLog values were measured 
with the new CAMDIS assay (A-C) and with the classical shake flask technique (D). Initial and 
equilibrium drug concentrations in bulk buffer (130 µL, 50 mM Tris, 114 mM NaCl, pH 7.4) were 
directly measured. The total concentration in octanol and the filter was estimated by difference. 
Triangles are experimental data; solid lines are fits to experimental data according to eq. 4. B: 
Concentrations of buspiron remaining in solution when using 15 µL octanol were too low for reliable 
analysis, and therefore only data obtained with octV  = 1 µL is shown. 
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Figure 7   UV response as a function of total concentration for olanzapine (A), chlorpromazine (B) 
and RO - 1 (C) after storing the drug solutions in a Teflon well plate for 18 h. The UV intensity is a 
measure of the free aqueous drug concentration remaining in solution. Drugs were dissolved in 
octanol pre-saturated buffer (50 mM Tris, 114 mM NaCl, pH 7.4). A: Non - adsorbing compound. 
The line is the linear fit to the experimental data (triangles) over the whole concentration range 
(r
2
 = 0.998). B, C: The lines are the fits to the experimental data over the whole concentration range 
(, polynomial fit) or in the range 0 - 20 µM (, linear fit). The discrepancy between both fits at 
100 µM indicates saturable drug adsorption to Teflon (B) or drug precipitation (C).  
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Figure 8   Decision tree for assessing the correct 
'log octD  
value taking into account i) drug adsorption 
to the filter (dark grey boxes, left) and ii) precipitation or drug adsorption to the well plate (light grey 
boxes, right). The most common and simplest case is, however, when no sorption occurs (white 
boxes, middle). *Valid, provided that neither in the 1:5 diluted reference nor in the actual distribution 
experiment precipitation occurs. If, however, discrepancies among 
'log octD  
values with different phase 
volume ratios are obtained, which are not within the scope of the expected filter - related error 
(compare Table 2, maximal 0.16 octDlog units), the assumption is violated and no 
'log octD  value can be 
obtained.  
 
4. Manuscripts 
 72 
 
 
Figure 9A:   Correlation between CAMDIS 
'log octD and literature shake flask 
'log octD  (or octDlog  ) 
values (pH 7.4) for bases (), neutrals (), acids () and zwitter - ionic compounds (). Shake 
flask 
'log octD  = 0.960 * CAMDIS 
'log octD  + 0.025 (correlation statistics: r
2
 = 0.996, SEE = 0.111, 
n = 52). Vertical error bars are the standard deviations of the literature data with respect to the 
different literature reports. Horizontal error bars are not shown and correspond approximately to the 
symbol size. B: Residulas of CAMDIS 
'log octD with respect to the literature values. 
Residuals = literature 
'log octD  - CAMDIS 
'log octD . 
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Figure 10   Applicability range of CAMDIS assuming adsorption of one monolayer at each interface 
(filter/buffer and filter/air) and allowing for an experimental error of 0.1 octDlog  units. The 
experimental error in octDlog  corresponds to the difference between the true octDlog and the estimated  
'log octD . 
'
octDLog  was calculated by entering the 
eq
fin  - estimate for propranolol into eq. 4 along with a 
given initial aqueous drug concentration (100 µM) and the octDlog value of interest. Simulations were 
performed with 1 µL () and 15 µL ()  octanol. The volume of the aqueous phase was set to 
150 µL.  
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Supporting Information 
S1. Estimation of 'log octD under Consideration of Drug Adsorption to the Filter 
Per definition, the octanol/water distribution coefficient is given by:  
 
 eqaqeqoctoct CCD /loglog  ,     (S1) 
 
where eqoctC  and 
eq
aqC denote the equilibrium drug concentrations in octanol and in the aqueous 
phase, respectively [21]. For practical reasons, eqoctC  is commonly determined by difference 
between initial ( 0
aqC ) and equilibrium (
eq
aqC ) aqueous drug concentrations. This approach is 
valid for a two-phase system comprised of octanol and water, however, the PVDF filter used 
in CAMDIS to facilitate the phase separation may constitute an additional compartment. In 
the ideal case, the filter should only act as a support for octanol without affecting the solute’s 
transfer between the phases and without promoting drug adsorption. Since the average pore 
size of a filter (0.45 µm = 4500 Å) is much larger than the typical cross sectional area of a 
drug (approximately70 Å
2
) [31], the filter does not bottleneck the transfer of drug. However, 
a possible drug adsorption to the filter needs to be considered in the mass balance equation 
which is given by  
 
eq
fi
eq
oct
eq
aqaq nnnn 
0 .    (S2) 
 
Here, the initial amount of drug in the aqueous phase, 0
aqn , will be distributed along the 
buffer - filter - octanol system yielding eqaqn  
, eq
fin  and 
eq
octn  moles of drug in each respective 
compartment (equilibrium conditions, Fig. S1). We define the filter - adsorbed drug, eq
fin , as a 
composite of the drug adsorbed to the filter matrix and that enriched at the filter - supported 
interfaces. Likewise, eqoctn comprises the drug in bulk octanol and that in filter - supported 
octanol. Expressed in terms of solute concentrations in the aqueous phase and in the octanol 
phase, eq.S2 corresponds to:  
 
eq
fioct
eq
octaq
eq
aqaqaq nVCVCVC 
0 ,     (S3) 
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where 
aqV and octV denote the volumes of the aqueous and the octanol phase, respectively. By 
rearrangement of equation S3, it can be shown that the difference between the initial and the 
equilibrium aqueous drug concentrations, corrected for the phase volume ratio 
(   octaqeqaqaq VVCC /0  ), corresponds to a composite parameter, i.e. the sum of the solute 
concentration in octanol and that at the filter according to:  
 
  octeqfieqoctoctaqeqaqaq VnCVVCC //0    .    (S4) 
 
Neglecting a compound’s adsorption to the filter and attributing the term 
  octaqeqaqaq VVCC /0  exclusively to the octanol phase thus yields erroneously high apparent 
'log octD values according to: 
 
 











oct
eq
aq
eq
fiaq
eq
aqaq
oct
VC
nVCC
D
0
' loglog .    (S5)  
 
 
 
 
Figure S1   Distribution of a basic compound along the buffer/filter/octanol system. At equilibrium, 
the initial amount of drug is distributed into the aqueous bulk compartment, into the filter which is 
composed of the filter supported interfase and the filter matrix, and into the octanol phase, composed 
of immobilized octanol and bulk octanol. 
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S2. Quantification of Drug Adsorption to the Filter 
Provided the boundary conditions are properly assessed, the apparent octanol/water 
distribution coefficient, 'log octD , can be used to estimate the molar amount of drug adsorbed at 
the filter - supported interface. eq
fin can be derived as follows: At a predefined initial 
concentration, 0
aqC  
, the equilibrium drug concentration in the bulk aqueous phase, eq
aqC  
, may 
be expressed as a function of the true  octDlog according to 
 
 1/10/ log0  aqoctDaqeqaq VVCC .    (S6) 
 
A combination of eq.S5 and eq. S6 yields  
 
  











octaqoct
D
aq
eq
fiaqaqoct
D
aqaq
oct
VVVC
nVVVCC
D
oct
oct
)1/10/(
1/10/
loglog
log0
log00
' .    (S7) 
 
In eq. S7, the composite parameter 'log octD is separated into a term for the distribution into 
octanol and into a term for the adsorption to the filter ( eq
fin  
). The unknown parameters in eq. 
S7, namely the true octanol/water distribution coefficient, octDlog  , and the amount of drug at 
the filter, eq
fin  
, can be obtained from a fit of eq. S7 to experimental 'log octD  - 
0
aqC profiles. 
The inherent assumption is that, within the applied concentration range, the filter - supported 
interface is saturated with solute, and thus eq
fin is constant. 
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S3. Investigated Lipophilicity Range in the 'log octD  - pH Profiles 
When measuring the octDlog ( 
'log octD  ) as a function of pH, the investigated lipophilicity 
range is approximately determined by the intrinsic lipophilicity of the non - ionized drug, 
octPlog , reduced by the fraction ionized according to [106]: 
 
base:  pHpKoctoct aPD  101logloglog     (S8) 
 
acid:  apKpHoctoct PD  101logloglog .    (S9) 
 
Equation S8 and S9 are simplified since the distribution of ionized species and ion pairs into 
octanol is ignored [16].  
 
 
 
S4. The Number of Drug Layers Sticking to the Filter 
From the estimate of the filter - bound drug amount, eq
fin  
, the total number of molecules at 
the filter, totalN  , can be calculated. This number can then be related to the number of 
molecules, monoayerN  
, required for saturating the filter surface with one monolayer. From the 
ratio of both, the number of drug layers at the filter, layerN  , can be gained according to 
 
Dfi
A
eq
fi
monolayer
total
layer
AA
Nn
N
N
N
/

              (S10) 
 
where AN is the Avogadro constant, fiA is the area of common interface between buffer and 
the filter (based on a filter diameter of 3.26 mm), and DA is the cross - sectional area of the 
drug in its most amphiphilic conformation[107], respectively. Eq. S10 assumes that the solute 
forms a condensed film on the filter. Cross sectional areas were calculated according to [107] 
yielding 39.5 Å
2
 and 47.8 Å
2
 for propranolol and buspiron, respectively. 
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ABSTRACT 
The octanol/water distribution coefficient, octDlog  , is a key physicochemical parameter for 
the prediction of a drug’s ADMET (Absorption, Distribution, Metabolism, Elimination, 
Toxicity) properties. In response to the industrial demand for fast and low - cost 
methodologies, shake flask octDlog   values are commonly measured with miniaturized 
high - throughput assays, implemented on (semi)automated screening platforms. The 
optimization in terms of throughput may, however, lead to experimental artifacts arising from 
increased non-specific binding to the assay construct and undetected compound 
precipitation/aggregation. At the example of 24 structurally different drugs, we i) 
characterized the processes leading to drug loss from aqueous solution to a miniaturized 
Teflon well plate, and we ii) investigated which experimental conditions warrant (and vice 
versa prevent) the accurate determination of octDlog , in case that non-specific binding to the 
well plate or precipitation occurs. Our data show that, even though large and lipophilic 
compounds tend to extensively adsorb to Teflon, accurate octDlog values are obtained, 
provided that only one drug layer adsorbs to the Teflon surface. Then, the distribution 
equilibrium is shifted towards drug dissolved in the octanol phase and drug adsorption to the 
well plate can be neglected. In contrast, drug precipitation in the well plate or the formation 
of stacked multilayers (typical for compounds with coplanar ring systems) lead to an 
underestimation of octDlog  , which is the more pronounced the lower the lipophilicity of a 
compound. Experimental artifacts can be counteracted by increasing the drug concentration 
(limited by solubility) and/or the volume of octanol, or by recovering adsorbed drug with 
2 - propanol. This work may contribute to avoid misinterpretations of measured octDlog values 
in order to guide the ADMETox optimization of drug candidates in a reasonable way.   
 
 
 
KEYWORDS 
Non-specific binding, Drug adsorption to Teflon, Drug recovery, Octanol/water distribution 
coefficient, Artifacts 
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1. Introduction 
Early ADMET profiling is of major importance in rational drug development in order to 
predict a drug candidate’s likely development success and to avoid high attrition rates in the 
later, most expensive clinical phases [1]. The octanol/water distribution coefficient, octDlog , is 
at the core of many ADMET properties [2] and related to such elementary parameters like 
permeability, solubility, biodistribution and metabolism.  
Determining octDlog  values with the traditional shake flask method is still considered the 
gold standard approach, and miniaturized versions thereof have found entry in many 
screening laboratories. Miniaturization, high-throughput (HT) technology and automation 
have generally become the industrial strategies to accelerate the nomination of drug 
candidates and to meet the industrial demand for speed, efficiency, and low costs [2]. 
Recently, however, it has been recognized that physicochemical artifacts like aggregation or 
non-specific binding to microtiter plates may falsify the measures of interest in HT screens, 
as shown for membrane permeability [2]  and target affinity [3].  
Various plastic materials are being used for the construction of microtiter plates including 
polystyrol, polypropylene and Teflon. Previous studies of non-specific binding to 
polypropylene and polystyrol demonstrated that particularly lipophilic non-ionic as well as 
lipophilic cationic compounds (polystyrol) show a high tendency for adsorption, indicating 
that hydrophobic and electrostatic interactions are involved in drug-plastic interactions [4]. 
On the contrary, Teflon is often considered as inert to adsorption [5] and therefore widely 
used as an alternative microtiter plate material. It is interesting to note that the sorptive loss of 
p-hydroxybenzoate [6], detergents [7, 8], organic environmental pollutants [9], inorganic 
acids/bases [10] and organic solvents [11] to Teflon has demonstrated that the common a 
priori assumption of negligible drug loss is invalid. However, previous studies of non-specific 
binding to Teflon have focused on single and/or non-drug-like compounds, whilst a 
comprehensive study on a large and structurally diverse dataset of drugs is lacking. 
Generalizations as to the rate and extent of drug loss to Teflon are thus not possible, and it is 
not clear which drug properties make a compound a prime candidate for sorptive loss. 
Moreover, the influence of drug loss on the measurement accuracy in miniaturized ADMET 
assays has barely been quantified so far, neither due to non-specific binding to plastics nor du 
to aggregation or degradation. This is all the more surprising in view of the extensive use of 
plastic material (microtiter plates, filter membranes, pipetting devices) in ADMET screens 
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and the high awareness of drug-plastic interactions in other research areas like clinical 
pharmacy [12] and environmental toxicology [13]. The attention drawn to poor recovery in 
Caco-2 assays and equilibrium dialysis, caused by non-specific binding to microtiter plates, is 
rather the exception than the rule [14, 15].  
The aim of this study was to provide a quantitative basis for the estimation of artifacts related 
to drug loss in miniaturized HT octDlog  assays. Specifically, we aimed to assess the 
experimental boundary conditions at which drug precipitation and non-specific binding to 
microtiter plates does not significantly compromise the accuracy of octDlog . To this purpose, 
we developed a mathematical model for the error estimation of octDlog which takes into 
account both a compound’s distribution between octanol and water, and its adsorption onto a 
microtiter plate. The latter process was investigated independently on a structurally diverse 
24 compound dataset which also allowed us to explore the physicochemical and structural 
properties making compounds prone to adsorption. Teflon was chosen as the well plate 
material of interest because it is widely used and preliminary studies in our lab were not in 
line with the often supposed inertness to adsorption. Results from the sorption studies were 
used to parameterize the proposed model, which was finally validated by comparison of 
octanol/water distribution coefficients measured with a miniaturized and a large scale shake 
flask experiment. A method for correcting erroneous octDlog  values is moreover proposed 
which may be applied to compounds for which low recovery would manifest as an 
underestimation in octDlog .  
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2. Theory 
2.1. Three-Compartment-Model for Drug Adsorption to Teflon and Drug Distribution 
between Octanol and Water 
When a volume of aqueous solution, aqV , containing totaln  drug is in contact with a 
miniaturized well plate, certain compounds will tend to stick to the assay plate yielding 0pn  
drug binding to the well plate and 0aqn  drug remaining free in solution:  
 
initial conditions (reference):     0pn ⇋
0
aqn ;               
00
paqtotal nnn      (1a) 
 
If an aliquot of octanol, octV , is added to the system, the drug will distribute once more until 
equilibrium between plastic-bound drug, eqpn , free drug in the aqueous phase, 
eq
aqn ,  and drug 
in the octanol phase, eqoctn , is attained. Due to the solubilizing properties of octanol, it is 
reasonable to assume that only drug from the aqueous solution, but not from the octanol 
phase, is lost to the well plate. The distribution system can then be summarized by a three-
compartmental model, as follows:  
 
distribution experiment:     eqpn ⇋
eq
aqn ⇋
eq
octn ;                
eq
p
eq
oct
eq
aqtotal nnnn  ,   (1b) 
 
A combination of eq. 1a and 1b yields the overall mass balance equation which is given by: 
 
eq
poct
eq
octaq
eq
aqpaqaqtotal nVCVCnVCn 
00 ,    (1c) 
 
where
0
aqC  and 
eq
aqC denote the free initial and the free equilibrium aqueous drug 
concentration, respectively, and eqoctC  denotes the equilibrium concentration of drug in octanol. 
The octanol/water distribution coefficient is defined by the ratio of eqoctC  and 
eq
aqC , or 
expressed in logarithmic form as:  
 
 eqaqeqoctoct CCD /loglog  .    (2) 
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When determining octDlog , and particularly if adsorption is suspected, it is clearly preferable 
to assay both phases, octanol and water, for the distributed solute [16]. However, in 
miniaturized well plates, very low volumes of octanol are required for measuring compounds 
with intermediate to high lipophilicity, which hampers the retrieval and direct analysis of the 
octanol phase. In such a situation, the drug distributed into octanol may be obtained by 
difference between initial and equilibrium aqueous drug concentrations, but then a potential 
adsorption to the well plate needs to be considered in the mass balance equation, such that 
(rearrangement of eq. 1c): 
 
 











oct
eq
aq
paq
eq
aqaq
oct
VC
nVCC
D
0
loglog .     (3a)  
 
The term eqppp nnn 
0  accounts for the fact that the amount of drug bound to the microtiter 
plate may differ between the reference (eq.1a) and the distribution experiment (eq.1b). While 
0
aqC  and
eq
aqC can be measured, pn is not accessible unless recovery experiments are 
performed.  
2.2. The Assessment of octDlog with a Simplified Mass Balance Equation 
In large - scale experiments, adsorption to the laboratory equipment may be neglected 
( 00  eqpp nn ) and eq. 3a simplifies to  
 
 











oct
eq
aq
aq
eq
aqaq
octoct
VC
VCC
DD
0
' logloglog ,    (3b) 
 
which is the most frequently used equation for the assessment of mass-balanced derived 
octanol/water distribution coefficients , indicated as 'log octD  (all parameters are known or can 
easily be measured). 
In contrast, plastic surface to phase volume ratios are elevated in miniaturized assays and a 
significant quantity of drug might be lost to the Teflon plate ( 00 pn , 0
eq
pn ). If the amount of 
drug sticking to the well plate is different in the reference and in the distribution experiment 
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( 0p
eq
p nn  , 0 pn ), then drug loss may lead to erroneous 
'log octD values. Yet, if pn becomes 
insignificant in relation to the amount of drug in octanol (   aqeqaqaqp VCCn  0 ), octDlog  is 
still approximated by eq.3b.  
During the course of this study, we i) characterized the process of drug loss to Teflon in order 
to ii) assess the experimental conditions which warrant (and vice versa prevent) the accurate 
determination of octDlog with eq. 3b, in case that non-specific binding to Teflon or drug 
precipitation occur.  
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3. Materials and Methods 
3.1. Drugs and Chemicals  
All drugs, buffers and solvents were either obtained from commercial sources (Sigma, Acros 
Organics, Bepharm Ltd., Chem Pacific, HRITIK Chemicals Cooperation, Molekula) or were 
available through our in-house Compound Depository Group as proprietary compounds. All 
chromatographic solvents were of HPLC grade.  
3.2. Selection of the Dataset 
A dataset was compiled containing drugs for which sorption to any kind of plastic material 
has been reported before, i.e. paclitaxel, doxorubicin, saquinavir, vinblastine, 
chlorpromazine, midazolam and diazepam [4, 17, 18]. Moreover, compounds were included 
which have not been studied yet in terms of drug-plastic interactions (colchicine, 
amprenavir), but for which we suspected that adsorption-related artifacts could potentially 
explain their behavior as outliers in a novel in vitro Lipid Membrane Binding Assay 
(LIMBA, accompanying manuscript 6). In order to increase the investigated physicochemical 
property space, additional compounds were selected which differed in at least one key 
property ( octDlog , Pc log , ionization state, molecular weight). Further selection criteria were 
(i) baseline separation from the internal standard caffeine in HPLC, (ii) a sensitive UV 
chromophore and (iii) compound stability during assay time (at least 16 h).  
3.3. Measurement of Drug Loss to a Teflon Microtiter Plate 
3.3.1. Time Dependence 
Assay buffer (227 µL, 50 mM Tris/114 mM NaCl/ pH 7.4) was first spiked with DMSO 
stock solutions (1.5 µL) of the test compounds and the internal standard caffeine (each 
10 mM) and was then filtered into an in-house made Teflon block. The filtrate thus contained 
50 µM caffeine, 50 µM of the test compound (= maximal nominal concentration, for exact 
concentrations see Table 1) and 1 %, v/v DMSO. Caffeine was inert to adsorption (data not 
shown) and was added to correct for potential changes in drug concentration due to 
evaporation. An aliquot of the filtrate (100 µL) was transferred into a 96 well Teflon plate 
and was immediately injected and analyzed on a HPLC-UV system. The well was sealed and 
all other sample solutions were consecutively transferred, injected and analyzed again after 
t = 1½ h, 3 h, 6 h, 16 h, 72 h and 2 weeks. All measurements were performed at room 
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temperature (RT). Drug loss in percent was estimated from the decrease of the test 
compound’s UV response according to: 
 
 









t
IS
t
D
ISD
AA
AA
lossDrug
00
100100% ,     (4) 
  
where 0DA , 
0
ISA , 
t
DA  and 
t
ISA  denote the peak areas of drug and the internal standard at t = 0 h 
and at a given time t . In order to exclude degradation as the source of drug loss, UV 
chromatograms were investigated with regard to additional peaks, along with ESI-MS spectra 
recorded after t = 72 h.   
3.3.2. Concentration Dependence 
Experiments were performed as described for the time dependent measurements; however, 
sample solutions covered a wide concentration range (0.5 - 500 μM) of diverse test 
compounds, i.e. doxorubicin, chlorpromazine, ritonavir, diazepam and indomethacin. The 
filtration step was omitted and drug loss in terms of percent was determined after t = 16 h as 
described above.  
The degree of binding was expressed as the molar amount of drug bound to Teflon, 
t
Teflonb nX  , per surface area of a Teflon well ( A =70*10-6 m
2
). The sorption isotherms 
( bX vs.
eq
aqC ) were fitted according to the Brunauer - Emmet - Teller (B.E.T.) - type of 
adsorption described by:  
 
   











sat
eq
aqeq
aqsat
eq
aqmonoeq
aq
C
C
kCC
Cnk
n
11
,     (5) 
where eqaqC is the free aqueous drug concentration after t = 16 h, 
eq
aqn is the amount of drug 
adsorbed at a given free aqueous drug concentration, k  is the sorption coefficient, monon  is the 
amount of drug required to form a single layer and satC  is the saturation concentration of the 
adsorbate. Note that even though equilibrium was not reached, the term eqaqC was used to be in 
line with the nomenclature used for the assessment of octDlog (
'log octD ).  
Alternatively, the Langmuir-type of adsorption was used to fit the data according to:  
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eq
aq
eq
aqeq
aq
Ck
Cnk
n



1
max ,     (6) 
 
where maxn is the amount of drug required to saturate the surface (monolayer adsorption). 
From the maxn -estimate, the total number of molecules adsorbed to Teflon, totalN  , was 
calculated. This number can then be related to the number of molecules, monolayerN  , required 
for saturating the Teflon surface with one monolayer. From the ratio of both, the number of 
layers on the Teflon surface, layerN  , can be gained according to 
 
DTeflon
A
monolayer
total
layer
AA
Nn
N
N
N
/
max   ,    (7) 
 
where AN  is the Avogadro constant, TeflonA is the area of common interface between buffer 
and a well of the Teflon microtiter plate ( TeflonA =70 mm
2
), and DA is the cross - sectional area 
of the drug in its most amphiphilic conformation [19]. Eq. 7 presumes that the solute forms a 
condensed film on the Teflon surface. Cross sectional areas were calculated according to 
[19], yielding 71.4 Å
2
  for doxorubicin, 55.3 Å
2 
for fluvoxamine, 120.6 Å
2 
for ritonavir, 
144.7 Å
2 
for saquinavir, 155.25 Å
2
 for paclitaxel and 47.8 Å
2
 for chlorpromazine.  
3.3.3. Calibration  
A calibration curve in HPLC/UV for the compounds investigated was obtained as follows: A 
defined amount of drug was dissolved in DMSO to obtain a stock solution (10 mM). Five 
consecutive dilutions in DMSO (1+1) were prepared and an aliquot of each secondary stock 
solution (3 µL) was further diluted with DMSO (297 µL). The dilutions were injected onto 
the HPLC-UV system. A plot of the UV response vs. the concentration yielded a straight line. 
Concentrations of drug compounds dissolved in aqueous buffer could be directly calculated 
from the correlation line obtained in DMSO since DMSO did not co-elute with the test 
compounds and therefore showed no influence on the UV spectra.  
3.4. HPLC Instrumentation and Chromatographic Conditions  
Drug concentrations in aqueous solutions were quantified using an Agilent 1290 Infinity 
HPLC-UV system. An aliquot (5 µL) of each sample was injected onto a Kinetex 2.6 µm, 
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2.1 x 50 mm analytical column. The flow rate was 2 mL/min and the integrated column 
heater was set to 60 °C. The mobile phase consisted of A (water) and B (acetonitrile), each 
containing formic acid (0.1 %, v/v). The gradient elution was performed as follows: initially 
2 % B, 0 - 0.35 min linear gradient from 2 % B to 95 % B, 0.35 min - 0.5 min 95 % B, post 
time: 0.3 min. The gradient program for doxorubicin, vinblastine, buspirone and colchicine 
was slightly different: initially 2 % B, 0 - 0.5 min linear gradient from 2 % B to 95 % B, 
0.5 min - 0.65 min 95 % B. Peak areas were recorded at an appropriate wavelength.  
3.5. Calculation of Molecular Descriptors and Development of a Prediction Model for 
Drug Adsorption to Teflon 
Partition coefficients were calculated using Pc log  v4.71 (Daylight Chemical Information 
Systems, Irvine, CA).  Calculations of three-dimensional descriptors were based on single 
conformations in vacuo generated with Corina v3.46 (Molecular Networks GmbH, Erlangen, 
Germany). Surface, volume, size and shape (d0, d1, d2) descriptors as well as the number of 
hydrogen bond donors were calculated with an in-house developed modeling package Moloc 
(Gerber Molecular Design, Amden, Switzerland). The number of hydrogen-bond acceptors 
was retrieved from the Pubchem database. Ionized fractions at pH 7.4 were calculated from 
measured apK values (in-house, potentiometrically) for each dissociable group, and the net 
charge for the whole molecule was derived. A summary of all calculated descriptors (n = 20) 
is provided in the Supporting Information.  
Data derived from the studies of drug loss to Teflon was pre-processed by applying the 
following steps: The percentage of drug loss, observed after 16 h from 5 µM drug solutions, 
was log transformed. Drugs which showed no adsorption to Teflon were arbitrarily set to 
lossDruglog  = -1, so that they could still be used for model generation. Partial least square 
(PLS) regression using centered and scaled descriptors was performed with Simca-P+ v12.0.1 
(Umetrics, Umea, Sweden). Due to the limited number of observations, a PLS analysis was 
performed on the complete dataset without assignment of an external test set. Cross-
validation was performed internally by the leave-1/7
th
-out approach. The number of principal 
components was determined considering the explained variation r
2
 (goodness of fit) and the 
predicted variation q
2
 obtained from prediction of the omitted group (goodness of prediction 
[20]). During model refinement, less important variables were permanently eliminated as 
judged by q
2
 and by the variable influence on projection. Redundant variables, identified as 
groups in the loading plot of the first two principal components, were left out if their 
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influence on q
2
 was evaluated as negligible or reluctant. In order to provide an estimation of 
the statistical significance of q
2
, 200 parallel models on randomly re-ordered lossDruglog data 
were developed. A comparison of q
2
 based on permuted and on real data was used to 
preclude a chance or overfitted model. Finally, the regression coefficients of the derived 
model were unscaled so that the contribution of each variable could enter an ordinary 
regression equation.  
3.6. Measurement of Octanol/Water Distribution Coefficients (Miniaturized Format)  
Octanol-water distribution coefficients were measured with a novel filter-based 96 well plate 
technique (CAMDIS) as described in our accompanying manuscript 1 [21]. Briefly, a 
hydrophobic PVDF membrane (pore size 0.45 µm) fixed on the bottom of the in-house 
developed DIFI tubes (EP 1232792) was impregnated with buffer-saturated octanol 
( octV = 0.9 µL). The tubes were dipped into a Teflon plate prefilled with filtrated drug 
solutions ( aqV = 140 µL, 
0
aqC = max. 22.2 µM drug, 50mM Tris/114 mM NaCl/pH 7.4, DMSO 
content 0.22 %, v/v). The assay kit was sealed and allowed to shake at room temperature for 
24 h. After removal of the tubes, buffer (46.7 µL) was added to the Teflon plate. The free 
equilibrium drug concentration in the buffer-diluted aqueous phase,
eq
aqC , was determined by 
HPLC-UV. The drug concentration in the octanol phase relied on mass balance and was 
obtained in two ways:  
i) A reference experiment was performed under the same conditions as described above but 
without octanol. The aqueous concentration of free drug in the reference well,
0
aqC , was 
measured and the drug concentration in octanol was estimated by difference  between 
0
aqC and 
eq
aqC . Eq.3b was used to calculate 
'log octD (uncorrected mass balance derived 
'log octD ) 
ii) An independent experiment was performed but instead of diluting the aqueous phase with 
assay buffer, 2 - propanol (46.7 µL) was used to discharge drug from the Teflon surface of 
the well plate after removal of the DIFI tubes (2 - propanol  was added in both the reference 
experiment and the distribution experiment).  
The drug concentration in octanol was estimated by difference between the total 
concentration of drug in the reference experiment, 0 ,totalaqC , and the total equilibrium aqueous 
drug concentration, eq totalaqC , , in the distribution experiment. Eq.9 was used to calculate 
'log octD  
(corrected, mass balanced derived 'log octD ). 
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The recovery of drug adsorbed to the microtiter plate by means of 2-propanol enabled the 
estimation of the percentage of drug adsorbed to Teflon, both in the reference and in the 
distribution experiment. Experiments were performed in triplicate and mean values were 
reported. 
3.7. Measurement of Octanol/Water Distribution Coefficients (Large Format) 
Stock solutions of the test compound (10 mM, except saquinavir/ritonavir:5 mM and 
paclitaxel: 2.5 mM) were prepared in DMSO and diluted with buffer (Tris/114 mM 
NaCl/pH7.4, saturated with octanol) to yield the final sample solutions (10 µM, except for 
saquinavir/ritonavir: 5 μM and paclitaxel: 2.5 µM,3). The aqueous drug solution was 
transferred into a 1L shake flask ( aqV = 1 L, except for doxorubicin: 500 mL) and octanol pre-
saturated with buffer was added ( aqV = 1 mL, except for doxorubicin: 500 mL). After 100 
phase inversions, the shake flasks were left undisturbed for at least 24 h, until the two phases 
were free from emulsions (visual inspection). Both phases were sampled with a 1 mL glass 
pipette, then they were transferred into a glass HPLC vial (aqueous phase) and into a 96 well 
PCR plate (octanol phase), respectively, and analyzed with HPLC-UV. Gold standard octDlog  
values and mass balanced derived 'log octD values were estimated by using eq. 2 and eq. 3b, 
respectively. Distribution experiments were performed in duplicate and mean values are 
reported.  
                                                          
3
 Compounds for which precipitation was suspected were measured at two concentrations (paclitaxel:5 µM and 2.5µM; 
saquinavir: 10 µM and 5 µM) and the difference of the logDoct values was within a standard deviation of 0.1 logDoct units  
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4. Results and Discussion 
4.1. Characterization of Drug Loss to Teflon  
4.1.1. Rate and Extent of Drug Loss  
The rate and extent of drug loss from aqueous bulk solution to a 96 well Teflon plate was 
measured at the example of 24 structurally diverse compounds including acids (3), bases (8), 
neutral (10) and zwitter - ionic (3) drugs  covering a wide physicochemical property space 
( octDlog  = -1.15 - 3.68, Pc log  = 0 - 5.3, Molecular weight, MW  = 194 - 854 g/mol). The 
preparation of aqueous test solutions followed a common practice in HT screening assays and 
involved i) dilution of DMSO stock solutions of test compounds (10 mM) with buffer, 
proceeded by ii) filtration and iii)  transfer of the filtrate to the microtiter plate of interest. 
Even though drug concentrations in the filtrate ( totalfiltrate CC  , Table 1) thus varied according 
to the compound’s solubility limit, we applied this protocol for the sake of higher informative 
content with respect to potential artifacts in HT assays. In addition, studies of drug loss to 
Teflon were conducted at a standardized drug concentration, totalC = 5 μM, which was > 50% 
below the lowest drug concentration measured in any of the filtrates. A summary of the 
extent of drug loss from both the filtrate and the 5 μM test solutions after t =16 h storage in a 
Teflon plate is provided in Table 1, along with key physicochemical properties of the 
compounds investigated. 
 
Table 1 
 
Fig. 1 gives a more detailed picture of drug loss from the filtrate over a period of two weeks. 
While drug loss of neutral (Fig. 1A) and basic (Fig. 1B) compounds ranged between 0 and 
99% after 2 weeks, drug loss of acidic (Fig. 1C) and zwitter-ionic (Fig. 1D) compounds was 
generally low and never exceeded 10%. More precisely, digoxin and rolipram (neutral), 
buspiron, sumatriptan and alfentanil (basic) as well as cetirizine and tigabine (zwitterionic) 
showed < 2% drug loss, irrespective of the charge class of the compounds. Moreover, drug 
loss of colchicine (neutral), diclofenac (acidic), dexamethasone, diazepam (both neutral) and 
ketorolac (acidic) was only evident after 2 weeks (compounds are given in order of 
decreasing drug loss with a maximum value of 10%). Compound degradation is a likely 
explanation for the delayed drug loss which cannot be excluded despite the absence of 
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additional peaks in HPLC-UV/MS. Drug loss of the remaining compounds was fastest within 
the first 1 ½ h and was highest for paclitaxel, followed by doxorubicin > chlorpromazine > 
saquinavir > ritonavir > raclopride > fluvoxamin > indomethacin > vinblastine > midazolam. 
Compound degradation was observed for chlorpromazine and indomethacin after t =72 h and 
t =2 weeks, respectively, and therefore the ranking of the compounds refers to drug loss after 
t =16 h.  
Fig. 1 
 
When comparing the time dependent drug loss profiles from filtrated and 5 μM test solutions, 
two characteristic profiles can be distinguished with an example of each given in Fig. 2A and 
Fig. 2B.  
 
Fig. 2 
 
Pertaining to the filtrate, drug loss was biphasic with a rapid initial phase which then either 
continued with reduced, yet pronounced extent (Fig. 2B, paclitaxel, and also doxorubicin) or 
approximated a plateauing minimum (Fig. 2A, ritonavir and all other drugs). Equilibrium was 
only approximated but not reached within the investigated time frame.  
Biexponential drug loss profiles as observed in Fig. 2 may result from various processes, 
including i) simple diffusion into the plastic matrix [22] and ii) a combination of fast drug 
adsorption to the plastic surface followed by either slower dissolution [23] or diffusion into 
the Teflon matrix [24]. Moreover iii) multilayer adsorption or iv) adsorption followed by 
kinetically hindered precipitation/aggregation are reasonable. Diffusion as the sole 
mechanisms could be excluded since experiments conducted at lower drug concentrations 
( totalC = 5μM) yielded a higher percentage drug loss for e.g. ritonavir as compared to the 
filtrate ( totalC = 13.2 μM), indicating saturation of available binding sites on the Teflon surface 
(Fig. 2A). A similar behavior was also observed for saquinavir, vinblastine and doxorubicin. 
In contrast, drug loss of paclitaxel was higher from the filtrate ( totalC = 13.2 μM) than from 
the 5 µM test solution (exact totalC = 3.1 µM) after t =16 h, pointing to supersaturation and 
delayed precipitation in the filtrate (same trend for raclopride and indomethacin, Table 1). 
Precipitation of paclitaxel in the filtered, but not the 5 µM test solution, was confirmed by an 
increase in UV absorbance (650 nm) over time (data not shown). The poor solubility of 
paclitaxel is well known, however, large variability in reported solubility data (solubility: 
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0.5 µM - 35 µM [25-27]) hampers a direct comparison with our results. Moreover, the slight 
recovery of paclitaxel after initially rapid drug loss at totalC = 5μM requires further 
investigation, in particular measurements at longer time points (the experiment was 
terminated after 3 d).  
4.1.2. Concentration Dependency of Drug Loss  
To further explore the nature of the processes underlying drug loss to Teflon, drug loss was 
studied over a wider concentration range (0.5-500 μM) using the example of diazepam and 
indomethacin (negatively charged) as well as chlorpromazine, doxorubicin (cationic) and 
ritonavir (non-ionic). Drug loss was recorded after t =16 h to avoid drug degradation and to 
take into account that a many ADMET assays involve overnight incubation, e.g. assays for 
the assessment of octDlog  (CAMDIS, accompanying manuscript 1), solubility (in-house 
assay, unpublished) and permeability (PAMPA) [28]. 
Diazepam and indomethacin barely adsorbed over the whole investigated concentration range 
(0.5 - 250 µM, Fig. 3A) whereas decreasing concentrations of the other compounds were 
associated with an exponential rise in percentage drug loss (Fig. 3A, logarithmic 
concentration axis).  
 
Fig. 3 
 
The respective sorption isotherms for chlorpromazine and doxorubicin are shown in 
Fig. 4B - D, and estimates for k , maxn and satC  from fits of the B.E.T (Fig. 3B) and the 
Langmuir-type  model (Fig.3C,D) to the experimental data are given in Table 2.
4
 
 
Table 2 
 
Regarding chlorpromazine, the sorption isotherm up to totalC = 500 µM (Fig. 3B) indicated 
multilayer adsorption or diffusion (B.E.T. model), whereas the Langmuir-type model for 
monolayer adsorption was only appropriate up to totalC  =25 µM (Fig. 3C). The surface 
coverage at totalC  =25 µM, estimated as layerN ~1, was in agreement with the Langmuir model. 
With respect to doxorubicin, precipitation hindered recording the adsorption profile at 
                                                          
4
 Adsorption isotherm for ritonavir not shown due to insufficient sensitivity in UV at the drug concentrations used.  
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totalC  > 500 µM (Fig. 3C). A fit of the Langmuir model to the data (up to totalC  =100µM) 
indicated multilayer adsorption or diffusion into the Teflon matrix ( layerN ~3).  
It is important to note that a differentiation between adsorption of multiple drug layers to the 
Teflon surface and diffusion into the Teflon block is not possible with the experimental setup 
used. Other authors assumed (but could not show evidence) that some extent of drug loss 
might occur due to incorporation of compound (p-hydroxybezoate) into the Teflon matrix 
while a significant amount of solute should remain on the surface [23]. In this respect it is 
worth noting that, apart from paclitaxel, chlorpromazine and doxorubicin, the maximum 
observed drug loss in this study corresponded to not more than approximately one drug layer 
covering the Teflon surface which points to the dominance of an adsorption process.   
This is in contrast to the main processes involved in drug loss to polyvinylchloride (PVC) 
which is prevailed by drug diffusion and dissolution into the PVC matrix [23, 28]. In contrast 
to Teflon, PVC contains plasticizers [29] which are the main offenders of drug - plastic 
interactions [28]. Plasticizers prevent the formation of a rigid network by weakening the 
polymer-polymer interactions thereby increasing the free volume for diffusion [30]. Although 
hard plastics, in general, and Teflon, in particular are therefore clearly advantageous 
compared to soft plastics [12], the reduced significance of diffusion should not mislead over 
the fact that drug loss by adsorption could become relevant in miniaturized formats. As our 
study shows, the widespread opinion that Teflon is inert to adsorption [5] is not true. 
4.1.3. Prediction of Drug Adsorption to Teflon  
In order to investigate the relationship between the physicochemical properties of a 
compound and its likelihood to show adsorption to Teflon, only drug loss data obtained 
at totalC = 5 µM and after t =16 h was considered. Data from experiments with filtrated drug 
solutions was not used for the development of a prediction model since non-uniform drug 
concentrations would complicate the distinction between concentration dependent and 
structure related effects.  
An attempt to relate measured or calculated molecular descriptors to log transformed 
adsorption data (expressed as lossDruglog ) in a two-dimensional manner resulted in rather 
weak correlation statistics, e.g. r
2 
= 0.61 ( MW ), r
2 
= 0.43 ( octDlog (pH 7.4), r
2 
= 0.26 ( Pc log ), 
r
2 
= 0.43 ( PSA ). The poor correlation between lossDruglog and Pc log can be attributed to i) the 
relevance of drug ionization for the adsorption process, which is not captured by Pc log , and 
ii) the high uncertainty in the Pc log estimate for doxorubicin ( Pc log (Daylight) = 0.33, 
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Pc log (XLogP, Pubchem database) = 1.3). Omitting doxorubicin from the dataset improved 
the correlation with Pc log (r
2 
= 0.43), and excluding all other charged drugs further improved 
the statistics (r
2 
= 0.61). It is worth noting that also the correlation of lossDruglog with 
octDlog (pH 7.4) was much weaker than that observed in literature studies which were based 
on smaller datasets or structurally related, nondrug-like compounds [9, 29, 30]. Apart from 
the limited physicochemical property space studied, previous prediction approaches relied on 
data describing diffusion into PVC rather than adsorption onto a Teflon surface [31]; the 
related driving forces are considerably different. While small, lipophilic compounds such as 
diazepam are in favor for diffusion [17], the adsorption of diazepam to Teflon was 
insignificant. Only midazolam, a compound with the same chemical scaffold but a higher 
octDlog was somewhat adsorbed (1.8%, see Table 1) pointing to the contribution of 
hydrophobic binding forces. 
Since the prediction accuracy based on univariate analysis was relatively poor, we 
investigated whether a PLS model based on 20 shape, lipophilicity, size and charge 
descriptors yields superior model performance. The 20-dimensional space was reduced to one 
principal component (r
2
 = 0.755, RMSEE = 0.53, q
2
 = 0.749) constructed by the following 
descriptors given in order of decreasing importance: MW > number of hydrogen-bond donors 
( HBD ) > measured octDlog (pH 7.4), such that: 
 
Predicted lossDruglog = -1.87 + 0.0023 · MW  + 0.18 · HBD  +0.25 · octDlog .   (8) 
 
Despite the fact that also the PLS model did not account for the full variability of the data, 
superior model performance as compared to univariate prediction approaches was achieved. 
Moreover, the PLS model was useful for illustrating the likelihood of drug adsorption to 
Teflon in a property-based classification map. The correlation between octDlog (pH 7.4) and 
molecular weight in Fig. 4 shows three regions which differ with respect to the extent of drug 
adsorption to Teflon (the darker the symbol the higher lossDruglog ). The number of HBD  is 
reflected by the size of the symbols.  
 
Fig. 4 
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Region I contains large, hydrophobic drugs which readily adsorb to Teflon (ritonavir (9), 
saquinavir (19), paclitaxel (8) and vinblastine (21)). Extensive drug loss of paclitaxel from 
other plastic materials (polystyrol, polyprolylene) and from glass containers has been 
recognized before [4, 32]. Moreover, pronounced non-specific binding reported for 
structurally related compounds (nelfniavir, saquinavir, vinblastine) to ultrafiltration and 
dialysis membranes is in line with our results [33, 34].  
Projections of small compounds ( MW < 450) with low to intermediate lipophilicity 
( octDlog <3) are embedded in region III where the probability for drug-Teflon interactions is 
very low. The only exception in Region III is fluvoxamine (18) which notably is the only 
fluorinated compound in region III. Increased drug adsorption of fluorinated compounds like 
midazolam and fluvoxamine would be in agreement with enhanced Teflon-interactions 
reported for fluorocarbons (e.g. fluorinated PEG - tags, [35]) and contrariwise the weak 
interaction of Teflon with hydrocarbons. A possible explanation on the molecular level could 
be a hydrophobic mismatch found between a CH2 and a CF2 group [36]. 
The central region II contains either large, but relatively hydrophilic compounds (e.g. digoxin 
(6), doxorubicin (17)), or vice versa small compounds with high lipophilicity (e.g. 
chlorpromazine (16), midazolam (7)).  The number of HBD and the shape of the compound 
seem to determine whether compounds in Region II show extensive or only moderate 
adsorption to Teflon. For example, at similar molecular weights, doxorubicin (17) is more 
hydrophilic than amprenavir (1). The nonetheless higher drug loss of doxorubicin may be 
explained by the better ability to build hydrogen bonds (7 vs. 4 HBD ) with negatively 
polarized fluorides from Teflon acting as H-bond acceptors [37]. Drug loss of doxorubicin to 
PTFE (Teflon) membranes has already been reported  [38], yet the possible contribution of 
hydrogen bonding for the prediction of drug adsorption to Teflon has not been recognized 
before.  Notably, the engagement of coplanar ring systems in stacking interactions is also 
plausible and in line with the formation of highly ordered structures of overlapping rings 
reported for doxorubicin [39] and other compounds [40]. Similarly, a comparison of 
chlorpromazine and midazolam (similar MW , octDlog and HBD ) shows that the compound 
with an almost planar ring structure, i.e. chlorpromazine, showed a higher extent of 
adsorption. The classification map in Fig. 4 does not take into account the shape of a 
molecule, however, stacking of coplanar ring systems should be considered as a potential 
driving force of adsorption.  
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The generally low drug loss found for acidic and zwitterionic drugs may be explained by the 
low tendency of negatively charged entities to interact with the hydrophobic but negatively 
polarized CF2 groups on the Teflon surface [37]. Negligible drug loss of acidic compounds 
has been reported before for other plastic materials (polypropylene and polystyrol) [4] and 
likewise electrostatic repulsion from negatively charged surfaces may be involved.  
4.2. Drug Loss to Teflon within octDlog Assays 
4.2.1. The Impact of Drug Adsorption to the Well Plate on the Accuracy of octDlog    
The drug loss - concentration profiles in Fig. 3 have demonstrated that non-specific binding 
to Teflon is an adsorption process and therefore concentration dependent, as long as the 
Teflon surface is not saturated. In an assay for the measurement of octDlog (
'log octD ) octanol 
attracts drug from the aqueous phase, leading to difference between the free initial and free 
equilibrium aqueous drug concentrations (
eq
aqC < 
0
aqC ) which will be mirrored in a difference 
in the amount of drug enriched at the Teflon surface such that 0 pn with
0
p
eq
p nn  . It follows 
that estimating 'log octD  with the simplified mass balance eq. 3b leads to an underestimation of 
the true octDlog , which is associated with the amount of drug released from Teflon in 
presence of octanol ( pn ). A numerical example of the impact of drug adsorption to Teflon 
on the accuracy of 'log octD  is given in Fig. 5.  
 
Fig. 5 
 
4.2.2. Distribution Coefficients from Traditional and Miniaturized Shake Flask Methods 
In order to experimentally verify the predicted adsorption-related underestimation of octDlog , 
we compared octanol/water distribution coefficients (pH 7.4) derived with i) 1 L shake flasks 
(glass, aqV =1 L, octV =1 mL, except for doxycycline: octaq VV  =500 mL) and with ii) a  
miniaturized assay in 96-well format (Teflon, aqV =140 µL, octV =1 µL, except for 
doxorubicin: octV =15 µL). Five test compounds (doxorubicin, fluvoxamine, ritonavir, 
saquinavir, paclitaxel) were investigated which showed pronounced drug loss from filtrated 
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test solutions (>3 % of drug loss after t = 16 h
5
), and which covered a wide lipophilicity 
range ( octDlog  = 0.36 - 3.65). 
The large format experiments with 1 L glass flasks provided the possibility to recover octanol 
at sufficient quantity and to assay both solvents for the distributed drug. This, in turn, allowed 
the estimation of octDlog  with eq. 2 making assumptions about mass balance unnecessary. 
octLogD  values measured in this way are considered the gold standard and are shown in 
Fig. 6A (white columns) for each investigated compound. For comparison, mass balance 
derived distribution coefficients ( 'log octD ) as estimated by eq. 3b are shown for both the large 
format experiments (Fig. 6A, grey columns) and for the miniaturized setup (Fig. 6A, black 
columns). The dashed columns in Fig. 6A relate to corrected 'log octD  values and will be 
discussed later (desorption with 2 - propanol was performed). 
 
Fig. 6 
 
No major discrepancy between octDlog  (gold standard, eq.2) and 
'log octD  (eq.3b) was evident, 
provided that experiments were performed with 1L glass flasks.  The only exception was 
doxorubicine, whose 'log octD was slightly too low by 0.19 octDlog  units.  Since the use of 1L 
glass flaks and large phase volumes ensures low surface to phase volume ratios, a possible 
adsorption to the glass surface can be neglected, at least at the drug concentrations tested (for 
discussion see below).  
Interestingly, the 'log octD values obtained from the miniaturized assay (Fig. 6A, black 
columns) were also in agreement with the gold standard octDlog  (Fig. 6A, white columns), 
except for paclitaxel (underestimation by 0.8 octDlog  units). The extent of drug loss (%) in 
the distribution experiment (Fig. 6B, grey columns) and in the reference experiment (Fig. 6B, 
black columns) seemed to be somehow associated with the error in octDlog  (paclitaxel), yet, it 
cannot explain the accuracy of 'log octD  obtained for ritonavir and saquinavir (Fig. 6A, black 
columns). Despite the fact that a significant fraction of both drugs was lost from aqueous bulk 
solution (Fig. 6B), the 'log octD values agreed well with the gold standard octDlog , just like in 
                                                          
5
 Chlorpromazine was also measured but logDoct values were overestimated with the filter-based assay due to 
enrichment at the filter supported interface. For details see accompanying manuscript 1. 
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case of fluvoxamine (maximal error 0.03 'log octD units). Adsorption to the well plate was 
however much less pronounced for fluvoxamine (Fig. 6B).  
A better predictor for the experimental error in 'log octD can be obtained when relating the 
amount of drug released from the well plate due to distribution into octanol, pn ,  to the drug 
entering the octanol phase eqoctn  (Fig. 6C). When pn becomes negligible with respect to
eq
octn , 
the preconditions for the validity of eq. 3b are fulfilled and the octanol/water distribution 
coefficients can be obtained from 
eq
aqC  and 
0
aqC . However, the larger the pn /
eq
octn ratio, the 
higher the error in 'log octD (Fig. 6C).  
The pn /
eq
octn  ratio was unfavorably high for paclitaxel, explaining the gross underestimation 
of octDlog . In this context it is important to note that the initial aqueous drug solutions in the 
miniaturized assay were prepared according to the standard industrial protocol which 
involves diluting 10 mM DMSO stock solutions with buffer and using the filtrated fraction 
for the measurement (maximal totalC = 22.2 µM). We could demonstrate that precipitation of 
paclitaxel continues with time (see also [37]), leading to drug loss greater than that expected 
from monolayer adsorption. Precipitation, similar to adsorption, causes an underestimation 
in 'log octD , but pn  is not restricted to the capacitance of the Teflon surface, with 
consequences for the accuracy of 'log octD . In case of paclitaxel, pn  can thus not be neglected 
despite the high lipophilicity (high eqoctn ) of the drug. Moreover, the total concentration of 
paclitaxel was lower compared to all other compounds due to poor solubility, both effects 
explaining the pronounced underestimation in octDlog . For clarity, the large scale experiments 
were performed at aqueous drug concentrations well below the solubility limit 
( totalC  = 10 μM; except for saquinavir/ritonavir: totalC = 5 μM, paclitaxel: totalC = 2.5 μM) to 
avoid post-filtration precipitation of sparingly soluble drugs. 
4.2.3. Comparison of octDlog Data (this Study) with Literature Shake Flask Data 
The literature was searched for measured shake flask octDlog values for the abovementioned 
compounds for the purpose of comparison with the gold standard octDlog values measured in 
this study (Table 3).  
 
Table 3 
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We explicitly abstained from considering the literature results as gold standards because large 
variations were encountered in reported shake flask data, particularly for paclitaxel. 
Unfortunately, experimental conditions in literature were not sufficiently specified to track 
back the source of variation in case of paclitaxel.  
Likewise, reliable octDlog  values for doxorubicin, measured at pH 7.4 and at RT, were not 
available. A octDlog  slightly higher than the octDlog value from this study was published 
( octDlog = 0.8 [35]), but at pH 7.3 (RT). Other reports better agreed with our data 
( octDlog = 0.52 and 0.44), albeit, the pH of the buffer or even the method for determination, 
respectively, have not been described. The literature octDlog value for fluvoxamine was in line 
with our result, and it was also the only compound for which the experimental conditions 
were comparable with this study (shake flask, both phases analyzed, pH7.4). With respect to 
ritonavir and saquinavir we found only internal, not further specified data or calculated 
values, respectively, disallowing a comparative evaluation with our own data. Since 
distribution coefficients are sensitive to e.g. pH, buffer, drug concentration and temperature 
we cannot isolate discrepancies arising from the sorption to the assay construct and those 
related to the other experimental conditions.  
4.2.4. Minimization of the Error in  'log octD  
As shown in Fig. 5, there is a risk of underestimating octanol/water distribution coefficients 
when calculating the drug concentration in octanol by difference between free initial and free 
equilibrium aqueous drug concentrations. However, the underestimation will not manifest as 
experimental artifact as long as pn can be neglected compared to the amount of drug 
entering the octanol phase, eqoctn . We therefore propose the following possibilities to minimize 
the pn /
eq
octn ratio and, in turn, the experimental error in 
'log octD : i) increase the analyte 
concentration such that eqoctn ↑ and pn ↓ - the drop in pn is related to the increasing saturation 
level of the Teflon surface, leading to a smaller difference between 0pn and 
eq
pn  ; and ii) 
increase the volume of octanol such that eqoctn ↑↑ - since the distribution of drug into octanol is 
not saturable, the increase in eqoctn  will outweigh the increase in pn .  
It is important to note that the pn /
eq
octn ratio not only depends on the experimental conditions, 
but also on the drug’s intrinsic lipophilicity which, to a large part, determines eqoctn . Hence, the 
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magnitude of error in 'log octD  associated with pn can be described as a function of octDlog . 
Fig. 7 shows the estimated error in 'log octD  as a function of the true octDlog for various sets of 
experimental conditions.  
 
Fig. 7 
 
The simulated error in 'log octD was derived from the difference between octDlog and 
'log octD  as 
described in the Supporting Information. Parameter estimates from the Langmuir adsorption 
isotherm of chlorpromazine were used (Table 2). We are aware of the fact, that 
chlorpromazine is only an example and the error would be higher when using e.g. the maxn - 
estimate and k -estimate from doxorubicin (Table 2), which showed multilayer adsorption. 
However, we describe the behavior of chlorpromazine because saturation was reached 
already at 25 µM corresponding to the drug concentration we used in our 
'log octD measurements ( max
0 nnp  was a precondition for applying the model, see Supporting 
Information). As expected, the experimental error in 'log octD increases exponentially with a 
drop in lipophilicity ( eqoctn ↓), and is the higher, the lower the total drug concentration and the 
lower the volume of octanol. For the theoretical case of two compounds with the same 
affinity to the well plate but different lipophilicity, the less lipophilic drug will then have the 
higher experimental error in 'log octD . Accordingly, compounds with low lipophilicity but high 
affinity for Teflon (e.g. doxorubicin [37]) are the most critical compounds. It is a favorable 
coincidence that hydrophilic compounds also demand the use of elevated volumes of octanol 
(for increased sensitivity) counteracting the influence of drug adsorption to Teflon. The 
model used for simulating the error in 'log octD was based on adsorption theory, and therefore 
the error estimate will be higher if precipitation occurs.  
4.2.5. Correction of Erroneous 'log octD Values by Recovery with 2-Propanol 
None of the methods suitable for counteracting adsorption of hydrophilic compounds is 
applicable for compounds with high lipophilicity. An increase of octV is precluded by the limit 
of detection in the aqueous phase; and an increase of drug concentration cannot go beyond 
the solubility limit which is often very low for lipophilic compounds. Even though sorption to 
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the well plate should not affect the accuracy of 'log octD  for lipophilic compounds (Fig. 7), 
precipitation potentially causes higher errors, and therefore needs to be considered.   
Here, we propose a method to correct erroneous 'log octD  values by recovery of adsorbent 
and/or precipitated drug with an organic solvent. If added to the aqueous phase in both the 
reference and the distribution experiment, the total initial, 0 ,totalaqC , and total equilibrium 
aqueous, eq totalaqC , , drug concentration can be assessed. The difference between them 
corresponds to eqoctC  (after normalization of phase volumes). Drug recovery from the well 
plate is possible with e.g. 2-propanol which among various investigated excipients proved to 
be favorable in terms of efficiency, practicability and compatibility with mass spectrometric 
analysis (accompanying manuscript 3). To avoid disturbing the phase equilibrium, 
2 - propanolol has to be added to the micotiter plate only after distribution equilibrium has 
been achieved and, importantly, after the octanol phase has been removed from the aqueous 
phase. Phase separation might be facilitated by immobilizing octanol on a filter support, as 
described elsewhere (accompanying manuscript 1, [21]).   
Note that the assessment of 'log octD still requires the measurement of the free equilibrium 
aqueous drug concentration, eqaqC , which can be obtained from an independent measurement 
conducted without 2-propanol. The corrected 'log octD value is then given by  
 
 











oct
eq
aq
aq
eq
totalaqtotalaq
octoct
VC
VCC
DD
,
logloglog
,
0
,' ,     (9) 
 
and should agree with the gold standard octDlog , even if 
0
p
eq
p nn  . A numerical example is 
given in Fig. 5. 
To prove the validity of the correction procedure, we compared the accuracies of the 
uncorrected and the corrected 'log octD  values (measured with the miniaturized assay), using 
the example of doxorubicin, fluvoxamine, ritonavir, saquinavir and paclitaxel. Inspection of 
Fig. 6A shows that the corrected 'log octD  value for paclitaxel (dashed column) was in better 
agreement with the gold standard octDlog (white column) than uncorrected 
'log octD values 
(black columns). The other compounds were not affected. The reason why the 'log octD value 
of paclitaxel was still slightly too low may be that paclitaxel could not be recovered to 100 %, 
or that aggregation changed the overall distribution behavior. Even if further research is 
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necessary to understand the slight discrepancy, we consider the recovery method by using 
2 - propanol as useful for approximating the true octDlog if adsorption or precipitation occurs. 
4.3. Recommendations for Managing Drug Loss in other in vitro Assays 
Non-specific binding to microtiter plates is a general problem likely to arise if several 
unfavorable conditions coincide, namely miniaturized assay constructs, submicromolar to 
micromolar concentrations, and test compounds with high affinity for plastic well plates. It is 
rather the rule than the exception that all of these criteria are met in a typical industrial 
screening assay; a octDlog assay is just one of many examples. 
To avoid experimental artifacts in other screenings assays which likewise rely on mass 
balance (e.g. PAMPA, CaCo-2) or on absolute concentrations (e.g. IC 50, solubility), we 
recommend considering the following: i) The main error in 'log octD was due to post-filtration 
precipitation (paclitaxel). Therefore we recommend to prepare sample solutions from DMSO 
stock solutions, and to wait at least ~2 h before filtration. The filtrate should be diluted with 
assay buffer afterwards to avoid drug concentrations close to or above the solubility limit, ii) 
each assay should be evaluated individually considering concentration ranges, phase 
volumes, etc. and iii) the assay plate should be selected carefully. As distinct from Teflon, 
surface treated polystyrol contains negative charges catalyzing the adsorption of cationic 
compounds [4]. Sorptive loss from a polypropylene plate was only slightly higher than from 
Teflon, but we observed that plastic components were leaching out from the plastic matrix 
after addition of 2-propanol. 
The use of glass containers might be a viable alternative to Teflon since no multilayer 
adsorption was observed and, e.g., only 5.5 % of filtrated doxorubicin remained unrecovered 
as compared to 19.9% drug loss when using a Teflon plate (Supplementary Information). 
However, the fragility of glass complicates the handling of well plates and, moreover, 
extensive non-specific binding of other compounds has been reported (e.g. anandamide [41]). 
Preliminary studies in our lab using metallic well plates indicated that drug adsorption is 
lower as compared to Teflon but further research is required to confirm the observed trend on 
a larger dataset.  
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5 Conclusions 
In summary we have shown that non-specific binding to a Teflon well plate is a very fast, 
saturable adsorption phenomenon which therefore likely occurs even in the highest-
throughput octDlog assay. Large, coplanar and lipophilic compounds with many H-bond 
donors showed the highest propensity to adsorption corresponding to hydrophobic, H-
bonding and stacking interactions. Drug loss to Teflon leads to an underestimation in 
octDlog for i) hydrophilic compounds with high affinity for Teflon and ii) compounds likely to 
precipitate during the time course of the distribution experiment. Even though lipophilic 
compounds likely adsorb to Teflon, the error in 'log octD  is negligible as long as only 
monolayer adsorption takes place. Then, the distribution equilibrium is shifted towards drug 
dissolved in the octanol phase and drug adsorption to the well plate can be neglected. 
Experimental artifacts related to drug loss can be counteracted by recovering drug from the 
Teflon surface with 2-Propanol (applicable for lipophilic compounds) or by increasing the 
volume of octanol (applicable for hydrophilic compounds). We consider our investigation as 
a guideline to eventually survey and improve also other miniaturized in vitro screens. More 
certainty in the desired outcome measure will avoid potentially costly misinterpretations and 
aid the drug discovery process in what it aims to be: efficient. 
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Table 2   Summary of model parameters for the adsorption isotherms shown in Fig. 3B - C 
along with the layern estimate at the Teflon surface for chlorpromazine and doxorubicin.  
Compound  Langmuir  B.E.T. 
  r
2 
 
k  
[µM
-1
] 
maxn
a
 
[µM/m
2
] 
layern   r
2 
 
k  
[µM
-1
] 
maxn
a
 
[µM/m
2
] 
satC  
[µM] 
Chlorpromazine  0.949 0.2895 1.433 1.2  0.997 9.19 6.98 645 
Doxorubicin  0.990 0.0282 7.239 2.9  - - - - 
a
 Estimated contact area of aqueous solution with the Teflon well: 70mm
2
. 
 
 
Table 3   Comparison of gold standard octDlog (pH 7.4) values obtained in this study (1L 
glass flasks, both phases analyzed) and octDlog values obtained from literature. 
Compound This study                  
(gold standard) 
Literature studies 
 
 
octDlog  
(pH 7.4)
 
 
SD 
 oct
Dlog  
Experimental 
conditions 
aqV , octV  Phase analyzed 
Doxorubicin 0.36 0.00 0.44[31] not specified ? ? 
   0.52[17] shake flask, pH ? 1mL both aqueous phase 
   0.8[35] shake flask, pH 7.3 
750μL 
both 
both phases 
Fluvoxamin 1.72 0.00 1.8[36] shake flask, pH 7.4 5mL, both octanol phase 
Ritonavir 3.65 0.00 3.1[32] not specified ? ? 
Saquinavir 3.58 0.00 4.1[4] calculated ? - - 
Paclitaxel 3.17 0.01 >2[17] shake flask, pH ? 1mL, both aqueous phase 
   2.49[33] 
shake flask, not 
further specified 
? ? 
   3.5[34] not specified ? ? 
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Figure 1   Drug loss from filtered aqueous test solutions to a 96 well Teflon plate for (A) 
neutral, (B) basic, (C) acidic and (D) zwitter-ionic compounds. Drug loss was measured over 
a period of maximal 2 weeks. Total concentrations of drug in the filtrate are given in Table 1.  
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Figure 2   Time dependent loss for ritonavir (A) and paclitaxel (B) from aqueous bulk 
solution stored in a 96 well Teflon plate. Experiments were performed at standardized drug 
concentrations ( totalC  =5 µM, ) or at drug concentrations obtained after filtration of 50 μM 
test solutions, yielding totalC  = 18.9 µM ritonavir and 13.2 µM paclitaxel (). Lines are 
biexponential decay curves fitted to the experimental data. 
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Figure 3   Concentration - dependency of drug loss from aqueous bulk solutions 
(0.5 - 500 μM drug in 50 mM Tris/114 mM NaCl/pH 7.4) after 16 h - storage in a Teflon 
plate. A: Percentage drug loss as a function of total aqueous concentrations of the bases 
doxorubicin () and chlorpromazine (), the neural drugs ritonavir () and diazepam () 
and the acid indomethacin (). B - D: Adsorption isotherms of chlorpromazine (B, C) and 
doxorubicin (D). Lines are fits to the experimental data using either the BET (B) or the 
Langmuir type (C, D) adsorption isotherm at maximal 500 µM (B), 25 µM (C) and 
100 µM (D) total concentration. Greyed out data points were not used for the fit and 
considered as real experimental artifacts (C) or were outliers because the compound 
precipitated (D).  
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Figure 4   Classification map for drug adsorption to Teflon based on octDlog , MW and 
number of H-bond donors (increasing size of the symbols with increasing numbers of HBD 
(range = 0 - 7)). Colors of the symbols reflect the extent of drug loss from 5 µM aqueous 
solutions after t = 16h: 0 – 1 % (), 1 – 5 %(), 5 – 25 % (), > 25 % () drug loss. 
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Figure 5   Numerical example showing the impact of drug adsorption to a well plate on the 
accuracy of logDoct (for simplicity: octaq VV  allowing to substitute concentrations, C , by 
amounts, n ). A1,2: Three-compartment model describing the distribution of a solute 
( totaln =100 µmol) throughout the well plate-buffer-octanol system yielding 
eq
pn , 
eq
aqn and 
eq
octn  
drug in each compartment (equilibrium conditions). The solute is distributed according to its 
affinity for the well plate (plastic sorption, S) and its octDlog  value 
(   2log/loglog  eqaqeqoctoct nnD ). While eqaqn  can be directly measured, eqoctn is usually assessed 
by difference between the free initial and the free equilibrium aqueous drug concentration 
( 0aqn ,
eq
aqn ) such that   eqaqeqaqaq nnnD /log'log 0  . A reference experiment without octanol (B) is 
performed to retrieve 0aqn . Provided that all available adsorption sides on the Teflon surface 
are saturated in the reference (B) and in the distribution experiment (A1), then eqpn =
0
pn , and 
application of the mass balance equation yields the correct octDlog  (=2). However, when the 
distribution of drug into octanol leads to a removal of drug from the well plate such that 
eq
pn <
0
pn , assumptions of mass balance are violated resulting in underestimation of 
'log octD  
( 'log octD =1.8) (A2). Recovery experiments with 2-propranol, involving the measurement of 
the total and the free aqueous drug concentration, will yield correct octDlog values 
(here:   2log)30/40100log(log ' octD ). 
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Figure 6A:   Shake flask octDlog  (pH 7.4) values measured in 1L glass flasks (white and grey 
columns) and in 96-well Teflon plates (black and dashed columns), respectively. octLogD  
values were obtained from concentration analysis in both phases (white columns) or by 
assaying only the aqueous phase and applying distinct mass balance equations: Disregard of 
precipitation or adsorption to glass or Teflon (eq.3b, grey and black columns) vs. correction 
with 2-propanol (eq. 9, dashed columns). Recovery from precipitated or adsorbed drug with 
2-propanol enabled quantification of the percentage drug loss shown in B: Drug loss from 
initial (grey columns) and from equilibrium (black columns) aqueous drug solutions 
corresponding to the reference experiment without octanol and to the actual distribution 
experiment with octanol. C: Experimental error in octDlog  as a function of the change in drug 
loss with respect to the reference and the distribution experiment, related to the amount of 
drug in octanol. The line is the linear fit to the experimental data (symbols). Doxorubicin was 
not included in the fit because phase volume ratios were different ( aqV =140 µL, octV =1 µL, 
except doxorubicin: octV =15 µL).  
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Figure 7   Expected experimental error in 'log octD  as a function of the true logDoct for the 
theoretical situation that compounds with different lipophilicity exhibit the same affinity for 
the microtiter plate. The experimental error corresponds to the difference between octDlog  
(simulated with eq. S4a) and 'log octD  (simulated with eq. S4b) calculated for different 
experimental conditions: totalC =25 µM, octV =1 µL (); totalC =9 µM, octV =1 µL 
(); totalC =9 µM, octV =15 µL (). aqV =const.=140 µL (corresponding contact area with 
Teflon~90 mm
2
). Parameter estimates for k  and maxn  were gained from the Langmuir-type 
adsorption isotherm of chlorpromazine (Fig. 3C), but corrected for the different contact area 
with Teflon. 
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Supporting Information 
The Magnitude of Error due to Drug Loss to Teflon as a Function of  octDlog  
When determining a solute’s octanol/water distribution coefficient, defined as  
 
 eqaqeqoctoct CCD /loglog  ,   (S1) 
 
direct concentration analysis of both phases for the distributed solute is clearly 
preferable rather than possibly violate mass balance by analyzing only one. If 
compounds show adsorption to the well plate, a third compartment needs to be 
considered in the mass balance equation which is given by (for details see Section 2 in 
the main manuscript):  
 
eq
poct
eq
octaq
eq
aqpaqaqtotal nVCVCnVCn 
00 .   (S2) 
 
Neglecting potential drug adsorption, and estimating octanol/water distribution 
coefficients with a simplified mass balance equation (eq. 3b) leads to an 
underestimation of octDlog , which is associated with 
eq
ppp nnn 
0 , or more precisely 
the ratio between pn and 
eq
octn  (see Section 4.2.2. in the main manuscript). 
Accordingly, the magnitude of error in mass balance derived 'log octD  values depends 
on the compound’s lipophilicity, and can be described as a function of the true octDlog  
.  
In this study, we related the error estimation to the simplest case, i.e. when drug 
adsorption cannot go beyond the point where one layer of adsorbate ( maxn ) is formed, 
and the amount of adsorbed drug ( eqpn ) at a certain aqueous concentration is 
approximated by the Langmuir type of isotherm (eq. 6, main manuscript). We further 
assumed that the applied concentration in the reference experiment (without octanol) 
is high enough to saturate the surface, such that max
0 nnp   and 
eq
pp nnn  max , leading 
to:  
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eq
aq
eq
aq
p
Ck
Cnk
nn



1
max
max .   (S3) 
 
Substitution of eq. S2 and eq. S3 into eq.S1 yields (after rearrangement): 
 
















oct
aq
oct
eq
aq
eq
aqoctoct
aqaq
eq
aq
oct
V
V
VCk
nk
CV
n
V
VC
C
D
1
1
1
loglog maxmax
0
,                         (S4a) 
 
where aqV  and octV are the given phase volumes, maxn and k can be obtained from an 
independent measurement of the adsorption isotherm and 0aqC is given by 
aqtotalaq VnCC /max
0  . When now allowing eqaqC  to vary, for each 
eq
aqC a corresponding 
octDlog may be calculated.  
It is then possible to simulate the situation when adsorption is neglected and 
experimentally derived 'log octD  values are obtained with eq. 3b, namely by simply 
discarding the adsorption-related terms in eq.S4a such that  
 











oct
aq
oct
aqaq
eq
aq
oct
V
V
V
VC
C
D
0
' 1loglog .            (S4b) 
 
The difference between octDlog (eq.S4a) and 
'log octD  (eq.S4b) corresponds to the 
experimental error in 'log octD  encountered when applying eq.3b despite the fact that 
adsorption to the well plate occurs.  
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Figure S1   Structures of the compounds investigated. 
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Table S1   Physicochemical and structural descriptors used for the development of the 
prediction model. 
Descriptor Comment  
clogP Calculated octanol-water partition coefficient  
LogDoct Measured octanol-buffer distribution coefficient at pH 7.4  
MW Molecular weight of the desalted drug 
Hydrophobic surface  
Hydrophobic volume  
PSA Polar surface area 
Hydrophilic volume   
Total surface  
Total volume  
AD  Calculated cross-sectional area of the drug in the membrane bound-conformation  
No. of rings  
No. of aromatic rings  
No. of H-bond acceptors Value taken from Pubchem database  
No. of H-bond donors calculated with our in-house developed modeling package Moloc 
No of sp3 carbons  
d0 Root mean square deviation of the atom positions from  the plane defined by the 
maximum and medium principal axes (2*d0 = “thickness” of the structure); Parameter 
representing the thickness of a molecule 
d1 Same as d0 but for the maximum and minimum axes (2*d1 = “width” of structure); 
Parameter representing the width of a molecule 
d2 Same as d0 but for the medium and minimum axes 
(2*d2 = “length” of structure); Parameter representing the length of a molecule 
d0/d2 d0 divided by d2; “Globularity” measure of a molecule. High values are indicative for 
“spherical” shaped molecules, molecules with low values are more prolate and 
elongated 
Fraction ionized Net charge at pH 7.4 as calculated from measured pKa according to Henderson-
Hasselbalch-equation.  
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Figure S2   Drug loss from filtrated aqueous bulk solutions (100 µL, 50 mM Tris/114 mM 
NaCl/pH 7.4) to microtiter plates (polystyrol, polypropylene, Teflon) and to glass vials. Only 
compounds are shown for which drug loss was > 2.5% to at least one vessel.  Drug sorption 
was arbitrarily set to 0 if less than 1% remained unrecovered. Paclitaxel, indomethacin, 
raclopride and saquinavir were excluded because precipitation occurred in at least one 
experiment. Vinblastine was excluded because co-elution of leaching plastic components 
from polypropylene disturbed the analysis.  
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ABSTRACT 
Drug adsorption to microtiter plates has been recognized as a potential source of 
experimental artifacts in high-throughput screening assays used in pre-clinical drug 
development, however, little efforts have been made to correct for adsorption. In this 
study, we investigated different excipients in terms of their ability to recover drug 
adsorbed to a Teflon well plate. Recovery experiments were performed at the example 
of 24 structurally diverse drugs and by using various classes of excipients including i) 
detergents of different charge state (taurocholic acid, CHAPS, CTAB, SDS, Brij 35, 
ii) cyclodextrines (2,6-di-O-methyl-β-cyclodextrin), and iii) organic solvents (2-
propanol, DMSO, acetonitrile). Drug adsorption before and after addition of 
excipients was measured in terms of percentage drug loss from aqueous bulk solution 
as determined by means of HPLC-UV. Drug loss before addition of excipients was 
generally negligible for anionic and zwitter-ionic drugs whereas some cationic 
(fluvoxamine, chlorpromazine, saquinavir, doxorubicin) and neutral drugs (ritonavir, 
paclitaxel) showed pronounced adsorption to Teflon. Complete recovery of neutral 
drugs was achieved by all of the investigated detergents, provided that experiments 
were performed above critical micellar concentrations such that solubilization into the 
micelle dominated over adsorption to the Teflon surface. Recovery of cationic drugs 
was detergent- and drug - specific and improved in the order of taurocholic acid ≈ 
CHAPS < Brij35 ≈ CTAB < SDS. The superior detergency of SDS may be explained 
by electrostatic repulsion between SDS residing at the Teflon surface and mixed SDS-
drug micelles free in solution. Submicellar concentrations of detergent should be 
avoided since drug recovery was either incomplete or adsorption of charged drugs 
reinforced by oppositely charged detergents. Regarding 2-propanol, acetonitrile and 
2,6-di-O-methyl-β-cyclodextrin, recovery of all drugs except for doxorubicin was 
achieved. Since 2-propanol was the only excipient which caused no ion suppression in 
mass spectrometry, we recommend using 2-propanol for drug recovery when relying 
concentration analysis on HPLC-MS, and SDS when relying on HPLC-UV. The 
proposed guideline for excipient-aided drug recovery may be applied for the 
correction of potentially erroneous results in high-throughput assays to avoid 
misinterpretations and achieve higher certainty in the data of interest.  
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1. Introduction 
Miniaturization, high throughput (HT) technology and automation have become 
routine standards in preclinical drug development to accelerate the nomination of drug 
candidates and to meet the demand for efficiency, speed and low costs. Assay 
miniaturization has evolved by the extensive use of plastic materials and the 
availability of microliter plates with as much as 1536 wells per plate. Recently, 
however, it has been recognized that non-specific binding to the lab ware as well as 
drug precipitation/aggregation may become significant in miniaturized assays and 
potentially lead to experimental artifacts [1]. Many examples for falsified 
experimental results due to non-specific binding have been reported including 
overestimation of IC50 values [2], underestimation of plasma, urine and cerebrospinal 
fluid (CSF) concentrations [3], misinterpretation of adsorption as protein binding [4], 
misjudged exposure to environmental pollutants [5] and unreliable drug permeability 
estimates [6].   
Drug sorption to a multitude of laboratory equipment (e.g. infusion bags, syringes, 
filtration units, tubings, microtiter plates, cover slips, pipettes, hollow fibres, 
microdialysis tubings [7-21]), has been studied and it is now well known that 
plasticizers, mainly present in polyvinylchloride (PVC), are a major source of 
pronounced drug loss to plastic material [22]. However, the absence of plasticizers in 
other commonly used laboratory materials such as polypropylene, polystyrol, glass 
and silicone does not necessarily guarantee inertness to drug adsorption. Notably, also 
sorptive loss to Teflon has been observed at the example of environmental pollutants 
[18], amphiphilic benzoates [23] and detergents [24] which disproves the widespread, 
but erroneous a priori assumption that Teflon is inert to adsorption. The affinity of 
proteins to Teflon membranes has even successfully been applied for the adsorption 
of proteins in Western blotting [25].  
Predominantly lipophilic compounds show a high likelihood of non-specific binding 
to plastic materials which points to the relevance of hydrophobic binding forces in 
drug-plastic interactions [23]. In addition, electrostatic interactions contribute to the 
process of drug loss if functionalized plastic materials containing charged surface 
residues are concerned. In our accompanying manuscript 2 we moreover show that 
hydrogen bonding and engagement of coplanar ring systems in stacking interactions 
can be associated with drug loss to Teflon, yet drug lipophilicity was a dominant 
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factor determining drug adsorption. Consequently, the trend towards favoring rather 
lipophilic drug candidates in the lead optimization and selection process increases the 
relevance of drug loss to the labware and poses new challenges for the development 
of HT screening assays.  
In view of potential experimental errors associated with drug loss to plastics, methods 
to inhibit or reverse drug adsorption are of major interest. Some insights can be 
gained from antigen diagnostics with the ELISA assay in which bovine serum 
albumin and detergents are applied to block the surface of the assay plate (polystyrol) 
and to prevent adsorption of excess antibody [26-28]. With respect to small 
molecules, much less attention has been paid to the inhibition or recovery of non-
specific binding. The existing knowledge is mainly based on case studies focusing on 
the minimization of drug loss to filtration units [29] and polypropylene containers for 
urine and CSF sampling [3, 30-34]. Desorption from other plastic lab ware has barley 
been investigated with the exception of polystyrol and polypropylene microtiter plates 
[35]. The typical strategy for minimizing drug loss involves the use of buffer additives 
such as organic solvents (acetonitrile, methanol, ethanol, DMSO, PEG 400, propylene 
glycol [35-39]), cyclodextrins [40], detergents [41, 42] and bovine serum albumin 
[43-45], which work by either or both  increasing drug solubility and competing with 
adsorbed drug for available binding sites on the plastic surface. It is interesting to note 
that organic solvents, cyclodextrines and detergents have also extensively been 
explored in terms of their ability to remediate contaminated soil from hydrophobic 
organic pollutants [46-48]. 
To the best of our knowledge, information about the inhibition of drug adsorption to 
Teflon, or the recovery of adsorbed drug is missing, reflecting the rather uncritical use 
of Teflon as ‘inert’ material. Moreover, it is unclear whether the knowledge gained 
from case studies of excipient-aided drug recovery is applicable to the minimization 
of drug loss to Teflon, in particular with respect to larger datasets.  
The aim of this study was to investigate various excipients in terms of their ability to 
reverse drug adsorption to Teflon. More specifically, we were also interested in the 
mechanisms of excipient-aided drug recovery in order to derive a general guideline 
for applying excipients for compounds of all types of charge classes and propensity to 
adsorption. To these purposes, we first studied the sorption of 24 structurally diverse 
drugs from aqueous bulk solution to a Teflon microtiter plate, followed by the study 
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of recovery of adsorbed drug after addition of excipients. Various classes of 
excipients were tested, including i) aliphatic and steroidal detergents of different 
ionization state, namely sodium dodecyl sulfate (SDS, anionic), 
cetyltrimethylammonium bromide (CTAB, cationic), Brij 35 (neutral), Na • 3-[(3-
Cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS, zwitterionic, 
steroidal) and taurocholic acid (anionic, steroidal). In addition, the desorbing ability of 
ii) organic solvents (DMSO, 2-propanol, acetonitrile) and iii) cyclodextrins was 
evaluated. The selection of the excipients was to a great extent inspired by case 
studies in which the minimization of drug loss to other plastic materials has been 
explored. From the multitude of commercially available cyclodextrins, we studied 
2,6-di-O-methyl--cyclodextrin because it showed the highest solubilizing power for 
paclitaxel [49]. The drug is well known for its pronounced likelihood for drug 
adsorption to various surfaces [35] and was therefore included in the dataset.  
A requirement for the application of excipients for minimizing drug loss to Teflon 
may not only be efficiency in recovering adsorbent drug, but also compatibility with 
mass spectrometric analysis. SDS, for example, is known to suppress the ionization 
efficiency of co-eluting analytes in electrospray ionization - mass spectrometry (ESI-
MS) [50]. In order to identify the most suitable excipient in terms of efficiency of 
drug recovery and MS compatibility, we finally explored matrix effects in ESI-MS in 
presence of the selected excipients at concentrations used in the desorption studies. A 
guideline for the best practice of excipient-aided drug discovery is derived and may 
be applied for correcting potentially erroneous results in HT screening assays.  
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2. Materials and Methods 
2.1. Drugs and Chemicals  
Caffeine, DMSO and cetyltrimethylammonium bromide (CTAB) were purchased 
from Acros (Geel, Belgium). 2-propanol was obtained from Burdick & Johnson 
(Seelze, Germany). Indomethacin, Tris, sodium chloride, sodium dodecylsulfate 
(SDS) and polyoxyethylene (23) lauryl ether (Brij 35, 10% solution) were purchased 
from Fluka (Buchs, Switzerland). Ritonavir was received from Molekula 
(Vaterstetten, Germany). Chlorpromazine • HCl, diclofenac • Na, taurocholic acid, 
Na• 3-[(3-Cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS) and 
2,6-di-O-methyl-β-cyclodextrin were supplied from Sigma (Steinheim, Germany). All 
other drugs were available through our in-house Compound Depository Group as 
proprietary compounds. Water and Acetonitril were supplied from Merck (Darmstadt, 
Germany) and were of HPLC-grade.  
2.2. Measurement of Drug Loss to a Teflon Microtiter Plate  
Assay buffer (227 µL, 50 mM Tris/114 mM NaCl/ pH 7.4) was first spiked with 
DMSO stock solutions (1.5 µL) of the test compounds and the internal standard 
caffeine (each 10 mM) and was then filtered into an in-house made Teflon block. The 
filtrate thus contained 50 µM caffeine, 50 µM of the test compound (= maximal 
nominal concentration, for exact concentrations see Table 1) and 1 % (v/v) DMSO. 
Caffeine was inert to adsorption (data not shown) and could therefore be used as an 
internal standard to compensate for evaporation and dilution (see Section 2.3). An 
aliquot of the filtrate ( filtrateV = 50 µL) was transferred into a 96 well Teflon plate and 
was immediately injected and analyzed on a HPLC-UV system. The well was sealed 
and all other sample solutions were consecutively transferred, injected and analyzed 
again after t = 16 h. All measurements were performed in duplicate at room 
temperature (RT). Drug loss was calculated according to: 
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where 0DA , 
0
ISA , 
t
DA  and 
t
ISA  denote the peak areas of drug and the internal standard at 
t = 0 h and after t = 16 h storage,  respectively.  
2.3. Measurement of Drug Recovery by Excipients  
Stock solutions of excipients were prepared in assay buffer at a concentration of 
C = 50 mM (taurocholic acid, CHAPS, CTAB, SDS, Brij35, 2,6-di-O-methyl-β-
cyclodextrin) and C = 0.5 mM (only detergents). An aliquot of the stock solution 
( stockV  = 10 µL) was added to the aged aqueous drug solution stored for t = 16 h in the 
Teflon plate. Since the analysis of drug loss at t = 0 h and after t = 16 h required 5 µL 
injection volume for each analysis, only filtrateV  = 40 µL was left in the Teflon plate 
and the dilution with stock solutions of excipients yielded a final excipient 
concentration of C = 10 mM and C  = 0.1 mM. Regarding recovery experiments with 
2-propanol, DMSO and acetonitrile, the respective organic solvent ( solventV =13.33 µL) 
was added to the aged aqueous drug solution instead of adding stock solutions of 
excipients. The final concentration of organic solvent in the drug solution was 
25% (v/v). Excipient-spiked test solutions were put on a shaker for 3 h before drug 
concentrations were analyzed again by means of HPLC-UV. Drug loss after addition 
of excipients was calculated in the same way as described above (eq.1). Experiments 
were performed in duplicate for each of the individual experimental conditions tested 
(n = 26).  
2.4. HPLC Instrumentation and Chromatographic Conditions  
Drug concentrations in aqueous solutions were quantified using an Agilent 1290 
Infinity HPLC-UV system. An aliquot (5 µL) of each sample was injected onto a 
Kinetex 2.6 µm, 2.1 x 50 mm analytical column. The flow rate was 2 mL/min and the 
integrated column heater was set to 60 °C. The mobile phase consisted of A (water) 
and B (acetonitrile), each containing formic acid (0.1 % (v/v)). The gradient elution 
was performed as follows: initially 2 % B, 0 - 0.35 min linear gradient from 2 % B to 
95 % B, 0.35 min - 0.5 min 95 % B, post time: 0.3 min. The gradient program for 
doxorubicin, vinblastine, buspirone and colchicine was slightly different: initially 2 % 
B, 0 - 0.5 min linear gradient from 2 % B to 95 % B, 0.5 min - 0.65 min 95 % B. Peak 
areas were recorded at an appropriate wavelength.  
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2.5. Determination of the Critical Micellar Concentration of the Detergents 
Surface activity experiments were carried out on a multichannel microtensiometer 
(Delta-8, Kibron, Helsinki) utilizing a modified Du Nouy method as described 
elsewhere [51]. Prior to the measurements, the system was cleaned by heating the 
microbalances and calibrated with distilled water to 72.8 mN/m. Stock solutions of 
SDS (12.5 mM), CTAB (1.5625 mM), Brij 35 (1.5625 mM), CHAPS (12.5 mM) and 
taurocholic acid (3.125 mM) were prepared in 10 mL glass flasks using the same 
assay buffer as described above (50 mM Tris, 114 mM NaCl, pH 7.4). Eleven 
consecutive 1:1 dilutions were made by diluting the detergent stock solution (1 mL) 
with assay buffer (1 mL) in a glass flask. An aliquot of each dilution (50 µL) was 
transferred to the 96-well measurement plate (aluminium) and the surface pressure, 
π = γ0 - γ, where γ0 is the surface tension of the pure buffer and γ the surface tension of 
the drug solution, was monitored in the order of increasing detergent concentration. 
The critical micellar concentration ( CMC ) was determined from π - concentration 
profiles in the usual manner. All experiments were performed at room temperature in 
triplicate and mean values are reported. 
2.6. Evaluation of Excipient-Related Matrix Effects in ESI/MS  
DMSO stock solutions of test analytes (rolipram or ketorolac) were dissolved in either 
blank buffer (50 mM Tris/114 mM NaCl/ pH 7.4) or excipient-spiked buffer yielding 
a final test solution containing C  = 25 µM analyte (DMSO content: 0.1 % (v/v)). 
Final excipients concentrations corresponded to the concentrations used in the drug 
recovery studies. The test solutions were injected onto a HPLC system (Agilent 1290 
Infinity) equipped with an API single quadrupole mass spectrometer (Agilent 6140) 
which was working at the following source settings: capillary voltage +3.5 kV/-
3.5 kV, drying gas flow (N2)  13 L/min, nebulizer pressure 60 psi, drying gas 
temperature 350 °C. The flow from the HPLC system was set to 1 mL/min (instead of 
2 mL/min in the sorption studies) and was introduced into the ESI interface with a 
delay time of 0.25 min to prevent contamination of the ionization source with buffer 
salts. Each 0.1 s the intensity of the pseudo - molecular ion, [M+H]
+
 (positive mode) 
and [M-H]
-
 (negative mode), respectively, was acquired in single reaction monitoring 
mode (SRM). Analyte recovery from excipient-spiked buffer was calculated from the 
ratio of the average mass responses of the analyte in presence and in absence of the 
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excipient (each time n = 5 consecutive injections). Experiments were conducted 
separately in both positive and negative ionization mode, using rolipram (neutral 
compound) and ketorolac (acidic compound, pKa 3.44 (potentiometric measurement, 
in-house)) as test analytes, respectively. Retention times in HPLC were similar for 
both compounds ( tR  = 0.54 min for rolipram and tR  = 0.546 min for ketorolac).  
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3. Results  
3.1. Characterization of the Dataset  
Drug adsorption from aqueous bulk solution to a 96 well Teflon plate and excipient-
aided drug recovery was studied at the example of 24 drugs including acids (3), bases 
(8), neutral (10) and zwitter-ionic (3) compounds. Compounds with known propensity 
to adsorption to any kind of plastic material were included in the dataset, i.e. 
paclitaxel, doxorubicin, saquinavir, vinblastine, chlorpromazine, midazolam and 
diazepam [8, 35, 52]. Moreover, compounds were investigated which have not been 
studied yet in terms of drug-plastic interactions (colchicine, amprenavir), but for 
which we suspected that adsorption-related artifacts could potentially explain their 
behavior as outliers in a novel in vitro Lipid Membrane Binding Assay (LIMBA, 
accompanying manuscript 6). The dataset was extended for anionic, zwitter-ionic and 
generally rather hydrophilic compounds resulting in a structurally diverse dataset 
covering a wide physicochemical property space ( octDlog  = -1.15 - 3.68, 
Pc log  = 0 - 5.3, molecular weight, MW  = 194 - 854 g/mol, Table 1). Structures of the 
investigated drugs are provided in the Supporting Information. 
 
Table 1 
 
3.2. Studies of Drug Loss from Blank Buffer to Teflon  
3.2.1. The Extent of Drug Loss to Teflon     
Percentages drug loss from filtrated aqueous bulk solution before addition of 
excipients were obtained from 26 independent measurements (n=2 for each 
independent measurement) and average values are provided in Table 1. The dataset 
was diverse in terms of likelihood of drug sorption to Teflon as indicated by the wide 
range of drug loss observed ( lossDrug <2 % (16 compounds) - 41.4 % (paclitaxel)).  
The following classes of compounds showed a moderate to high extent of drug loss: i) 
large and lipophilic compounds ( octDlog  (pH 7.4) > 3, here: MW > 670) such as 
paclitaxel ( lossDrug  = 41.4 %), ritonavir (8.2 %), saquinavir (12.0 %) and vinblastine 
(4.3 %); ii) Compounds which are either moderately large and moderately lipophilic 
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and carry many hydrogen-bond donors (doxorubicin, 21.6% drug loss), or which are 
iii) small, lipophilic and fluorinated (fluvoxamine and midazolam). In addition, the 
presence of a planar ring system seems to be associated with increased drug loss (e.g. 
doxorubicin, chlorpromazine (12.1 %)). Drug loss from blank buffer was negligible 
(< 2 %) for 16 of the 24 compounds investigated. More precisely, all anionic and 
zwitter-ionic compounds showed no or negligible adsorption to Teflon in addition to 
small compounds with low to intermediate lipophilicity ( octDlog  (pH 7.4)  < 3) 
lacking the abovementioned patterns. For details about the relationship between the 
physicochemical properties of a drug and the extent of drug adsorption to Teflon 
(measured at a standardized concentration ( filtrateC = 5 μM), the reader is referred to 
our accompanying manuscript 2. 
3.2.2. Reproducibility of Drug Loss Data  
Drug loss data from blank buffer was available from 26 independent measurements 
since drug recovery studies in presence of excipients required the study of drug 
adsorption in advance. Each of the 26 independent experiments was performed in 
duplicate on the same day, using the same stock solution and the same microtiter 
plates.  
The variability of drug loss with respect to all 26 independent experiments was 
exceptionally high for paclitaxel (standard deviation, SD = 24.2%) and doxorubicin 
(SD = 9.9%), whereas data obtained within one independent experimental run (n = 2) 
showed much better reproducibility (average SD = 2.36% and 1.73% for paclitaxel 
and doxorubicin, respectively). A possible explanation for the high variability may be 
the protocol applied for the preparation of aqueous test solutions which involved i) 
dilution of DMSO stock solutions of test compounds (10 mM) with buffer, proceeded 
by ii) filtration and iii)  transfer of the filtrate to the Teflon plate. In order to remain as 
close as possible to the common practice in HT screening assays, we followed this 
protocol, however, drug concentrations in the filtrate (maximal nominal 
filtrateC = 50 μM, Table 1) thus varied according to the compound’s solubility limit. 
Moreover, fast sorption to the preparation plate and the filtration unit as well as post-
filtration precipitation (paclitaxel) introduced some of degree of variability in the 
initial aqueous drug concentrations (e.g. filtrateC  for paclitaxel and doxorubicin ranged 
from 3.1 - 14.3 µM and from 34.8 - 56.2 µM, respectively). In this respect it is 
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important to note that drug loss to Teflon is saturable and therefore concentration 
dependent (accompanying manuscript 2). However, we consider the variability of the 
drug loss data as secondary since our primary interest in this study was to identify an 
excipient allowing for the complete recovery of adsorbed drug, irrespective of the 
extent of adsorption. 
3.3. Drug Recovery Studies  
Despite the fact that drug loss from blank buffer was negligible for 16 of the 24 
compounds investigated, drug recovery studies with excipients were performed on the 
whole dataset in order to verify that the addition of excipients does not adversely 
affect compounds with a low propensity to adsorption. In the following, only data for 
compounds will be presented for which either drug loss from blank buffer was > 4% 
(ritonavir, paclitaxel, fluvoxamine, chlorpromazine, saquinavir, doxorubicin; 
vinblastine was excluded due to interference with most excipients in HPLC) or for 
which adsorption became evident after addition of excipients (diclofenac, 
indomethacin in combination with detergents).  
3.3.1. Recovery Studies with Detergents 
3.3.1.1. Characterization of the Detergents 
Aliphatic and steroidal detergents of different ionization state were investigated in 
terms of their desorbing efficiency using the example of CHAPS and taurocholic acid 
(both steroidal) as well as SDS, CTAB and Brij 35 (aliphatic). Structures and charge 
classes of the detergents are shown in Table 2, along with CMC  values in buffer and 
in water as derived from surface pressure - concentration profiles (Supporting 
Information) and literature reports, respectively.  
 
Table 2 
 
The buffer used for the CMC assessment in this study was the same as in the sorption-
desorption experiments and contained physiological concentrations of salt (50 mM 
Tris, 114 mM NaCl at pH 7.4). It is worth noting that the CMC  of ionic surfactants in 
buffer was much lower than reported CMC values in water due to NaCl-mediated 
charge screening. The buffer-related reduction of repulsion between charged head 
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groups enables closer packing of the detergents and explains the reduced CMC  of 
ionic detergents in buffer. However, due to absence of electrostatic repulsion, the 
CMC  in buffer was lowest for non-ionic surfactant Brij 35 and increased in the 
following rank order: Brij 35 < CTAB < SDS < taurocholic acid < CHAPS. As 
expected, the ranking points to a generally higher CMC  of detergents with a bulky 
residue, i.e. of steroidal detergents (taurocholic acid, CHAPS) as compared to those 
with an aliphatic tail group (Brij 35, CTAB, SDS). 
3.3.1.2. Recovery Studies with Aliphatic Surfactants 
Each detergent was investigated at concentrations well above the CMC  
( ergentCdet =10 mM) in order to enable the solubilization of drug in the micellar 
pseudophase. However, during the course of this study it became evident that such 
high detergent concentrations cause matrix effects in ESI/MS (see below), and hence 
recovery studies were also performed at ergentCdet = 0.1 mM.  
 
CTAB (cationic): Drug loss to Teflon before and after addition of CTAB at 
submicellar (0.1 mM) and at micellar (10 mM) concentrations is shown in Fig.1a and 
Fig. 1A, respectively. 
 
Fig. 1 
 
Regarding the addition of 0.1 mM CTAB (cationic), adsorption of negatively charged 
drugs was reinforced while drug loss for neutral and cationic compounds remained 
unaffected. Complete desorption of positively charged drugs was only achieved for 
the strong bases fluvoxamine and chlorpromazine (pKa> 9 and hence >98% ionized at 
pH 7.4), whereas the pronounced drug loss observed for saquinavir and doxorubicin 
was not minimized. Regarding micellar concentrations of CTAB (Fig. 1A), the 
detergent-mediated adsorption of negatively charged drugs was no longer evident. All 
neutral and most basic compounds were completely recovered with the exception of 
doxorubicin (no effect) and chlorpromazine (~6% unrecovered).  
 
SDS (anionic): Drug loss before and after addition of submicellar (0.1 mM) and 
micellar (10mM) concentrations of SDS is shown in Fig.1b and Fig.1B, respectively. 
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In contrast to CTAB, the addition of 0.1 mM SDS reinforced the adsorption of 
cationic compounds whereas anionic drugs remained unaffected and showed no 
adsorption, irrespective of the concentration of SDS applied. With respect to neutral 
drugs, the effects of SDS and CTAB were comparable, i.e. micellar detergent 
concentrations were required for an effective desorption, whilst submicellar 
concentrations were inefficient. The addition of 10 mM SDS allowed moreover 
almost complete recovery of cationic compounds (5% of doxorubicin and < 3.5% of 
all other drugs were unrecovered) which demonstrates the superior detergency of SDS 
as compared to CTAB.  
 
Brij 35 (non-charged): Drug loss before and after addition of Brij 35 is shown in 
Fig.1c (0.1 mM) and Fig.1C (10 mM). An inspection of drug loss data at 
ergentCdet = 0.1 mM (Fig. 1c) reveals that Brij 35 neither influenced the sorption of 
acidic nor of that of basic compounds significantly. Regarding nonionic drugs, the 
recovering potency was weak, but better as compared to ionic detergents (5% of 
adsorbed ritonavir and 16 % of adsorbed paclitaxel were recovered, Fig. 1c). A 
possible explanation is the presence of micelles at 0.1 mM Brij 35, whereas the CMC  
for CTAB and SDS was not yet reached. At concentrations in large excess of 
the CMC , complete recovery of neutral drugs was achieved after addition of Brij 35. 
However, similar to CTAB, the adsorption of doxorubicin was not minimized, and the 
recovery of chlorpromazine was incomplete.    
3.3.1.3. Recovery Studies with Steroidal Surfactants 
Fig. 2A and Fig.2B shows drug loss to Teflon before and after addition of the 
steroidal detergents, CHAPS (zwitter-ionic) and taurocholic acid (anionic), 
respectively, at concentrations well above the CMC  (10 mM). Neutral drugs (ritonavir 
and paclitaxel) were almost completely recovered from adsorption to Teflon 
regardless of the charge state of the detergents. However, neither CHAPS nor 
taurocholic acid enabled the complete recovery of adsorbed cationic drugs. 
 
Fig. 2 
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3.3.2. Recovery Studies with Cyclodextrins 
Fig. 3 shows the drug loss before and after addition of 2,6-di-O-methyl--
cyclodextrin applied at pH 7.4 and at pH 3 (for clarity only drug loss before addition 
of the pH 7.4 solution is shown). Recovery of all drugs, except for doxorubicin, was 
achieved when working at pH 7.4 (drug loss of doxorubicin > 15%). An increase of 
the fraction of doxorubicin in its ionized form by acidification to pH 3 lowered, but 
not completely reversed the adsorption of doxorubicin (11 % unrecovered). It is 
interesting to note that acidification to pH 3 resulted in degradation of midazolam 
(data not shown) in buffer and also in buffer - organic solvent mixtures (2 - propanol 
and DMSO, see below), whereas 2,6-di-O-methyl-β-cyclodextrin prevented 
degradation.  
 
Fig. 3 
 
3.3.3. Recovery Studies with Organic Solvents  
Recovery from drug loss to Teflon after addition of DMSO, acetonitrile and 
2 - propanol (25 %, v/v) is shown in Fig. 4A, 4B and 4C, respectively. All organic 
solvents showed only a negligible effect on the pronounced adsorption of 
doxorubicin, however, almost complete recovery of all other drugs was achieved 
(max. 4 % unrecovered in presence of 2-propanol and acetonitril). DMSO was slightly 
less effective than 2-propanol and acetonitrile with respect to the recovery of 
saquinavir and fluvoxamine (7 % and 5 % unrecovered, respectively). A rise in the 
DMSO content up to 40 % completely reversed the adsorption of the latter two 
compounds, whereas even 60 % of DMSO was insufficient to accomplish a complete 
recovery of doxorubicin (11 % and 6 % unrecovered at 40 % and at 60 % DMSO, 
respectively, data not shown). Pre-acidification of 2 - propanol resulting in pH 3 of 
the solvent-buffer solution recovered most doxorubicin from the Teflon plate (3.2 % 
unrecovered), but lower concentrations of 2-propanol (12.5 %, pH 3) were not 
effective (32.7 % doxorubicin unrecovered, data not shown).  
 
Fig. 4 
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3.4 Study of Excipient-Related Matrix Effects in ESI-MS  
3.4.1 Compatibility of Detergents with ESI/MS 
In order to detect potential changes in the ionization efficiency in ESI/MS in presence 
of excipients (‘matrix effect’), the mass responses of two test analytes, dissolved in 
either blank buffer or excipient-spiked buffer, were compared. Matrix effects 
observed as a decrease (ionization suppression) or increase (ionization enhancement) 
in analyte response in presence of different detergent concentrations 
( ergentCdet = 0.1 mM, 1 mM and 10 mM) are illustrated in Fig. 5. More precisely, 
Fig  5A and Fig. 5B show matrix effects in presence of Brij 35, CTAB and SDS in 
positive and negative ionization mode, respectively.  
 
Fig. 5 
 
With respect to Brij 35, matrix effects were independent of the ionization mode 
applied: no interference with the test analyte was observed at 0.1 mM Brij 35, 
whereas at ergentCdet  > 0.1 mM ionization suppression was evident and increased with 
increasing detergent concentrations (13-18% and ~ 50 % drop in mass response 
at ergentCdet = 1 mM and 10 mM, respectively).  
In contrast to Brij 35, ion suppression in presence of ionic detergents was dependent 
on the ionization mode, and was most pronounced if analyte and detergent carried the 
same charge. Accordingly, inspection of CTAB (positively charged) in positive 
ionization mode (Fig. 5A), and SDS (negatively charged) in negative ionization mode 
(Fig. 5B), revealed ionization suppression even at the lowest investigated detergent 
concentration (12 % and 5% drop in mass response at ergentCdet  = 0.1 mM CTAB and 
SDS, respectively). A rise in the detergent concentration caused a further depression 
in the ionization efficiency with only 23% and 25% of the analyte recovered at 
ergentCdet  = 10 mM SDS and CTAB, respectively.  
Matrix effects were much less pronounced when the test analyte (more precisely its 
gas phase ion) and the detergent were oppositely charged, i.e. when the effect of 
CTAB (positive charge) on the ionization efficiency of ketorolac (negative ion) was 
observed in negative ionization mode (Fig. 5B) and the effect of SDS (negative 
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charge) on the ionization efficiency of rolipram (positive ion) was observed in 
positive ionization mode (Fig. 5A). Under these conditions, matrix effects were only 
evident at ergentCdet  > 0.1 mM with maximal 22 % signal decrease at 
ergentCdet  = 10 mM CTAB.  However, the first injection of excipient-spiked buffer 
caused a signal increase in presence of SDS (data not shown), and only subsequent 
injections (n = 4) were consistent and are shown in Fig. 5B. The reason for the initial 
ionization enhancement is unknown.  
3.4.2 Compatibility of Cyclodextrins and Organic Solvents with ESI/MS 
Matrix effects in HPLC - MS in presence of DMSO, 2,6-di-O-methyl--cyclodextrin 
and 2-propanol are illustrated in Fig.6 for both ionization modes. 2,6-di-O-methyl--
cyclodextrin showed the most pronounced matrix effects with > 90 % decrease in the 
analyte response,  irrespective of the ionization mode applied. Regarding the organic 
solvents, DMSO caused a decrease in the recovery of the test analyte by 62% 
(positive ionization mode) and 90% (negative ionization mode), whereas 2-propanol 
did not interfere with MS.  
 
Fig. 6 
 
It is well known that ion suppression only occurs if analyte and matrix components 
co-elute. In order to verify that 2-propanol does not disturb the analysis of compounds 
with a retention time different from that of rolipram and ketorolac, 15 additional drugs 
covering a broad lipophilicity range and eluting at various retention times were tested. 
For the calculation of analyte recovery in MS, the UV response was used as an 
internal reference to compensate for variations in injection volume and to account for 
the release of ‘sticky’ compounds from the well plate after addition of 2-propanol. 
The UV-normalized recovery of mass response is given in Table 3 along with the fold 
increase of the mass response after adding 2-propanol. Only compounds which were 
released from the Teflon plate after adding 2-propanol (fold increase >1) showed a 
reduced recovery in MS. Therefore, it is plausible that the relative drop in analye 
signal was due to higher analyte concentrations rather than due to 2-propanol - related 
matrix effects.  
Table 3 
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4. Discussion 
Non-specific binding to miniaturized microtiter plates and other labware has recently 
been recognized as a potential source of experimental artifacts in high-throughput 
screening assays [1]. In order to correct for non-specific binding, we have evaluated 
the ability of i) surfactants of different charge class, ii) cyclodextrins and iii) organic 
solvents to recover drug adsorbed to a Teflon well plate, using the example of 24 
structurally diverse drugs. To the best of our knowledge this is the largest set of drugs 
and excipients investigated so far in terms excipient-aided drug recovery. The 
desorption efficiency of the excipients was depending on the drug properties as well 
as on the type and concentration of the excipient applied. Our data showed that 
sorption of anionic and zwitter-ionic compounds from blank buffer was generally 
negligible, and desorption of neutral drugs was achieved by each of the investigated 
excipients, provided that micellar detergent concentrations were used. The superior 
efficiency of the anionic surfactant SDS ( ergentCdet  = 10 mM) for the recovery of 
cationic drugs may be explained by different mechanisms involved in the desorption 
process, which will be discussed in the following. In addition, the compatibility of 
excipients with ESI/MS was evaluated and will be considered in a guideline proposed 
for the selection of excipients with potential application in miniaturized screening 
assays. 
4.1 Mechanisms of Excipient - Aided Drug Recovery  
4.1.1. The Effect of Charge and Concentration in Detergent-Aided Desorption 
Improved drug recovery at micellar concentrations ( ergentCdet  = 10 mM) of CTAB and 
SDS as opposed to submicellar concentrations (CTAB, SDS, 0.1 mM) was observed 
which indicates that solubilization of drug in the micellar phase is one major process 
involved in the desorption process. Although no comparison between micellar and 
submicellar concentrations of Brij35 was performed, improved drug recovery at 
10 mM Brij 35 as compared to 0.1 mM (both ergentCdet > CMC ) points to the 
importance of also the number of micelles available for solubilization.  
Indirect evidence for the interaction of paclitaxel [53, 54], saquinavir [55], ritonavir 
[55] and fluvoxamine [56] with SDS can be derived from micellar capillary 
electrophoresis studies and, moreover, solubilization of e.g. paclitaxel into non-ionic 
4. Manuscripts 
 147 
 
mixed micelles (Pluronic P123/F127) is well documented [57] and in support of our 
results. Notably, binding constants of e.g. doxorubicin and chlorpromazine to cationic 
(CTAB; CTAC), anionic (SDS; HPS) and non-ionic (Tween 20; Brij35) micelles have 
been reported (excipients given in order of increasing affinity), but neither the trend 
for micellar affinities (nonionic > anionic > cationic) nor the abundance of micelles 
( 35BrjiCMC < CTABCMC  < SDSCMC , Table 2) mirrors the efficiency of detergents in terms 
of drug recovery [58-60]: Since complete recovery of doxorubicin and 
chlorpromazine was only achieved with SDS, other mechanisms apart from 
solubilization are likely to be involved in the desorption process.  
Our data indicate that electrostatic repulsion between SDS enriched at the Teflon 
surface and SDS incorporated in drug-loaded micelles (net negatively charged) is of 
importance for the desorption process and provides a possible explanation for the 
superior desorption efficiency of SDS. The formation of mixed micelles of SDS and 
doxorubicin (chlorpromazine) [59, 60] is well documented and in support of the 
proposed mechanism. Moreover, increased adsorption observed for cationic and 
anionic drugs after addition of submicellar concentrations of SDS (anionic) and 
CTAB (cationic), respectively, indicates adsorption of detergents at the Teflon surface 
and electrostatic attraction of oppositely charged drugs. However, at micellar 
concentrations of SDS, cationic drugs can be considered as desorbed from adsorbed 
detergents and solubilized in free SDS micelles, as also described elsewhere in more 
general terms [61]. The presence of SDS residing at the Teflon surface then likely 
leads to the repulsion of drug-loaded SDS micelles with a net charge dominated by 
excess SDS. Our study showed that cationic, but not anionic drugs are prone to 
adsorption to Teflon. Electrostatic attraction between cationic drugs and negatively 
charged detergents may result in higher drug affinity to SDS as opposed to negatively 
charged CTAB, which likely contributes to the superior desorbing ability of SDS. 
Nonionic detergents such as Brij 35 lack the contribution of charge repulsion which 
could explain the weaker desorbing potency.  
The addition of ionic detergents at submicellar concentrations should be avoided since 
drug loss of oppositely charged drugs was reinforced, however, only for compounds 
carrying a hydrophobic residue (e.g. diclofenac and indomethacin, but not ketorolac, 
in presence of 0.1 mM CTAB). This points to the importance of not only electrostatic, 
but also hydrophobic interactions and suggests the incorporation of hydrophobic drug 
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into a layer of detergents residing at the Teflon surface. The phenomenon has been 
described as adsobilization [61] and has notably found application for e.g. the 
adsorption of negatively charged antibiotics to vascular PTFE (Teflon) catheters by 
means of cationic surfactants (CTAB, benzalkonium chloride).  
On the molecular level, an orientation of detergents on the Teflon surface, such that 
the hydrophobic tail interacts with the hydrophobic polymer and the head group 
points towards the aqueous phase, is reasonable and has been proposed by several 
authors [62, 63]. This would be in line with both, the coadsorption of drugs with 
hydrophobic residues of detergents at CMCC  (drug and detergent oppositely 
charged), and the repulsion of drug loaded micelles at CMCC  . 
From a theoretical point of view, another possible desorption mechanisms involves 
electrostatic repulsion and competition of equally charged drug and detergent for 
available adsorption sites on the Teflon surface. However, only compounds with 
almost 100 % positive charge (fluvoxamine, chlorpromazine) could be recovered by 
use of submicellar concentrations of cationic CTAB. However, CTAB was inefficient 
for saquinavir and doxorubicin carrying 28% and 84% positive charge, respectively, 
which suggests that neither electrostatic repulsion nor displacement of adsorbent 
drugs with submicellar detergent concentrations are sufficient to overcome the 
hydrophobic attraction between Teflon and partially charged drugs. This, in turn, 
points to rather weak surfactant - Teflon interactions which is in line with the reported 
weak affinity of SDS, CTAB and Brij 35 for Teflon [63]. Therefore, another 
conceivable desorption mechanism, involving the hydrophilization of the Teflon 
surface by detergent adsorption (van der Waals attraction decreases [48]), seems to 
play only a minor role and is insufficient without the contribution of micellar 
solubilization. 
The inferior desorbing potency found for steroidal detergents as compared to CTAB, 
SDS and Brij 35 can be explained by the lower tendency of bulky amphiphiles to 
assemble into micelles (high CMC values, Table 2) [48]. Detergents with bulky 
residues are also less likely to adsorb to surfaces which is a possible explanation for 
the weaker effectiveness of taurocholic acid as compared to SDS (both negatively 
charged). 
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4.1.2. Mechanisms of Desorption with Solvents and Cyclodextrins  
Similar to detergents, cyclodextrins and organic solvents are well known to increase 
the solubility of hydrophobic compounds which, in turn, contributes to the shift from 
adsorbed towards solubilized drug [47, 64].  
The complete recovery of paclitaxel after addition of 2,6-di-O-methyl-β-cyclodextrin 
is in line with the well documented increase in drug solubility [65] associated with the 
formation of paclitaxel-cyclodextrin inclusion complexes. Complete desorption with 
2,6-di-O-methyl-β-cyclodextrin was also achieved for saquinavir, ritonavir and 
chlorpromazine, even though structurally slightly different cyclodextrines are 
typically applied for their solubilization [66-68]. However, both 2,6-di-O-methyl-β-
cyclodextrin (7 sugar units) and γ-cyclodextrin (8 sugar units, data not shown), for 
which a higher affinity for doxorubicin has been reported [69], were unsuccessful in 
desorbing doxorubicin, which confirms that solubilization alone may be insufficient 
for the recovery of certain drugs.  
Like cyclodextrines, organic solvents lack the effect of electrostatic repulsion, 
explaining the weaker desorbing potency as compared to anionic SDS. Similar to 
SDS, enrichment of 2-propanol at Tefon surfaces has interestingly been reported [70], 
however, the associated hydrophilization of the Teflon surface was apparently not 
sufficient for the release of adsorbed doxorubicin. Acidification to pH 3, leading to an 
increase in the fraction of drug in its ionized form, enhanced the drug recovery which 
is in line with literature reports demonstrating pH dependent adsorption of 
doxorubicin to intravenous filters [71]. 
4.2 Comparison with Excipient-Aided Desorption from other Plastic Materials 
Information about drug adsorption to Teflon and excipient-aided drug recovery is 
very scarce and therefore a discussion of our results only possible in comparison with 
other hydrophobic surfaces.  
With respect to steroidal detergents, taurocholic acid (anionic) and particularly 
CHAPS (zwitterionic) have been used for minimization of drug loss in urine and CSF 
samples (polypropylene) [30], however, our results confirmed that the success of their 
application is compounds specific [33] and drug recovery may only be achieved for 
some, but not all drugs.  
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Regarding SDS, Chen et al. [41] and Silvester et al. [72] reported that the detergent 
was less efficient for the reversal of drug adsorption to polypropylene containers as 
compared to sodium dodecylbenzene sulfonate (SDBS), which is more hydrophobic. 
Interestingly, SDS has successfully been applied in soil remediation [46] which points 
to the difficulty of translating experience gained from one specific compound and 
detergent to other drugs and experimental conditions. We abstained from using SDBS 
because of the presence of a chromophore likely to interfer with UV analytics. For the 
same reason we investigated Brij 35 rather than Tween 20 (80) or Triton-X 100 as an 
example of non-ionic polyoxyethylene detergents. The inferior efficiency of Brij 35 to 
recover chlorpromazine and doxorubicin as compared to SDS was surprising because 
of the frequent use of Tween and Triton - X 100 for blocking protein adsorption in 
ELISA (non-ionic detergents are mandatory to maintain the protein conformation) 
[26, 28], and for minimization of drug loss in urine sampling [72]. However, it has 
also been reported that non-ionic detergents are generally not as effective as anionic 
agents for the removal of particulate soil [48]. Rosen pointed out that this was due to 
the fact that adsorption of non-ionic surfactants to the substrate does not significantly 
increase the electrical potential at the Stern layer [48], which is in line with our 
explanation for the superior detergency of SDS as compared to Brij 35.  
Pertaining to the desorbing ability of cyclodextrins, more efficient minimization of 
drug loss has been reported when cyclodextrins were applied before the addition of 
drugs (pre-treatmant as opposed to post-treatment), and even then complete recovery 
was not achieved for all compounds [33], which is in line with our results.  
Regarding the organic solvents, the concentration we found efficient for the recovery 
of most compounds (25%, but not 12.5%), was of the same order of magnitude used 
by many other authors [33, 35]. The preference for the addition of 20-30% organic 
solvent may be due to the constituted change in the solubilization mechanisms at 10-
20% organic cosovent which is accompanied with a change from a linear to an 
exponential increase in solubility [73].  
4.3 Compatibility of the Excipients with Mass Spectrometric Analysis 
There is a consensus that competition for charge and/or space on the surface of 
electrosprayed droplets in ESI/MS is involved in the phenomenon of ion suppression 
since only what resides on the droplet surface can enter the gas phase [74, 75]. Other 
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factors that disturb the droplet formation and/or the droplet evolution in ESI/MS have 
also been stressed, among them the presence of additives which are surface active 
[74], increase the viscosity [76] or form non-volatile ion pairs with the analyte [77]. In 
a very abstract way, the mechanisms leading to the reversal of drug loss to Teflon, i.e. 
competition for adsorption sites on the Teflon surface, micellar solubilization of drugs 
as well as reduction of interfacial tension, are very similar to the mechanisms 
provoking ion suppression in ESI/MS. Therefore it is conclusive that strongly 
amphiphilic detergents (Brij35, SDS and CTAB) suppressed the ionization of less 
amphiphilic test analytes, unfortunately at detergent concentration necessary to be 
efficient for desorption.  
Matrix effects caused by SDS are well documented [50], whereas matrix effects 
caused by Brij 35 and CTAB have not been recognized before. Yet, reduced analyte 
response in presence of structurally related nonionic detergents (Tween 80, Triton-X 
100) [76], and likewise cationic model amphiphiles, has been observed before which 
is in support of our results. To the best of our knowledge, this is also the first study 
showing evidence for ion suppression in presence of 2,6-di-O-methyl-β-cyclodextrin 
which is consistent with preliminary studies showing ion suppression for other 
cyclodextrin analogues [40]. With respect to DMSO, matrix effects have been 
reported before, but received not much attention [38]. We confirmed the DMSO-
related matrix effect which likely results from the lower volatility of DMSO as 
compared to acetonitrile and 2-propanol.  
Our initial aim for identifying an excipient which is most suitable in terms of 
efficiency of drug recovery and MS compatibility turned out to be explicit: the only 
excipients which are MS compatible at concentrations necessary for desorption are 2-
propanol and acetonitrile. 
4.4. Guideline for the Selection of a Desorbing Excipient  
As a strategy to avoid adsorption-related experimental artifacts in an in vitro assay we 
propose adding excipients to sample solution containing compounds with a high 
probability for adsorption. The extent of drug loss can roughly be predicted by a 
linear combination of lipophilicity, molecular weight, number of H-bond donors and 
molecular shape as described in more detail in our accompanying manuscript 2. It is 
important to note that excipients can have a major impact on the biological or 
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physicochemical process of interest, examples of which are the excipient-related 
changes in artificial membrane permeability [78] and solubility [79]. Leaving the drug 
undisturbed during the experiment and recovering already adsorbed at the end would 
circumvent the problem of eliminating one artifact by creating just another. Therefore 
we recommend adding excipients at the end of the process of interest. SDS used at 
concentrations above the CMC should be the first choice, whereas 2-propanol (25%, 
v/v) at pH 3 would be an appropriate alternative if compatibility with ESI/MS is 
required.  
A drawback of using 2-propanol is the detrimental effect on the peak shape of 
compounds eluting close to the solvent front in HPLC (not shown). However, the 
elution behavior of compounds showing a high propensity to adsorption, i.e. lipophilic 
drugs with long tR  in HPLC, are not affected by 2-propanol and therefore we consider 
this issue as secondary. If peak splitting in HPLC occurs, despite having filtered out 
hydrophilic compounds by means of the prediction model, the experiment could be 
repeated with acetonitrile. The reason for not choosing acetonitrile as a primary MS 
compatible excipient is the higher tendency to evaporate which complicates the assay 
automation. Fig. 7 summarized the proposed guideline in a flow chart.  
 
Fig. 7 
 
4.5. Limitations and Future Perspectives 
Despite the relatively large set of drugs tested, monitoring the desorbing ability of 
excipients (in particular SDS, 2-propanol) on an extended dataset is still desirable for 
the purpose of a higher statistical certainty of our results.  
Furthermore, fluor surfactants may provide a promising alternative to SDS and 2-
propanol since i) very low CMC values have been reported indicating high efficiency 
of solubilization, ii) fluor surfactants show a higher tendency for adsorption to Teflon 
as compared to hydrocarbons which may lead to more effective competition with 
drugs for available adsorption sites on the Teflon surface  [80]. iii) It was shown that 
fluor surfactants caused no ion suppression in ESI/MS [41]. Despite these theoretical 
considerations, the efficiency of fluor surfactants in terms of minimizing drug 
adsorption to plastic labware still needs to be demonstrated.  
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Potential areas of application for the recovery of adsorbed drug by means of 
excipients are, e.g., miniaturized in vitro screening assays implemented in drug 
discovery and development programs. The assessment of the fraction of drug free in 
solution and bound to the assay plate could be used to correct potentially erroneous 
assay read-outs, or e.g. to flag compounds according to their likelihood for adsorption 
to the assay construct. 
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5 Conclusions 
In summary, we have shown at the example of 24 structurally diverse compounds that 
drug adsorption from aqueous solution to a Teflon microtiter plate can completely be 
reversed by addition of micellar concentration of SDS. Our data suggests that i) 
solubilization of drug in the micellar phase and ii) electrostatic repulsion between 
SDS enriched at the Teflon surface and drug-loaded SDS micelles free in solution are 
involved in the drug recovery process. SDS and all other investigated excipients, 
except for 2-propanol, caused matrix effects in ESI/MS and therefore we recommend 
using SDS for drug recovery experiments only as long as concentration analysis relies 
on UV. When mass-spectrometric analysis is a necessary criterion for applicability, 2-
propanol provides a useful alternative to SDS. The inferior recovery of doxorubicin 
with 2-propanol as compared to SDS can be resolved by pH adjustment to pH 3, 
which increases the fraction of drug in its ionized form, and thereby decreases the 
fraction of drug adsorbed. The proposed guideline for excipient-aided drug recovery 
may be applied for the correction of potentially erroneous results in a multitude of 
miniaturized in vitro assays implemented in drug development programs. Our results 
may thus contribute to avoiding misinterpretations and achieving higher reliability of 
the experimental data in case that drug adsorption to plastic lab ware, in particular 
Teflon, occurs.  
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Table2   Charge class, critical micellar concentrations ( CMC ) and structures of the 
investigated detergents. 
Tenside Charge 
class 
CMC  
(buffer) 
CMC
(H20)
a 
Investigated 
concentration  
Structure 
  (mM) (mM) (mM)  
CHAPS zwitter-
ionic 
3.46±0.12 6 10 
 
OH
OH
OH
N
H
O
N
+ S
O
O
O
H
HH
 
Taurocholic 
acid 
anionic 2.60 ± 0.73 3-11 10 
OH
OH
OH
N
H
O
S O
O
O
H
HH
Na
+
 
CTAB cationic 0.14 ± 0.02 1 0.1, 10 
N
+
Br
 
SDS anionic 
 
1.02 ± 0.06 7-10 0.1, 10 
 
O
S
O
O
O
Na
+
 
Brij 35 neutral 0.07 ± 0.00 0.09 0.1, 10 
OH
O
23
 
a
 Values taken from [48] 
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Table 3   Charge class, octanol/water distribution coefficients, retention times in HPLC, 
recovery of the mass response and the fold increase of the absolute mass signal in presence of 
2-propanol for the 16 compounds investigated (given in ascending order of recovery in MS).  
Compound  Charge 
class
a
 
octLogD
b
 Retention 
time 
Recovery in MS, 
corrected
c
 
Increase of mass signal 
with 2-propanol 
   [min] [%] fold 
Trifluperazine B 4.0 0.544 75.2 1.8 
PK 11195 N 3.8 0.736 81.3 1.3 
Thioridazine B 3.6 0.541 84.6 1.5 
Cyclobenzaprine B 3.0 0.506 89.4 1.1 
Verapamil  B 2.5 0.513 91.3 1.1 
Amitriptyline B 2.8 0.512 92.3 1.1 
Maprotiline B 1.5 0.509 94.1 1.0 
Midazolam N 3.2 0.490 94.9 1.1 
Rolipram N 1.9 0.580 99.5 1.0 
Metoclopramide B 0.2 0.448 99.9 1.0 
Flumazenil N 1.1 0.525 100.3 1.0 
Carbamazepine N 1.6 0.560 100.8 1.0 
Zaleplon N 1.2 0.560 100.9 1.0 
Phenytoin  A 2.3 0.551 107.3 1.1 
Theophylline A -0.2 0.419   
Rizatriptan B -0.7 0.373    
a
N: neutral (less than 3 % ionization at pH 7.4); A: acid with ApKa < 8.9; B: base BpKa >6; pKa 
measured potentiometrically, in-house 
b
measured with CAMDIS.
c
The peak area in ESI/MS was 
divided by the peak area in UV of the same run to correct for non-specific binding to the instrument 
and the well plate. The ratio with and without 2-propanol was related and corresponds to the corrected 
recovery in MS. Drug concentration: 25µM.  
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Figure 1   Drug loss from aqueous bulk solution to Teflon before (black columns) and after 
(grey columns) addition of aliphatic detergents: (a,A) positively charged CTAB, (b,B) 
negatively charged SDS, (c,C) non-charged Brij 35. Detergents were investigated at 
ergentCdet = 0.1 mM (a,b,c) and ergentCdet  = 10 mM (A,B,C). The compounds shown are 
diclofenac and indomethacin (anionic), ritonavir and paclitaxel (neutral) as well as 
fluvoxamine, chlorpromazine, saquinavir and doxorubicin (bases). 
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Figure 2   Drug loss from aqueous bulk solution to Teflon before (black columns) and after 
(grey columns) addition of steroidal detergents: (A) anionic taurocholic acid, (B) zwitter-ionic 
CHAPS (both 10 mM). Compounds as indicated in Fig. 1. 
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Figure 3   Drug loss from aqueous bulk solution to Teflon (black columns) and recovery from 
drug loss with 2,6-di-O-methyl--cyclodextrin (10 mM) applied at pH 7.4 (grey columns) and 
at pH 3 (dashed columns). Compounds as indicated in Fig. 1. 
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Figure 4   Drug loss from aqueous bulk solution to Teflon before (black columns) and after 
(grey columns) addition of organic solvents: (A) DMSO; (B) acetonitrile and (C) 2-propanol. 
The final concentration of solvent was 25 % (v/v). Compounds as indicated in Fig. 1. 
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Figure 5 A, B:   Concentration dependency of mass analyzed analyte recoveries in presence 
of Brij 35 (), CTAB () and SDS (). Recovery studies were conducted separately in 
positive (A) and negative (B) ionization mode, using rolipram and ketorolac, respectively, as 
test analytes (both 25 µM, buffer: 50 mM Tris, 114 mM NaCl, pH 7.4). The ion intensities of 
the (M+H]
+
 (rolipram) and the M-H]
- 
(ketorolac)
 
trace were monitored in SIM mode. All 
samples were processed with a fast gradient HPLC method before introduction into the 
ionization source (ESI) of the single quadrupole mass spectrometer. 
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Figure 6   Recovery of mass response after addition of 2-propanol, DMSO (both 25 %, v/v) 
and 2,6-di-O-methyl--cyclodextrin (10 mM) in positive (black column) and negative 
(hatched columns) ionization mode. 
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Figure 7   Guideline for the selection of an appropriate detergent for the remediation of drug 
loss to Teflon. For the prediction of a compound’s likelihood for non-specific binding, the 
reader is referred to our accompanying manuscript 2. 
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Figure S1   Structures of compounds for which adsorption onto Teflon was evident before 
(ritonavir, paclitaxel, fluvoxamine, chlorpromazine, saquinavir, doxorubicin) or after 
(diclofenac, indomethacin) addition of excipients. 
 
1E-6 1E-5 1E-4 1E-3 0.01
0
5
10
15
20
25
30
35
40
S
u
rf
a
c
e
 p
re
s
s
u
re
 
 (
m
N
/m
)
Detergent concentration (M)
 
Figure S2   Surface pressure - concentration profiles for Brij 35(), CTAB (), SDS (), 
taurocholic acid () and CHAPS () dissolved in 50mM Tris/114mM NaCl/pH 7.4 buffer.  
Experiments were carried out at room temperature, on a multichannel microtensiometer 
(Delta-8, Kibron, Helsinki) using an aluminium assay plate (capacity: V = 50µL). 
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ABSTRACT 
The Parallel Artificial Membrane Permeability Assay (PAMPA) has emerged as a widely 
used primary in vitro screen for passive permeability of potential drug candidates. Excipients 
such as solubilizers and formulation agents are frequently applied in PAMPA, however, they 
may suppress the ionization efficiency of the analyte of interest (matrix effect). To ensure the 
accuracy of mass-analyzed passive permeability, it was crucial to investigate matrix effects 
related to excipients commonly used in PAMPA, namely glycocholic acid (0.5 %, m/v), 
hydroxypropyl--cyclodextrin, propylene glycol, N-methyl-2-pyrrolidone (each 0.24 %, m/v) 
and, in addition, the FaSSIF/FeSSIF media. Recovery and post-column infusion studies of the 
test analyte rolipram were conducted in presence and in absence of excipients. Concentration 
analysis was achieved with a fast generic gradient method on a HPLC system coupled to an 
electro-spray single-quadrupole mass spectrometer (HPLC-ESI/MS) working in single 
reaction monitoring mode. The excipients were characterized by means of surface activity 
measurements. Matrix effects were pronounced for excipients favoring the air-water interface 
(glycocholic acid, the FaSSIF/FeSSIF media), forming multiply-charged ions 
(hydroxypropyl-β-cyclodextrin) and/or carrying a proton acceptor in the form of a nitrogen 
(1-methyl-2-pyrrolidone). Propylene glycol showed the weakest matrix effect. The non-
uniform presence of ion-suppressing excipients only in the PAMPA donor compartment 
resulted in overestimation of membrane permeability, as was demonstrated with glycocholic 
acid. We recommend i) to provide the same concentration of excipients in each PAMPA 
compartment prior to injecting the analyte solution onto the HPLC-MS system and ii) to 
replace the frequently used solubilizer glycocholic acid with propylene glycol. However, 
when using HPLC-MS for concentration analysis in PAMPA it should be critically tested 
whether or not a solubilizer improves the net sensitivity in HPLC-MS. In addition, we 
suggest surface tension measurements for investigating a potential ion-suppressing effect of 
buffer matrix components.  
 
 
KEYWORDS 
Excipients, PAMPA, Ion suppression, Matrix effects, ESI-MS 
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1. Introduction 
Membrane permeability plays a key role in drug absorption and drug distribution; its 
assessment has therefore become an integral part of the early ADME (Absorption, 
Distribution, Metabolism, Elimination) profiling process[1]. PAMPA (Parallel Artificial 
Membrane Permeability Assay) has emerged as a widely used primary in vitro screen for 
passive membrane permeability [2, 3] and provides a fast and low - cost alternative to 
cell-based permeability assays.While the 96 - well plate format allows for the processing of 
several hundred compounds per week in parallel, concentration analysis remains the 
bottleneck of PAMPA [4]. Rapid quantification with a UV plate reader is often hampered by 
the presence of impurities, the lack of a UV chromophore, and the low solubility of many 
research compounds. Efforts to improve the assay sensitivity and/or selectivity involved for 
instance the use of solubilizers, the transfer from UV to HPLC-MS analysis, or a combination 
of both [5]. Particularly MS systems equipped with an electrospray ionization source (ESI-
MS) have found entry in many laboratories owing to the gentle ionization of the analytes.  
However, reduced ionization efficiency of an analyte in presence of coeluting substances (the 
‘matrix’) is a major concern in ESI-MS and has been referred to as ion suppression or matrix 
effect [6]. Ion suppression not only impairs the sensitivity but may even lead to erroneous 
results if variations in the matrix composition among different samples are neglected. The 
fact that MS is able to monitor a single molecule in complex matrixes can turn out to be a 
pitfall because coelution of an analyte with other substances is easily overlooked. Use of fast 
generic gradient methods to accomplish the demand for higher throughput goes at the 
expense of separation efficiency and further increases the probability of matrix effects [7].  
The underlying mechanisms of matrix effects are not yet fully understood and can involve 
both solution and gas phase processes, the former of which has been considered the more 
relevant [8].  For example, the formation of charged droplets at the capillary needle entering 
the ionization source is susceptible to changes in surface tension, conductivity and viscosity, 
and is thus likely perturbed by coeluting matrix compounds [9-11]. Additionally, competition 
for the limited charge and/or space on the surface of the electrosprayed droplet has been 
proposed as a major factor involved in ion suppression [12, 13]: According to the ion 
evaporation model [14], only molecules which reside on the surface of the electrosprayed 
droplets can be considered as precursors of the gas phase ions that finally enter the mass 
spectrometer [15]. Therefore, surface active ions enriching on the droplet surface have been 
found to prevent less amphiphilic compounds from ion evaporation [11, 16, 17]. The 
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observation that precursors of the gas phase ions (i.e. the offspring droplets) are formed from 
the liquid close to the surface of the parent droplet further enhances the importance of surface 
activity [18]. Other processes involved in ion suppression are the formation of solid residues 
from highly concentrated analyte and/or matrix solutions [8] in addition to proton transfer 
reactions in the gas phase [19].  
Much of the knowledge about the underlying mechanisms of ion suppression must be 
credited to Kebarle and coworkers [20] and Enke [16], who primarily focused on the 
concentration dependent mass responses of simple amines. In the last decade, excipients used 
as dosing vehicles in DMPK (Drug Metabolism and Pharmacokinetics) studies have also 
been recognized to cause ion suppression and, in turn, erroneous estimates of 
pharmacokinetic parameters [10, 21-26]. Notably, an EMEA guideline [27] provides 
recommendations for the evaluation of matrix effects in bioanalytical studies. In view of the 
above it is all the more surprising that excipient-related matrix effects have barely been 
considered in classical physicochemical screening assays such as PAMPA. Excipients are 
frequently used in PAMPA, either as solubilizers [28] , model formulation agents [29] or sink 
compounds [30], at concentrations several orders of magnitude higher than the analyte itself.  
The aim of this study was to test whether the excipients used in PAMPA cause ion 
suppression in ESI-MS, and whether the presence of ion suppression affects the accuracy of 
the permeability measures. We investigated (i) the amphiphilic solubilizer glycocholic acid 
(GCA), (ii) the model formulation agents propylene glycol (PG), 2-hydroxypropyl--
cyclodextrin (HP-β-CD) and N-methyl-2-pyrrolidone (NMP), and (iii) the simulated 
gastrointestinal fluid in the fasted (FaSSIF) and the fed (FeSSIF) state (taurocholic acid-
phospholipid-salt mixture)[31]. Although pure taurocholic acid has been studied as a model 
formulation agent in PAMPA [29], we studied the FaSSIF/FeSSIF media instead,  to account 
for the greater relevance for predicting food-induced changes in permeability [32]. 
There is a certain overlap between the dosing vehicles which have already been evaluated in 
the framework of DMPK studies (PG, HP - β - CD) and the excipients tested in this study. 
However, the literature lacks information on possible matrix effects in the presence of the 
FaSSIF/FeSSIF media, GCA and NMP. In addition, the published studies on excipient-
related matrix effects focus on concentrations matching the expected excipient concentrations 
in plasma. Here, we were interested in the effect of higher concentrations required for 
efficient solubilization in PAMPA. Moreover, the implications from literature studies on the 
impact of PG and HP - β - CD on the accuracy of MS were based on recovery studies of a 
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specific analyte without giving insight into the elution behavior of the excipient [10]. For a 
more complete picture of excipient-related matrix effects, we performed recovery and post-
column infusion studies with the test analyte rolipram, and diagnosed coelution with the 
excipients by means of full scan MS experiments. In addition the effect of non-uniform 
presence of excipients in the PAMPA sandwich on the accuracy of mass-analyzed 
permeability values was evaluated using GCA as an example.  
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2. Materials and Methods 
2.1. Drugs and Chemicals  
Rolipram, amitriptyline, midazolam, PK 11195, thioridazine · HCl, trifluperazine · HCl, 
verapamil · HCl and zaleplone were available through our in-house Compound Depository 
Group as proprietary compound. Theophylline was obtained from Acros (New Jersey, MA, 
USA). Rizatriptane was available from Bepharm (Shanghai, China). Carbamazepine, 
cyclobenzaprine · HCl, flumazenil, maprotiline · HCl, metoclopramide · HCl, phenytoin, 
GCA, HP--CD and PG were purchased from Sigma (Steinheim, Switzerland). Tris, sodium 
chloride, sodium dihydrogen phosphate and acetic acid were obtained from Fluka (Buchs, 
Germany). DMSO was obtained from Acros (Geel, Belgium). N - methyl-2-pyrrolidone 
(NMP) was purchased from Merck (Hohenbrunn, Germany). SIF Powder for the preparation 
of the FaSSIF / FeSSIF media was obtained from Phares (Muttenz, Switzerland). Formic 
acid, water and acetonitril were supplied from Merck (Darmstadt, Germany) and were of 
HPLC-grade.  
2.2. HPLC Instrumentation and Chromatographic Conditions 
All experiments were performed on an Agilent 1290 Infinity HPLC system equipped with 
degasser, auto - sampler, column oven, pump, DAD detector and mass spectrometer. If not 
mentioned otherwise, the sample solution (5 µL) was injected onto a Kinetex C18 analytical 
column (2.6 µm particle size, 2.1 x 50 mm, Phenomenex, Torrence, CA) operated at 60 °C. 
The mobile phase was delivered at 1 mL/min and consisted of A (water) and B (acetonitril), 
each containing 0.1 % (v/v) formic acid. In the gradient program, B was held at 5 % for 
0.1 min and then was linearly increased to 40 % in 0.1 min and further to 95 % in 0.4 min. 
After 2.5 min, the gradient was set back from 95 % B to the initial conditions. 
2.3. Mass Spectrometry 
The API single quadrupole mass spectrometer (Agilent 6140) was equipped with an 
electrospray ionization source operated in positive mode. Each 0.1 s the intensity of the 
pseudo - molecular ion, [M+H]
+
, was acquired in single reaction monitoring mode (SRM). 
Recovery studies were also conducted in full scan mode (MRM dwell time 50 ms) at m/z in 
the range 50 – 1350 (NMP, HP--CD, PG) or 100 - 1000 (all other excipients). The source 
settings were as follows: capillary voltage + 3.5 kV, drying gas flow (N2) 13 L/min, nebulizer 
pressure 60 psi, drying gas temperature 350 °C. In the recovery studies and permeability 
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measurements, the flow from the HPLC system was introduced into the ESI interface only 
after 0.25 min to prevent contamination with buffer salts and DMSO. In contrast, the whole 
time window without any delay was used to monitor matrix effects in the post-column 
infusion studies.  
2.4. Evaluation of Matrix Effects 
2.4.1. Selection of the Test Analyte  
The selection of the test analyte rolipram was based on the following criteria: (i) presence of 
a UV chromophore enabling direct comparison of analyte response in MS and UV (the UV 
analysis was not disturbed by the presence of excipients, see Figure 11A in Results and 
Discussion), (ii) negligible adsorption to plastic plates and pipetting devices (data not shown), 
which could otherwise bias the recovery studies, and (iii) moderate lipophilicity (measured 
logDoct 1.91 at pH 7.4 [33]), which meets the intention to study a drug with intermediate 
retention in HPLC.  
2.4.2. Concentration of Excipient Solutions and their Preparation 
Excipient solutions spiked with GCA and the formulation agents (HP--CD, PG and NMP) 
were prepared in blank buffer (50 mM Tris, 114 mM NaCl, pH 7.4). The final working 
concentrations corresponded to those routinely used in the Roche PAMPA setup (GCA, 
0.5 %, m/v) or applied in PAMPA excipient profiling to resemble the quantities expected in 
gastrointestinal fluids under clinically relevant conditions (formulation agents, each 0.24 %, 
m/v)[29]. FaSSIF and FeSSIF medium, respectively, was prepared from blank FaSSIF buffer 
(0.029 M phosphate, 0.106 M NaCl, pH 6.5) and blank FeSSIF buffer (0.144 M acetate, 
0.203 M NaCl, pH 5.0). Instant SIF Powder (2.24 g/L and 11.2 g/L) was reconstituted in the 
corresponding blank buffers resulting in 3 mM and 15 mM sodium taurocholate and 0.75 mM 
and 3.75 mM lecithin of the final FaSSIF and the FeSSIF medium, respectively. For the post-
column infusion studies, all excipient solutions were prepared in an eluent mixture (50:50 
water-acetonitril, 0.1% formic acid) instead of using buffer.  
2.4.3. Recovery Studies 
Analyte solutions containing the test drug (25μM rolipram, DMSO content: 0.25%, v/v) were 
prepared either in excipient-spiked buffer (50 mM Tris, 114 mM NaCl, pH 7.4, excipient 
concentrations see above) or in blank buffer (reference). The reference was injected onto the 
HPLC-MS system (n=5), followed by five consecutive injections of the excipient-spiked test 
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solutions. Recovery of the test drug was determined from the ratio of the average peak area in 
presence and in absence of excipient.  
2.4.4. Post-Column Infusion Studies 
Analyte solution (25 µM rolipram in eluent, DMSO content: 0.25 %, v/v) was infused into 
the HPLC-MS system using an external pump (Dionex P680 HPLC Pump) set at 50 µL/min. 
During the infusion, eluent spiked with excipient was injected on - column via the installed 
autosampler (n=5). Between the injection of excipients, blank eluent was injected five times 
to confirm complete recovery and to provide an initial reference. The flow from the HPLC 
column (1 mL/min) was combined with the constant flow of the analyte solution from the 
external pump via a T-piece, implemented directly before the ionization source.  
2.5. Measurement of Surface Activity 
Surface activity experiments were carried out on a multichannel microtensiometer (Delta-8, 
Kibron, Helsinki) utilizing a modified Du Nouy method as described elsewhere [34]. Prior to 
the measurements, the system was cleaned by heating the microbalances and calibrated with 
distilled water to 72.8 mN/m. Stock solutions of GCA (12.5mM), NMP (5M), PG (5M) and 
HP-β-CD  (100 mM) were prepared in 50mM Tris/ 114mM NaCl/ pH 7.4 buffer.  Eleven 
consecutive 1:1 dilutions of the excipient stock solutions and the FaSSIF medium (buffer: 
0.029 M phosphate, 0.106 M NaCl, pH 6.5) were perpared and an aliquot of each dilution 
(50 µL) was transferred to the 96-well measurement plate (aluminium). The surface pressure, 
π=γ0-γ, where γ0 is the surface tension of the pure buffer and γ the surface tension of the drug 
solution, was monitored in the order of increasing excipient concentration (n=3). The air-
water partition coefficient, awK , was gained from extrapolation of the linear part of the 
π/ Clog  plot to zero surface pressure as described elsewhere [34, 35].  
2.6. Prediction of Matrix Effects by Means of logDoct (pH3.3) 
The recoveries from GCA-spiked buffer as well as the retention times in HPLC/MS were 
recorded for an extended 16 compound dataset covering a wide physicochemical property 
space. Key properties, i.e. molecular weight ( MW ), apK , and calculated octanol/water 
partition coefficients, Pc log , for the test compounds are enclosed in Supporting Information. 
Experimental conditions (25μM analyte, 0.5%, m/v GCA, MS in SIM) were the same as 
described in Section 2.4.3. However, the UV response was used as an internal standard to 
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correct for the loss of lipophilic compounds to labware devices. The PC log  values for the test 
compounds were calculated using Pc log  v4.71 (Daylight Chemical Information Systems, 
Irvine, CA), and the Henderson-Hasselbalch equation was used to calculate octDlog  (pH 3.3) 
from the PC log values and from the in-house measured apK . The retention times for the test 
compounds in HPLC-MS were linearly correlated with the calculated octDlog (pH 3.3) values.  
2.7. PAMPA Measurements 
In PAMPA, a sandwich is formed consisting of an aqueous donor solution spiked with 
analyte, an artifiical membrane and an aqueous acceptor solution. The permeation of the test 
analyte rolipram across the membrane was measured according to the following protocol and 
as summarized in Figure 1.  
 
Fig. 1 
 
An aliquot (320 μL) of buffer solution (50 mM Tris/114 mM NaCl/ pH 7.4, DMSO content: 
0.25 %, v/v) containing the analyte (100 μM rolipram) and a solubilizer (0.5 % (m/v) GCA) 
was transferred into an in-house made Teflon plate constituting the PAMPA donor 
compartment. The remaining solution was kept as a reference. A hydrophobic filter (PVDF, 
125 µm, pore size 0.45 µm) fixed at the bottom of an acceptor plate (Millipore, Billerica, 
MA), MAIPN 4550) was coated with 4 µL lipid mixture (10 % (m/v) egg lecithin, 0.5 % 
(m/v) cholesterol, dissolved in dodecane) forming the barrier between the donor and the 
acceptor compartment. The pre-coated acceptor plate was filled with 280 µL of blank buffer 
devoid of glycocholic acid (50 mM Tris/ 114 mM NaCl/ pH 7.4) and was placed on top of the 
donor plate. The so formed sandwich was left undisturbed for 19 hours (room temperature) 
while the permeation of rolipram occurred. Then, the sandwich was disassembled and the 
reference, the donor and the acceptor compartment were assayed for the distributed drug. 
Sample injection onto the HPLC-UV-ESI/MS system followed three strategies (n=3),  a) the 
reference, donor and acceptor solutions were directly injected, b) the reference, donor and 
acceptor solutions were  diluted 1:100 with blank buffer and c) the concentration of excipient 
in each compartment was adjusted to the same level (0.25% GCA). For this purpose, the 
reference and the donor solution (each 50 µL) were diluted 1:1 with blank buffer, while the 
acceptor solution (50 µL) was diluted 1:1 with buffer containing 0.5 % GCA. 
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For determining the test analyte’s concentration in each compartment, a calibration curve 
using external standards was created (a calibration with different injection volumes is not 
viable, see Figure 11B in Results and Discussion ).  Therefore, sixteen consecutive dilutions 
of a stock solution (200 µM rolipram, in 50 mM Tris/114  mM NaCl/pH 7.4,  0.25 % (m/v) 
GCA, DMSO content 0.25 %, v/v) were prepared to cover the whole concentration range of 
rolipram (1.25 µM – 200 µM)  while keeping the GCA concentration constant. Since the 
calibration function yielded a straight line (r
2
 in UV and MS > 0.998, through origin), the 
concentration of rolipram in the donor and acceptor compartment was expressed as 
percentage of the analyte’s response in the reference solution. Mass balance was used to 
determine the amount of rolipram remaining in the PAMPA barrier. The effective 
permeability, eP , was calculated according to [28] and as described below:  
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where A is the area of the filter, t  the time, st  the time at steady state, AV  and DV  the 
acceptor and the donor volumes, respectively and tAC ,  and tDC ,  are the measured acceptor 
and donor concentrations at time t . The retention factor R  is defined as:  
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2.8. Matrix Effects at Various Sample Loads 
Analyte solutions (100 µM rolipram) containing increasing amounts of GCA (0.005, 0.05, 
0.1, 0.5%, m/v) were prepared in buffer (50 mM Tris/114 mM NaCl/pH 7.4, DMSO content: 
1%, v/v). Aliquots of these solutions (1-10 µL, incremented by 1µL) were then injected onto 
the HPLC-ESI/MS system. The peak areas of rolipram in UV and MS (m/z 276.2) were 
plotted as a function of the concentration of rolipram. 
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3. Results and Discussion  
3.1. Recovery Studies  
Matrix effects were evaluated by comparing the HPLC-ESI/MS - analyzed signal intensity of 
the test analyte rolipram (Figure 2) in presence and in absence of excipients. The structures 
and concentrations of the investigated excipients, namely GCA (0.5 %, m/v), NMP, HP--
CD, PG (each 0.24 %, m/v) as well as of taurocholic acid (the main component in the 
FaSSIF/FeSSIF media) are shown in Figure 3. We used different excipient concentrations in 
order to match the quantities applied in PAMPA, either for solubilization of drugs (GCA) [9] 
or for the simulation of formulation (NMP, HP -  - CD, PG [4]) and food effects 
(FaSSIF/FeSSIF) on drug permeability.  
 
Fig. 2, Fig. 3 
 
Figure 4A shows an example of overlaid mass chromatograms of rolipram (m/z 276.2) in 
absence and in presence of GCA, obtained with a generic fast gradient HPLC-ESI/MS 
method. Setting the mass response of rolipram in blank buffer to 100 %, the intensity in 
excipient - spiked buffer was depressed by 89.3 ± 0.03% corresponding to 10.6 ± 0.03% 
recovery. In Figure 4B, the recovery from each investigated excipient solution is shown. 
Solutions spiked with HP--CD or PG did not disturb the MS analysis, whereas recovery was 
severely diminished in presence of the other excipients given in order of increasing analyte 
recovery: GCA (recovery 10.6  ± 0.03%) < NMP (64.0 ± 1.62%) < FaSSIF 
(76.0  ± 0.6%) ~ FeSSIF (76.7 ±0.7%). 
 
Fig. 4 
 
3.2. Proof of Coelution 
For the sake of improved sensitivity, monitoring only the [M+H]
+
 trace of rolipram was 
favored in the recovery studies. However, information about coelution with the excipients 
was gained from full scan experiments. The full scan mass chromatograms of GCA, the 
FeSSIF medium (also representative for FaSSIF) and NMP shown in Figure 5 in conjunction 
with the retention time of rolipram (Rt=0.575 min) confirm coelution in each case.  
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Fig. 5 
 
The broad elution window of the excipients, particularly for the FeSSIF medium and NMP, 
can be explained as follows: First, the FeSSIF medium consists of several components 
including taurocholic acid (sharp peak at Rt = 0.626 min) and a mixture of various 
phospholipids [36]. Second, the investigated excipient concentrations were extremely high 
(millimolar range) giving rise to overload of the column and ‘breakthrough’ with the dead 
volume. The mass chromatograms of PG and HP --CD (not shown) were less informative 
and only slightly different from blank buffer, probably due to weaker ionization tendency 
(PG) and the limitations of the used mass spectrometer at the boundaries of the specified 
mass range (mass range ESI-MS: 50-1350; MW (PG) = 74; MW (HP--CD) ~1350 [37]).  
3.3. The Influence of Excipients on the Mass Spectra  
In order to provide further evidence for ion suppression, changes in the mass spectra of 
rolipram in presence of excipients were investigated. Fig. 6 A-C shows a snapshot of the 
mass spectra of rolipram (Fig. 6A), GCA (Fig. 6B) and the mixture of both (Fig. 6C), 
depicted at the retention time of rolipram.  
 
Fig. 6 
 
The mass spectrum of pure rolipram (Fig. 6A) was dominated by the sodium adduct of its 
dimer and the mono - protonated pseudo - molecular ion. In contrast, the characteristic 
spectrum of rolipram in the mixture of GCA and rolipram (Fig. 6C) was almost completely 
superimposed by that of GCA (Fig. 6B). Mass spectra of rolipram in presence of the other 
excipients are enclosed in Supporting Information. The abundance of the [M+H]
+
 trace of 
rolipram was higher in presence of the other excipients as compared to GCA, which is in line 
with the results from the recovery studies (Fig. 4B).  
3.4. Post-Column Infusion Studies  
The effect of excipients on the mass response over the whole time window of the gradient 
method was investigated by means of post-column infusion (setup see Fig. 7) [6].  
 
Fig. 7 
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Matrix effects were evaluated by comparing the infusion chromatograms of rolipram after on-
column injection of either blank eluent (buffer) or excipient-spiked eluent (buffer). Figure 
8A’ shows the overlaid mass chromatograms of rolipram obtained from the injection of 
buffer in presence and in absence of GCA. Both chromatograms showed a negative peak 
close to the solvent front (Rt = 0.15 min) which was absent in the experiments with eluent 
(Figure 8A) instead of buffer (Fig. 8A’). The first negative peak could thus be attributed to 
the buffer salts used, either NaCl or Tris, which of the two was not further investigated. The 
negative peak at the higher retention time (Rt ~0.6 - 0.7 min) was only observed in presence 
of GCA, independent of whether buffer or eluent was used as solvent (Fig. 8A’ und Fig. 8A). 
The suppression zone mirrored the elution window of GCA from the full scan experiments 
(Fig. 5A) and thus gave further evidence for ion suppression as the reason for the incomplete 
recovery of rolipram.  
 
Fig. 8 
 
Post-column infusion studies of all other excipients are shown only in eluent (Fig. 8 B - E). 
The FeSSIF medium, NMP and HP--CD caused severe ion suppression, observed as broad 
negative peaks (NMP, Fig. 8C), and in case of the FeSSIF medium (Fig. 8B) and HP -  - CD 
(Fig. 8D) even several suppression zones were evident. Similar to the FeSSIF medium (see 
above), HP -  - CD is not a single molecule, but a mixture of -cyclodextrins labeled on 
average with 0.6 – 0.8 hydroxypropyl units per glucose molecule (information provided by 
the supplier Sigma). The broad suppression zones are probably a reflection of the various 
retention times of the different derivatives. The primary negative peak caused by HP -  - CD 
is most likely the consequence of column overload. Also the FeSSIF medium (Fig. 8B) 
showed a suppression region close to the solvent front which – in contrast to NMP- was not 
seen in the full scan spectra shown in Fig. 5. Rather hydrophilic and probably low molecular 
weight components, not observed in the full scan chromatograms in sufficient intensity, 
might be responsible for the additional ion suppression zone. Even though PG also showed a 
reduction in the signal intensity close to the solvent front (Fig. 8E), it was lower than for any 
other investigated excipient. While for both, PG and HP -  - CD, no ion suppression was 
observed in the preliminary recovery studies (Fig. 4B), the post-column infusion 
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chromatograms indicate that pronounced ion suppression in presence of HP -  - CD is likely 
for analytes eluting earlier than rolipram.  
3.5. Trend Analysis of the Excipients-Related Matrix Effects 
The extent of ion suppression observed in the recovery and post-column infusion studies 
varied considerably between the excipients. However, strictly speaking a comparison is only 
possible in a qualitative manner because different excipient concentrations, eC , were used 
(Fig. 3).  
An inspection of the surface pressure, π, vs. eC profiles (Fig. 9) revealed that each excipient 
tested has the tendency to enrich at the air-water interface (Gibbs adsorption isotherm), 
thereby lowering the surface tension of pure buffer and, vice versa, increasing the surface 
pressure, π. By extrapolation of the linear part of the π- Clog  plot to zero π, the air-water 
partition coefficients of the excipients, awK , can be approximated (Table 1) together with the 
maximal surface pressures, πmax [38]. The excipients, which showed the most pronounced ion 
suppression zones in the post-column infusion studies, i.e. GCA (Fig. 8B), HP -  - CD 
(Fig. 8D) and the FaSSIF/FeSSIF (Fig. 8B) media, showed also a higher surface activity than 
the other formulation agents, NMP (Fig. 8C) and PG (Fig. 8E). This was indicated by the 
higher tendency of GCA, HP -  - CD and the FaSSIF/FeSSIF media to adsorb at the air-
water interface and the concomitant stronger increase of π at the applied excipient 
concentration (π > 10 mN/m).  
 
Fig. 9, Table 1 
 
The trend towards pronounced matrix effects with increasing surface activity is in line with 
the observation of Tang and coworkers [11] on simple amines: The authors recognized that in 
a two - component mixture of electrolytes the electrolyte with the higher surface activity 
yielded the higher relative ion intensity in MS. They attributed the effect to the elevated 
surface population of amphiphilic electrolytes on the ESI droplet. The ions finally observed 
in the mass spectra are most likely those that constitute the excess surface charge (see 
Introduction).  
Applied to excipients, our data suggests that a stronger partitioning of e.g. GCA to the air-
water interface as compared to NMP ( awK  (GCA) >> awK (NMP)) resulted in a stronger 
competition with rolipram for the limited charge and/or space on the surface of the ESI 
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droplet, even though GCA was applied at lower molar concentrations than NMP (10.2 mM 
GCA, 24.3 mM NMP). Considering the nitrogen in NMP and GCA as the most probable 
protonation site, the ranking of ionization suppression goes along with the larger N-residue of 
GCA which renders GCA more surface active.  
Regarding the FaSSIF/FeSSIF media, the surface activity of the main component, taurocholic 
acid, was similar to that of the structurally related GCA (π- Clog  plot of taurocholic acid not 
shown). However, taurocholic acid did not coelute with rolipram (Fig. 5B), and the matrix 
effect observed in the recovery studies (Fig. 4B) had to be attributed to the presence of 
phospholipids. The decline in recovery was moderate, not only because the concentration of 
lipids was much lower compared to that of the other excipients (Fig. 3) but also because only 
a fractional amount of lipids coeluted with rolipram (Fig. 5B). The substantial matrix effect 
observed in the post-column infusion study (Fig. 8B) renders a more complete picture which 
is in line with literature reports on matrix effects caused by endogenous phospholipids in 
tissue and plasma samples [10] [39].  
It is important to note that surface activity alone was not the only property relevant for the 
extent of matrix effects as the following example shows: Whereas the π- Clog  profiles of 
NMP and PG were comparable (Fig. 9), matrix effects were stronger in presence of NMP 
despite lower concentrations (24.2 mM NMP vs. 31.5 mM PG, respectively, Fig. C,E). This 
could be explained by the stronger basicity of the amide-nitrogen in NMP as compared to the 
hydroxyl-groups present in PG. Chech and Enke
19, 39]
 notably stressed that basicity is one 
determining factor for the relative gas phase ion intensities. Tong et al. [10] related the 
stronger matrix effect observed for HP -  - CD (multiply-charged ion) as compared to PG 
(singly-charged ion) to the different charge densities and inferred that gas-phase reactions 
might play a major role in ion suppression. Our results confirm the inverse relationship 
between number of charges and extent of matrix effects. However, rather than by gas phase 
proton transfer reactions, the stronger matrix effect of HP -  - CD may also be explained by 
more effective displacement of rolipram from the surface of the ESI droplet, which is 
supported by the higher preference of HP-β-CD for the air-water interface ( awK (HP-β-CD) 
>> awK  (PG)). Irrespective of which mechanism applies, our results confirm that PG caused 
the least matrix effect, which we suggest was due to a combination of i) the low surface 
activity, ii) the lack of basic nitrogen, and iii) the presence of only two OH-groups available 
for protonation.  
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In contrast to our results, Shou et al. did not observe matrix effects  in presence of HP-CD, 
but they used other test compounds and experimental conditions [21]. This clearly illustrates 
the need for careful and compound-specific evaluation of matrix effects. Generalization from 
recovery studies should be treated with caution, particularly if information on the elution 
behavior of both analyte and excipient is lacking. 
3.6. Prediction of Matrix Effects 
Coelution is a precondition for ion suppression [21], and therefore the prediction of matrix 
effects is theoretically possible from estimates of an analyte’s retention time in HPLC-MS 
and knowledge about the elution behavior of the excipient. Retention times on reversed phase 
columns have been frequently used as surrogates for octDlog (pH 7.4) [40]. Vice versa, we 
evaluated whether the octDlog  value at pH 3.3 (corresponding to the eluent pH at 95% 
acetonitrile) is predictive for an analyte’s retention time in HPLC/MS and, moreover, whether 
this information allows the prediction of matrix effects at sufficient accuracy. Prediction 
packages for the calculation of Pc log  are commonly available; and from knowledge of an 
analyte’s apK  (which can be predicted) and the eluent’s pH (pH 3.3), the octDlog  values at pH 
3.3 can easily be estimated. 
For validation purposes, we prepared analyte solutions of 16 physicochemically different 
drugs in excipient-spiked buffer (0.5%, m/v GCA) and determined their recoveries and 
retention times in HPLC-MS, in addition to their octDlog  (pH 3.3) values. Figure 10A, 
showing the recovery of each test compounds as a function of retention time, confirms that 
only analytes coeluting with GCA (rolipram, no.15) severely suffered from ion suppression 
(> 90 % suppression).  
 
Fig. 10 
 
Compounds close to the elution window of GCA (no. 10-14 [Rt = 0.545-0.556 min]; no. 16 
[Rt = 0.733 min]) were moderately suppressed (recovery 78.1-87.4 %, carbamazepine (no. 
14) 94.9 %), pointing to trace amounts of GCA present in the ESI source. It is interesting to 
note that despite equal retention times of carbamazepine (no. 14) and zaleplone (no. 13) 
(Rt = 0.556 min), differences in the recovery rates (94.9 % vs. 78.1 %) were observed. The 
higher recovery of the more lipophilic compound (carbamazepine, Pc log  2.4 vs. zaleplone, 
Pc log  1.4) is in line with literature describing hydrophilic compounds as more vulnerable to 
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matrix effects [7]. Like for excipients, drug compounds with a hydrophobic moiety attached 
to the protonation side are favored for the place on the electrosprayed droplet surface due to 
their higher amphiphilicity. Rolipram is relatively hydrophilic and less amphiphilic as 
compared to GCA which explains the low analyte recovery. 
In the next step, we transformed the critical range of retention times (Rt = 0.545-0.556 min) 
into the more useful, critical range of octDlog (pH 3.3) values. Therefore, we plotted 
octDlog (pH 3.3) of the analytes as a function of their retention times (Figure 10 B) yielding a 
straight line with r
2
 = 0.62 (standard error of estimate, see = 1.54, Figure 10B). A weaker 
correlation was observed with Pc log  (r
2
 = 0.16, SEE = 1.71) and octDlog at pH 7.4 (r
2
 = 0.53, 
see = 1.08). The latter two parameters do not account for the different ionization state of the 
drugs at the eluent pH. According to the above correlation, we could identify a critical 
octDlog (pH 3.3) range in which severe ionization suppression due to coelution of GCA would 
be expected (i.e. octDc log  (pH 3.3) range 1-4). Hence, under the given experimental 
conditions, the prediction model is able to exclude matrix effects for compounds 
with octDc log <1 and octDc log  >4. For compounds in the intermediate octDc log range 1-4, the 
surface activity of the compound in relation to that of the excipient and other parameters (e.g. 
concentration ratio, proton base affinity) will determine the extent of ion suppression. 
Although surface active, lipophilic compounds are less susceptible to ion suppression, an 
ultimate proof of the presence or absence of matrix effects requires recovery or post-column 
infusion studies.  
3.7. The Effect of Excipients on the PAMPA Read-Out 
The results obtained so far have shown that the excipients used in PAMPA cause matrix 
effects; the extent of which relates to the properties of both the excipient and the analyte. In 
the next step we pursued our overall goal, namely to investigate whether the presence of 
excipients in PAMPA eventually affects the accuracy of permeability measures, and if so, 
how to correct the assay read-out. The concern of matrix effects arises because excipients are 
commonly applied non-uniformly in the PAMPA compartments, i.e. either in the donor or in 
the acceptor compartment of the PAMPA sandwich. GCA, for example, is frequently used as 
a solubilizer in the donor and in the reference solution (Figure 1, Roche setup[28]) while 
blank buffer is applied in the acceptor. On the other hand, the post-experimental addition of 
matrix to the acceptor compartment, to obtain the same matrix effect, reduces significantly 
the analytical sensitivity.  
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For the evaluation of matrix effects in PAMPA, we followed the above protocol using GCA 
(0.5%, m/v) as a solubilizer and rolipram (100μM) as a model analyte. The permeation of 
rolipram from the donor across an artificial membrane into the acceptor compartment was 
measured by determining the concentration of rolipram in each compartment (after 19h 
incubation), using HPLC-UV and HPLC-MS for concentration analysis. The presence of 
GCA did not affect the UV data (see below, Figure 11A) which therefore provided a gold 
standard to prove the accuracy of the mass-analyzed results. Regarding the mass 
spectrometric analysis, differences in the matrix composition of the various compartments 
were (a) disregarded, (b) reduced (by 1:100 dilution of each compartment) or (c) adjusted (by 
providing in each compartment the same concentration of excipient before injection onto the 
HPLC-MS system). A summary of the assay read-outs (compartmental distribution of 
rolipram, proof of mass balance, permeability) obtained from each analytical strategy is given 
in Table 2. 
 
Table 2 
 
The UV analysis yielded 65.9 ± 2.3 % of rolipram left in the donor and 34.9 ± 0.7 % 
permeated into the acceptor indicating approximetely 100% recovery. When using the MS 
data, disregard of ion suppression in the reference and in the donor solution resulted in 12.6 
fold overestimation of the percentage rolipram present in the acceptor (437.8 ± 23%), which 
was obviously not in agreement with mass balance (the sum of drug in the donor and acceptor 
compartment was 505.3% of the initial drug amount in the reference). While the 1:100 
dilution of each solution still yielded 1.6 fold overestimation of the acceptor concentration 
due to residuals of GCA, the results obtained after adjustment of each compartment to the 
same GCA content (0.25 %, m/v) were consistent with the UV data. The erroneous 
compartmental concentration of rolipram from untreated (a) or diluted (b) solutions are 
mirrored in the effective permeability values showing 31.5 fold and 2.9 fold overestimation, 
respectively (details for the calculation of eP see Table 2).  
3.8. Minimization of Matrix Effects  
While several possibilities to eliminate or handle matrix effects have been proposed, most of 
them are not feasible in the earliest phase of the drug discovery process when PAMPA 
measurements are conducted. For example, a deuterated internal standard compensating for 
matrix effects [41] is usually not available. Although optimization of chromatographic 
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separation may be a possibility for a limited amount of compounds [23], the broad range of 
physicochemical properties covered by research compounds and screened in PAMPA 
complicates the situation. Solid and liquid phase extraction generally bare the risk of 
incomplete recovery of the test analyte itself [42]which again cannot be compensated by an 
internal standard. Another option is the dilute-and-shoot-approach which involves diluting 
the analyte solutions prior to injecting them onto the HPLC-MS. From a practical point of 
view this would be feasible, however, even a 1:100 dilution of the PAMPA donor and 
reference solution (GCA concentration 0.5 %, m/v) yielded reduced ion intensities as 
compared to the acceptor solution (Table 2, injection volume: 5 μL).  
A reduction in sample load injected onto the HPLC-MS system may further minimize the 
matrix effects and the associated error in effective permeability. To evaluate this strategy, we 
studied the mass and UV response of rolipram (100 μM) as a function of injection volume 
(1 - 10 μL) for a broad range of GCA concentrations (0 - 0.5 %, m/v). Inspection of Fig. 11A 
reveals that the UV response was not disturbed by the presence of GCA as observed by the 
linear calibration function, which was independent of the excipient concentration. In contrast, 
a non-linear behavior was evident when using MS (Fig. 11B).  
 
Fig. 11 
 
The mass responses of the analyte in excipient-spiked buffer was lower than that in 
excipient - free buffer, except for the two smallest injection volumes (1 μL and 2 μL) of the 
0.005 % GCA sample. Hence, matrix effects in PAMPA can be minimized in this specific 
case by a 1:100 dilution of the GCA concentration (0.5 % to 0.005 %, m/v) in combination 
with a reduction in injection volume (5 μL to 1 μL). Similar to the adjustment of excipient 
concentrations in each compartment (Table 2), accurate results would be provided, however, 
at the expense of sensitivity.  
Regarding the application of GCA as a solubilizer, its replacement with PG is a viable 
alternative. At a concentration of 0.24 % (m/v), PG showed only minor matrix effects in the 
post-column studies (Fig. 8E). However, Fig. 12 shows that with increasing concentrations of 
PG an exponential decrease in analyte response was observed that was the higher the closer 
the retention time was to the solvent front.  
 
Fig. 12 
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Nevertheless, even at 20 % PG, the matrix effect was still moderate as compared to GCA 
(e.g. rizatriptan, Rt = 0.372 min, recovery in PG: 54 %). Our results provide a more complete 
picture of PG effects in ESI-MS than can be drawn from published dosing vehicle studies 
[10]. In literature a focus has only been put on max.1 % excipient solution corresponding to 
the expected plasma concentration. As Figure 12 shows, ion suppression caused by PG is 
compound specific and concentration dependent, and therefore generalizations cannot be 
made from  negligible or moderate (15 % recovery) [4] matrix effects reported for other 
datasets. Our results show that PG is the most suitable solubilizer with respect to MS 
compatibility. But contrary to an uncritical use of PG, sample pretreatment is still required 
regarding compounds eluting close to the solvent front. For the sake of completeness, we 
would like to mention that the solubilizing power of PG needs to be evaluated and distinct 
effects on passive permeability of the different excipients should be considered [29]. 
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4. Conclusions 
In summary, we have investigated matrix effects related to excipients commonly used in 
PAMPA. All of the tested excipients reduced the gas phase ion intensities of the test analyte 
rolipram to some extent, but PG was the excipient best compatible with MS. The strongest 
matrix effects were observed for excipients that enriched at the air-water interface (GCA, the 
FaSSIF/FeSSIF media) and/or that carried multiple charges (HP -  - CD). Appropriate 
management of excipient-related matrix effects is essential to avoid overestimation (excipient 
in donor compartment) or underestimation (excipient in acceptor compartment) of 
permeability values retrieved via HPLC-MS analysis. Excipients distributed non-uniformly in 
the different PAMPA compartments during the actual permeation process, for instance to 
study formulation effects, to increase compound solubility, or to simulate sink conditions, 
should be adjusted to the same excipient level before injecting aliquots of each compartment 
onto the HPLC-MS system. This also applies to the external calibration standards. The 
sample pretreatment can only be avoided if ion suppression caused by coeluting matrix 
components can be excluded in advance, either based on recovery studies or on octDlog  (pH 
3.3) based prediction of the elution behavior. If the use of excipients aims to increase 
compound solubility, rather than to inspect a specific effect of one particular excipient, 
replacement of the frequently used GCA by PG is suggested. However, when using HPLC-
MS for concentration analysis, the gain in sensitivity due to higher analyte concentration in 
presence of a solubilizer should be viewed in context with the possible loss in sensitivity due 
to ion suppression. It should therefore be critically tested whether or not a solubilzer is 
required for higher sensitivity.  
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TABLES 
Table 1   The air-water partition coefficients, awK , of the excipients tested and the maximum surface 
pressures, πmax, reached in their presence. Due to the fact that the FaSSIF medium is a taurocholic - 
phospholipid - mixture, no awK is given.  
Excipient awK  πmax[mN/m] 
Glycocholic acid 3.42E+04 25.9 
FaSSIF  >37.8 
N-methyl-2-pyrrolidone 1.57E+01 >21.0 
2-hydroxypropyl--cyclodextrin 4.67E+04 >18.0 
 
 
 
Table 2   Comparison of the assay read-outs of a typical PAMPA measurement (Roche setup) using 
HPLC-UV and HPLC-MS, and different approaches for sample pretreatment. Rolipram (25μM) was 
used as the test analyte and glycocholic acid (0.5 %, m/v) as a model solubilizer in the donor but not 
in the acceptor compartment. 
Detection 
Mode 
Sample pretreatment Drug amount in compartment
a
 Mass balance
a
 Pe
b
 
  [%],      
Donor 
[%],    
Acceptor 
[% ],              
Donor + Acceptor 
[10
-6
cms
-1
] 
UV None 65.9±2.3 34.9±0.7 100.7±1.8 10.5±0.6 
MS None 67.5±2.0 437.8±23.1 505.3±25.1 (330.5±0) 
MS 1:100 dilution 62.5±3.5 56.2±2.1 118.7±5.6 30.1±10.1 
MS Matrix adjustment 66.0±1.0 36.4±1.0 102.5±2.0 11.4±0.2 
a
A part of the donor solution was not used for the permeability measurement but was used as the reference. The 
amounts in the donor and acceptor compartment (after incubation) were calculated as the percentage of the 
analyte response in the reference. If the concentration in the acceptor measured in HPLC-MS was higher than in 
the reference (due to ion suppression), the sum of analyte in the donor and the acceptor was considered as a new 
reference in order to still enable the calculation of effective permeability values (Pe).  
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FIGURES 
 
Figure 1   Setup of PAMPA.  
 
 
 
O
O
N
O
 
Figure 2   Structure of the test analyte rolipram                                                                                                                                   
(MW 275.35, octDlog (pH 7.4) 1.91, no apK ) 
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Figure 3   Structures, concentrations and molecular weights of the investigated excipients  
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Figure 4 A, B:   The effect of excipients on the signal intensity of rolipram (25 µM) in 
HPLC - ESI/MS (SIM mode). A: Example of overlaid mass chromatograms of rolipram (m/z 276.2, 
[M+H]+ trace) in absence () and in presence () of glycocholic acid (0.5 %, m/v). B: Percentage 
recovery of rolipram in presence of excipients (dashed bars): GCA (0.5 %, m/v), the FaSSIF and 
FeSSIF media, NMP (0.24 %, m/v), HP-CD (0.24 %, m/v) and PG (0.24 %, m/v). The black columns 
show the percentage recovery of rolipram in blank buffer after preliminary injection of the excipient-
spiked buffer.  
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Figure 5   Full scan mass chromatograms obtained from fast gradient elution of GCA (0.5 %, m/v) 
(A), the FeSSIF medium (B) and NMP (0.24 %, m/v) (C). The retention time of rolipram is indicated 
by the vertical dashed line.  
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Figure 6   Comparison of the mass spectra of A: buffer spiked with rolipram, B: buffer spiked with 
glycocholic acid and C: buffer spiked with both, rolipram and glycocholic acid. The concentration of 
rolipram and glycocholic acid was 25 µM and 0.5 % (m/v), respectively. The spectra were obtained at 
0.575 min corresponding to the retention time of rolipram.  
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Figure 7   Setup for assessment of matrix effects with the post-column infusion technique. The 
analyte (rolipram, 25 µM), dissolved in eluent (50:50 mixture of water : acetonitril), was continuously 
infused at 50 µL/min by means of an external pump. Blank matrix (excipient dissolved in eluent), or 
eluent (reference), was injected into the LC column and eluted with 1 mL/min using a fast gradient 
method. Both flows were combined with a T - piece before entering the ESI-interface of the mass 
spectrometer.  
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Figure 8   Overlaid post-column infusion chromatograms of rolipram ([M+H]+ trace) in absence () 
and in presence () of excipients. The mass chromatograms with and without glycocholic acid were 
obtained using either buffer (A’) or eluent (A) as solvent. The mass chromatograms of all other 
excipients, i.e. the FeSSIF medium (B), NMP (C), HP-β-CD (D) and PG (E), are only shown in 
eluent. The excipient concentrations were matching those used in the recovery studies described in 
Fig. 3. The retention time of rolipram is indicated by the vertical dashed line.  
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Figure 9   Surface pressure - concentration profiles for the FaSSIF media () and the excipients 
GCA (), HP-β-CD (), NMP () and PG () dissolved in 50mM Tris/114mM NaCl/pH 7.4 
buffer.  For comparison, the surface pressure-concentration profile of the test analyte rolipram () is 
shown (50mM Tris/114mM NaCl/pH 7.4/1%DMSO). The arrows indicate the concentrations of the 
excipients and rolipram used in the ion suppression studies. Although the FaSSIF medium is a 
taurocholic - phospholipid - mixture, the concentration used for the plot relates to the concentration of 
taurocholic acid (maximal 3 mM). The π -logC - profiles were measured at room temperature with a 
multichannel microtensiometer (Delta-8, Kibron, Helsinki). 
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Figure 10 A:   Percentage recovery for 16 compounds (each 25 µM) in presence of GCA (0.5%, m/v) 
and B: octDlog (pH 3.3=eluent pH) as a function of retention time. Analytes were measured 
independently with a fast gradient LC/ESI-MS method. The Henderson-Hasselbalch equation was 
used to calculate  o c tDl og (pH 3.3) from Pc log  and in-house measured apK values. Rizatiptan (1), 
theophylline (2), metoclopramide (3), midazolam (4), cyclobenzaprine (5), maprotiline (6), verapamil 
(7), amitriptyline (8), flumazenil (9), thioridazine (10), phenytoin (11), trifluperazine (12), zaleplon 
(13), carbamazepine (14), rolipram (15), PK 11195 (16). B: The y-intercept confined by the 
interception point of the correlation line and the elution window of GCA describes the 
octDlog  (pH 3.3) range in which severe ionization suppression due to coelution of GCA is expected 
( octDlog  (pH 3.3) range 1 - 4). 
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Figure 11   Intensity of analyte response (100 µM rolipram, 50mM Tris/114mM NaCl, pH 7.4) in A: 
UV and B: MS (SIM) as a function of the volume injected into an HPLC-ESI-MS system. The test 
solutions contained different concentrations of glycocholic acid (0-0.5 %, m/v). The UV responses of 
rolipram at a particular injection volume were averaged taking into account all different 
concentrations of GCA (n=5, the standard deviation was smaller than the size of the symbol).  
0 10 20 30 40
50
60
70
80
90
100
110
R
e
c
o
v
e
ry
 a
n
a
ly
te
 (
%
)
Concentration propylene glycol in buffer (%, m/v)
 
Figure 12   Recovery obtained in HPLC-ESI/MS of rolipram (, Rt = 0.579 min), theophyllin (, 
Rt = 0.420 min) and rizatriptan (, Rt = 0.372 min) from buffer spiked with increasing 
concentrations of propylene glycol. Analysis of rizatriptan at 40 % propylenglycol was obviated due 
to the detrimental effect of propylene glycol on the peak shape at concentrations above 20 %.  
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Supporting Information 
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Figure S1   Mass spectra of buffer spiked with rolipram (A) and buffer spiked with rolipram and 
excipient (B-F): glycocholic acid, 0.5%, m/V (B), the FeSSIF media (C), NMP, 0.24%, m/v (D), HP-
β-CD, 0.24%, m/v (E) and propylene glycol, 0.24%, m/v (F). The concentration of rolipram was 
25 µM. The spectra were obtained at 0.575 min corresponding to the retention time of rolipram. The 
assigned m/z ratios correspond to the sodium adduct of the dimer of rolipram and the mono-
protonated pseudo-molecular ion. For experimental conditions see Materials and Methods.  
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Table S1   Properties for the 16 compounds used for recovery studies with glycocholic acid (0.5%, 
m/v. The drugs are sorted in ascending order of retention time n HPLC.   
No. 
 
Compound  MW c 
[g/mol] 
apK (acid)
a apK (base)
a clogP
b 
1 Rizatriptan 269.4  9.59 1.2 
2 Theophylline 180.2 8.51  0.0 
3 Metoclopramide 299.8  9.36 2.2 
4 Midazolam 325.8  5.71 3.4 
5 Cyclobenzaprined 275.4  9.32 5.1 
6 Maprotiline 277.4  10.2 4.5 
7 Verapamil  491.1  8.8 4.5 
8 Amitriptyline 277.4  9.49 4.9 
9 Flumazenil 303.3   1.3 
10 Thioridazine 370.6  9.68 6.0 
11 Phenytoin  252.2 8.18  2.1 
12 Trifluperazine 407.5  8.43/3.74 4.7 
13 Zaleplon 305.3   1.4 
14 Carbamazepine 236.3   2.4 
15 Rolipram 275.2e   1.7 
16 PK 11195 352.9   4.6 
a
measured photometrically (SGA), 
b
clog P v4.71 Daylight 
c
[Molecular weight + H]
+
 ion monitored in 
ESI/MS,
d
measured with capillary electrophorsis 
e
monoisotopic 
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ABSTRACT 
The parallel artificial membrane permeability assay (PAMPA) has emerged as a widely used 
primary in vitro screen for passive permeability of potential drug candidates. However, the 
structure of the permeation barrier (filter supported alkane - lipid mixture) had never been 
characterized on a molecular level. Therefore we investigated the organization of lipids in the 
PAMPA barrier by means of different nuclear magnetic resonance (NMR) techniques: i) the 
phase behavior of the egg lecithin - dodecane system in presence and in absence of water, 
cholesterol and a PVDF filter support was investigated by 
31
P-NMR; ii) the diffusion 
coefficients of the individual lipid components in the egg lecithin - cholesterol - dodecane 
system were determined using the pulsed magnetic field gradient NMR technique (
1
H-NMR). 
In addition, the distribution of several test drugs between the PAMPA-lipid solution and 
buffer was measured ( 'log PAMPAD (pH7.4)). Addition of n-dodecane to the system egg 
lecithin - water (lamellar phase, Lα) induced the formation of inverted hexagonal (Hii) and 
isotropic phases. At n - dodecane concentrations matching those used in PAMPA (9 %, m/v) 
only an ‘isotropic’ phase was observed, irrespective of whether or not a filter-support was 
used. The ‘isotropic’ phase corresponded to lipid aggregates of a diameter assessed as 
d  = 4 - 7 nm. The data can be explained by the existence of inverted micelles. A size cutoff 
for 'log PAMPAD , typically observed for the binding of drugs to biological membranes (bilayers), 
was not found. The data suggests that the binding to and, in turn, the diffusion across the 
PAMPA barrier is facilitated by the presence of reversed egg lecithin micelles. They act as a 
carrier rather than as a barrier particularly for amphiphilic solutes.  
 
 
KEYWORDS 
PAMPA, Lipid organization, NMR, Bilayer, Phase transition  
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1. Introduction 
The importance of an appropriate absorption, distribution, metabolism, excretion and toxicity 
(ADME/Tox) profile for the likely success of a drug candidate has widely been recognized in 
today’s drug development programs [1]. Membrane permeability is at the core of many 
ADME/Tox parameters and determines for example the extent of gastrointestinal absorption 
and blood-brain-barrier (BBB) permeation of a drug [2]. Early assessment of permeability is 
therefore crucial in order to identify molecules with inadequate properties and to guide 
structural optimization of promising lead series [3]. 
Various systems of different complexity have been used to mimic the barrier properties of 
biological membranes in vivo, among them cell-based in vitro models (e.g. CaCo-2 assay 
[4]), artificial membranes (e.g. liposomes [5], black lipid membranes [6]) as well as 
membrane-mimicking systems [7] (e.g. octanol-water [8], immobilized artificial membranes, 
IAM [9]). Although cell-based models are favored for studying active transport pathways, the 
lower throughput and higher cost as compared to the artificial systems has limited their 
application [10]. The popularity of membrane mimicking systems originates from the fact 
that most compounds (exception: peptides and peptidomimetics) cross biological membranes 
by passive diffusion; the extent of which depends on both, the properties of the membrane 
and the diffusing drug [11].  
Biological membranes are highly ordered, anisotropic systems, made up of lipid bilayers into 
which proteins are embedded [12]. The bilayer ordering and packing is determined by the 
lipid composition which, in turn, governs the barrier properties of the membrane. In the first 
step of passive diffusion, the drug binds to the membrane by hydrophobic, hydrogen - bond 
and ionic interactions with the phospholipid head group and then penetrates into the 
lipophilic core. Charged and uncharged molecules can insert into the lipid - water - interface, 
but only the fraction of uncharged drugs can permeate a lipid membrane. The energy ( W ) 
required to form a cavity in the bilayer large enough to accommodate the solute is 
proportional to the lateral packing density of the lipid layer ( M ) and the cross sectional area 
( DA ) of the penetrating compound ( DM AW   ) [13, 14]. This explains the greater 
resistance to permeation with increasing lipid chain ordering and permeant size [2, 15]. 
Unlike binding to anisotropic membranes, the partitioning into bulk organic phases, such as 
n - octanol and n - hexadecane, increases with molecular volume as a result of the less 
structured nature of organic solvents [14]. Despite the great popularity of particularly 
n - octanol as surrogate for membrane binding and permeation, bulk solvents in general fail to 
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mimic the anisotropy of the bilayer as well as the charge of the phospholipid head group. The 
linear relationship between bulk octanol/water distribution coefficients ( *log owK = octDlog ) and 
lipid bilayer/water distribution coefficients ( *log lwK ) therefore likely breaks down for 
compounds which are large (usually also high octDlog ) [14, 16], ionized [17] or structurally 
unrelated (different hydrogen-bonding, etc.).  
The example of octDlog  illustrates that knowledge of the molecular organization and 
properties of a membrane-mimicking system is crucial for understanding the limitations of a 
particular model system. Surprisingly, the molecular organization of the standard industrial 
membrane model for passive permeability [18, 19], present in the Parallel Artificial 
Membrane Permeability Assay (PAMPA), is still unresolved [20]. The PAMPA barrier 
consists of synthetic or natural phospholipids (e.g. egg yolk lecithin, exception Novartis: 
100 % hexadecane) dissolved in excess organic solvent (e.g. n - dodecance), coated on a filter 
support (e.g. polyvinylidene difluoride (PVDF)) which is in contact with an aqueous buffer 
solution [19]. The widespread assumption that bilayers are formed in the PAMPA filter can 
be traced back to the early work of Thompson et al. on several microfiltration units used as 
stabilizing support for black (= bilayer) lipid membranes (BLM) [21]. Based upon 
electrochemical similarities between macro-BLMs and the filter-lipid system, and largely 
relying on the effect of amphothericin, the author hypothesized that each pore in the filter was 
spanned by a single lipid bilayer [21]. Notably, the combination of solvent (n - decane), filter 
material (polytetrafluorethylene (PTFE), cellulose ester, polycarbonate) and lipid (egg 
phosphatidylcholine, cholesterol) studied by Thompson et al. has never been used for 
PAMPA and the transferability of the results to other experimental conditions is uncertain. 
Phung et al. recently evaluated the suitability of a greater variety of filter materials with 
respect to the ability to support membranes for biosensors [22]. Unfortunately the solvent 
(n - octane) used was again different from that applied in PAMPA and therefore the 
observation that micro-BLM were formed in a PTFE but not in a PVDF filter (PAMPA filter 
= PVDF) is still insufficient to allow conclusions to be drawn on the PAMPA barrier. 
Nevertheless it demonstrates the importance to rely on the particular combination of filter, 
lipid, and organic solvent used when discussing the molecular organization of lipids in the 
system of interest.  
It is worth to note that considerable effort has been put into optimization of PAMPA, and 
specifically its barrier property, towards improved predictability of e.g. gastrointestinal drug 
absorption and BBB permeation. Every individual barrier component has been varied 
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including the organic solvent (e.g. hexadecane [23], 1,7 octadiene [24]), the lipid (1-
palmitoyl-2-oleoyl-phosphatidylcholine (POPC), soy lecithin [25], brain polar lipids, 
biomimetic lipid mixtures [26]) and the filter unit (PVDF [18], polycarbonate [23]). 
However, none of the optimization procedures was guided by an inspection of the filter-
supported barrier at a molecular level. Relationships found between lipid composition and 
bilayer membrane fluidity, on the one hand, and PAMPA permeability, on the other hand, 
relied on fluorescence anisotropy measurements of liposomes whereas anisotropy 
measurements of the PAMPA barrier itself failed [27]. However, disregarding the presence of 
both, organic solvent and filter support, in the interpretation of the PAMPA barrier structure 
and function is only of limited value.  
The purpose of this study was to investigate the lipid structure in the PAMPA barrier by 
means of 
31
P-NMR and 
1
H-NMR self-diffusion experiments, specifically we addressed the 
question whether the terms bilayer membrane and PAMPA membrane can be used 
synonymously. We centered our investigation around the PAMPA-lipid solution used at F. 
Hoffmann-La Roche which is a mixture of egg yolk lecithin (9 %, m/v), cholesterol 
(0.45 %, m/v) and excess n - dodecane
6
, supported on a lipophilic PVDF filter [28].  
The 
31
P-NMR technique is a powerful tool to study the long range order of phospholipids and 
to allow a distinction between coarse dispersions of lipid bilayers, hexagonal phases and lipid 
phases in which ‘isotropic’ motion occurs [29]. The pulsed field gradient NMR (PFGNMR) 
technique was used to estimate the individual diffusion coefficients in the PAMPA - lipid 
solution which in turn were related to the size of the diffusing associates [30]. Background 
information on the principles of 
31
P-NMR and PFGNMR is provided in the Appendix. In 
addition, we measured the permeability across, and the distribution into, the PAMPA barrier 
for drugs of different charge state, lipophilicity, size, and concentration, and moreover, as a 
function of the egg lecithin content of the PAMPA barrier. The results were interpreted in 
terms of barrier properties and function of the PAMPA-lipid solution. 
                                                          
6
 In literature 10 %, m/v egg lecithin and 0.5 %, m/v cholesterol is reported, however, this is not exact, because 
adding egg lecithin to dodecane increases the volume of the resultant solution which has not been considered so 
far.  
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2. Materials and Methods 
2.1. Materials  
Egg yolk lecithin (60 % TLC), n - dodecane, deuterated n - dodecane - d26 and diazepam 
were purchased from Sigma (Steinheim, Germany). 1-palmitoyl-2-oleoyl-
phosphatidylcholine (POPC) and phosphatidylethanolamine (PE) were obtained from Avanti 
Polar Lipids (Alabaster, Alabama). Propanolol was available through our in - house 
Compound Depository Group as proprietary compound. Tris and sodium chloride were 
obtained from Fluka (Buchs, Germany). DMSO was obtained from Acros (Geel, Belgium). 
Formic acid, water and acetonitril were supplied from Merck (Darmstadt, Germany) and were 
of HPLC-grade.  
2.2. 
31
P-NMR and 
1
H-NMR Studies 
2.2.1. Sample Preparation  
Samples for the 
31
P-NMR studies were prepared as follows: Lipid as a powder (egg yolk 
lecithin, pure POPC, or egg yolk lecithin - cholesterol at a ratio (m/m) 5 : 1) was dissolved in 
dichlormethane (52 %, m/v) and the solvent was removed by rotary evaporation and 
subsequent high vacuum evaporation for > 6h. The dry lipid film was dispersed in buffer 
(50 mM Tris/114 mM NaCl, pH 7.4) at a molar POPC : water ratio of 1 : 45 (51 wt % water). 
Regarding the egg lecithin samples, the molar ratio referred to the amount of POPC, which 
was present at ~ 60 wt % in the egg lecithin batch used. The lipid dispersion was covered 
with an Argon layer, vortexed vigorously and freeze - thawed in at least five cycles until no 
more sediments were visible by eye. Each freeze - thaw cycle consisted of three steps: 
freezing the sample in dry ice, warming to room temperature and vortexing. Dodecane was 
added to the homogenous lipid suspension (0.25; 0.5; 1; 2; 3; 4; 5; 33.5 mol dodecane per 
mol POPC) up to the POPC : dodecane ratio typically used in PAMPA (1 : 33.5). The 
samples were vortexed, freeze - thawed, vortexed again and appropriate amounts were then 
instantly transferred into in - house made glass tubes which were flame sealed. The samples 
were thermally equilibrated for at least 1 h before the measurements.  
A second series of samples was prepared containing only egg lecithin and dodecane at the 
same POPC : dodecane ratio as described above. Dodecane was added directly to the lipid 
and the samples were vortexed, freeze - thawed and transferred into the NMR tubes.  
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A third series of experiments involved the PAMPA - lipid solution as prepared for the high 
throughput permeability screens: a mixture of egg yolk lecithin (2.5 g), cholesterol (125 mg) 
and dodecane (25 mL) was stirred for >1h, filtrated (paper filter) and i) transferred into the 
NMR tube without further treatment, ii) added to a PVDF filter (diameter 3 mm, 
punched - out from a Millipore filter plate, Cat. MAIPN 4550, 4.5 μL per filter) with 40 of 
them stacked into the NMR tube or iii) added to the PVDF filter and stacked as in ii) but with 
a hydrophilic filter (punched - out from a Millipore filter plate, Cat. MSGVN 22; 
impregnated with 5 μL H20) separating each PVDF layer.  
The samples for the diffusion experiments (
1
H-NMR) were prepared by adding 5 mL 
perdeuterated dodecane to 0.5 g egg yolk lecithin and 25 mg cholesterol in a 10 mL glass 
flask. The mixture was vortexed thoroughly, filtrated and filled in disposable 5 mm NMR 
tubes.  
2.2.2. 
31
P-NMR  
Solid-state 
31
P-NMR measurements were recorded at 298 K on a Bruker Avance 400 
spectrometer (Bruker AXS, Karlsruhe, Germany) operating at a phosphorous - 31 frequency 
of 161 MHz and using a pulse - acquire sequence with broadband proton decoupling 
(400 MHz). The recycling delay and the excitation pulse length were 6 s and 3 µs, 
respectively. A typical spectrum was obtained from 500 - 12.000 scans depending on the lipid 
content of the sample. 
2.2.3. 
1
H-NMR Self-Diffusion Measurements  
Translational diffusion coefficients of phosphatidylcholine, phosphatidylethanolamine and 
cholesterol in the egg lecithin - cholesterol - d26 - dodecane system (PAMPA - lipid solution) 
were determined using the pulsed field gradient technique (PFGNMR [31]). Measurements 
were carried out on a Bruker 600-MHz Avance II spectrometer equipped with a cryogenic 
TCI probe head and a Bruker pulsed magnetic field gradient unit. Experiments were 
performed at 303 K with an internal lock on d26 - dodecane. Spectrometer operation and data 
processing were performed using Topspin 2.1 (Bruker, Fällanden, Switzerland). A pulsed 
gradient stimulated echo pulse sequence incorporating bipolar gradient pulses [32] was used 
to generate the magnetic field gradient. The proton signals (i.e. the spin echo amplitudes) of 
phosphatidylcholine (chemical shift, δ = 3.42 ppm), phosphatidylethanolamine 
(δ = 1.62 ppm), cholesterol (δ = 0.77 ppm) and dodecane (δ = 0.87 ppm) were analyzed after 
Fourier transformation in the frequency domain.  
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In presence of a gradient, molecular diffusion attenuates the 
1
H signal amplitude, I , 
according to  
 
  2/3/exp 2220   gDII ,         (1)
  
where 0I  is the 
1
H signal intensity in absence of a gradient, D  is the diffusion coefficient of 
the nuclei,   is the gyromagnetic ratio, g  is the gradient strength (0 - 45 Gcm
-1
),   is the 
duration of the pulse ( = 1 ms),   is the interval between the gradient pulses (    = 300 ms) 
and   is the time spacing between the individual bipolar gradient pulses (  = 1 ms). Other 
parameters were as follows: 32k data points, 18 ppm spectroscopical line width, 1.5 s 
interscan delay, no H20 suppression, exponential filtering (LB = 1 Hz), smoothed square 
gradient shape (SMSQ10.100), manual baseline correction of the 
1
H integral regions.  
A plot of the signal attenuation, 0ln II , versus 
2g , yielded a straight line (in most cases) with 
a negative slope (Slopelipid, Slopedodecane) relating to the individual diffusion coefficients 
(Dlipid, Ddodecane). The diffusion constant of dodecane at 303 K (Ddodecane = 9.15 10
-10
m
2
s
-1
) 
was used to calibrate the magnitude of the field gradient pulses such that  
 
doedcanedodecaneipidlipid SlopeDSlopeD / .        (2)
      
The D -estimate for dodecane at 303 K was estimated by performing a linear regression on 
the known temperature - dependent self - diffusion constants of dodecane [33].  
The apparent hydrodynamic radius ( 0r ) of the diffusing aggregates was obtained using the 
Stokes-Einstein equation:  
 
06 r
kT
D

 ,            (3) 
 
where k  is the Boltzmann constant (1.38×10
−23
J K
-1
), T  is the temperature (303 K) and   is 
the solvent viscosity at 303 K (1.24 mPas, estimated from a biexponential decay fit of the 
known temperature dependent viscosities of dodecane [34]).  
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2.3. Studies on the Function of the PAMPA Barrier 
2.3.1. Measurement of PAMPA - Lipid Solution/Buffer Distribution Coefficients  
For the measurement of the PAMPA-lipid/buffer distribution coefficients as a function of the 
egg lecithin concentration, stock solutions of propranolol and diazepam were prepared in 
DMSO (10 mM and 2.5 mM). The stock solutions were diluted 1 : 100 to obtain the final 
sample solutions (100 µM and 25 µM test compound, DMSO content 1 %, v/v). Similarly, 
stock solutions of propranolol (0.5, 1.25, 2.5, 10, 20 and 30 mM) were used to prepare the 
sample solutions (5, 12.5, 25, 100, 200 and 300 µM propranolol, 1 % DMSO, v/v) for the 
measurement of 'log PAMPAD  - drug concentration profiles. The sample solutions 
( aqV  = 200 µL) were transferred into an in-house made 96 - well Teflon plate which was 
covered with a 96 - well filter plate (PVDF, pore size 0.45 um, Cat. 4550, Millipore, 
Billerica, MA) pre - coated with PAMPA-lipid solution ( lipidV  = 2.25 µL). To investigate the 
influence of the egg lecithin concentration, PAMPA - lipid solutions containing 0 - 50 wt % 
egg yolk lecithin (Sigma) dissolved in dodecane were used (0; 1; 2; 3; 4; 5, 6; 7; 8; 9; 10; 
12.5; 15; 17.5; 20; 22.5; 25; 30; 35; 40; 45; 50 wt %). For the 'log PAMPAD - drug concentration 
profiles only one concentration of egg lecithin was investigated, namely that used in the 
Roche PAMPA setup (11.9 wt % egg lecithin, corresponding to 9 %, m/v). It is important to 
note that the assay construct was designed such that the PAMPA   lipid solution was not in 
contact with the border of the Teflon well (Supplementary Information). The assembly was 
sealed and left undisturbed (room temperature) for at least 8 h during which the solute was 
allowed to distribute into the PAMPA-lipid solution. It was assured that equilibrium was 
reached within the 8 h of incubation (Supplementary Information). After removal of the filter 
plate, the drug concentration left in the aqueous phase,
eq
aqC , was determined by means of 
HPLC - UV. The PAMPA - lipid solution/buffer distribution coefficient was calculated by 
mass balance according to:  
 
 











lipid
eq
aq
aq
eq
aqaq
PAMPA
VC
VCC
D
0
' loglog ,         (4) 
 
where 
0
aqC  is the initial aqueous drug concentration, which was obtained from a reference 
experiment, carried out under the same conditions but without coating the filter with lipid 
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solution. The apostrophe indicates that the distribution coefficient was determined by mass 
balance rather than by measuring both phases directly. Therefore 'log PAMPAD  is a composite 
parameter reflecting the drug distribution into the PAMPA-lipid solution and the adsorption 
of drug at the filter-supported interface.  
The results from the concentration dependent 'log PAMPAD  measurements were converted into 
binding data such that the degree of binding, bX , was determined as the molar ratio of bound 
drug, Dn , per total lipid, Ln , according to LDb nnX / , where 
  POPClipiddodecaneL MlipidVn  %  (in a simplified manner the density of dodecane 
(  =0.75 gcm
-3
) and the molecular weight of POPC ( POPCMW  = 760.1 g/mol) was used.  
2.3.2. Measurement of PAMPA - Lipid Solution/Buffer Distribution Coefficients in Combination with 
Permeability for a Large Dataset  
Stock solutions of the test compounds (10 mM) in DMSO were diluted with buffer (50 mM 
Tris/114 mM NaCl/pH 7.4) to obtain an aqueous drug solution (150 μM). The solution was 
filtrated and the filtrate ( DV  = 320 µL) was transferred into a Teflon donor plate which was 
covered with a 96 - well filter plate (PVDF, pore size 0.45 μm, Cat. 4550, Millipore, 
Billerica, MA) pre-coated with the PAMPA-lipid solution ( lipidV  = 4.5µL). In contrast to the 
measurements described above, blank assay buffer ( AV  = 280 µL, 50 mM Tris/114 mM 
NaCl/pH 7.4) was added on top of the filter pate. After 19.5 h incubation, the sandwich was 
separated and the amount of drug in the acceptor and the donor solution was determined by 
comparison with the UV spectra from the initial filtrate using a 96 - well UV plate reader 
(Molecular Devices, model Spectra Max 190, Sunnyvale, CA and pION PSR4 p software). 
All measurements were performed in triplicate with an automated liquid handling system. 
Effective permeability values ( eP ) were calculated as described by [35]. Briefly, eP  values 
can be calculated according to the following equation which also takes into account the 
membrane retention of the compound: 
 

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where A  is the area of the filter (corrected for the apparent filter porosity, as described by 
[36]), t  the time, st  the time at steady-state, DV and AV are the acceptor and the donor 
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volumes, respectively, and tAC ,  and tDC , are the measured acceptor and donor concentrations, 
respectively, at time t . The PAMPA barrier retention factor R  can be obtained by mass 
balance according to:  
 







 

0,
,, /
1
tD
DAtAtD
C
VVCC
R .          (6) 
Distribution coefficients, 'log PAMPAD , were calculated as described above but with 
ADaq VVV  . 
2.3.3. Measurement of Octanol/Buffer Distribution Coefficients  
Octanol / buffer (50 mM Tris/114 mM NaCl/pH 7.4) distribution coefficients, 
'log octD (pH 7.4), were measured by a miniaturized filter - based shake flask assay, referred to 
as CAMDS and described in full detail in our accompanying manuscript 1. As described for 
'log PAMPAD , the apostrophe indicates that the distribution coefficients were determined by 
mass balance rather than by measuring both phases directly. 
2.4. HPLC Instrumentation and Chromatographic Conditions  
Drug concentrations in aqueous solutions were quantified using an Agilent 1290 Infinity 
HPLC-UV system. A 5 µL aliquot of each sample was injected onto a Kinetex 2.6 µm, 
2.1 x 50 mm analytical column. The flow rate was 2 mL/min and the integrated column 
heater was set to 60 °C. The mobile phase consisted of A (water) and B (acetonitril), each 
containing 0.1 % (v/v) formic acid. The gradient elution was performed as follows: initial 
2 % B, 0 - 0.35 min linear gradient from 2 % B to 95 % B, 0.35 min - 0.5 min 95 % B, 
posttime 0.3 min. The gradient program for doxorubicin, vinblastine, buspirone and 
colchicine was slightly different: initial 2 % B, 0 - 0.5 min linear gradient from 2 % B to 
95 % B, 0.5 min - 0.65 min 95 % B. Peak areas were recorded at an appropriate wavelength. 
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3. Results 
3.1. Characterization and Specification of Egg Lecithin  
The egg lecithin used in our studies was a yellow to orange-colored, sticky and not odorless 
material, isolated from egg yolk and used as received from the supplier (Sigma). It is 
important to note that lecithin in this sense is not synonymous with the well - defined, pure 
lecithin POPC. Rather it is a crude mixture of phospholipids, other lipids as well as a variety 
of other components such as triglycerides, sterols (e.g. cholesterol), fatty acids, glycolipids 
and carbohydrates. The exact composition of egg lecithin depends on the stage of the 
purification process (extraction solvent, deoiling, bleaching, hydrolysis, etc. [37]) and also 
varies batch - wise within one supplier chain (personal communication, Sigma). The 
composition of the egg lecithin used in our studies is given in Table 1 and relies on thin layer 
chromatography analysis provided by the selected supplier (Sigma).  
 
Table 1 
 
3.2. Characterization of the Filter 
Fig. 1 shows a scanning electron micrograph of the PVDF filter used by ourselves and by 
most PAMPA experimenters. The filter was punched out from the Millipore filter plate 
constituting the support for the PAMPA - lipid solution and shown herein in the form of the 
non - coated filter. The structure of the filter is highly porous, irregular in shape and without 
any preferred orientation of the fibers. The pore size of the filter ranges from approximately 
0.4 - 2.5 μM, showing that the nominal aperture (0.45 μM) is only a rough average. It should 
be mentioned that SEM images of PVDF have been published before [38], but we preferred 
to characterize the particular filter that was used throughout our studies. Thereby we took into 
account that the structure of the filter, in particular the pore size, vary among different 
suppliers and, in addition, that surface treatment and stretching of the filter during the 
manufacturing process might change the morphology of the filter.  
 
Fig. 1 
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3.3. NMR Studies on the Structure of the PAMPA Barrier 
 3.3.1. Phase Equilibria in the System Egg lecithin - Dodecane - H20 ( - Cholesterol)  
The first question we addressed in a series of 
31
P-NMR experiments was whether egg yolk 
lecithin, used as received without further purification, is able to form lipid bilayers under 
optimal experimental conditions, i.e. in presence of water. Furthermore, we investigated the 
effect of increasing amounts of dodecane on the phase behavior of the egg lecithin - H20 
system at 298 K. Therefore, egg lecithin was dispersed in excess water (water : phospholipid 
ratio was 45 : 1 corresponding to 51 wt % water) and dodecane was added, up to the 
dodecane : phospholipid ratio typically used in PAMPA (33.5 mol dodecane : 1 mol 
phospholipid  corresponding to 11.8 wt % egg lecithin). The mol percentages were referred 
not to egg lecithin as a whole, but to the POPC content present therein. In addition we tested 
the effect of cholesterol taking into consideration that small quantities (0.45 %, m/v) are used 
as a stabilizer in the Roche PAMPA - lipid solution (personal communication). The 
cholesterol quantity was selected to match the concentration used in PAMPA (6 mol 
phospholipid : 1 mol cholesterol) while the selection of the water concentration was 
somewhat arbitrary (but small enough to create multilamellar vesicles).  
The 
31
P-NMR spectra of the egg lecithin - H20 and the egg lecithin - cholesterol - H20 system 
in presence of increasing amounts of dodecane are shown in Fig. 2. Generally, the spectra of 
both systems (with and without cholesterol) were almost superimposable indicating that the 
applied quantities of cholesterol were too small to alter significantly the long-range order of 
the lipids.  
 
Fig. 2 
 
In the absence of dodecane (Fig. 2A) the line width, shape (low field shoulder and high field 
peak) and the residual chemical shielding anisotropy (approximately - 50 ppm) of the spectra 
were characteristic for coarse dispersions of lipid bilayers. Upon addition of 0.25 mol 
(Fig. 2B) and 0.5 mol (Fig. 2C) dodecane per mol phospholipid the bilayer structure was 
essentially preserved, although, a small isotropic line was superimposed on the bilayer 
spectra. At 1 mol dodecane per mol phospholipid (Fig. 2D), the 
31
P-NMR spectra 
corresponded to a pure hexagonal phase. Further addition of dodecane caused the 
homogenous phase to separate which was macroscopically observed as islands of pure 
dodecane alongside the lipid dispersion. The 
31
P-NMR spectrum at 2 mol dodecane per mol 
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phospholipid (Fig. 2E) was a superimposition of all three types of spectra, namely those 
corresponding to coarse lipid bilayers, hexagonal and isotropic phases. With increasing 
amounts of dodecane up to 5 mol dodecane per mol phospholipid, the portion of the 
‘isotropic’ phase increased at the expense of the lamellar and the hexagonal phase 
(Fig. 2F - H). At 33.5 mol dodecane per mol phospholipid (Fig. 2I), which meets the 
dodecane - lecithin ratio in the Roche PAMPA setup, the intrinsic chemical shielding 
anisotropy was almost completely averaged out and a single isotropic peak at 0 ppm 
predominated.  
In the above described experiments, dodecane was subsequently added to the coarse bilayer 
dispersions. The 
31
P-NMR spectra of samples prepared in an inverse order (addition of water 
to the egg lecithin-dodecane mixture) were essentially identical (spectra not shown). 
However, when pure POPC instead of egg lecithin was used as the lipid and dodecane was 
added to the POPC-buffer dispersions, the bilayer structure was preserved except for a very 
small isotropic peak at >0.5 mol dodecane  :  mol POPC (Fig. 3A-I). 
 
Fig. 3 
 
3.3.2. Phase Equilibria in the System Egg lecithin - Dodecane  
In the next series of experiments, the PAMPA - lipid solution was not spiked with water to 
take into account that also the bulk phase of the PAMPA barrier only contains moisture 
water. Since homogeneity of an egg lecithin - cholesterol mixture would not be easily 
achieved at low dodecane concentrations, we abstained also from the addition of cholesterol. 
Facilitated mixing in dichlormethane following evaporation of the solvent was not 
undertaken to avoid falsifying the residual water content. Fig. 4A - F show the 
31
P - NMR 
spectra of egg lecithin in presence of increasing amounts of dodecane up to the 
dodecane : lipid ratio used in PAMPA (Fig. 4F).  
 
Fig. 4 
 
It is interesting to note that two batches of egg lecithin, namely an “old” one (stored for > 3 
month at 2 - 8°C) and a new one just ordered, yielded different spectra at low 
dodecane : phospholipid ratios (up to 1 mol dodecane : mol phospholipid). The overlayed 
spectra of the two batches are shown in Fig. 4A at the most striking example of “pure” egg 
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lecithin (no dodecane added). Phospholipids are extremely hygroscopic and the bilayer 
pattern observed in the aged batch as compared to the powder pattern in the new batch 
indicates that water had been readily adsorbed. Although it is not uncommon to use aged egg 
lecithin in PAMPA (a bottle from Sigma contains 100 g egg lecithin), all experiments 
(including the studies above in presence of 45 mol water per mol phospholipid) were 
performed with the new batch. An inspection of Fig. 4A - I reveals that with increasing 
amounts of dodecane the line width narrows and the powder type of spectra collapsed into a 
classical isotropic peak which characterizes the egg lecithin - dodecane mixture used in 
PAMPA (33.5 mol dodecane per mol phospholipid, Fig. 4F).  
3.3.3. Phase Equilibria in the System Egg Lecithin - Dodecane - Cholesterol (- Filter)  
The first two series of experiments have demonstrated that a large excess of dodecane with 
respect to egg lecithin (such as in PAMPA) induces the lamellar-to-isotropic phase transition, 
irrespective of the presence of extra water. However, if painted across a smooth Teflon 
aperture immersed in water, lipid-organic solvent solutions containing as low as 2% (m/v) 
phospholipid are known to form bilayer (black) lipid membranes [39] . Therefore we tested 
whether in analogy to BLMs the phase equilibrium changes when coating the PAMPA-lipid 
solution across multiple apertures (i.e. the PVDF filter), specifically we were interested if an 
isotropic-to-lamellar phase transition occurs. Fig. 5A and Fig. 5B show the 
31
P-NMR spectra 
of the PAMPA-lipid solution either free in solution or coated on a PVDF filter. The spectra 
were essentially identical and correspond to an isotropic movement of the phospholipids. 
Separating the phospholipid - coated PVDF filters by means of hydrophilic filters soaked 
with water (alternate stacking) did not change the pattern of the spectra (Fig. 5C). 
 
Fig. 5 
 
3.3.4. Diffusion in the Isotropic Phase of the System Egg lecithin - Dodecane - Cholesterol   
The presence of an isotropic phase as observed in the 
31
P - NMR spectra of the 
PAMPA - lipid solution (Fig. 5A - C) does not exclude lipid association with a definite 
microstructure [29]. Since the viscosity of the PAMPA-lipid solution is low, it is safe to say 
that the isotropic peak does not correspond to a cubic phase.  
To further characterize the isotropic phase we measured the translational diffusion 
coefficients of phosphatidylcholine (PC), phosphatidylethanolamie (PE), cholesterol and 
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dodecane in the egg lecithin - dodecane - cholesterol system, by means of 
1
H - NMR 
diffusion experiments. First, it was necessary to assign the signals in the 
1
H-NMR spectrum 
(Fig. 6A,B) of the PAMPA lipid-solution (egg lecithin-dodecane-cholesterol).  
 
Fig. 6 
 
As indicated above, the composition of egg lecithin is complex and therefore not all signals 
could be identified, moreover, a number of peaks displayed a superposition of various 
components. For diffusion experiments, we paid attention to follow the spin echo decay of 
only pure peaks or of peak shoulders with a single diffusion pattern. In order to investigate 
the influence of the egg lecithin concentration in dodecane we tested the PAMPA - lipid itself 
and also a 1:4, 1:16 and 1:64 dilution thereof in dodecane. 
Experimental spin echo decays of PC, PE, cholesterol, and d26 - dodecane at the four 
concentrations are shown in Fig. 7 A, B, C and D, respectively, as a function of the squared 
gradient strength (Stejskal - Tanner plot). The interpretation of the plots is straightforward: 
the faster the signal decay (i.e. the steeper the slope), the faster the translational diffusion of 
the particle. The diffusion constants were derived from the slopes and are listed in Table 2 
along with the corresponding apparent hydrodynamic diameters of the diffusing objects. The 
latter were obtained via the Stokes - Einstein equation and were based upon the assumption 
that the particles were spherical. The diffusion constant of dodecance was independent on the 
egg lecithin concentration and therefore the average value was used for calibration.  
 
Fig. 7, Table 2 
 
The rate of diffusion increased in the following order: PC < PE << cholesterol << dodecane, 
which corresponds to the reverse order of particle size. There was a clear trend towards 
decreased diffusion at higher egg lecithin concentration which was most pronounced for 
cholesterol. In the undiluted PAMPA - lipid solution, the diffusion of cholesterol was 
approximately twice as fast as PC whereas in the most diluted solution it was about seven 
fold faster. The sensitivity of the diffusion coefficient of cholesterol to concentration was 
mirrored in the varying apparent hydrodynamic diameters ranging from 0.8 - 3.5 nm. The 
growth in aggregate size with an increase in the egg lecithin concentration was also observed 
for PE and PC. The apparent hydrodynamic radius of PE (4.1 - 4.6 nm) was at each 
concentration slightly lower than that of PC (5.9 - 6.9 nm). 
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It is important to note that the echo decays of PE (Fig. 7B) deviated from a simple Gaussian 
diffusion behavior for which a straight line in the Stejskal - Tanner plot would be predicted. 
Non-spherical geometry of the diffusing particles and overlap of the selected PE signal with 
another component (either chemically different or another aggregate form of associates) 
could contribute to the deviation. Measurements with a lipid - coated filter failed due to the 
severe line - broadening which most disturbed the homogeneity of the magnetic field.  
3.4. Studies on the Function of the PAMPA Barrier  
3.4.1. The Binding of Propranolol and Diazepam to the PAMPA - Lipid Solution   
The NMR studies gave insight into the organization of lipids in the lipid - dodecane - filter 
system. In order to understand also the role of the lipids for the permeation process, we first 
studied the binding of drugs to the PAMPA - lipid phase as a function of the egg lecithin 
content in dodecane. For this purposes, we investigated compounds of different charge state 
and lipophilicity, namely diazepam (neutral, lipophilic) and propranolol (cationic, 
intermediate lipophilicity), at two drug concentrations (100 μM and 25 μM) to gain additional 
information about the role of electrostatics (charged species) for the binding step. The 
structures, octDlog (pH7.4) and apK values of the two test compounds are given in Table 3 
along with the number of hydrogen bond donors and acceptors (the latter were reported to 
play an important role for the permeation of solutes [25]).  
 
Table 3 
 
The distribution coefficients between the PAMPA - lipid solution (coated on the PVDF filter) 
and buffer were determined by mass balance, i.e. the drug that has left the aqueous phase was 
considered as distributed into the PAMPA - lipid solution. A direct concentration analysis in 
both phases was not possible due to the inaccessibility of the PAMPA - lipid solution which 
resided in the pores of the PVDF filter. The distribution coefficients for each drug 
concentration and egg lecithin content are shown in Fig. 8A for propranolol and Fig. 8B for 
diazepam.  
 
Fig. 8 
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Generally, the more egg lecithin was present in the PAMPA - lipid solution, the higher was 
the distribution coefficient. However, there were marked differences between the distribution 
patterns of the two drugs: i) in contrast to diazepam where distribution was concentration 
independent, lipid binding of propranolol was higher for the lower drug concentration (details 
see below), ii) the ‘booster’ effect of egg lecithin was more pronounced for propranolol 
giving rise to even higher 'log PAMPAD  (pH 7.4) values (if % egg lecithin > ~20%) for 
propranolol than for diazepam despite the lower octDlog  (pH 7.4). The component responsible 
for the distribution of propranolol was therefore essentially egg lecithin and not dodecance 
(see discussion). iii) Only for propranolol was an exceptionally strong effect of egg lecithin 
observed when comparing the distribution coefficients into pure dodecane with those into a 
1 % egg lecithin - dodecane mixture (see discussion).  
The observed discrepancy between 'log PAMPAD  (pH 7.4) obtained with 25 μM and 100 μM 
propranolol was further investigated. For this purpose we measured the binding of drug to a 
9 % egg lecithin - dodecane mixture (= egg lecithin content like in Roche PAMPA) for a 
larger range of propranolol concentrations (
0
aqC = 5 - 300 μM). For comparison we also 
coated the filter support with octanol and measured the distribution coefficients in the same 
manner as with the PAMPA - lipid solution. Fig. 9A shows the 'log PAMPAD  (pH 7.4), 
and 'log octD  (pH 7.4) values as a function of 
0
aqC  confirming the trend towards lower 
distribution coefficients at higher drug concentrations. The discrepancy between the lowest 
and the highest 'log octD was much higher for the PAMPA - lipid solution (Δ
'log PAMPAD  = 0.96) 
whereas almost constant distribution coefficients were obtained with octanol 
(Δ 'log octD  = 0.22).  
 
Fig. 9 
 
A transformation of the data shown in Fig. 9A for the PAMPA - lipid solution into a 
conventional adsorption isotherm (Fig. 9B) shows a typical saturation curve. When the same 
data is redrawn into a Scatchard plot (Fig. 9A), a biphasic pattern becomes evident which can 
formerly be interpreted in terms of two binding sites. However, it is well known from binding 
studies to lipid bilayers that the same type of pattern may be a consequence of membrane 
surface charge [40]: The insertion of cationic drugs such as propranolol into the electrically 
neutral PAMPA - lipid phase should create a positive surface potential, 0 , which leads to 
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the repulsion of molecules with the same charge. Therefore surface distribution becomes 
increasingly difficult at higher drug concentrations and the apparent 'log D (interfacial and 
bulk phase distribution) decreases. Apart from saturation- and electrostatic effects at the 
PAMPA - lipid solution/water interface, the same principles may apply for the interface 
created by the reverse phopspholipid micelles present in bulk dodecane.   
3.4.2. Binding to and Permeation across the PAMPA Barrier for a Large Set of Drugs   
Hitherto we have concentrated our study on the structure of the PAMPA barrier and the 
binding of drugs to it. However, membrane binding is only the first step in the process of 
passive diffusion and we were also interested in how membrane binding relates to 
permeability, with a particular focus on the role of size and charge.  
It is well known that the linear correlation between effective membrane permeability ( eP ) in 
PAMPA and distribution into octanol levels off [41] at approximately octDlog  > 3 (Roche 
data), i.e. when compounds become increasingly large. We specifically raised the question 
whether the bilinear relationship is due to a size restriction of the PAMPA barrier, not 
reflected by the distribution of drug into bulk octanol. Therefore, we investigated the 
relationship between 'log PAMPAD  and 
'log octD  and tested whether their correlation pattern 
reflects the typical bilinear relationship between  eP  and 
'log octD . The dataset tested (Table 4) 
included 104 structurally diverse acidic, basic and non-charged compounds spanning a wide 
range of lipophilicity ( 'log octD  = - 1.15 - 4.41) and molecular size (cross sectional area, 
DA  = 25 - 155 Å
2
). The eP  values were obtained from a classical PAMPA experiment and 
from the fraction of drug retained in the membrane we deduced 'log PAMPAD , which is shown in 
Fig. 10A as a function of 'log octD .  
 
Table 4, Fig. 10 
 
'
PAMPALogD  linearly increases with an increase in
'log octD  although the data considerably scatter 
around the linear regression line (r
2 
= 0.782, standard deviation, SD = 0.571). There is a clear 
trend towards higher 'log PAMPAD values for cationic drugs and lower 
'log PAMPAD values for 
anionic drugs as compared to the non - charged compounds. Moreover, it becomes evident 
that basic compounds with low 'log octD  values (approximately 
'log octD < 1.5) tend to prefer the 
PAMPA-lipid solution as compared to octanol ( 'log PAMPAD >
'log octD ), and vice versa 
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compounds with high 'log octD  values tend to have a lower 
'log PAMPAD . Non-charged and 
anionic drugs have higher 'log octD  values as compared to 
'log PAMPAD  with the exception of 
ketorolac, indomethacin and theobromin (the exceptions are however close to the 1:1 line). 
Strictly speaking, an evaluation of whether or not the PAMPA membrane impedes the 
insertion of large compounds must be confined to an inspection of non - charged drugs. This 
circumvents the problem of concentration effects due to charge repulsion (see above) and 
takes into account that the initial drug concentrations differed according to solubility.  
An inspection of the 'log PAMPAD  - 
'log octD  profiles for the non-charged drugs (grey symbols) 
reveals that large molecules are equally good accommodated in octanol and in the PAMPA 
barrier. For example, paclitaxel (60), the compound with the largest DA , did not deviate from 
the regression line, and just a slight discrepancy was observed for ritonavir (77) and indinavir 
(39).   
Therefore, it can be excluded that the bilinear relationship between eP  and 
'log octD  (Fig. 10B) 
is due to a size restriction of the PAMPA barrier and a loss of linear correlation between 
'log PAMPAD  and 
'log octD  for increasingly large compounds. It can be inferred that the presence 
of the unstirred water layer [42], which limits the diffusion of lipophilic compounds, is the 
main reason for the observed bilinearity.   
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4. Discussion 
Predicting a drug candidate’s permeation in vivo by means of an in vitro membrane 
mimicking system requires an understanding of the structure and barrier properties of the 
particular model system in order to assess its scope and limitations. In response to the hitherto 
unexplored structure of the PAMPA barrier, we have performed NMR studies which gave 
insight into the organization of PAMPA lipids on the molecular level. Moreover, we have 
investigated the role of concentration, charge and size for the binding of drugs to the PAMPA 
barrier. In the following, the results will be interpreted in terms of structure and function of 
the lipids. Finally, a hypothetical model for the permeation mechanisms across the PAMPA 
barrier will be proposed.  
4.1. The Structure of the PAMPA Barrier  
4.1.1. The Instability of a Bilayer in Presence of Excess Dodecane  
One major difference between the composition of biological membranes and the PAMPA 
barrier is the presence of excess dodecane in PAMPA [18]. This was the main reason for 
studying the phase behavior of the egg lecithin - water system upon addition of dodecane. We 
could show that dodecane promotes the formation of an inverted hexagonal (Hii) phase, at a 
relatively low dodecane concentration (1 mol %), and an isotropic phase, at higher dodecane 
concentrations (>10 mol %), with domains in between where Lα, Hii and isotropic phases 
coexist. In previous studies, dodecane has only been added up to 2 mol dodecane : 1 mol pure 
phospholipid which is far below the dodecane concentration present in PAMPA. Our results 
at low dodecane concentrations are in line with the literature [43-45], however, we expanded 
our investigation to the dodecane : phospholipid ratio used in PAMPA (i.e. 33.5 mol 
dodecane : 1 mol POPC). Under these experimental conditions, essentially all lipids were 
organized in an isotropic phase, irrespective of whether or not cholesterol or water was added 
or whether a filter was used as support for the lipid mixture.  
Thus we consider it a gross oversimplification when disregarding the presence of dodecane 
for interpreting PAMPA permeabilities. Specifically we consider it invalid to use the 
membrane fluidity assessed for bilayer liposomes as a correlate for the barrier fluidity and 
permeability in PAMPA [27]. 
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4.1.2. The Influence of the Filter 
The absence of bilayers in the PAMPA barrier may be surprising at the first moment since 
Thomspon et al. [40] provided evidence for the existence of micro BLM in the particular 
filter - lipid-solvent systems investigated. Much of Thompson’s line of argument relied on the 
increase of conductivity upon addition of amphothericin, a peptide spanning exactly one 
leaflet of a membrane bilayer membrane. However, the filter used for these key experiments 
was polycarbonate, characterized by a highly uniform series of holes separated by smooth 
non - porous polymer [40]. In contrast, the AFM photograph (Fig. 1) of the PVDF filter 
applied in PAMPA demonstrates its rough surface which has been recognized as unfavorably 
for providing an aperture for BLMs. 
In a series of screening experiments, Phung et al. [22] tested the ability of various filters to 
support BLMs for biosensors. He came to the conclusion that PVDF does not support 
bilayers which is in line with our results, even though Phung et al. used a different 
lipid - solvent mixture. The inability of PVDF to support BLM should not only be attributed 
to the roughness of the surface but also to the relative hydrophilicity of PVDF as compared to 
e.g. Teflon (PTFE). Ever since the pioneering work of Montal and Müller, hydrophobic 
surfaces have been preferred for the formation of BLM [6].  
4.1.3. The Influence of the Lipid Composition  
It has been known for a long time that highly purified lipids are of utmost importance for the 
stability of pore spanning membranes. In this light, crude egg yolk extract such as used in 
PAMPA must be considered unsuitable for the formation of BLM, which is confirmed by the 
isotropic phase observed by 
31
P-NMR spectroscopy (Fig. 2I).  
It is worth noting that the dodecane - lecithin systems investigated hitherto concerned pure 
lipid species (POPC; 1,2-dioleoyl-sn-glycero-3-phosphocholine [DOPC] [43, 44]) as distinct 
from crude extracts of egg yolk used for PAMPA (Roche). Our results demonstrated that 
crude egg lecithin bilayers are more prone to undergo the lamellar - to - isotropic phase 
transition as compared to pure POPC, pointing to the higher instability of the egg lecithin 
bilayer. In support of our results, alkane - spiked bilayers made up of purified phospholipids 
have been reported to equilibrate extremely slowly such that even after long - term storage 
(several month) phase equilibrium was not achieved. In contrast, it is well known that the 
dispersion of phospholipids (e.g. POPC, DOPC) in dodecane prior to the addition of water 
yields isotropic and hexagonal phases (see above [34, 44]). In case of the egg lecithin tested 
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in this study, the order of adding dodecane did not matter and a lamellar - to-isotropic phase 
transition was observed in each case.  
4.1.4. A Proposal for the Structure of the PAMPA Barrier 
In order to further characterize the isotropic phase we have measured self - diffusion 
coefficients for the individual components of the PAMPA-lipid solution. The diameters 
assessed for PC and PE as d  = 6.9 nm and 4.6 nm, respectively (undiluted PAMPA solution), 
can be explained by the presence of reverse micelles. Phospholipids most likely orient 
themselves with the head group towards the residual water (maximal 2 %, according to 
Sigma) and the tails pointing towards the surrounding dodecane phase.  
The high diffusion coefficient of dodecane suggests that the largest part of the solvent is not 
incorporated in the micelles but that bulk dodecane surrounds the lipid aggregates. Likewise, 
cholesterol appears not to be incorporated completely in the reverse micellar structure. This is 
indicated by the diffusion coefficient of cholesterol in the intermediate range between that of 
dodecane and PC/PE. Notably, the diffusion coefficients assessed are an average of the 
diffusion coefficients for the different physical states of a chemically defined species, 
weighted according to the relative proportion of that physical state. This means that the 
coexistence of monomers and lipid aggregates gives rise to an average diffusion coefficient 
and, in turn, an average estimate for the aggregate diameter. In the undiluted PAMPA lipid 
solution, the proportion of the monomeric form of phospholipids is the lowest which means 
that its influence on the diffusion coefficient is the smallest. Thus the diameter - estimate 
should approximate the diameter of the reverse micelle. However, the aggregate size is still 
only an approximate value since the non-linearity of the spin echo decays points to the 
presence of non - spherical particles. Using the Stokes Einstein equation for assessing the 
diameters of the diffusing lipid aggregates is therefore a simplification which we considered 
nevertheless useful for gaining an approximate aggregate size. 
The presence of reverse micelles is in line with a large body of knowledge that has been 
acquired on the organization of amphiphiles (e.g. phospholipids) in non-polar organic 
solvents (best characterized solvent: cyclohexane) [46]. In qualitative terms, such system 
corresponds to the PAMPA mixture before its coating on a filter support. It is established that 
purified phospholipids assemble into spherical reverse micelles which transform into reverse 
tubular structures in the micrometer range upon addition of low amounts of water. These 
worm - like micelles are assumed to entangle and form continuous three - dimensional 
networks with pronounced gel properties [47-50]. The PAMPA lipid solution is not gel - like 
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which shows that a network of worm - like micelles is unlikely to be formed. The absence of 
which is in line with literature since it has been already recognized that purified but not crude 
soy lecithin dissolved in dodecane undergoes the liquid - to - gel transition. However, the 
presence of short worm - like micelles in the PAMPA lipid solution could explain the 
deviation from linearity of the spin echo decays.  
The self - diffusion NMR experiments were conducted with the PAMPA lipid solution 
without using a filter support since the associated disturbance of the magnetic field is in 
conflict with high resolution NMR. We cannot exclude that the filter changes the size of the 
aggregates, however, the 
31
P - NMR clearly demonstrated that the lipid aggregates tumble 
rapidly with respect to the time scale of NMR. Moreover, the size of the micelles (6.9 nm) is 
manifold smaller than the size of the pores in a PAMPA filter (0.45 μM) and therefore we 
assume that our results are applicable to the filter - phospholipid - solvent system.  
4.2. The Function of the Lipids and a Proposed Permeation Mechanism  
Our studies on the distribution of propranolol and diazepam showed that the higher the egg 
lecithin content in the PAMPA barrier, the higher the distribution coefficient which points to 
a carrier role of the phospholipids. For propranolol (cationic amphiphilic), the increase in the 
distribution coefficient was exceptionally high when increasing the egg lecithin content from 
0 to 1 %. This indicates that the mechanism by which propranolol binds to the membrane 
changes in presence of egg lecithin, supposedly by micellar solubilization of the deprotonated 
drug. The data suggest that amphiphilic, hydrophilic molecules benefit more from the 
presence egg lecithin while lipophilic, barely amphiphilic solutes such as diazepam are 
already well solubilized in bulk dodecane. 
Evidence for the binding of the charged species to the liquid - water interface is provided by 
the fact that the distribution coefficients for propranolol showed a concentration dependency. 
We suppose that not only amphiphilic drugs but also the phospholipids reside on the surface 
forming a monolayer. However, the ratio between the bulk lipid phase and the interface is 
approximately 1 : 3000 which explains that we could not verify the presence of a monolayer 
by means of 
31
P-NMR. Both, the NMR studies and the 'log PAMPAD measurements, point to the 
proposed transport mechanism of solutes across the PAMPA barrier as summarized in Fig. 
11.  
 
Fig. 11 
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5. Conclusions 
In summary, we have shown that in the bulk phase of the PAMPA-lipid solution (11.8 w t% 
egg lecithin in dodecane) egg lecithin particles are formed, however, the existence of 
multilamellar lipid bilayers or lipid hexagonal phases could not be verified. In fact, the 
addition of excess dodecane, such as used in PAMPA, to coarse dispersions of egg lecithin 
bilayers promotes a lamellar - to - isotropic phase transition. Likewise, pure egg 
lecithin - dodecane mixtures (PAMPA - lipid solution), whether or not spiked with 
cholesterol, adopted a non - bilayer phase in which isotropic motion occured. The isotropic 
phase also dominated when coating the PAMPA - lipid solution on a PVDF filter which was 
in contact with interfacial water. From the several lipid phases possibly giving rise to 
isotropic motion, inverted micelles are in best agreement with the low viscosity of the 
PAMPA - lipid solution and the lack of larger amounts of water (only moisture). Since the 
binding of cationic amphiphilic drugs to the PAMPA barrier strongly increases with a rise 
from 0 to 1 % egg lecithin, a change in the binding mechanism, specifically the formation of 
inverted drug - lipid mixed micelles, seems plausible. The generally stronger binding of drugs 
to the PAMPA-lipid barrier with increasing concentrations of egg lecithin demonstrates that 
the lipid acts as a carrier, rather than a barrier, for drug permeation. This distinguishes 
PAMPA from biological membranes. The size dependence, arising from attenuated insertion 
into densely packed biological membranes, is not observed in PAMPA and therefore we 
recommend considering effective PAMPA permeability values for bulky compounds as 
possibly too high. 
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6. Appendix 
6.1. Background on Solid - State 
31
P - NMR 
31
P - NMR is a powerful tool to study the motion and average orientation of the phosphate 
head group of lipid dispersions [51]. The fact that different spectra are obtained for lipids 
incorporated into bilayer structures or in hexagonal and isotropic phases can be explained as 
follows: The magnetic field applied externally is reduced (shielded) by the electron cloud 
surrounding the phosphorous nuclei. Since the electron density is asymmetric, the chemical 
shielding is effective to a different extent depending on the orientation of the phosphate group 
with respect to the external magnetic field. This implies that the 
31
P resonance frequencies 
and accordingly the chemical shifts (or shielding constants) vary with the molecular 
orientation giving rise to the so called chemical shielding anisotropy. The latter can be 
defined by the three principal components, 11 , 22  and 33 , of the chemical shielding tensor, 
which correspond to the chemical shifts along the three principal directions. A 
31
P - NMR 
spectrum is a probability - weighted superposition of all the chemical shifts that arise from 
the possible orientations of the phosphate head group in the magnetic field. In case of a 
randomly oriented sample, all orientations are populated and hence the spectrum is 
characterized by a broad line width (around 190 ppm) with a typical line shape ( 11  and 
33 define the shoulders and 22  leads to a peak). If a phospholipid is incorporated into a lipid 
bilayer, rapid rotation of the phosphate group around the axis perpendicular to the bilayer 
surface partially averages out the chemical shielding anisotropy. The residual chemical 
shielding anisotropy,   (measured as the distance between the weak low-field and the 
intense high-field shoulder), amounts to ca.   = - 50 ppm for most of the yet studied 
bilayers (example: Fig. 2A). If the lipid is incorporated into a hexagonal phase, the line width 
is further reduced by a factor of two and the chemical shielding anisotropy has changed its 
sign (example: Fig. 2D). Finally, for small molecules or aggregates in solution, rapid 
tumbling (on the time scale of NMR) completely averages out the chemical shielding 
anisotropy and the NMR spectrum collapses to a single narrow resonance signal in the range 
of a few ppm. A variety of structures could give rise to a narrow (‘isotropic’) 31P - NMR 
signal, such as micelles, inverted micelles, single walled vesicles and cubic phases [38].  
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6.2. Background on the Pulsed - Field Gradient NMR technique (
1
H - NMR) 
NMR spectroscopy allows estimating the self - diffusion coefficients ( D ) of objects in 
solution (molecules, micelles) by using magnetic field gradients [30]. Self - diffusion relates 
to the random translational motion of diffusing objects (Brownian motion) according to their 
size (Stokes - Einstein relation) and should not be confused with rotational diffusion.  
As distinct from conventional NMR experiments, the sample is placed in a homogenous 
magnetic field (magnetic field strength 0B ) upon which a magnetic field gradient ( G ) is 
imposed [52-54]. The strength of the field gradient varies linearly along the direction of 0B  
(z-axis), i.e. along the long direction of the NMR tube. This means that also the Larmor 
frequency, which depends on the magnetic field strength, varies linearly along the direction 
of G  and therefore depends on the location of the nucleus in the NMR tube. In other words, 
the magnetic field gradient can be used to encode (or label) the position of a nucleus in an 
indirect manner, i.e. through the Larmor frequency.   
Accordingly, a change of position due to diffusion can be viewed as the effect on the resonant 
absorption (i.e. the NMR) signal. In self - diffusion experiments, the NMR signal observed is 
a so called spin echo which eliminates the effect of unwanted inhomogeneity in the static 
magnetic field (for details see basic NMR literature). Upon the 90° pulse involved in the 
generation of the spin echo, a gradient pulse is applied which encodes the position of the 
nuclei. Waiting for a short time after this first gradient pulse allows the nuclei to change their 
position. A second gradient pulse with the same duration (  ) and amplitude ( g ) is used to 
decode the position of the nuclei. If the nuclei did not undergo translational diffusion during 
the time span between the two gradient pulses (  ), the effects of the two gradient pulses 
cancel each other out and the maximal spin echo will be observed. If, however, diffusion took 
place, a proportion of nuclei will not be in the same position with respect to the z - axis. 
Therefore, the net magnetization (i.e. the vector of the sum of the magnetic moments of all 
spins) will be changed which results in an attenuation of the NMR signal. The signal decay 
depends on the strength of the applied gradients ( g ), the time between the gradients (  ), the 
gyromagnetic ratio of the nuclei (  ) and the diffusion coefficient ( D ); and therefore gives a 
measure of the motion of the particles (eq. see Materials and Methods).  
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TABLES 
Table 1   Composition of egg lecithin ‘powder’ used for preparation of the PAMPA - lipid solution  
Component Fraction [wt %] 
Phospholipids min. 72 
thereof  
 Phosphatidylcholine
a
 min.59 
 Phosphatidylethanolamine min. 6 
 Lyso-Phosphatidylcholine max. 3 
 Other Phospholipids min. 4 
Triglycerides max. 18 
Cholesterol  max. 8 
Water max. 2 
a
for calculations phosphatidylcholine was taken as POPC.  
 
 
 
 
Table 2   Diffusion coefficients and hydrodynamic radii of phosphatidylcholine (PC), 
phosphatidylethanolamine (PE) and cholesterol in the PAMPA lipid solution and a 1:4, 1:16 and 1:64 
dilution thereof in dodecane - d26.  
Conc. egg 
lecithin in 
dodecane 
Conc. 
cholesterol in 
dodecane 
Apparent Diffusion coefficient
a
  Apparent hydrodynamic diameter 
of the droplet 
[%] [%] 10
-12
 [M
2
s
-1
]  [nm] 
  PC PE Cholesterol  PC PE Cholesterol 
0.141 0.007 60.2 88.3 441.3  5.9 4.1 0.8 
0.563 0.028 58.6 84.1 296.0  6.1 4.3 1.2 
2.250 0.113 54.6 79.9 186.4  6.6 4.5 1.9 
9.000 0.450 52.1 78.1 102.5  6.9 4.6 3.5 
a
The diffusion coefficient of dodecane ( dodecaneD  = 915 10
-12
m2s
-1
) was used as a calibrant.  
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Table 3   Structure, octDlog  (pH 7.4), apK , fraction of ionized drug and the number of hydrogen 
bond donors and acceptors for the compounds investigated.   
Compound Structure 
octDlog  
pH 7.4)
a
 
apK
b
 Fraction 
ionized 
(%)
c
 
No. H-
bond 
donors 
No H-
bond 
acceptors 
Diazepam 
N
O
N Cl
 
2.84 3.38 0 0 3 
Propranolol 
O
OH
N
H
 
1.21 9.48 99.2 2 3 
a
in-house CAMDIS, 
b
in-house potentiometric apK  ; 
c
calculated for pH 7.4 from measured apK using the 
Henderson-Hasselbalch equation.  
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Table 4   Charge class, apK  values, molecular weights (desalted), cross sectional areas, DA , 
calculated octanol/water partition coefficients, Pc log , octanol/water distribution coefficients, 
octDlog (pH 7.4), and PAMPA-lipid solution - water distribution coefficients, PAMPADlog (pH 7.4) for a 
representative set of drugs (n = 104). 
No 
 
 
Compound  Charge 
classa 
apK  
(acid)b 
apK  
(base)b 
MW  
[g/mol] 
DA
c 
[Å2] 
Pc log d  'log octD  
(pH 7.4)e 
'log PAMPAD  
(pH 7.4) 
1 Amitriptyline B   9.49 277 55 4.85 2.77 2.34±0.09 
2 Amoxapine B   8.4/3.28 314 57 3.41 2.30  1.95±0.13 
3 Atomoxetine B   10.2 255 54 3.94 1.03 1.73±0.05 
4 Bupropion B   8.32 240 45 3.21 2.15 1.42±0.19 
5 Buspirone B   7.61 386 40 2.19 2.13 1.01±0.04 
6 Caffeine N    194 29 -0.04 -0.10 -0.27±0.00 
7 Carbamazepine N     236 60 2.38 1.58 0.17±0.77 
8 Celecoxib N 11.1   381 64 4.37 3.90 2.97±0.27 
9 Chlorpromazine B   9.38 319 48 5.30 3.23 2.61±0.23 
10 Ciglitazone A 6.88   333 37 5.07 3.96 2.51±0.34 
11 Cimetidine B   6.96 252 53 0.38 0.50 -0.27±0.00 
12 Citalopram B   9.52 324 62 3.13 1.40 1.52±0.02 
13 Clozapine B   7.68/3.9 327 53 3.71 2.73 2.19±0.06 
14 Colchicine N     399 89 1.20 0.95 0.05±0.28 
15 Cyclobenzaprine B   9.32 275 53 5.10 3.00 2.12±0.02 
16 Desloratadine B   9.78/4.57 311 52 3.83 1.20 1.88±0.10 
17 Dexamethasone N     392 73 1.79 1.79 1.34±0.17 
18 Diazepam N   3.38 285 58 2.96 2.84 1.77±0.09 
19 Diclofenac A 4.02   296 49 4.73 1.15 0.10±0.63 
20 Ddigoxin N     781 76 1.42 1.34 -0.27±0.00 
21 Diphenhydramine B   9.12 255 56 3.45 1.65 1.36±0.20 
22 Diprenorphine B 9.57 8.48 426 98 2.66 2.43 1.52±0.05 
23 Donepezil B   8.88 379 76 4.60 2.26 1.27±0.09 
24 Doxepin B   9.22 279 52 4.09 2.26 2.13±0.15 
25 Doxorubicin B 9.45 8.16 544 71 0.32 0.36 1.39±0.10 
26 Eletriptan B   9.59 383 61 3.36 0.84 1.64±0.09 
27 Etoricoxib N   4.53 359 64 2.35 2.23 1.32±0.29 
28 Fallypride B   8.22 364 57 3.18 2.02 1.22±0.21 
29 Fentanyl B   8.38 336 74 3.62 2.90 1.25±0.15 
30 Flumazenil N    303 53 1.29 1.08 -0.27±0.00 
31 Fluoxetine B   9.71 309 59 4.57 1.91 2.07±0.10 
32 Fluphenazine B   7.76/3.67 438 57 4.12 3.50 2.40±0.19 
33 Flurbiprofen A 4.03   244 36 3.75 0.87 -0.27±0.00 
34 Fluvoxamine B   9.11/5.82 318 55 3.03 1.56 1.76±0.09 
35 Haloperidol B   8.64 376 79 3.85 2.74 1.56±0.36 
36 Hydrocodone B   8.9 299 54 1.13 0.27 1.13±0.30 
37 Hydroxyzine B   7.51/2.66 375 63 4.00 3.09 1.99±0.03 
38 Ibuprofen A 4.45   206 34 3.68 0.95 0.24±0.89 
39 Indinavir N   5.77/4.01 614 125 3.68 2.97 0.87±0.11 
40 Indometacin A 4.43   358 51 4.18 0.79 0.91±0.04 
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No 
 
 
Compound  Charge 
classa 
apK  
(acid)b 
apK  
(base)b 
MW  
[g/mol] 
DA
c 
[Å2] 
Pc log d  'log octD  
(pH 7.4)e 
'log PAMPAD  
(pH 7.4) 
41 Ketorolac A 3.44   255 31 1.62 -0.58 -0.21±0.10 
42 Lamotrigine N   5.51 256 35 2.53 1.14 0.88±0.29 
43 Loperamide B   8.61 477 104 4.66 3.32 2.15±0.10 
44 Loratadine N   4.72 383 63 5.05 3.96 3.01±0.30 
45 Loxapine B   7.49/3.05 328 60 3.98 3.47 2.89±0.10 
46 Maprotiline B   10.2 277 54 4.52 1.47 1.92±0.16 
47 MDL 100907 B   9.02 373 65 3.29 1.87 1.49±0.12 
48 Mesoridazine B   9.55 387 63 4.44 1.75 1.64±0.07 
49 Methadone B   9.26 309 69 4.17 1.60 1.72±0.04 
50 Metoclopramide B   9.36 300 40 2.23 0.22 0.66±0.24 
51 Midazolam N   5.71 326 63 3.42 3.32 1.68±0.06 
52 Mirtazapine B   7.79/3.59 265 48 2.81 2.52 1.65±0.10 
53 Morphine B 9.35 8.08 285 61 0.57 0.12 0.41±0.59 
54 Naproxen A 4.12   230 38 2.82 0.30 0.15±0.54 
55 Naratriptan B   9.43 335 63 1.70 -0.20 1.20±0.07 
56 Nelfinavir B 9.63 6.01 568 120 5.84 4.04 2.37±0.34 
57 Norclozapine B   8.56/4.13 313 54 3.14 1.62 1.95±0.15 
58 Nortriptyline B   10.13 263 52 4.32 1.59 2.06±0.02 
59 Olanzapine B   8.01/5.6 312 44 3.01 2.02 1.40±0.16 
60 Paclitaxel N     854 155 4.73 2.99 2.19±0.22 
61 Paracetamol N 9.45   151 35 0.49 0.22 -0.27±0.00 
62 Paroxetine B   9.7 329 59 4.24 1.63 2.15±0.03 
63 Pemoline N   3.08 176 29 0.46 0.15 -0.27±0.00 
64 Pergolide B   7.91 314 68 4.40 2.88 2.57±0.20 
65 Perphenazine B   7.86/3.7 404 54 3.81 3.39 2.57±0.01 
66 Phenelzine B   7.32 136 25 1.03 0.47 1.22±0.06 
67 Phenytoin A 8.18   252 55 2.09 2.29 1.66±0.06 
68 Pioglitazone A 6.6 5.7 356 41 3.53 2.94 2.13±0.07 
69 PK 11195 N     353 73 4.62 3.79 2.28±0.04 
70 Propoxyphene B   9.06 339 68 5.21 2.39 1.95±0.04 
71 Propranolol B   9.48 259 48 2.75 1.14 1.72±0.02 
72 Quetiapine B   6.92/3.96 384 53 2.99 2.80 1.79±0.08 
73 Quinidine B   8.59/4.36 324 79 2.79 2.06 1.39±0.13 
74 Ranitidine B   8.38 314 70 0.67 -0.83 0.00±0.26 
75 Risperidone B   8.31/3.45 410 79 2.71 1.87 0.96±0.21 
76 9-hydroxy-Risperidone B   8.28/2.43 426 53 1.07 1.17 1.42±0.11 
77 Ritonavir N     721 121 4.94 4.41 2.29±0.12 
78 Rizatriptan B   9.59/1.77 269 48 1.18 -0.74 0.46±0.19 
79 Rofecoxib N     314 57 1.80 1.81 1.66±0.11 
80 Rolipram N     275 43 1.72 1.91 1.01±0.05 
81 saquinavir B   7/3 671 145 4.73 4.09 2.99±0.40 
82 Selegiline B   7.46 187 40 3.02 2.21 2.14±0.06 
83 Sertraline B   9.48 306 44 5.35 3.00 2.87±0.08 
84 Spiperone B   8.29 395 69 2.82 2.55 2.14±0.08 
85 Sulpiride B 10.01 9.01 341 65 1.11 -1.15 0.52±0.76 
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No 
 
 
Compound  Charge 
classa 
apK  
(acid)b 
apK  
(base)b 
MW  
[g/mol] 
DA
c 
[Å2] 
Pc log d  'log octD  
(pH 7.4)e 
'log PAMPAD  
(pH 7.4) 
86 Sumatriptan B   9.49 295 59 0.74 -1.15 0.62±0.24 
87 Tacrine B   9.81 198 37 3.27 -0.06 -0.27±0.00 
88 Temazepam N 9.14   301 63 2.34 2.10 1.51±0.09 
89 Theobromine N 9.79   180 30 -0.67 -0.72 0.46±0.33 
90 Theophylline A 8.51   180 30 -0.03 -0.15 -0.14±0.23 
91 Thiopental A 7.5   242 41 2.98 2.68 0.70±0.84 
92 Thioridazine B   9.68 371 60 6.00 3.59 2.84±0.15 
93 Thiothixene B   7.75/3.59 444 64 3.23 3.22 2.29±0.18 
94 Trazodone B   6.81 372 48 3.85 2.61 1.58±0.02 
95 Trifluperazine B   8.43/3.74 407 56 4.69 3.99 2.78±0.34 
96 Triprolidine B   9.47/3.75 278 54 3.63 1.84 0.50±0.68 
97 Valdecoxib N 9.69   314 50 1.83 2.43 2.27±0.01 
98 Venlafaxine B   9.62 277 63 3.27 0.64 1.12±0.06 
99 Verapamil B   8.8 455 86 4.47 2.54 1.81±0.05 
100 WAY 100635 B   6.71 423 105 4.09 3.05 1.50±0.02 
101 Zaleplon N     305 52 1.44 1.24 0.23±0.19 
102 Ziprasidone B   6.57 413 76 4.21 2.80 1.77±0.07 
103 Zolmitriptane B   9.6 287 53 1.29 -1.00 -0.12±0.54 
104 Zolpidem B   6.47 307 61 3.03 2.29 0.77±0.12 
a
neutral (less than 3 % ionization at pH 7.4); A: acid pKa < 8.9; B: base pKa >6; Z: zwitterions with acid pKa 
<8.9 and base pKa >6; 
b
in-house measured (potentiometric); 
c
calculated at pH 7.4 as described elsewhere [55]; 
d
 
clog P v4.71 Daylight; 
e
in-house CAMDIS 'log octD  (buffer: 50mM Tris, 114mM NaCl, pH 7.4) 
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FIGURES 
 
Figure 1   Scanning electron micrograph of the PAMPA membrane (polyvinylidendifluorid, 
Millipore, MAIPN, nominal pore size 0.45 μM, the length of the black line corresponds to 20 μM).  
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Figure 2   Experimental 162-MHz 31P-NMR spectra (recorded at 25°C) of egg lecithin containing 
45 mol H2O per mol lipid and increasing amounts of n-dodecane: 0 (A), 0.25 (B), 0.5 (C), 1 (D), 2 
(E), 3(F), 4(G), 5(H) and 33.5 (I) mol dodecane/mol lipid. Samples were prepared without () or 
with () 10 % cholesterol (m/m lipid).  
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Figure 3   Experimental 162-MHz 31P-NMR spectra (recorded at 25°C) of POPC containing 45 mol 
H2O per mol lipid and increasing amounts of n-dodecane: 0 (A), 0.25 (B), 0.5 (C), 1 (D), 2 (E), 3(F), 
4(G), 5(H) and 33.5 (I) mol dodecane/mol lipid. 
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Figure 4   Experimental 162-MHz 31P-NMR spectra (recorded at 25°C) of egg lecithin without 
additional H2O and with increasing amounts of n-dodecane: 0 (A), 2 (B), 3 (C), 4 (D), 5 (E) and 
33.5(F) mol dodecane/mol lipid. Samples were prepared with an “old” batch of egg lecithin stored for 
>3 month at 4-8°C () in the fridge and, such as in the other series of experiments with a new batch 
(). The data with the old and the new batch were not comparable up to 1 mol dodecane/mol lipid 
and therefore only higher dodecane/egg lecithin ratios are presented. 
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Figure 5   Experimental 162-MHz 31P-NMR spectra (recorded at 25°C) of samples containing 
PAMPA lipid (10 % egg lecithin (m/V), 0.5 % cholesterol (m/V) in n-dodecane: (A) pure PAMPA 
lipid without filter device. (B) 40 stacks of hydrophobic PVDF filter devices (pore size 0.45 µm) 
impregnated with 4.5 µL of PAMPA lipid per filter. (C) according to (B) but each layer was separated 
by a hydrophilic PVDF filter device impregnated with 5 µL of H2O. 
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Figure 6 A:   1H-NMR spectra of the PAMPA lipid solution (egg lecithin, 10 % (m/v) dissolved in 
n - dodecane-d-26). PC: phosphatidylcholine, PE: phosphatidylethanolamin, Cho: cholesterol, TG: 
triglycerides, Do: dodecane, u: unidentified, additional components present. B: Structures of the main 
components in the PAMPA lipid solution  
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Figure 7   Echo attenuation of the 1H resonances as a function of gradient strength. 
A: phosphatidylcholine (chemical shift 3.42 ppm), B: phosphatidylethanolamine (chemical shift 
1.62 ppm), C: cholesterol (chemical shift 0.77 ppm) and D: dodecane (chemical shift 0.87 ppm). The 
concentration of egg lecithin in dodecane - d26 (m/v) was: 0.156 %(), 0.625 %(), 2.5 % () and 
10 % () corresponding to the PAMPA lipid solution and a 1:4, 1:16 and 1:64 dilution thereof in 
dodecane-d26. Lines are linear fits to the data. Grey symbols were not included in the fitting. 
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Figure 8   Egg-lecithin-dodecane/buffer distribution coefficients of (A) propranolol and (B) diazepam 
as a function of the amount of egg lecithin dissolved in dodecane. Distribution coefficients were 
measured at 25 µM () and 100 µM () initial drug concentrations. Only one direction for the 
standard deviation is shown in A. The standard deviation in B is not shown as it was smaller than the 
size of symbol.  
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Figure 9   Binding data of propranolol. A: PAMPA lipid solution/buffer distribution coefficients () 
and octanol/buffer distribution coefficients () at pH 7.4 as a function of the total drug concentration 
(buffer : 50 mM Tris, 114 mM NaCl, pH 7.4). B: Adsorption isotherm. C: Scatchard plot.  
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Figure 10 A:   Relationship between the PAMPA - lipid solution/water distribution coefficients at pH 
7.4 and the octanol/water distribution coefficients at pH 7.4 for a set of 104 structurally diverse drugs. 
() line of identity, () linear regression line (correlation statistics: 'log PAMPAD  = 0.538 · 
'log octD + 
0.405 (n = 104, r
2 
= 0.782, SD = 0.571). B: Relationship between the effective permeability across the 
PAMPA barrier and 'log octD  for the same dataset. Colors according to charge class: nonionic (), 
cationic (), anionic (); size according to the cross sectional area of the drug  
A 
B 
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Figure 11   Hypothesized structure of the PAMPA barrier and two proposed mechanisms of transport. 
A: penetration across the PAMPA-lipid solution/water interface and transport via the continuous 
dodecane phase (light grey background). Once in the dodecane phase, the solute is also assumed to 
bind to and diffuse with the inverted micelles to the other liquid-liquid interface. The mechanism may 
play an important role for compounds with high solubility in dodecane. B: Direct transfer from the 
aqueous phase to the reverse micelles via the formation of a hemimicelle-like structure at the 
PAMPA-lipid solution/water interface. The drug-loaded reverse micelle detaches from the interface 
and diffuses to the other interface where the same mechanism takes place in a reverse order. 
Mechanism B is assumed to play a crucial role in the transport of amphiphilic drugs with low 
solubility in dodecane (black triangles). The irregular shaped regions denote the PVDF filter. Lipid in 
excess of the volume required to fill the pores is discounted.  
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Supporting Information 
 
 
 
 
Figure S1   Assay construct for the measurement of distribution coefficients between the PAMPA-
lipid solution and buffer. A 96 well filter plate (f) with a lipophilic membrane (m) fixed at the bottom 
of each single well was dipped into an acceptor Teflon plate (a) containing buffer spiked with the test 
compound. The filter membrane was pre-coated before with PAMPA-lipid solution. In order to avoid 
contact of the lipids with the borders of the acceptor plate, a Teflon frame (t) was constructed placed 
on top of the plane acceptor plate, carrying the filter plate and minimizing evaporation of the aqueous 
phase. The sandwich was left undisturbed for 22 h allowing the solute to distribute into the PAMPA-
lipid solution. Afterwards the phases were separated by removal of the filter plate and the 
concentration in the aqueous phase was determined.  
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Figure S2   Apparent distribution coefficients of diazepam (
0
aqC  = 100 µM) in the 
PAMPA - barrier/buffer system as measured for different contents of egg lecithin in dodecane. The 
'log PAMPAD  (pH 7.4) values were determined after 2 - 20 h incubation of both phases. Only one 
direction for the standard deviation is shown.  
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ABSTRACT 
The assessment of the unbound fraction of drug in brain, brainuf , , is of major interest in CNS 
drug development in order to estimate active site, unbound drug concentrations from total 
drug exposure and moreover, to aid the understanding of 
pharmacokinetic/pharmacodynamics (PK/PD) relationships. Equilibrium dialysis with brain 
homogenate is commonly used to determine brainuf , , however, relatively large amounts of 
brain tissue are required which hampers the application of the method for routine screening. 
In this study, we present a novel assay, referred to as Lipid Membrane Binding Assay 
(LIMBA), which enables the high-throughput measurement of brain tissue/ water distribution 
coefficients ( brainDlog ) at minimal expense of animal tissue. LIMBA was validated on a set of 
126 structurally diverse, marketed drugs with reported brainuf , data obtained from equilibrium 
dialysis in rat and mouse. The accuracy of brainuf ,  predictions using LIMBA- brainDlog  was 
evaluated in comparison with i) octanol/water distribution and partition coefficients ( octDlog , 
Plog ) and ii) fractions of drug retained in the permeation barrier of PAMPA. octLogD and 
Plog  poorly described brainuf ,  (r
2 
octDlog  = 0.23 , r
2
 Plog = 0.49), whereas an improved 
correlation was achieved with the membrane fraction in PAMPA (r
2
= 0.61), provided that 
optimized lipid and buffer composition were used. LIMBA- brainDlog  values yielded the best 
agreement with brainuf , data (r
2
= 0.74) and therefore we propose LIMBA as a viable alternative 
to equilibrium dialysis for the high throughput screening of brain tissue binding at 
significantly reduced consumption of animal tissue. 
 
 
 
KEYWORDS 
Brain tissue binding, Equilibrium dialysis, LIMBA  
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1. Introduction 
One of the major challenges in CNS drug development is the design of compounds which are 
able to cross the blood brain barrier (BBB) with sufficient rate and extent [1-3] as a 
prerequisite for in vivo efficacy. Traditionally, the extent of brain penetration has been 
defined in terms of total brain to total plasma concentration ratios ( pK ). However, according 
to the free drug hypothesis, unbound rather than total concentrations at the target site govern 
the pharmacological effect [4, 5] and hence it has been suggested to optimize compounds 
towards high unbound brain to unbound plasma concentrations ratios ( puuK )[6]. Due to the 
presence of the blood brain barrier (BBB), constituted of endothelial capillary cells with tight 
junctions and active influx and efflux transporters, puuK values in brain may significantly 
deviate from unity. In particular, P-glycorpotein (P-gp)-mediated efflux plays a crucial rule in 
the regulation and restriction of drug penetration into brain leading to unbound brain 
concentrations lower than those in plasma ( puuK <1) [7]. In order to derive the contribution of 
active transport at the BBB and to relate plasma to tissue pharmacokinetics, the measurement 
of plasma but also brain concentrations in the unbound state is required [3]. This may 
ultimately aid the understanding of dose-receptor occupancy relationships and allow for 
extrapolation of in vitro measurements to in vivo effects for the purpose of e.g. optimal 
dosing selection and compound prioritization.  
Unbound drug concentrations in the interstitial fluid (ISF) in brain can experimentally be 
determined using in vivo microdialysis at steady state, however, the method is labor-intensive 
and not suitable for (mostly lipophilic) compounds adsorbing at the microdialysis equipment 
[6]. Alternatively, drug concentrations in the cerebrospinal fluid (CSF) from the cisterna 
magna have been used as surrogates for ISF, yet with limited value since the BBB and the 
blood-cerebrospinal fluid barrier (BCSFB) are separate barriers and concentrations in ISF and 
CSF may thus differ [3]. The measurement of total drug exposure in brain in vivo in 
combination with an in vitro method for the assessment of drug distribution within brain 
tissue provides a more viable and relevant approach for estimating unbound ISF drug levels 
[8].  
The brain slice method is considered the gold standard in vitro method for measuring drug 
distribution in tissue because overall uptake including non-specific binding to phospholipid 
membranes and proteins, active uptake at the level of the brain parenchym as well as 
lysosomal trapping is quantified in terms of the volume of distribution of the unbound drug 
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( brainuV , ) [9]. In contrast, the unbound fraction of drug in brain tissue ( brainuf , ) available from 
equilibrium dialysis with brain homogenate reflects only the contribution of non-specific 
binding which, however, is the dominant factor of tissue distribution particularly for 
compounds with intermediate to high membrane affinity. Potential discrepancies between 
brainuf , and brainuV ,  , associated with the disruption of subcellular compartments (e.g. acidic 
lysosomes) and the resulting depletion of intracellular pH gradients, can be corrected for by 
applying a mathematical pH partitioning model [8]. With the exception of compounds for 
which carrier-mediated cellular uptake may occur [8], equilibrium dialysis is therefore 
considered a reliable and more convenient alternative to the brain slice method which has 
found application in preclinical drug development programs. 
A major drawback of the dialysis technique is, however, the requirement for relatively large 
amounts of tissue ( ogenateVhom =150 μL) which limits the throughput of the method for ethical 
reasons. A high-throughput microemulsion electrokinetic chromatography (MEEKC) method 
working with lauric acid rather than biological tissue has been proposed for the prediction of 
drug distribution in brain tissue [10]. MEEKC retention factors showed a very good 
correlation with brainuf , on a set of 42 compounds, albeit, the correlation between retention 
factors and measured octanol-water partition coefficients ( Plog ) was likewise excellent. 
Thus, no general statement can be made of whether or not the MEEKC method is superior to 
measured Plog  regarding the prediction of tissue binding. Other authors [11] have used brain 
lipid membrane vesicles stabilized on silica beads (TRANSIL brain absorption), and 
membrane affinities have been correlated with brainuf , data showing a good agreement on a set 
of 65 drugs. Brain tissue obtained from porcine was still required for the preparation of the 
brain extract, yet only the lipid fraction was used for the preparation of membrane vesicles. It 
is also interesting to note that equilibrium dialysis with human embryonic kidney cells 
(HEK293) has recently been proposed as an inexpensive and easily available brain tissue 
surrogate resulting in binding data comparable with brainuf , values for a set of 46 drugs [12]. 
Importantly, system dependent differences in binding capacity had to be corrected for by 
deriving and applying a scaling factor which should accordingly be adjusted in other 
laboratories [12].  
Certainly, all proposed methods based on brain tissue surrogates are valuable; nonetheless, 
the use of brain homogenate itself as the test tissue of interest may still be the closest 
approximation to the in vivo situation. The purpose of this study was to establish a novel in 
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vitro assay for the determination of non-specific binding of drugs to brain tissue. The assay, 
in the following referred to as Lipid Membrane Binding Assay (LIMBA), works with 
significantly reduced consumption of brain homogenate ( ogenateVhom =1.2 μL) as compared to 
equilibrium dialysis. We validated LIMBA on a set of 127 structurally diverse marketed 
drugs with reported brainuf , data obtained from equilibrium dialysis in rat and mouse. The 
accuracy of brainuf ,  predictions using LIMBA was evaluated in comparison with i) 
octanol/water distribution and partition coefficients ( octDlog , Plog ) available from a recently 
described Carrier Mediated Distribution System (CAMDIS) [13], and ii) fractions of drug 
retained in the permeation barrier of the parallel artificial membrane permeability assay 
(PAMPA). To the best of our knowledge, the membrane fraction in PAMPA has never been 
evaluated before in terms of the ability to predict drug distribution in tissue. A comparison 
between brainuf ,  prediction approaches based on CAMDIS octDlog  and Plog , the PAMPA 
membrane fraction as well as binding data measured with LIMBA is provided and results will 
be discussed in terms of the trade-off between prediction accuracy, practicability and the 
requirement for brain tissue. 
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2. Materials and Methods 
2.1. Materials  
Drugs were either available through our in-house Compound Depository Group as 
proprietary compounds or were purchased from ABX (Radeberg, Germany), AK Scientific 
(Mountain View, Ca), Acros Organics (Morris Plains, NJ), Aldrich (Milwaukee, WI), 
Bepharm Ltd. (Shanghai, China), Chem Pacific (Baltimore, MD), Fluka (Buchs, 
Switzerland), HRITIK Chemicals Cooperation (Mumbai, India), Molekula (Vaterstetten 
Germany), Sequoia (Pangbourne, UK), Socochim (Lausanne, Switzerland), TCI Europe 
(Zwijndrecht, Belgium), Tocris (Bristol, UK), TRC (Toronto, Canada) and Sigma (Steinheim, 
Germany).  
Tris and sodium chloride were obtained from Fluka (Buchs, Switzerland). Tapso was 
obtained from AppliChem (Darmstadt, Germany). Mopso, octanol, glycocholic acid, egg 
yolk lecithin (60% TLC), cholesterol and dodecane were purchased from Sigma (Steinheim, 
Germany). Potassium hydrogen phthalate was obtained from Merck (Darmstadt, Germany). 
Brain polar and total lipid extract (porcine) were purchased from Avanti (Alabaster, AL). 
DMSO was obtained from Acros (Geel, Belgium). 2-propanol was purchased from Burdick 
& Johnson (Seelze, Germany). Buffer kits for CE- apK  measurements were obtained from 
Advanced Analytical (Ames, IA). Water and acetonitrile for HPLC were supplied from 
Merck (Darmstadt, Germany) and were of HPLC-grade.  
2.2. Compilation of a Validation Dataset 
The literature was searched for compounds with reported brainuf , data as determined by means 
of equilibrium dialysis with brain homogenate. Since Wan et al. [14] demonstrated that 
species differences in drug binding to rat and mouse brain tissue can be neglected, brainuf , data 
measured in either or both species were included for the purpose of an extended dataset. 
However, if both rat and mouse data was reported within one single study [14], preference 
was given to rat data thus taking into account that LIMBA was conducted with rat brain 
homogenate. Drug binding to tissue was expressed as )/)1log(( ,, brainubrainu ff and mean values 
from literature are reported. 
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2.3. Measurement of Brain Tissue/Water Distribution Coefficients with LIMBA 
2.3.1. Experimental Setup  
LIMBA is an in vitro assay for the measurement of the concentration ratio of a drug 
distributed between an aqueous phase and brain homogenate. The assay involves coating a 
filter support with brain homogenate and incubation of the coated filter with analyte-spiked 
aqueous phase as described in Fig. 1. The so formed sandwich can easily be disassembled to 
enable concentration analysis in the aqueous phase at steady state. The implementation in a 
96 well plate format allows for the measurement of brain tissue/ water distribution 
coefficients ( brainDlog , see below) in a medium-to-high-throughput manner.  
 
Fig. 1 
 
2.3.2. Assay Protocol  
Brain tissue (rat) /water distribution coefficients, )4.7(log pHDbrain , were determined with 
LIMBA as follows: On the day of the study, drug-naive female Wistar rats were sacrificed in 
a CO2 chamber and the whole brain was sampled and immersed in assay buffer (50 mM 
TRIS/114 mM NaCl/ pH 7.4) to remove adherent blood. Experiments were conducted in 
accordance with the current Cantonal and Federal legislation on the welfare of experimental 
animals. The rat brain was weighted and homogenized on ice in 2 volumes (w/v) of n-
dodecane using an ultrasonic probe (Branson sonifier, G. Heinemann, Schwäbisch Gmünd, 
Germany). A part of the fresh brain homogenate was used for the distribution experiments, 
and the rest was stored at 4°C for comparative purposes.  
For the preparation of the aqueous phase, test compounds were introduced into the assay 
buffer (50 mM TRIS/114 mM NaCl/pH 7.4) as DMSO stock solutions (10 mM). The 
resulting aqueous drug solution (nominal concentration = 25 μM, DMSO content 0.25 %) 
was filtered (Millipore Deepwell Multiscreen Filter plate, MDRLN0410) into a 96-deep well 
receiver plate (NUNC, 278752) and aliquots of the filtrate ( aqV = 50 µL) were transferred into 
an in-house made Teflon plate. In parallel, the rat brain homogenate ( brainV =1.2 μL) was 
coated on a PVDF filter attached to the bottom of the customized and commercially available 
DIFI tubes (Weidmann Plastics Technology AG, Rapperswill, Switzerland, 23358) [15]. The 
pipetting of brain homogenate was conducted with a Hamilton robotic system using new 
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pipetting tips (10 μL disposable tips) for each coating step and a sealed 96 well PCR plate 
(Eppendorf) for the storage of brain homogenate. During the pipetting, the PCR plate was put 
on a shaker. The coated DIFI tubes were added on top of the Teflon plate pre-filled with 
aqueous drug solution thus forming a sandwich. The kit was sealed and allowed to shake at 
room temperature (RT) for 15 h. The incubation time was based on prior experiments 
showing that distribution equilibrium was achieved after 15 h. After removal of the DIFI 
tubes, the equilibrium drug concentration in the aqueous phase, eqaqC , was analyzed with 
HPLC - UV. A reference experiment was carried out in the same plate but without brain 
homogenate, to obtain the initial aqueous drug concentration, oaqC . )4.7( pHLogDbrain  values 
were obtained by mass balance according to,  
 
brain
aq
eq
aq
eq
aqaq
brain
V
V
C
CC
LogD 


0
,         (1) 
 
All distribution experiments were performed in triplicate and mean )4.7(log pHDbrain values are 
reported. 
2.4. Measurement of n-Octanol/Water Distribution Coefficients with CAMDIS 
)4.7( pHLogDoct  values were measured with CAMDIS, an in-house miniaturized shake flask 
assay based on the use of a filter-support for octanol as described above. Details about the 
validation of the assay are provided in our accompanying manuscript 1 [13].  
The assay protocol was very similar to LIMBA, however, the aqueous drug concentration of 
the filtrate was 100 μM (DMSO content 1 %, v/v) and the volume of the aqueous phase was 
aqV  = 150 μL. Different phase volume ratios were chosen to optimize CAMDIS and LIMBA 
in terms of applicability range. Drug concentrations in LIMBA were slightly lower as 
compared to CAMDIS to avoid saturation of binding sites (e.g. to phospholipids) in brain 
homogenate. In contrast to LIMBA; the filter support in CAMDIS was coated with octanol 
( octV = 1 µL and 15 µL; n = 3 for each volume) using of a Tecan robotic system. The octanol-
coated DIFI tubes were incubated with the aqueous phase as described for LIMBA, however, 
the equilibration time was slightly longer in CAMDIS (16-22 h). octLogD values were 
obtained by mass-balance according to the calculation of brainLogD . 
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2.5. Measurement of PAMPA-Lipid Solution/Buffer Distribution Coefficients 
Aqueous drug solutions (150 μM) were prepared by diluting DMSO stock solutions (10 mM) 
of the test compound in i) 50 mM MOPSO/0.5 % (m/v) glycocholic acid/ pH 6.5 ('Roche 
buffer'), ii) 50 mM MOPSO/pH 6.5 and iii) 50 mM Tris/114 mM NaCl/pH 7.4. The drug 
solution was filtered and a part of the filtrate (150 μL) was kept as a reference whereas 
another part ( DV = 320 µL) was transferred into a 96-well Teflon donor plate. The PAMPA 
membrane was formed by coating the filter (PVDF, pore size 0.45 μm) of a 96-well acceptor 
plate (Cat. 4550, Millipore, Billerica, MA) with a lipid-dodecane solution (10 %, m/v lipid: 
egg yolk lecithin, brain polar lipid or brain total lipids; MV =4.5 µL). The acceptor filter plate 
and the donor plate were carefully assembled to form a sandwich. Blank assay buffer 
( AV =280 µL, 50 mM Tris/114 mM NaCl/pH 7.4 or 50 mM MOPSO/pH 6.5) was added on 
top of the pre-coated filter plate. After 19.5 h incubation, the sandwich was separated and the 
amount of drug in the acceptor and donor compartment was determined by comparison with 
the UV spectra from the reference using a 96-well UV plate reader (Molecular Devices, 
model Spectra Max 190, Sunnyvale, CA and pION PSR4 p software). All measurements 
were performed in triplicate with an automated liquid handling system. Mass balance was 
used to determine the amount of drug remaining in the membrane barrier and the PAMPA-
lipid solution/buffer distribution coefficient, PAMPADlog , was calculated according to:  
 
M
AD
eq
D
eq
A
eq
M
PAMPA
V
VV
CC
C
LogD



 ,        (2) 
where eqMC , 
eq
DC  and 
eq
AC  are the equilibrium drug concentrations in the PAMPA membrane, 
the donor and the acceptor compartment, respectively.  
2.6. HPLC -MS Instrumentation and Chromatographic Conditions 
Drug concentrations in aqueous solutions were quantified using an Agilent 1290 Infinity 
HPLC-MS system (Agilent Technologies, CA, USA) equipped with a DAD detector and an 
API single quadrupole mass spectrometer (Agilent 6140). An aliquot of each sample (5 µL) 
was injected onto a Kinetex 2.6 µm, 2.1 x 50 mm analytical column (Phenomenex, Germany) 
operated at 60°C. The mobile phase consisted of A (water) and B (acetonitril), both 
containing 0.1 % (v/v) formic acid. The gradient elution was performed as follows: initial 
2 % B, 0 min - 0.35 min linear gradient from 2 % B to 95 % B, 0.35 min - 0.65 min 95 % B, 
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post time 0.5 min. After passing the DAD detector, the eluent was introduced into the 
electrospray interface maintaining the following source settings: capillary voltage + 3.5 kV, 
drying gas flow (N2)  13 L/min, nebulizer pressure 60 psi, drying gas temperature 350°C. The 
integral of the pseudo - molecular ion intensity, [M+H]
+
, was acquired in single reaction 
monitoring mode (SRM). Internal calibration for MS data analysis was accomplished by 
injection of 1, 3, and 5 µL of the sample solution. If UV sensitivity was sufficient, peak areas 
at appropriate wavelength were used for the calculation of octDlog  and brainDlog .  
2.7. Determination of Ionization Constants 
Ionization constants ( apK ) were determined potentiometrically on a Gemini Profiler
TM
 (pION 
INC, Woburn, MA, USA). Solutions of cationic and non-charged compounds in KCL were 
pre-acidified to pH 1.8 - 3.5 with HCL and were titrated alkalimetrically with standardized 
KOH (0.5 M) to an appropriate pH (maximum pH 12.5). The measurement of acids started at 
pH 11 following titration with HCL (0.5 M). All measurements were carried out at 25°C, at 
constant ionic strength (0.15 M KCl), under Argon atmosphere. The initial apK  - estimates, 
obtained from Bjerrum difference plots, were refined by a weighted non-linear least squares 
procedure [16] using the pS Data Refinement Program (pION, Version 3.2). The apK  values 
of compounds which precipitated were obtained by extrapolation to about one pH unit 
outside the data range collected. The aqueous apK  of thioridazine was obtained by Yasuda-
Shedlovsky extrapolation of the apK  values obtained in 35 - 65% (m/v) methanol. The apK  
of hydrocodone was determined by capillary electrophoresis (CE) on a apK  Analyzer ProTM 
system as follows: sample solutions containing 0.25 mM test compound and 0.1 % DMSO as 
EOF (electroosmotic flow) marker were prepared in CE running buffer at 24 different pH 
values ranging from pH 1.8 -11. Aliquots of the filtrated sample solutions (10 nL) were 
injected into a 96-well fused–silica capillary device prefilled with aqueous running buffer. 
Separation followed after application of 3.5 kV and -0.2 psi. The effective mobility (µeff) 
was calculated at each pH from the migration time of DMSO and that of the test compound. 
The apK  was derived from the inflection point in the µeff - pH plot.  
2.8. 
31
P-NMR Studies 
Solid-state 
31
P-NMR measurements were recorded on a Bruker Avance 400 spectrometer 
(Bruker AXS, Karlsruhe, Germany) operating at a phosphorous-31 frequency of 161 MHz 
and using a pulse-acquire sequence with broadband proton decoupling (400 MHz). The 
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recycling delay and the excitation pulse length was 6 s and 3 µs, respectively. A typical 
spectrum was obtained from 500 - 12.000 scans depending on the lipid content of the sample. 
The samples were prepared as follows: Drug-naive female wistar rats were sacrificed in a 
CO2 chamber, the whole brain was sampled and immersed in assay buffer (50 mM Tris, 11  
mM NaCl, pH 7.4). Brain tissue was homogenized on ice  in i) 0.5, 1 and 2 volumes (w/v) of 
dodecane ii) in 2 volumes (w/v) of assay buffer(50  mM Tris, 114 mM NaCl, pH 7.4). The 
homogenates and undisrupted brain were transferred to in-house made glass tubes which 
were flame sealed (only the homogenate).  
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3. Results 
3.1. Characterization of the Dataset 
In order to test the predictive power of LIMBA for estimating drug binding to brain tissue, a 
dataset of 126 compounds with reported brainuf , data, obtained from equilibrium dialysis with 
brain homogenate (rat, mouse), was collated as described in Materials and Methods. The 
whole dataset was structurally diverse and included neutral, acidic, basic and zwitter-ionic 
compounds covering a broad physicochemical property space and a wide range of range 
of brainuf ,  (Table 1,2)  
 
Table 1,2 
 
For the stepwise optimization of LIMBA and PAMPA on a high quality dataset of reasonable 
size, a subset (Dataset 1) was selected with brainuf , data (rat or mouse) determined in at least 
two independent studies by means of equilibrium dialysis. Even though brainuf , data for 
theobromine and theophylline has only been determined within one equilibrium dialysis 
study, the compounds were included in Dataset 1 since brainuf ,  data obtained from equilibrium 
dialysis and the brain slice method were in excellent agreement. In contrast, caffeine, 
sumatriptan as well as NFPS were excluded due to high standard deviations (SD > 0.25 
brainuf , units) between individual equilibrium dialysis studies (caffeine, sumatriptan) and 
between equilibrium dialysis and brain slice uptake data (NFPS), respectively. Dataset 1 was 
thus comprised of 35 drugs and covered a broad physicochemical property space, however 
with a smaller range in terms of lipophilicity and molecular weight (Table 1) as compared to 
the whole 126 compound dataset. The remaining compounds (n = 88), for which brainuf , data 
was available from only one equilibrium dialysis study, were assigned to Dataset 2.  
3.2. Development of LIMBA 
The basic concept of LIMBA was to facilitate the measurement of brain tissue/water 
distribution coefficients ( brainDlog ) by immobilizing brain tissue on a filter support, thus 
preventing contamination of the aqueous phase with matrix components and allowing for 
convenient and complete phase separation after distribution equilibrium is achieved. As such, 
LIMBA can be considered a further development of CAMDIS, a recently described high-
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throughput assay for the measurement of octDlog , which likewise involves the use of a filter 
support for the lipophilic phase [13]. Whilst octanol is used in CAMDIS, the filter in LIMBA 
is impregnated with brain tissue homogenized in a solvent. Various combinations of solvents 
and filter supports for the homogenization and immobilization of brain tissue, respectively, 
were investigated, including water and organic solvents as well as hydrophobic and 
hydrophilic filters materials. As outlined in the Supporting Information, dodecane in 
combination with a hydrophobic PVDF filter was most suitable since homogenates amenable 
for pipetting were obtained and contamination of the aqueous phase with brain tissue was 
prevented.  
Details about the development of LIMBA in terms of equilibration time, selection of drug 
concentrations, influence of the presence of DMSO on tissue binding as well reproducibility 
are described in the Supporting Information. A summary of the selected experimental 
conditions is provided in Table 3.  
 
Table 3 
 
It is worth emphasizing that LIMBA is generally conducted with brain homogenate from rat, 
however, a comparison between LIMBA brainDlog  values in rat and mouse, using a subset of 
compounds from Dataset 1, showed that species differences are negligible (Fig. S4, 
Supporting Information) which is in line with literature [14]. Therefore a comparative 
evaluation of LIMBA brainDlog (rat) values and brainuf , data (rat, mouse) collated from 
literature is valid and will be presented in the following along with results from other 
membrane surrogate systems, i.e. CAMDIS and PAMPA. 
3.3. Comparative Evaluation of LIMBA, CAMDIS and PAMPA for the Prediction of 
Brain Tissue Binding (Dataset 1) 
3.3.1 The Relationship between brainDlog  (LIMBA) as well as octDlog  (CAMDIS) and Equilibrium 
Dialysis Data 
The relationship between drug binding to brain tissue (equilibrium dialysis data), expressed 
as )/)1log(( ,, brainubrainu ff , and brainDlog  (pH 7.4) measured with LIMBA is presented in 
Fig. 2A at the example of 27 test compounds from Dataset 1.  
 
Fig. 2 
4. Manuscripts 
 261 
 
Selegilin, carisoprodol and meprobamate were excluded due to poor analytics and only 
compounds within the applicability range of LIMBA ( brainDlog > 0.4) are shown, yielding the 
following correlation statistics:  
 
)/)1log(( ,, brainubrainu ff  = 1.102* brainDlog  (pH 7.4) - 0.346     (3) 
(r
2
 = 0.911, n = 27) 
 
The slope close to 1 and the intercept close to 0 indicate excellent agreement between 
LIMBA and equilibrium dialysis data for all compounds, however, it is important to note that 
Dataset 1 is dominated by neutral and basic compounds whereas only two weak acids were 
measured.  
In contrast to LIMBA, octDlog  (pH 7.4) only poorly described )/)1log(( ,, brainubrainu ff  (Fig. 2B, 
r
2 
= 0.518, n = 35), especially for lipophilic basic compounds whose tissue binding was 
under-predicted by octDlog . Interestingly, the correlation of )/)1log(( ,, brainubrainu ff  with 
Plog rather than octDlog  (pH 7.4) yielded improved prediction accuracy (r
2 
= 0.827, n = 35) 
due to less deviation of basic compounds from the correlation line. Note that 35 compounds 
could be measured with CAMDIS, however, when relying statistics on 27 compounds 
amenable for measurement with LIMBA, the ranking of surrogate systems according to their 
correlation with equilibrium dialysis data remained the same (LIMBA brainDlog > Plog > 
CAMDIS octDlog ) (Table 4). 
 
Table 4 
 
3.3.2 The Optimization of PAMPA and the Relationship between PAMPADlog  and Equilibrium Dialysis 
Data 
PAMPA has been introduced as a more physiologically relevant system for the screening of 
passive permeability as compared to preceding methods largely based on organic 
solvent/water partitioning [17]. The permeation barrier in PAMPA usually consists of 
synthetic or natural phospholipids (e.g. egg yolk lecithin, exception Novartis: 100 % 
hexadecane) dissolved in excess organic solvent (e.g. n - dodecance) and coated on a filter 
support (e.g. (PVDF). The permeation of test compounds from an aqueous donor 
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compartment across the so formed membrane into an aqueous acceptor compartment can be 
measured and is corrected for the fraction of drug retained in the membrane. A drug’s 
membrane retention is therefore a side product which we evaluated in terms of its surrogate 
properties for the prediction of drug binding to brain tissue.  
It is worth noting that considerable efforts have been put into optimization of PAMPA, 
towards improved predictability of e.g. gastrointestinal drug absorption and BBB permeation. 
Every individual component has been varied including the organic solvent (e.g. dodecane 
[17], hexadecane [18], 1,7 octadiene [19], the lipid (1-palmitoyl-2-oleoyl-
phosphatidylcholine (POPC), soy lecithin [20], brain polar lipids, biomimetic lipid mixtures 
[21]), the filter unit (PVDF [17], polycarbonate [18]) as well as the buffer composition [22]. 
In this study, the PAMPA setup routinely applied at Roche was investigated and used as a 
starting point for the optimization towards improved predictive power for brain tissue 
binding. The modification of the buffer and lipid composition was thereby inspired by 
previously reported optimization strategies with regard to the prediction of in vivo 
permeability (a summary of experimental conditions used in this study is provided in 
Table 4).  
Fig. 3A-F show the correlation between literature )/)1log(( ,, brainubrainu ff data obtained from 
equilibrium dialysis and PAMPADlog at the example of 32 test compounds from Dataset 1 (same 
exclusion criteria like for CAMDIS octDlog , in addition carisoprodol, meprobamat and 
selegiline were excluded due to poor UV absorption), and for the different setups 
investigated. The standard Roche setup (donor and acceptor: pH 6.5; donor spiked with 
glycocholic acid; membrane: 10% (m/v) egg lecithin in dodecane) yielded poor correlation 
statistics (r
2 
= 0.521) and high standard deviations (Fig. 2A), however, both parameters 
improved when omitting glycocholic acid from the donor compartment (Fig. 2B). Lower 
standard deviations in absence of glycocholic acid indicate that the solubilizer distorts the 
integrity of the PAMPA membrane. Moreover, PAMPADlog (pH 6.5) values in presence of 
glycocholic acid were lower for 27 of 32 compounds than in its absence which can be 
explained by the shift in distribution equilibria towards drug solubilized in glycocholic acid 
micelles (exceptions are the acid theophylline, the weak bases zolpidem and trazodone, as 
well as hydrocodone and methylphenidate (both showing poor UV absorption)). The effect of 
solubilization is missing in literature equilibrium dialysis studies, and even though drug 
binding to plasma proteins in vivo might occur, it adds an undesired layer of complexity to 
the in vitro data and leads to a prediction bias towards underestimated drug binding to brain 
4. Manuscripts 
 263 
tissue, in particular for lipophilic basic drugs (see deviation of correlation line at 
)/)1log(( ,, brainubrainu ff  > 1.8). 
Apart from the effect of glycocholic acid, the pH in the Roche setup (pH 6.5) also deviates 
from the pH in brain ISF (pH 7.3 [8]) giving rise to higher ionized fractions of drugs with a 
basic apK  and, in turn, a decrease of drug retention in the PAMPA membrane. In order to 
conduct measurements at physiological conditions, PAMPADlog values were measured at pH 7.4 
(absence of glycocholic acid) leading to increased binding of basic drugs with intermediate to 
high lipophilicity and further improved correlation with )/)1log(( ,, brainubrainu ff  (Fig. 2C, 
r
2 
= 0.791). However, the trend towards increased binding was not observed for all basic 
drugs. 
In the next step, the optimized buffer composition was adopted (pH 7.4, no glycocholic acid) 
and the effect of lipid composition on the performance of tissue binding prediction with 
PAMPA was investigated. Due to the large excess of dodecane in the egg lecithin-solvent 
mixture (10% (m/v) egg lecithin) applied above, the question as to the relevance of 
phospholipids for the extent of membrane retention arises. Fig. 2D shows that omitting egg 
lecithin from the lipid mixture and performing experiments with pure dodecane drastically 
decreases the correlation with )/)1log(( ,, brainubrainu ff (r
2 
= 0.326), and increases the trend 
towards under-prediction of brain tissue binding, in particular for lipophilic basic drugs. 
However, a reduction in membrane retention in absence of egg lecithin was not evident for all 
drugs (e.g. chlorpromazine) and further research is required to understand the nature of the 
binding process (accompanying manuscript 5) 
In contrast to egg lecithin, brain tissue is relatively rich in acidic phospholipids (between 9.4 
and 20.8 % of total phospholipids) as estimated from the phospholipid composition in brain 
tissue reported for rat [23]. In order to remain as close as possible to the in vivo situation, it 
would be preferable to use the brain homogenate applied in LIMBA for the formation of a 
permeation barrier in PAMPA, however, the addition of an aqueous acceptor phase on top of 
the coated filter distorted the barrier integrity. In contrast, lipids extracted from porcine brain 
and dissolved in dodecane (10% (m/v) lipid) yielded stable membranes in presence of the 
acceptor phase which allowed for the measurement of PAMPADlog values with commercially 
available i) brain total lipid (BTL) extract and ii) brain polar lipid (BPL) extract. An 
inspection of the lipid composition (Table 5) reveals that both brain extracts contain higher 
amounts of negatively charged phospholipids (egg lecithin < BTL < BPL) and lower amounts 
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of net neutral phosphatidylcholine as compared to egg lecithin used in the standard PAMPA 
setup at Roche. 
 
Table 5 
 
Fig. 3C, E, F shows the correlation between )/)1log(( ,, brainubrainu ff (equilibrium dialysis data) 
and PAMPADlog (pH 7.4) values derived from experiments with egg lecithin (Fig. 3C, r
2
=0.791), 
BTL extract (Fig. 3E, r2=0.800) and BPL extract (Fig. 3F, r2=0.850). Only minor differences 
between PAMPADlog (pH 7.4) from the different setups were observed with slightly more 
pronounced binding of hydrophilic basic compounds to membranes formed from BPL and 
egg lecithin as compared to BTL. Since a major part of the lipid extracts was uncharacterized, 
further research is required to understand the rather good agreement between BPL and egg 
lecithin data despite the higher content of negatively charged phospholipids in BPL extract. 
From a theoretical point of view, the presence of negatively charged phospholipids should 
lead to electrostatic attraction of basic compounds, and. in turn, an increase of drug binding to 
BPL. The best overall correlation statistics was, albeit, obtained with BPL extract (r2 = 0.850) 
which we therefore used for further investigation on an extended dataset, along with the egg 
lecithin-dodecane mixture for comparative purposes. More information about the 
optimization of PAMPA is provided in the Supporting Information showing 1:1 correlations 
of PAMPADlog data obtained with the various experimental conditions (Figure S5). 
3.4. Comparative Evaluation of CAMDIS, Optimized PAMPA, LIMBA and 
Equilibrium Dialysis on an Extended Dataset 
The correlations shown in Section 3.2 were based on high quality brainuf ,  data reported in at 
least two independent studies showing that LIMBA brainDlog (pH 7.4) values were in best 
agreement with equilibrium dialysis data. Good correlation statistics were also obtained with 
PAMPADlog available from the optimized PAMPA setup (pH 7.4, no glycocholic acid, 
membrane formed of BPL in dodecane) as well as measured Plog data, even though in the 
latter case previous literature reports suggest that a considerable scatter in the correlation may 
be encountered [14, 24]. However, the physicochemical property space of Dataset 1 was 
limited and dominated by neutral and basic compounds.  
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In order to test the predictive power of LIMBA brainDlog (pH 7.4) in comparison with i) 
octDlog  (pH 7.4), ii) Plog (CAMDIS) and iii) PAMPADlog (pH 7.4, optimized setup) on an 
extended dataset, compounds from Dataset 2 were measured in each assay allowing for the 
evaluation of assay performances on the complete 126 compound dataset. Fig. 4A-F show the 
correlations between )/)1log(( ,, brainubrainu ff and the various surrogate parameters confirming 
poor predictive power of octDlog (pH 7.4) (Fig. 4A, r
2
=0.564, n = 112, for exclusion criteria 
see Fig. 4) as already observed with Dataset 1.  
 
Fig. 4 
 
It was also confirmed that predictions of brain tissue binding based on measured and 
calculated Plog data improved the correlation statistics (r
2
=0.606 and r
2
=0.649, respectively, 
n = 112) however, a considerable scatter of the data was still evident (Fig. 4B,C). It is worth 
noting that brain tissue binding of acidic compounds tend to be under-predicted by measured 
Plog , and to a minor degree by calculated Plog values , which can be explained by i) 
electrostatic repulsion of acidic compounds from negatively charged phospholipids present in 
brain tissue but not in octanol, and ii) by the disregard of ion partitioning when extrapolating 
Plog data from measured octDlog (pH 7.4) and apK using the Hendersson-Hasselbalch 
equation. The resulting overestimation of Plog is the higher, the higher the discrepancy 
between pH = 7.4 and the apK , which explains the pronounced deviation from the correlation 
line for compounds with low acidic apK values. 
With respect to the performance of PAMPADlog (pH 7.4) (optimized PAMPA setup), improved 
correlation statistics were obtained as compared to prediction approaches based on 
octDlog (pH 7.4) and Plog . More specifically, it was confirmed that drug distribution into 
membranes constituted of egg lecithin (Fig. 4D) and BPL extract (Fig.4 E) was similar and 
resulted in the same trend towards generally reasonable correlations 
with )/)1log(( ,, brainubrainu ff . However, brain tissue binding for compounds with 
)/)1log(( ,, brainubrainu ff > 2.5 was underestimated.   
Among all investigated surrogate systems, LIMBA brainDlog (pH 7.4) was in best agreement 
with brain tissue binding available from equilibrium dialysis (Fig. 4F, r
2
=0.741, n = 73), 
however, a trend towards underestimation of )/)1log(( ,, brainubrainu ff  for acidic and 
zwitterionic compounds was evident in both PAMPA and LIMBA. A strong outlier, 
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ziprasidone (base), was observed in each surrogate assay, which, may thus be explained by 
experimental variability in the equilibrium dialysis study (only one reported brainuf , value was 
available).  
3.5. The Influence of Dodecane on the Lipid Organization in LIMBA 
As outlined above and in the Supporting Information, dodecane was used for the 
homogenization of brain tissue, which may have an influence on the organization of 
phospholipids (e.g. formation of hexagonal and iotropic phases) as reported for other lipid-
organic solvent-water systems [25-27]. Therefore, we investigated the phospholipid 
organization in brain tissue as well as brain tissue homogenized in i) water and ii) dodcane, at 
a constant tissue:solvent ratio (1:2 (m/v), Fig. 5A), and at increasing concentrations of 
dodecane (Fig.5B).  
Fig. 5A shows typical bilayer NMR spectra for undisrupted brain tissue and brain tissue 
homogenized in water, which, however, were superimposed by an isotropic phase in presence 
of dodecane that becomes the more pronounced the higher the dodecane content. At the 
tissue:dodecane ratio used in LIMBA (1:2 (m/v)), a portion of bilayer was still present, yet 
with a not further quantified portion of isotropic phase pointing to the formation of reversed 
micelles.  
 
Fig. 5 
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4. Discussion 
Equilibrium dialysis is a standard method for the measurement of tissue binding, however, 
the requirement for relatively large amounts of animal tissue limits the throughput of the 
technique and alternative assays relying on lower or less consumption of animal tissue were 
investigated during the course of this study. In particular, we have developed a novel Lipid 
Membrane Binding Assay (LIMBA) for the assessment of drug binding to brain tissue, which 
was evaluated in comparison with other membrane surrogate systems, i.e. CAMDIS and 
PAMPA, in terms of their agreement with brainuf , data available from equilibrium dialysis.  
The poor correlation between octDlog (pH 7.4) (CAMDIS) and 
)/)1log(( ,, brainubrainu ff (equilibrium dialysis) confirms results from previous studies on smaller 
datasets [28] and can partly be explained by the higher contribution of ionized species to 
overall membrane binding as compared to drug distribution into octanol dominated by the 
non-ionized form [22]. Moreover, the presence of negatively charged phospholipids in tissue 
but not octanol gives rise to electrostatic attraction of cationic drugs resulting in increased 
membrane binding. For instance, Yata et al. showed that the extent of tissue binding is 
positively correlated to the content of negatively charged phosphatidylserine [29] as observed 
for a range of different tissues and drugs. Accordingly, it can be explained that the 
underestimation of brain tissue binding by octDlog (pH 7.4) for basic compounds is less 
pronounced when relying prediction approaches on Plog  leading to improved overall 
correlation statistics. Yet, octanol lacks the anisotropy and asymmetry of a biological 
membrane [7], and therefore it is not surprising that PAMPADlog (PAMPA), reflecting drug 
distribution into reverse micelles formed from phospholipids in dodecane (accompanying 
manuscript 5), showed better agreement with )/)1log(( ,, brainubrainu ff . It is important to note 
that reasonable correlation statistics were only obtained with an optimized PAMPA setup 
(pH 7.4, no solubilizer, BPL membrane) whereas the default setup at Roche performed poorly 
due to the non-physiological pH (with respect to brain) and membrane composition as well as 
the disturbance of the membrane integrity in presence of solubilizers.  
From all surrogate systems investigated, brainDlog (pH 7.4) values measured with LIMBA 
were in best agreement with equilibrium dialysis data, reflecting the fact that brain tissue 
homogenized in dodecane is the closest approximation of the in vivo situation with respect to 
surrogate systems tested within this study. The miniaturized format of LIMBA allows 
working with minute amounts of brain homogenate ( brainV  = 1.2 μL), which is optimized for 
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the characterization of compounds with intermediate to high tissue binding ( brainDlog  > 0.4) 
matching the typical physicochemical property space encountered in drug development 
programs. A trend towards under-prediction of brain tissue binding was observed for anionic 
and zwitterionic compounds in both LIMBA and PAMPA which might be explained by the 
negative surface potential of the PVDF filter support for the tissue surrogate, giving rise to 
reinforced electrostatic repulsion of compounds with an acidic apK . However, cationic and 
non-ionic compound predominate in most drug discovery programs.  
The good agreement between LIMBA brainDlog and equilibrium dialysis data for this majority 
of compounds demonstrates that preparing tissue homogenate in dodecane (rather than 
aqueous buffer) does not change the ranking between the two tissue binding scales, with 
respect to the chemical space investigated. In this regard, it is important to note that 
compounds with a high likelihood for adsorption to Teflon (predominantly large and 
lipophilic compounds, for prediction model see accompanying manuscript 2) were excluded 
from the dataset to avoid experimental artifacts. However, the NMR spectra showed that 
dodecane disrupts the phospholipid bilayer of undisrupted brain tissue in favor of an isotropic 
phase suggesting the formation of reverse micelles. Since the insertion into densely packed 
bilayers requires more energy than the insertion into isotropic systems [7], a deviation from 
the good agreement between LIMBA and equilibrium dialysis data for larger compounds is 
thus likely. Further research is required to address this question.  
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5. Conclusions  
In summary, we have demonstrated on a large dataset that octanol is only a poor surrogate for 
brain tissue binding ( )/)1log(( ,, brainubrainu ff measured with equilibrium dialysis, even though 
slightly improved prediction accuracy was achieved when using Plog rather than octDlog (pH 
7.4). The correlation with equilibrium dialysis data further improved when using the fraction 
of drug retained in the PAMPA membrane, provided that experiments were conducted under 
optimized experimental conditions in terms of buffer and lipid composition (brain polar 
lipids). The best agreement with equilibrium dialysis data was yielded when relying 
predictions on brainDlog values available through the novel LIMBA assay, albeit tissue binding 
for acidic and zwitter-ionic compounds was slightly under-predicted. With this limitation, 
LIMBA may provide a useful alternative to equilibrium dialysis for the medium-to-high 
throughput screening of drug binding to brain tissue, at significantly reduced consumption of 
brain homogenate.  
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TABLES 
 
Table 1   Key molecular properties of the complete dataset and the subset (Dataset 1) used for the 
development and comparative evaluation of CAMDIS, PAMPA and LIMBA.  
Parameter 
Range 
n = 126, whole dataset n = 36, Dataset 1 
brainuf ,  [%] 0.009 - 100  0.078 - 83% 
Molecular weight [g/mol] 146 - 875  151 - 477 
Highest basic apK - lowest acidic apK  10.59  - 1.94  10.13 - 1.94 
Pc log
a
 -2.5 - 6.1  -0.67 - 5.35 
octDlog  at pH 7.4 (shake flask) -2.0 - 5.4  -1.15 - 3.32 
a 
Pc log  v4.71 Daylight 
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Table 3   Summary of optimized experimental conditions and applicability domain of LIMBA. 
Experimental conditions Specification 
Phase volume ratios
a
 aqV =50µL; brainV =1.2µL (homogenate) 
Initial aqueous drug concentration  
0
aqC =25 µM  
DMSO content in the aqueous phase 0.25% (v/v) 
Filter support hydrophobic PVDF (DiFi tubes) 
Equilibration time 15 h  
Applicability range
 
brainDLog = 0.4 to maximal 4.2
b
 
a
 solvents used in this study: 50 mM TRIS/114 mM NaCl/pH 7.4, rat brain homogenized in 2 volumes (w/v) of 
n-dodecane. 
b 
upper 
brainDLog limited by the sensitivity of HPLC-UV/MS and by drug adsorption of basic compounds to the 
filter-supported interface as described in our accompanying manuscript 1. 
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Table 4   Surrogate systems evaluated in terms of their ability to predict drug binding to brain tissue. 
Correlation statistics obtained from linear fits of octDlog , Plog (CAMDIS), PAMPADlog (PAMPA) and 
brainDlog (LIMBA) with )/)1log(( ,, brainubrainu ff (equilibrium dialysis data) for Dataset 1 and an 
extended Dataset (1+2).  
Surrogate System Statistics (r
2
) 
Assay 
Specification 
Dataset 1 
(n=27)
a
 
Whole 
Dataset 
(n=73)
b
 
Octanol    
CAMDIS octDlog  (pH 7.4)  0.370 0.232 
'measured' Plog  derived from measured octDlog and apK  0.796   0.493 
calculated Plog  
 
clog P v4.71 Daylight 0.786 
 
0.495 
PAMPA barrier    
PAMPA 01 
(default at Roche)  
 
pH 6.5, egg lecithin,  
donor spiked with 0.5% glycocholic acid  0.375 not tested 
PAMPA 02 pH 6.5, egg lecithin 0.564 not tested 
PAMPA 03 pH 7.4, egg lecithin 0.710 0.572 
PAMPA 04 pH 7.4, dodecane 0.290 not tested 
PAMPA 05 pH 7.4, brain total lipids 0.812 not tested 
PAMPA06 pH 7.4, brain polar lipids 
 
0.805 0.612 
Brain homogenate     
LIMBA brainDlog  (pH 7.4) pH 7.4, brain homogenate in dodecane 0.911 0.741 
a
from the initial set of 38 compounds with brainuf , data reported in two independent studies (details see Section 
3.1), caffeine, sumatriptan and NFPS were excluded due to high standard deviation of the brainuf , data. 
Moreover, carisoprolol, meprobamat and selegiline were excluded due to poor UC absorption. LIMBA 
brainDlog values could only be determined at  brainDlog > 0.4 and statistics for the other surrogate systems refer 
to the same subset of compounds (n = 27). 
b
statistics refer to the same subset that was measured with LIMBA 
(for exclusion criteria see Fig. 4).  
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Table 5   Lipid composition of egg lecithin, brain total lipids and brain polar lipids 
% Lipid (m/m) Pampa Standard     
(egg lecithin)
a
  
Brain Total 
Lipids
b
 
Brain Polar 
Lipids
b
 
Phosphatidylethanolamine 5.7 16.7 33.1 
Phosphatidylserine (acidic)   10.6 18.5 
Phosphatidylcholine 59.0 9.6 12.6 
Phosphatidic acid (acidic)   2.8 0.8 
Phosphatidylinositol (acidic)   1.6 4.1 
Cholesterol 12.4     
Triglyceride 17.1     
Sphingomyelin       
Cerebroside       
Sulfatides        
Other 5.7 58.7 30.9 
a
product information provided by the supplier; 
b
as reported on http://avantilipids.com/ 
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FIGURES 
 
Figure 1   Work flow for determining brain tissue / water distribution coefficients, BrainDlog (pH 7.4),  
with LIMBA.  
 
   
Figure 2   Relationship between drug binding to brain tissue (equilibrium dialysis data), expressed 
as )/)1log(( ,, brainubrainu ff , and A: BrainDlog (pH 7.4) measured with LIMBA (r
2
=0.911, n = 27), B: 
octDlog  (pH 7.4) measured with CAMDIS (r
2
=0.518, n=35) and C: Plog derived from measured 
octDlog and measured apK   (r
2
=0.827, n = 35). Data in B and C is shown for n=35 compounds from 
Dataset 1 (caffeine, sumatriptan, NFPS were excluded due to high standard deviation of the 
brainuf , data). The same exclusion criteria were applied for the LIMBA data (A), however selegiline, 
meprobamate and carisoprodol was excluded due to poor analytics, and only the applicability range, 
i.e. BrainDlog > 0.4, is presented. Colors according to charge class: nonionic (), cationic (), anionic 
(). Black lines are fits to the experimental data, grey lines are lines of identiy. 
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Figure 3   Relationship between )/)1log(( ,, brainubrainu ff , obtained from equilibrium dialysis, and 
membrane retention in PAMPA, expressed as PAMPADlog , for n = 32 compounds from Dataset 1 
(exclusion criteria as described in Fig. 2). Different experimental conditions in PAMPA are shown 
(A - F) with details provided in Table 3. Correlation statistics (n = 32): A: PAMPA 1 (default setup at 
Roche, r
2
=0.521); B: PAMPA 2 (r
2
=0.597); C:  PAMPA 4 (r
2
=0.791); D: PAMPA 3 (r2=0.326); 
E: PAMPA 5 (r
2
=0.800); F: PAMPA 6 (r2=0.850). Colors according to charge class: nonionic (), 
cationic (), anionic (). Black lines are fits to the experimental data, grey lines are lines of identiy. 
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Figure 4   Relationship between )/)1log(( ,, brainubrainu ff , obtained from equilibrium dialysis, and A: 
octDlog  (pH 7.4) measured with CAMDIS (r
2
=0.564, n=112); B: Plog derived from measured 
octDlog and apK   (r
2
=0.606, n = 112); C: calculated Plog (r
2
=0.649, n = 112); D: PAMPADlog (pH 7.4, 
membrane formed from egg lecithin, r
2
=0.607, n = 90); E: PAMPADlog (pH 7.4, membrane formed 
from BPL r
2
=0.6, n = 90) and F: BrainDlog (pH 7.4) measured with LIMBA (r
2
=0.741, n = 73). 
Statistics without acidic and zwitterionic compounds and without ziprasidone (outlier in all assays): 
r
2
=0.824, n = 66.The following compounds were excluded from the correlation: caffeine, 
sumatriptan, NFPS (high standard deviation of the brainuf , data); ergotamine (instable); doxorubicin, 
digoxin, indinavir, paclitaxel, vinblastine, ritonavir, saquinavir, nelfinavir adsorption to Teflon (> 5%) 
as predicted by a PLS model described in our accompanying manuscript 2. In addition, only 
compounds within the applicability range of PAMPA ( PAMPADlog > -0.27) and LIMBA ( BrainDlog > 
0.4) are shown in D/E and F, respectively. Since no access to the HPLC/MS system was possible at 
the time of LIMBA measurements, only compounds with good analytics in HPLC/UV are shown in F. 
Likewise, PAMPA was measured with a UV (platereader) and therefore compounds with poor UV 
absorption were excluded (carisoprodol, meprobamat, selegiline). Colors according to charge class: 
nonionic (), cationic (), anionic (), zwitter-ionic (). Black lines are fits to the experimental 
data, grey lines are lines of identiy. 
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Figure 5A: Experimental 162-MHz
 31
P-NMR spectra of brain tissue in the form of (A) undisrupted 
tissue, (B) homogenate in aqueous buffer (2:1, v/m, buffer:50 mM Tris, 114 mM NaCl, pH 7.4) at 
25°C, (C) same like (B) but at 37°C and (D) homogenized in dodecane (2:1, v/m). B: 
31
P-NMR spectra 
recorded from brain tissue homogenized with increasing amounts of dodecane. 
 
 
 
 
 
 
4. Manuscripts 
 284 
Supporting Information 
S1. LIMBA - Assay Development 
Data provided in the following was obtained from preliminary series of experiments with 
LIMBA not conducted with a liquid handling system. Therefore, the data may deviate 
slightly from the data from the validation setup provided in the main manuscript and obtained 
from the optimized LIMBA setup.  
S1.1. Selection of the Filter-Solvent System 
The basic concept of LIMBA was to facilitate the measurement of brain tissue/water 
distribution coefficients ( brainDlog ) by immobilizing brain tissue on a filter support thus 
preventing contamination of the aqueous phase and allowing for convenient and complete 
phase separation after distribution equilibrium is achieved. Since LIMBA was designed as a 
medium - to - high throughput assay, brain homogenate (rather than undisrupted brain tissue) 
was used which can be dispensed with a robotic liquid handling system.  
Various combinations of solvents and filter supports for the homogenization and 
immobilization of brain tissue, respectively, were investigated, including water and organic 
solvents as well as hydrophobic and hydrophilic filters materials. For the preparation of the 
homogenates, mouse brain was homogenized on ice in 2 volumes (w/v) of solvent by means 
of an ultrasonic probe. In order to detect a potential contamination of the aqueous phase with 
matrix components from brain tissue, the UV absorbance in the aqueous phase before and 
after incubation with tissue-coated filter was measured.  
Water would clearly be preferable for homogenization in order to remain as close as possible 
to the in vivo situation and, in particular, to maintain the bilayer structure of brain tissue. 
However, phase separation was not achieved when coating aqueous homogenate on a 
hydrophilic filter, and vice versa, a hydrophobic filter was not wetted which would thus 
prevent solute partitioning. Among the organic solvents investigated (Table S1), octanol and 
other alcohols as well as olive oil were generally unsuitable since mixtures with brain tissue 
flocculated. Short chain alkanes (e.g. hexane) yielded homogenates, but their fast evaporation 
complicates the application. Moreover, the UV check revealed that organic solvents of 
medium - to - high polarity (e.g. 1,9-decadien) in combination with hydrophilic filter 
materials (e.g. hydrophilic PVDF) are unsuitable since phase separation was incomplete. 
Only long chain, saturated alkanes prevented a contamination of the aqueous phase with brain 
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homogenate, irrespective of whether a hydrophilic (polycarbonate) or a lipophilic filter 
(PVDF) was used. Tissue - hexadecane mixtures were too viscous for pipetting and the 
addition of hexane was required with the drawback of introducing variability due to 
evaporation of hexane. The combination of a hydrophobic filter (PVDF) and dodecane, 
showing low solubility in water, and allowing for the preparation of homogenates amenable 
for pipetting, was considered the most suitable setup which was further applied for the 
development and validation of LIMBA. It is worth noting that also homogenization of brain 
tissue in dodecane and coating of a hydrophilic polycarbonate filter would be feasible, 
however, the absorption capacity of the PVDF filter investigated was higher (thickness 
 = 125 μM, PVDF vs. 10 μM, polycarbonate) and therefore PVDF was preferred. 
 
Table S1 Solvents tested for the homogenization of brain tissue and their properties with respect to 
the applicability for LIMBA.  
Solvent Homogenisation 
achieved? 
Hydrophobic filter 
wettable?a 
Phase separation achieved 
(hydrophobic filter ?b 
Water yes no filter not wettable 
Alcohols    
- Octanol, butanol, 1,6-heptadienol no not tested not tested 
Unsaturated  alkanes    
- 1,7-octadien, 1,8-nonadiene, 1,9-decadien yes filter opalescent no 
Saturated alkanes    
Short chain: pentane, hexane, heptane yes yes, but evaporation no  
Long chain: dodecane, hexadecane yes yes yes 
Other    
2-n-octyloxynitrobenzen no not tested not tested 
Olive oil no not tested not tested 
a
assessed by visual check whether or not the filter (hydrophobic PVDF) was transparent; 
b
assessed by 
measurement of the UV absorption of the aqueous phase before and after incubation with  a tissue-coated PVDF 
filter 
 
S1.2. Equilibration Time  
In order to determine the time required to reach distribution equilibrium in LIMBA, brainDlog  
(pH 7.4) values were measured in a time dependent manner for two test compound with 
different lipophilicity, namely cyclobenzaprine ( octDlog = 3; brainDlog  = 2.47) and risperidone 
( octDlog  = 1.87; brainDlog  = 1.47). Fig. S1 shows that distribution equilibrium for 
cyclobenzaprine and risperidone was reached after t  = 10 h and t  = 15 h, respectively. In the 
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following, aqueous drug solutions were incubated for t  = 15 h with brain tissue before 
determining brainDlog . 
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Figure S1   Kinetics of drug distribution in the brain tissue - filter - buffer system for cyclobenzaprine 
and riserpidone (25μM in 50mM Tris/114mM NaCl/pH 7.4). The brainDlog  were measured with 
LIMBA using 1.2 μL brain homogenate (solvent: dodecane ) and a lipophilic PVDF filter.  
 
S1.2. Concentration Dependency of Tissue Binding and the Selection of Optimal Drug Concentrations  
LIMBA brainDlog  (pH 7.4) values were measured as a function of drug concentration ( drugC ) at 
the example of three test compounds with different lipophilicity and charge state, namely 
risperidone ( octDlog  = 1.87, cationic), cyclobenzaprine ( octDlog = 3, cationic) and 
carbamazepine ( octDlog  = 1.58, neutral). An inspection of the brainDlog  - drugC profiles 
(Fig. S2) reveals that brainDlog values for the neutral test compound (carbamazepine) were 
insensitive to variations in drug concentration. In contrast, a trend towards lower brainDlog  
values at higher concentrations of cationic compounds was evident. A similar trend was also 
observed when determining CAMDIS octDlog values by mass balance (accompanying 
manuscript 1), i.e. when only initial and equilibrium aqueous drug concentrations were 
analyzed, and drug concentrations in the octanol phase were estimated by difference. Drug 
adsorbed to the filter-supported octanol/water interface is then wrongly assigned to the 
octanol phase leading to an overestimation of octDlog . The same effect likely explains the 
overestimation of LIMBA, brainDlog at low drug concentrations.  
During the optimization of CAMDIS it became clear that drug adsorption to the filter can be 
neglected at higher drug concentrations ( drugC  = 100 μM), however, drug concentrations in 
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LIMBA should also be selected such that saturation of the brain lipids is avoided. As a 
compromise, we selected drugC  = 25 μM as the default drug concentration applied in LIMBA. 
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Figure S2   LIMBA brainDlog  (pH 7.4) values as a function of drug concentration at the example of  
carbamazepine (), risperidone () and cyclobenzaprine (). 
 
S1.3. The Influence of DMSO on Tissue Binding  
In LIMBA, test compounds are introduced into the aqueous phase as DMSO stock solutions 
which simplifies the assay automation as a requirement for a screening assay. In order to test 
whether the presence of DMSO affects the extent of tissue binding, brainDlog  (pH 7.4) values 
were measured as a function of the DMSO content ( DMSOC  = 0.125 - 3%) using risperidone 
and cyclobenzaprine as representative test compounds.  
Fig. S3 shows that the influence of DMSO on brainDlog  (pH 7.4) was negligible, however, a 
slight trend towards lower brainDlog  values with increasing concentrations of DMSO (above 
1%) was evident for cyclobenzaprine, which is the compound with the higher affinity for 
brain tissue. In the following, LIMBA brainDlog values were determined at DMSOC  < 0.25 % 
where the influence of DMSO was negligible.  
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Figure S3   The brainDlog values of cyclobenzaprine () and risperidone () as a function of the 
DMSO content in the aqueous drug solution.  
 
S1.4. Reproducibility of LIMBA 
Intraday reproducibility of LIMBA was assessed by filling each well of a 96 well plate with 
an aqueous solution of the same test compound followed by measurement of brainDlog values 
for the whole plate. More precisely, a filtrate containing the test compound was prepared for 
6 wells, of which 3 were incubated with brain tissue and 3 were used as a reference for the 
assessment of the initial drug concentrations. Thus, 16 brainDlog values were measured on a 96 
well plate at the example of cyclobenzaprine ( octDlog =3; brainDlog  2.47) and risperidone 
( octDlog =1.87; brainDlog 1.47). Slightly better reproducibility was achieved for the compounds 
with the higher brainDlog value (cyclobenzaprine, SD = 0.08 brainDlog units) as compared to 
risperidone (SD = 0.10) which can be explained by the phase volume ratio ( brainV  = 1.2μL, 
aqV  = 50 μL) optimized for lipophilic compounds. 
S1.5. Species Differences in Brain Tissue Binding 
For practical and ethical reasons, LIMBA was conducted with brain homogenate from rat 
since higher yields of tissue per animal can be gained as compared to the other most 
commonly used pre-clinical species, i.e. mouse. However, since LIMBA was validated with 
equilibrium dialysis data from both rat and mouse brain, we were interested whether species 
differences in tissue binding become evident in LIMBA. To this purpose, LIMBA 
brainDlog values were determined with brain homogenate from both rat and mouse, using a 
small subset of compounds from Dataset 1 (n = 21) with good analytical properties. The 
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species comparison of LIMBA brainDlog values (Fig. S4) demonstrates that differences in drug 
binding to rat and mouse brain tissue assessed with LIMBA are negligible which is in line 
with equilibrium dialysis data [14].  
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Figure S4   LIMBA brainDlog (pH 7.4) values determined from brain homogenate of mouse and rat on 
a 21-compound dataset: Buspirone, Carbamazepine, Chlorpromazine, Citalopram, Clozapine, 
Cyclobenzaprine, Diazepam, Fluoxetine, Fluvoxamine, Methylphenidate, Metoclopramide, 
Midazolam, Nortriptyline, Paroxetine, Propanolol, Quinidine, Risperidone, Trazodone, Venlafaxine. 
Correlation statistics: LIMBA brainDlog (mouse) = 1.031*LIMBA brainDlog (mouse) -0.005, r
2
 = 0.975.  
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S2. Optimization of PAMPA 
 
   
   
 
Figure S5   Membrane retention in PAMPA, expressed as PAMPADlog , for n = 32 compounds from 
Dataset 1 using different experimental setups showing A: the influence of glycocholic acid, GCA; B: 
the influence of pH; C: the effect of the presence of egg lecithin (egg l.) in excess dodecane D: the 
comparison between drug distribution in membranes formed from egg lecithin and brain total lipid 
(BTL) extract as well as E: brain polar lipid (BPL) extract. Moreover, F: the comparison between 
drug distribution in BPL and BTL membranes is shown. Colors according to charge class: nonionic 
(), cationic (), anionic (). Black lines are fits to the experimental data, grey lines are lines of 
identiy. 
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ABSTRACT 
Positron emission tomography (PET) is a valuable technique for the visualization of drug 
tissue distribution and receptor occupancy at the target site in living animals and men. Many 
potential PET tracers, however, fail due to an unfavorably high non-specific binding to non-
target proteins and phospholipid membranes which compromises the sensitivity of PET. 
Hence, there is a high demand to assess the extent of non-specific binding as early as possible 
in the PET tracer development process, preferentially before labeling of the ligand and 
elaborate autoradiography studies. The purpose of this study was to establish a Lipid 
Membrane Binding Assay (LIMBA) for estimating non-specific binding in brain tissue. To 
test LIMBA we used i) 30 tracers characterized with in vitro autoradiography (rat, mouse) 
and ii) 10 tracers investigated with in vivo PET (literature data, human). Rat brain 
tissue/water distribution coefficients, )4.7(log pHDbrain , of the unlabeled test compounds were 
measured with LIMBA which allows for medium-throughput screening at minimal expense 
of animal tissue. With respect to the autoradiography data, good prediction accuracy was 
achieved (r
2
 ≥ 0.87) whereas octanol/water distribution coefficients, )4.7(log pHDoct were less 
predictive). Moreover, LIMBA yielded )4.7(log pHDbrain  values in good agreement with 
non - specific binding estimates derived from PET studies, pertaining to tracers classified as 
non - substrates of P-glycoprotein. In conclusion, LIMBA provides a fast and reliable tool for 
identifying compounds with unfavorably high non-specific binding in brain tissue. The data 
may be used in conjunction with other image-determining parameters like permeability, 
target affinity and receptor density for predicting the likely development success of potential 
PET tracers. 
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1. Introduction 
Positron Emission Tomography (PET) has emerged as a valuable tool in the drug 
development process to study the biodistribution and receptor occupancy of drug candidates 
at the target site in living animals and men [1]. The value of PET as a non-invasive imaging 
technique is of particular interest in the field of CNS drug discovery where large 
discrepancies may arise between plasma and biophase pharmacokinetics and, moreover, 
where animal models may not adequately reflect the complexity of human disease [2]. The 
study of dose-receptor occupancy relationships by means of PET allows not only for optimal 
dosing selection to achieve maximal target vs. off target responses but may also improve our 
understanding of the relationship between receptor occupancy and pharmacodynamics, both 
in healthy and in diseased state. The advancement of small animal PET cameras has 
furthermore paved the way for PET studies in preclinical species with great promise to bridge 
the gap between preclinical and clinical drug discovery [3].  
In order to exploit the full potential of PET for drug development, drug candidates and the 
corresponding PET tracer for the target site of interest should ideally be developed in parallel. 
Notably, there is still a lack of suitable PET tracers for many targets, and their innovation is 
challenging given the large number of sometimes conflicting requirements to be fulfilled, 
particularly for imaging agents that bind to specific targets in the brain [4, 5]. A high binding 
sites density is desirable and only the unmetabolized radiotracer should pass the blood-brain 
barrier (BBB) to bind with high affinity and specificity to the target site of interest (specific 
binding, SB) [6]. In contrast, non-specific binding (NSB) to non-target proteins and lipids 
should be low to ensure a high SB to NSB ratio. The higher the ratio, the higher the 
sensitivity of PET to monitor changes of the available binding sites due to drug-related 
receptor occupancy [4, 7]. Radiotracers should achieve SB/NSB ratios in the range 3-10 to be 
successfully applied in vivo [7, 8], and [4] stressed that ”most of the failures in ligand 
development result from an unfavorable combination of target density, ligand affinity and 
nonspecific binding”. 
The full characterization of a PET tracer is time-consuming, expensive and requires expert 
knowledge of a radiotracer imaging team as well as special technical facilities [9]. To 
concentrate resources only on the most promising candidates, preliminary and less resource 
demanding assays are applied for selecting radiotracers with the desired properties.  Ex vivo 
autoradiography studies, for example, can be performed to image the in vivo distribution of 
radiotracers throughout the entire body, without the need to incorporate positron emitting 
4. Manuscripts 
296 
 
nuclei into the ligands. Autoradiography studies performed in vitro (i.e. incubation of 
radioligands with tissue slices) can further accelerate the pace by which images of SB and 
NSB can be obtained and quantified. Even though pharmacokinetic aspects such as the 
presence of permeation barriers as well as drug clearance and distribution across different 
organs are disregarded, a primary measure of the SB/NSB ratio becomes available. Tracers 
are rejected when e.g. a major part of the total binding (TB=SB+NSB) in the brain region of 
interest (ROI) is originating from an unfavorably high NSB, as assessed in a reference region 
(RREF) devoid of receptors. Yet, failing at this point of the tracer development process is 
costly given that autoradiography studies are time-consuming, require radiolabeling of the 
ligand and the sacrifice of animals. 
To provide a faster and less resource-intensive estimation of NSB, in vitro methods working 
with the unlabeled compound are highly desirable. The octanol/water distribution coefficient, 
octDlog (pH 7.4) is the commonly used parameter for assessing the NSB of potential PET 
tracers, albeit with limited prediction accuracy for structurally unrelated compounds [4, 10]. 
The unbound fraction of a ligand in brain, brainuf , , available from equilibrium dialysis with 
brain homogenate, provides a physiologically more relevant NSB-estimate which has 
successfully been applied for the parameterization of a comprehensive radiotracer kinetic 
model [11]. The dialysis technique has found entry in many laboratories as a higher 
throughput alternative to measure tissue binding [12-14] when compared to the brain slice 
uptake technique [15, 16]. Potential experimental errors in brainuf , , associated with the 
disruption of tissue and the resulting depletion of intracellular pH gradients, can be corrected 
by a pH partitioning model [17]. However, a drawback of the homogenate dialysis is the high 
consumption of tissue which impedes the screening of larger datasets at reasonable expense 
of laboratory animals. Recently, a vesicle electrokinetic chromatography (VEKC) method 
working with an artificial anionic detergent (Sodium bis(2-ethylhexyl) sulfosuccinate, AOT)  
has been developed for the prediction of NSB showing a good correlation between 
chromatographic retention factors and in vitro NSB derived from equilibrium dialysis. The 
VEKC method has also been shown to provide a useful tool for the classification of either 
successful or terminated PET ligands tested in vivo, however, on a qualitative level only [18].  
Quantitative in vivo NSB estimates, expressed as the volume of distribution of non-
specifically bound tracer in brain, FNSV , , have been derived from kinetic analysis of PET 
scans and were used for the validation of a computational NSB prediction method.  A good 
correlation with calculated drug-lipid interaction energy and FNSV , was found [10, 19], yet, the 
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ab initio quantum mechanical method was computationally expensive and relied on the 
interaction of the ligand with 1,2-dioleoyl-sn-glycero-3-phosphorylcholine (DOPC) 
neglecting the full complexity of a biological membrane.  
The purpose of the present study was to test whether a novel in vitro assay, referred to as 
Lipid Membrane Binding Assay (LIMBA), proves useful for estimating the NSB of potential 
PET tracers. LIMBA relies on the use of rat brain tissue, albeit requires only small amounts 
thereof for the label-free assessment of tissue binding. The medium-throughput assay was 
recently developed in our laboratory and yields brain tissue/water distribution 
coefficients, brainDlog  in excellent agreement with brainuf ,  (homogenate dialysis) [20], even 
when brain tissue was replaced by a microemulsion of brain polar lipids [21]. In the course of 
this study, we evaluated LIMBA on a set of i) 30 publicly available and proprietary tritiated 
radioligands for which NSB-estimates in brain were available from in vitro autoradiography 
studies (in-house data, in rat and mouse), and ii) 10 PET tracers for which NSB data was 
retrieved from in vivo PET studies (literature data, in human). The ability of LIMBA for 
predicting NSB was evaluated in comparison with octDlog (pH 7.4), and outliers for the 
FNSV , prediction  are discussed by taking into account the effect of P-glycoprotein (P-gp), an 
important efflux transporter protein present at the BBB [22]. In addition, we investigated 
whether a threshold-NSB value can be assessed above which the likelihood of a sufficient 
TB/NSB ratio in autoradiography is low and the rejection of compounds for later-stage in 
vivo studies indicated. 
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2. Materials and Methods 
2.1. Drugs and Chemicals  
Fallypride and 3-amino-4-[2-[(di(methyl)amino)methyl]phenyl]sulfanylbenzonitrile (DASB) 
were purchased from ABX (Radeberg, Germany). Diprenorphine, SCH 23390 and SR 
222200 were obtained from Tocris (Bristol, UK). Flumazenil and raclopride·tartrat were 
purchased from Sigma (Steinheim, Germany). All other drugs were available through our in-
house Compound Depository Group as proprietary compounds. TRIS, TAPSO and sodium 
chloride were obtained from Fluka (Buchs, Switzerland). Octanol and dodecane were 
purchased from Sigma (Steinheim, Germany). DMSO was obtained from Acros (Geel, 
Belgium). Water and acetonitrile for HPLC were supplied from Merck (Darmstadt, Germany) 
and were of HPLC-grade.  
2.2. Determination of n-Octanol/Water Distribution Coefficients 
Unless otherwise stated, )4.7(log pHDoct  values were measured with a miniaturized shake 
flask technique. In brief, a DMSO stock solution of the test compound (0.5 mM) was 
dispensed in aqueous buffer (50 mM TAPSO /pH 7.4, final DMSO content 5 %) which was 
pre-saturated with octanol.  The aqueous drug solution (25 μM) was filtrated and an aliquot 
of the filtrate was transferred to a 96-well PCR plate (Eppendorf). After adding buffer-
saturated octanol on top of the filtrate, the PCR plate was sealed and incubated for two hours 
at room temperature (RT), while shaking. The plate was left undisturbed overnight and was 
then centrifuged for 10 min at 3000 rpm (Eppendorf, Centrifuge 5810R). The aqueous drug 
solution was sampled with a robotic pipetting system (Tecan) and the equilibrium aqueous 
drug concentration, eqaqC , was determined with a UV plate reader (SpectraMax). In parallel, a 
reference experiment was carried out under the same conditions but without octanol in order 
to obtain the initial aqueous drug concentration, 0aqC . )4.7( pHLogDoct  values were obtained by 
mass balance according to 
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where aqV and octV denote the volume of the aqueous and the octanol phase, respectively.  
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2.3. Determination of Brain Tissue/Water Distribution Coefficients (LIMBA) 
Brain tissue (rat) /water distribution coefficients, )4.7(log pHDbrain , were determined with the 
in-house LIMBA assay as described below. Briefly, drug-naive female Wistar rats were 
sacrificed in a CO2 chamber and the whole brain was sampled and immersed in assay buffer 
(50 mM TRIS/114 mM NaCl/ pH 7.4) to remove adherent blood. The rat brain was weighted 
and homogenized on ice in 2 volumes (w/v) of n-dodecane using an ultrasonic probe 
(Branson sonifier, G. Heinemann, Schwäbisch Gmünd, Germany). Experiments were 
conducted in accordance with the current Cantonal and Federal legislation on the welfare of 
experimental animals. For the preparation of the aqueous phase, test compounds were 
introduced into the assay buffer (50 mM TRIS/114 mM NaCl/pH 7.4) as DMSO stock 
solutions (10 mM). The resulting aqueous drug solution (25 μM, DMSO content 0.25 %) was 
filtrated (Millipore Multiscreen plates, MDRLN0410) and aliquots of the filtrate 
( aqV = 50 µL) were transferred into an in-house made Teflon plate. In parallel, rat brain 
homogenate ( brV =1.2 μL) was coated on a PVDF filter attached to the bottom of the 
customized and commercially available DIFI tubes (Weidmann Plastics Technology AG, 
Rapperswill, Switzerland, 23358) [23]. The pipetting was conducted with a Hamilton robotic 
system using new pipetting tips (disposable, 10 μL) for each coating step and a sealed 96 well 
PCR plate (Eppendorf) for the storage of brain homogenate, which was put on a shaker. The 
coated DIFI tubes were added on top of the Teflon plate pre-filled with aqueous drug solution 
thus forming a sandwich. The kit was sealed and allowed to shake at RT for 15 h. The 
incubation time was based on prior experiments showing that distribution equilibrium was 
achieved after 15 h. After removal of the DIFI tubes, the equilibrium drug concentration in 
the aqueous phase, eqaqC , was analyzed with HPLC - UV/MS. A reference experiment was 
carried out in the same plate but without brain homogenate. )4.7( pHLogDbrain  values were 
obtained by mass balance according to the assessment of )4.7(log pHDoct . All distribution 
experiments were performed in triplicate and mean )4.7(log pHDbrain values are reported. 
2.4. HPLC-MS Instrumentation and Chromatographic Conditions 
Drug concentrations in aqueous solutions were quantified using an Agilent 1290 Infinity 
HPLC-MS system (Agilent Technologies, CA, USA) equipped with a DAD detector and an 
API single quadrupole mass spectrometer (Agilent 6140). An aliquot of each sample (5 µL) 
was injected onto a Kinetex 2.6 µm, 2.1 x 50 mm analytical column (Phenomenex, Germany) 
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operated at 60 °C. The mobile phase consisted of A (water) and B (acetonitril), both 
containing 0.1 % (V/V) formic acid. The gradient elution was performed as follows: initial 
2 % B, 0 - 0.35 min linear gradient from 2 % B to 95 % B, 0.35 min - 0.65 min 95 % B, post 
time 0.5 min. After passing the DAD detector, the eluent was introduced into the electrospray 
interface maintaining the following source settings: capillary voltage + 3.5 kV, drying gas 
flow (N2)  13 L/min, nebulizer pressure 60 psi, drying gas temperature 350 °C. The integral 
of the pseudo - molecular ion intensity, [M+H]
+
, was acquired in single reaction monitoring 
mode. Internal calibration for MS data analysis was accomplished by injection of 1, 3, and 
5 µL of the sample solution. Peak areas at appropriate wavelength (UV) or mass responses (if 
UV sensitivity was insufficient) were used for the calculation of brainDlog .  
2.5. Determination of [
3
H]-Radioligand Binding in Brain by in vitro Autoradiography 
A dataset of 30 tritiated radioligands was comprised from our in-house database and included 
radioligands with known NSB data from in vitro autoradiography studies in brain. 
Autoradiography studies were performed as follows and as described elsewhere in more 
detail [24]. Laboratory animals (mice, gerbil, rats) were housed at controlled temperature 
(20 – 22°C) and 12 h light/dark cycle. All animals were allowed ad libitum access to food 
and water. The animals were killed by decapitation and the brains were rapidly removed from 
the skull and immediately frozen on dry ice. Sections (10 - 20 μm) from brain were cut in a 
cryostat and thaw-mounted onto silane-coated microscope slides (HistoBond, Paul 
Marienfeld GmbH, Lauda-Königshofen, Germany). Brain sections (n = 10) were dried at RT 
and stored at -20 °C until the day of the autoradiography measurements. Brain sections 
(n = 5) were first pre-incubated (10 - 20 min) in assay buffer (in most cases TRIS/pH 7.4) and 
then in assay buffer containing the tritium-labeled ligand (concentration of the ligand: 
0.08 - 23.5 nM; incubation time: 12 - 120 min; RT or 37 °C). NSB was measured using five 
additional brain sections incubated in presence of a non-radiolabeled compound that compete 
with the radioligand for the same binding site (concentration of the antagonist: 1 - 100 μM). 
Brain sections were subsequently rinsed in ice-cold assay buffer (washing time 
washt = 2 - 10 min) and dipped briefly (n = 1 - 3) in distilled water at 4 °C to remove buffer 
salts. The brain sections were dried at RT and exposed, together with a tritium microscale 
(RPA-510, GE Healthcare, Glattbrugg, Switzerland), to tritium-sensitive imaging plates 
(BAS-TR 2025, Fujifilm, Dielsdorf, Switzerland) for 5 - 6 days. The imaging plate was 
scanned in a Fujifilm high-resolution plate scanner (BAS-5000, Bucher Biotec AG, Basel, 
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Switzerland) and images were quantified with an MCID M2 image analysis system (Imaging 
Research Inc., St. Catherines, Ontario, Canada). The total amount of radioligand bound in the 
ROI and in the reference region devoid of receptors (NSB) was expressed as fmol of bound 
radioligand per mg of protein (total binding = TB). A quantitative estimate of NSB was also 
obtained after blocking the receptors with an unlabeled molecule. The nominal tracer 
concentration for the determination of NSB was 3 nM, and the measured radioactivity was 
corrected for the real concentration. The experimental conditions (buffer, incubation 
temperature, animal species, length of incubation/rinsing) used for quantification of receptor 
binding and NSB were notably optimized for each tracer and are enclosed in detail in the 
Supplementary Information. The following selection criteria for the inclusion of compounds 
in our dataset were applied: i) presence of an unlabeled ligand for blocking of specific 
binding sites and allowing for the assessment of NSB ii) agreement of results for the extent of 
NSB at two different radioligand concentrations and iii) a exposure time of the brain slices to 
a washing solution (after incubation with the assay buffer) of washt  ≤ 10min.  
2.6. Compilation of NSB Data from in vivo PET Studies 
A database of 10 radioligands was compiled from literature and, if not otherwise stated, 
included PET tracers investigated with in vivo PET in living man. Different tracer kinetic 
models [25], e.g. one tissue and two tissue compartmental models, have been used in the 
reported studies for the analysis of radioligand - time activity curves in PET. The volume of 
distribution of the non-specifically bound radioligand in a reference region with respect the 
total plasma concentration ( NSV ) was extracted from the published kinetic PET data and was 
expressed with respect to the free plasma concentration ( FNSV , ) according to:  
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where NDV  is the is volume of distribution of the non-displaceable radioligand (free +non-
specifically bound) with respect to the total plasma concentration in a reference region, and 
pf  is the unbound fraction of radioligand in  plasma reported in literature (for references see 
Table 3). '1K and 
'
2k denote the rate constants for the transfer of radioligand from plasma into 
the brain and vice versa, respectively. The term FNSV , reflects the extent of NSB in brain, 
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provided that a radioligand passes the BBB by passive diffusion [26]. Further details 
regarding the derivation of Eq.2 including relevant background information about 
compartmental analysis and tracer kinetic modelling are provided in the Supplementary 
Information. Eq. 2 is similar to that derived by [10], however, for clarity we distinguish NSV  
(distribution volume related to the total plasma concentration) from FNSV , (distribution volume 
related to the free plasma concentration). No FNSV , - data from in vivo PET studies in human 
brain was available for rolipram and therefore data from PET studies in porcine brain was 
used for regression analysis.  
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3. Results and Discussion  
A high NSB of radiotracers to membranes and non-target proteins affects the accuracy with 
which the specific binding to a target site (receptor occupancy) can be measured by means of 
PET. Many PET tracers fail due to an unfavorable combination of low receptor density, low 
receptor affinity and, in particular, high NSB [4]. In order to enhance the confidence in the 
likely quality of a tracer, we have evaluated the ability of a novel medium-throughput assay 
(LIMBA) to predict the extent of NSB of the unlabeled compound, as well as the likelihood 
to achieve sufficient TB/NSB ratios. The results are shown and discussed below in 
comparison with )4.7(log pHDoct , using the example of radioligands characterized with i) in 
vitro autoradiography and ii) in vivo PET. 
3.1. Characterization of the in vitro Autoradiography Dataset  
A dataset of 30 radiotracers with known NSB-estimates in brain sections (rat, mouse), 
available from in vitro autoradiography studies, was compiled as described in Materials and 
Methods. The larger body of NSB autoradiography data as compared to PET data allowed us 
to form a structurally diverse database covering a wide physicochemical property space. The 
dataset was comprised of both publicly disclosed and proprietary radiotracers in the tritium-
labelled form, yet, the measurement of octDlog  and brainDlog  was performed with the 
unlabelled ligands. The structures for 13 ligands, for which no potential conflict of interest 
might prevent publication, are disclosed in the Supplementary Information. Key 
physicochemical properties (molecular weight, apK , Pc log , octDlog (pH 7.4)) of all 30 
compounds are provided in Table 1 along with NSB data obtained from in vitro 
autoradiography. The dataset included neutral, basic, and zwitter-ionic compounds covering a 
broad range of octDlog  values ( octDlog (pH 7.4) = -0.64 - 4.35) and NSB-estimates (NSB = 7.6 
- 3151.1 fmol/mg protein).  
 
Table 1 
 
It is important to note that the NSB-estimates provided in Table 1, and used for comparison 
with octDlog (pH 7.4) and brainDlog  (pH 7.4), refer to the TB in a reference region in presence 
of a receptor blocker. From a theoretical point of view, an NSB-estimate may also be 
obtained under non-blocking conditions from the TB in a reference region which is, by 
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definition, devoid of receptors and should therefore solely reflect NSB. However, the 
presence of specific binding sites cannot a priori be excluded. This is supported by the 
example of the NK3 receptor antagonist [
3
H]-SR222200 (No. 11) for which in vitro 
autoradiographs in absence and in presence of a blocker (osanetant) are shown in Fig. 1A1 
and Fig. 1A2, respectively.  
 
Fig. 1 
 
The TB in the reference region (hippocampus) in absence of the unlabeled blocker was 
approximately twice as high as the NSB in the same region under blocking conditions. A 
saturation of NSB sites (phospholipid lipid membranes, non-target proteins) with the 
unlabeled receptor blocker is unlikely considering the excess of lipids relative to the 
concentration of the receptor blocker ( kerblocC = 10 μM). Since SR222200 is non-charged, it is 
also safe to exclude that electrostatic repulsion of the ligand by the cationic blocker leads to a 
decrease of NSB. The higher TB in the reference region in absence of a blocker may rather be 
explained by the presence of low - but not zero - levels of NK3 receptors [27] in the 
hippocampus, which has historically been considered as reference region.  
The TB in a reference region in absence and in presence of a blocker was further assessed for 
the complete autoradiography dataset (Fig. 2) revealing a higher TB under non-blocking 
conditions for 11 of the 30 ligands tested, which confirmed the trend observed for [
3
H]-
SR222200.   
 
Fig. 2 
 
The autoradiographs under non-blocking conditions were also analyzed in terms of TB in a 
ROI in order to retrieve the TB/NSB binding ratios which are provided in Table 1 (for 
discussion see Section 3.4). Contrary to [
3
H]-SR222200 (Fig. 1A), the dopamine D2 receptor 
antagonist [
3
H]-raclopride (No. 16) is an example for a tracer with an excellent signal to noise 
(TB/NSB) ratio, irrespective of whether or not a dopamine receptor blocker was employed 
for determining NSB (Fig. 1B).  
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3.2. The Relationship between Non-specific Binding in Brain (Autoradiography Data) 
and octLogD     
octLogD (pH 7.4) is the most commonly used parameter for estimating the NSB of potential 
PET tracers, however, the datasets investigated hitherto were rather small and a trend 
between octDlog  and NSB was only observed when structurally similar ligands were 
compared [4]. In order to evaluate the predictive ability of octDlog (pH 7.4) on a larger and 
structurally diverse set of compounds, we compared the NSB-estimates from the in vitro 
autoradiography dataset (in presence of a blocker) with measured octDlog (pH 7.4) values.  
At this point it should be noted that the times brain slices were exposed to a washing solution 
in autoradiography were slightly different and optimized for the individual tracers. Longer 
washing times are likely associated with a reduction in NSB (see below) and are therefore 
desirable to yield higher signal-to-noise ratios (TB/NSB) for more reliable quantification of 
receptor densities and affinities. However, in order to analyse the relationship between 
octDlog (pH 7.4) and NSB, it was necessary to analyse NSB autoradiography data at different 
washing times (subsets: washt = 2 - 4 min and washt  = 7 - 10 min) separately as shown in Fig. 
3A.  
 
Fig. 3 
 
The correlation statistics for the two subsets based on binned washing times are summarized 
in Table 2 showing improved, but still unsatisfactory fits to the experimental NSB data as 
compared to the correlation based on the whole dataset. A clear trend was evident towards 
lower NSB at longer incubation times of brain slices with the washing buffer. The 
discrepancy in NSB is reflected by the intercepts of the linear regression lines which are more 
than one log unit apart. Due to the scatter of the data, no clear trend in terms of the predictive 
power of octDlog (pH 7.4) for different charge classes can be drawn. However, for the less 
scattered subset at washing times washt =7 - 10 min, an underestimation of NSB by octDlog (pH 
7.4) is evident for the most hydrophilic basic compound (No. 25), while the remaining basic 
and neutral compounds roughly cluster.  
With respect to the rather poor correlation between octDlog (pH 7.4) and NSB, it is worth to 
note that even though octanol is widely considered as a surrogate for lipid bilayer 
membranes, it lacks the anisotropy of a bilayer and the charge of a phospholipid head group 
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[28]. Depending on the charge state, the binding of drugs to phospholipid membranes may be 
driven by both hydrophobic and electrostatic interactions. At the example of propranolol and 
other bases, it has been shown that neutral and cationic species of a basic drug can bind to a 
net neutral phospholipid membrane with a relatively large contribution of the ionized species 
to the overall extent of membrane binding [29, 30]. The minor contribution of ionized species 
to the partitioning into octanol (here observed for compound No.25) may accordingly reflect 
the difference between bulk phase partitioning (octanol) and drug binding in an anisotropic 
amphiphilic environment in which charged drugs can bind to a membrane surface. The 
presence of negatively charged phospholipids (e.g. phosphatidylserine (PS), 
phosphatidylinositol (PI), phopshatidylglycerol (PG), phosphatidic acid (PA)) in a biological 
membrane may further enhance the membrane affinity of basic drugs by electrostatic 
interactions with the acidic phospholipid head groups. Pronounced distribution of basic drugs 
into tissues containing high concentration of negatively charged phospholipids is well 
documented [31-33], and in particular the presence of PS has been identified as a main 
determinant of interorgan variation in tissue distribution [34]. Notably, brain tissue is 
relatively rich in acidic phospholipids (between 9.4 and 20.8 % of total phospholipids) as 
estimated from the phospholipid composition in brain tissue reported for rat: 50 mg of lipid 
phosphorous / g of tissue, thereof 0.23-5.9 mg/g PS, 2.79 mg/g PI, 1.10 mg/g PG and 0.6 
mg/g PA [32].  
3.3. The Prediction of NSB in Brain (Autoradiography Data) Using LIMBA  
brainDLog  (pH 7.4) values for the complete autoradiography dataset were measured with a 
novel in vitro assay, LIMBA, as described in Materials and Methods. As opposed to the 
octanol shake flask technique, LIMBA works with minimal consumption of brain 
homogenate in dodecane (here: rat) which more likely resembles the composition and 
properties of brain tissue (see Section 3.2). The assay has been optimized for compounds with 
intermediate to high tissue binding, allowing the measurement of brainDlog  (pH 7.4) values in 
the range of brainDlog (pH 7.4) = 0.35 - 4. This range applied to 27 of the 30 compounds tested 
for which the results are presented in Table 1.  
Fig. 3B shows the correlation and the linear regression lines between NSB and brainDlog  (pH 
7.4) for the different times brain slices were exposed to the washing solution. An inspection 
of the correlation statistics (Table 2) in comparison with those obtained with octDlog (pH 7.4) 
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reveals a higher statistical certainty (r
2 
= 0.87 - 0.91) in the estimates of NSB when using 
brainDlog  (pH 7.4).  
 
Table 2 
 
No clear outliers for compounds of different charge classes were observed indicating that the 
applied brain homogenate provides a fairly good surrogate for brain tissue, despite the 
presence of dodecane. It is interesting to note that alkanes (e.g. dodecane) have been shown 
to change the membrane fluidity and, at higher concentrations, the long range order of 
phospholipids in a membrane [35-38]. The effect of high concentrations of dodecane (as used 
herein) on the membrane structure has been investigated in great detail in our laboratory and 
further details will be published separately [39]. 
3.4. The Relationship between TB/NSB Ratios and NSB in Brain  
We could show that the NSB in rodent brain, derived from autoradiography experiments, can 
reliably be predicted using LIMBA, however, NSB should not be considered in isolation 
from the TB in a ROI; the ratio between both (i.e. TB/NSB) determines the image quality and 
therefore the likely development success, or failure, of potential PET tracers [4]. Both 
parameters (TB/NSB and NSB) are closely related, however their relationship is not trivial. 
On the one hand, high NSB obscures the TB in the ROI and therefore reduces the sensitivity 
of PET to changes in receptor occupancy. On the other hand, pronounced NSB (i.e. high 
affinity for lipid membranes and non-target proteins) may also be associated with a higher 
affinity for the target site. It would therefore be interesting to proof whether a limit with 
respect to NSB exists above which the probability to obtain sufficient TB/NSB ratios is low. 
A correlation between TB/NSB and NSB for the complete autoradiography dataset is shown 
in Fig. 4A and may be used as a classification map.  
 
Fig. 4 
 
According to [8] the signal-to-background noise ratio (SB/NSB) in a PET scan should be at 
least 4, which corresponds to a TB/NSB ratio of at least 5. At NSB values > 3, none of the 
radioligands (n=3; No. 13, 14, 15) fulfilled the requirement for the suggested TB/NSB limit 
(Fig. 4A). It is important to note that those compounds with sufficient TB/NSB ratios were 
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exposed for  longer incubation times to the washing solution (open symbols) leading to 
artificially high TB/NSB ratios (see Section 3.5).   
3.5. Identification of Radioligands with Inadequate TB/NSB Ratios using LIMBA  
In the next step, we investigated whether ligands with a TB/NSB ratio < 5 at high NSB 
values can be identified with a classification map that is based on LIMBA brainDlog  (pH 7.4) 
values rather than on NSB in vitro autoradiography data (Fig. 4B). All three critical 
compounds identified in Fig. 4A matched those in the corresponding TB/NSB - brainDlog  
(pH 7.4) classification map (Fig. 4B), provided that the threshold value was set to 
brainDlog (pH) = 2.1. However, two compounds (No. 28, 29) with TB/NSB > 5 showed 
brainDlog  values > 2.1, and were thus misclassified in LIMBA as likely to fail. It is important 
to note that brain slices for both misclassified compounds were exposed for relatively long 
times to a washing solution (t = 10 min), which leads to a decrease in NSB and, in turn, an 
artificial increase in the TB/NSB ratio. A reduction of washing times would accordingly shift 
both misclassified compounds to the lower right corner of the classification map, which 
would then agree with the high brainDlog (pH 7.4) values. All compounds for which shorter 
washing times (t = 2-4 min) were applied, and for which the specified brainDlog  (pH 7.4) 
threshold was exceeded, were correctly classified by LIMBA (No. 13, 14, 15). The 
classification map may thus be used as a guideline for optimizing potential PET tracers with 
undesirably high NSB values, without the need for autoradiography studies and prior to 
radioactive labelling. Whether or not compounds below the critical NSB or brainDlog (pH 7.4) 
threshold yield sufficient TB/NSB ratios depends on the target affinity and the receptor 
density which are available from classical receptor binding studies and/or from literature. 
It is worth to reiterate that long washing procedures of brain slices in autoradiography might 
be desirable to maximize TB/NSB ratios, however, the situation in vivo lacks the benefit of 
washing. Therefore, we propose limiting the exposure times of brain slices to washing 
solutions to maximal 4 minutes to achieve the elimination of buffer salts, yet, without 
reducing NSB in an unphysiological manner. Likewise, a non-washing procedure as proposed 
by other authors may be applied [40], as long as a uniform protocol is used for all ligands of 
interest.   
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3.6. Predicting Non-specific Binding in PET using LIMBA  
Hitherto, we have based the analysis of prediction methods for radioligand bindig in brain on 
autoradiography data which was more readily available as compared to PET studies and 
therefore beneficial for the explanatory power of the validation. Moreover, it was 
advantageous that NSB-estimates available from in vitro autoradiography were not 
confounded by active transport mechanisms at the BBB because brain slices were directly 
exposed to the radioligand incubation medium. However, we have shown that results 
obtained from the autoradiography experiments were sensitive to the assay conditions.  
In order to test the applicability of LIMBA for predicting  in vivo NSB observed by PET, a 
database of 10 well characterized PET tracers studied in living human was compiled from 
literature and comprised tracers acting on a variety of molecular targets in the CNS (Table 3). 
Rate constants governing the transfer from plasma into brain and vice versa ( '1K and 
'
2k , 
respectively) have been reported and were used to infer the volume of distribution for non-
specifically bound tracer with reference to the unbound plasma concentration ( pNSFNS fVV /,  , 
Eq.2). Provided that radioligands pass the BBB by passive diffusion, the term FNSV ,  can be 
considered as an expression for NSB [26], and could therefore be used to investigate the 
suitability of LIMBA - brainDlog (pH 7.4) for the prediction of NSB in vivo. Measured LIMBA-
brainDlog (pH 7.4) values as well as NSVlog and pf data for the investigated PET tracers are 
provided in Table 3, along with some key physicochemical properties including the cross-
sectional areas, DA . 
 
Table 3 
 
It is well known that compounds with DA  > 70Å
2
 are associated with reduced brain uptake as 
a result of reinforced efflux by P-gp [28, 41]. This would notably lead to FNSV ,  levels below 
those reflecting only passive drug-tissue distribution under steady state. The relationship 
between FNSV ,  and brainDlog (pH 7.4) for compounds with DA  values below and above the 
critical DA  threshold is shown in Fig. 4.  
 
Fig. 4 
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Linear regression analysis demonstrated excellent correlation statistics (r
2
=0.94, SD=0.21) 
for compounds with DA  ≤ 70 Å
2
, which we classified as non-substrates for P-gp based on DA . 
In contrast, FNSV , values observed for compounds with DA  > 70 Å
2 
(fallypride, PK 11195 and 
WAY 100635) were generally lower than FNSV , values predicted by brainDlog (pH 7.4). In this 
regard, it is important to note that LIMBA is only capable of assessing drug distribution 
governed by passive mechanisms since active transport proteins are not functional in the 
brain homogenate due to the presence of dodecane and the absence of ATP. Accordingly, any 
active efflux (influx) transport processes present in vivo will translate into an overestimation 
(underestimation) of FNSV , values by LIMBA, as observed for fallypride, PK 11195 and 
WAY 100635. All three compounds have experimentally been identified as substrates [42, 
43] or modulators (PK 11195, [44]) of the efflux transport protein P-gp which is in line with 
our classification based on DA . With regard to the PET tracers with DA  ≤ 70 Å
2
, literature 
supported our classification as non-P-gp substrates in case of rolipram [45], diprenorphine 
[46] , raclopride [47]  and DASB (no literature with contrary information was found).  For 
Spiperone, a borderline compound in terms of DA  ( DA  = 70 Å
2
), efflux by P- gp was reported 
[48] and a slightly, but not significant overestimation of FNSV ,  by brainDlog (pH 7.4) was 
observed (Fig. 4). Active efflux in vivo in rodents was reported for flumazenil [47, 49], which 
is in contrast to our classification. Notably, in vitro transport studies using MDCKII cells 
transfected with human multidrug resistance (MDR1) genes suggested that flumazenil cannot 
be considered as substrate of human P-gp.  Since the brainDlog (pH 7.4) value for flumazenil 
was below the applicability range of LIMBA a direct comparison between brainDlog (pH 7.4) 
and the FNSV , data could not be made. Further research is therefore required to address this 
question, however, it is worth noting that the classification of whether or not a compound is a 
substrate of P-gp is heavily dependent on the compound concentration [50]. Even though the 
DA -based classification gives only a first indication for the likelihood of active efflux, the 
size restriction of the BBB is well documented [51, 52] and we considered our classification 
useful for rationalizing the relationship between FNSV ,  and brainDlog (pH7.4). In summary, 
LIMBA- brainDlog (pH 7.4) values were highly predictive for in vivo FNSV , data -estimates in 
human brain with respect to compounds classified as non-P-gp substrates ( DA  ≤ 70 Å
2
). This 
is in line with the results obtained from in vitro autoradiography experiments showing 
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excellent performance of LIMBA for predicting the NSB in rodent brain for tritium-labelled 
compounds.  
3.7. Limitations and Future Perspectives 
The likely development success of potential PET tracers depends on a multitude of factors 
apart from NSB. The list of requirements is long and includes e.g. sufficient target density 
and affinity, target selectivity, low protein binding, brain permeability, resistance to rapid 
metabolism and absence of brain penetrant metabolites [6]. The aim for achieving low NSB, 
on the one hand, and a high affinity for the target site as well as high brain permeability, on 
the other hand, are potentially conflicting and thus the need for balancing lipophilicity cannot 
be overemphasized [53].  
For future applications, brainDlog  (pH 7.4) values available through LIMBA should therefore 
not be considered in isolation but rather within the framework of an integrative strategy. 
Recently, a bio-mathematical modelling approach has been successfully applied to predict the 
image quality in PET by integrating the properties of both, the tracer candidate and the 
biological system, into one prediction model [11]. An important input parameter was the 
unbound fraction of PET tracers in brain, as determined by equilibrium dialysis. An estimate 
for brainuf , , or in other terms NSB, can now be derived at higher throughput and with lower 
consumption of brain homogenate  by using LIMBA, which we propose as a novel assay for 
estimating NSB in brain.  
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4. Conclusions 
In summary, the novel LIMBA assay yields brainDlog  (pH 7.4) values in excellent agreement 
with NSB-estimates in brain, as demonstrated on a large dataset studied with in vitro 
autoradiography. Moreover, good prediction accuracy was achieved for the estimation of 
NSB in in vivo PET, provided that tracers are not classified as P-glycoprotein substrates. The 
weaker statistical performance of octDlog  (pH 7.4) shows that bulk octanol is rather a poor 
surrogate for brain tissue. Since LIMBA works with minimum consumption of brain 
homogenate (1.2 μL) and, moreover, does not require radioactive labeling, reliable NSB-
estimates can be obtained at higher throughput as compared to autoradiography and 
equilibrium dialysis studies. Tracer candidates with an unfavourably high NSB can be 
identified with LIMBA, however, other factors such as brain permeability as well as 
sufficient receptor density and target affinity are equally important for the success of a PET 
tracer. brainDLog  (pH 7.4) values may thus be used in conjunction with other physiological 
and physicochemical parameters to predict the image quality in PET by means of tracer 
kinetic modelling and simulation. Therefore, LIMBA holds much promise to accelerate the 
optimization of novel PET tracers in order to exploit the full potential of PET neuroimaging 
for drug discovery and development.  
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Table 2   Correlation statistics for the data shown in Fig. 3.A and Fig.3B. 
twash octLogD (pH 7.4)  brainLogD (pH 7.4) 
[min] 
Regression equation (n=27) r
2
 sd  Regression equation (n=27) r
2
 sd 
2-4 logNSB=0.36*logDoct+1.33 0.48 0.69  logNSB=0.88*logDbrain+1.15 0.91 0.34 
7-10 logNSB=0.65*logDoct+0.13 0.74 0.39  logNSB=0.92*logDbrain+0.47 0.87 0.29 
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FIGURES 
 
Figure 1   In vitro autoradiographs of [
3
H]-radioligands in absence (Fig. A1, B1) and in presence (Fig. 
A2, B2) of an unlabeled receptor blocker. A: [
3
H]-SR222200 (NK3 receptor antagonist) at 
C=2.49 nM. The total binding in the Region of interest (cortex) and in the reference region 
(hippocampus) under non-blocking conditions was 776 and 809 fmol/mg protein, respectively (Fig. 
A1). The total binding in the reference region under blocking conditions (NSB, presence of osanetant 
at C=10 μM) was 591 fmol/mg protein (Fig. A2). B: [3H]-raclopride (D2 receptor antagonist) at 
C=3 nM. The total binding in the region of interest (striatum) was 1307 fmol/mg protein under non-
blocking conditions (Fig. B1). The total binding in the reference region under blocking and non-
blocking conditions (NSB, presence of butaclamol at C=10μM) was 7 fmol/mg protein, respectively 
(Fig. B1,2). 
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Figure 2   Comparison between non-specific binding measurements: total binding in the reference 
region vs. non-specific binding in the same reference region after blocking the targets with cold ligand. 
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Figure 3 Nonspecific binding (autoradiography data) as a function of A: the octanol/water distribution 
coefficient, octDlog  (pH 7.4), and B: the brain tissue/water distribution coefficient, brainDlog  (pH 7.4), 
measured with LIMBA. The color and the shape of the symbols correspond to the charge class of the 
compounds (neutral:; basic: ; zwitter-ionic: ) and the exposure time of brain slices to a 
washing solution after incubation with the tritiated tracer (twash=2-4 min:; twash=7 - 10 min:). 
 
0.5 1.0 1.5 2.0 2.5 3.0 3.5
1
10
100
T
B
/N
S
B
, 
a
u
to
ra
d
io
g
ra
p
h
y
Log NSB, autoradiography
(fmol/mg protein)
13
1415
29
28
A
0.0 0.5 1.0 1.5 2.0 2.5
1
10
100
T
B
/N
S
B
, 
a
u
to
ra
d
io
g
ra
p
h
y
 
LogD
brain
 (pH 7.4), LIMBA
13
15
14
29
28
B
 
Figure 4   Signal-to-noise ratio (i.e. total binding in a region of interest / non-specific binding in a 
reference region) for a representative set of radioligands as a function of A: non-specific binding 
measured with in vitro autoradiography (n=30) and B: brain tissue /water distribution coefficients,  
(pH 7.4), measured with LIMBA (n=27). Shape of the symbols according to exposure times of brain 
slices to a washing solution (t=2-4 min:; t=7-10 min:). 
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Figure 5   In vivo non-specific binding in PET (expressed as the volume of distribution of non-
specifically bound radiotracer in the non-displaceable compartment) as a function of the brain tissue 
/water distribution coefficient, brainDlog  (pH 7.4), for 10 PET tracers (Table 3). Size of the symbols 
according to the cross-sectional area, DA , of the ligands; compounds with DA  > 70Å
2 
() and 
DA  ≤ 70Å
2 
() have a high likelihood to be apparent P-gp substrates and to be non-substrates for P-
gp, respectively. Correlation statistics: LogVNS,F (PET)= 0.83 * logDbrain (LIMBA) + 0.46 (r
2
=0.94, 
SD = 0.21).  
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Supporting Information 
S1 Tracer kinetic modeling and the estimation of volumes of distribution 
PET experiments seek to derive quantitative information on target binding in terms of 
‘binding potential’ ( FBP ) which equals the equilibrium concentration ratio between 
specifically bound ( SC ) and free ligand in the tissue ( FTC ) [4, 25, 26, 67, 68]. At tracer doses, 
such that DFT KC  and SC  is a negligible fraction of the receptor density available to bind 
ligand ( availB ), FBP  reflects the product of availB  and affinity ( DK/1 ).  
D
avail
FT
S
F
K
B
C
C
BP   .         (S1) 
The recorded PET data represent a composite of all tissue and blood components. In order to 
isolate the various signals, a mathematical framework relating the observed time activity 
curve in the region of interest (ROI) to the time activity curve in the arterial plasma is 
required. Most approaches rely on compartmental modeling in which binding and transport 
are expressed as a combination of rate constants ( 1K , 2k , 3k , 4k ) that govern the transfer 
between the different compartments. In a target region, three compartments correspond to the 
concentrations of unmetabolized radioligand in plasma ( pC ), free plus nonspecifically bound 
radioligand in brain ( NDC , nondisplaceable compartment) and radioligand specifically bound 
to receptors ( SC ) (Fig.S1). The concept of free fraction arises from the underlying assumption 
that the transfer between free and nonspecifically bound ligand is rapid compared to receptor 
binding and thus the free fraction in brain, NDf , denotes the fraction of total tracer in NDC in 
the unbound state. In addition, it is assumed that only the unbound concentration is available 
for receptor binding and similarly that only the free fraction in plasma ( pf ) can cross the 
blood brain barrier. Then, FBP  can be expressed as 
4
3
kf
k
Cf
C
BP
NDNDND
S
F  ,         (S2) 
where the rate constants derived from fitting the three-compartmental model are entering the 
equation. Since NDf  measurements in human are limited to post-mortem studies, a more 
practical derivation of FBP  is given by equation S3, which is valid at equilibrium state and if 
transport across the blood brain barrier is passive, such that ppNDND CfCf   , and 
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kkf
kK
Cf
C
BP
ppp
S
F  .          (S3) 
While it is mathematically feasible to find estimates of all four rate constants, the most 
reliable outcome measure is the total volume of distribution TV . It refers to the sum of binding 
in the individual compartments as a ratio to the total plasma concentration, such that 
SNSFTSND
p
T
T VVVVV
C
C
V  ,         (S4) 
where pNDND CCV /  and pSS CCV /  and. pNSNS CCV / . 
In a region with specific binding , TV  (ROI) is the sum of NDV  (nondisplaceable compartment) 
and SV  (specific binding). NDV  is the sum of the volume of distribution of the non-specifically 
bound radiotracer ( NSV ) and the volume of distribution of free radiotracer in tissue, FTV . 
Assuming equal nonspecific binding characteristics in all brain regions, TV  in a reference 
region devoid of receptors ( SV =0) gives an estimate of NDV  in the ROI. FBP will then be 
obtained as follows:  
p
REFNDT
p
S
F
f
RVROIV
f
V
BP
)()( 
 ,        (S5) 
where 









4
3
2
1
1
)(
k
k
k
K
ROIVT ,          (S6) 
and  
ND
REFND
fk
K
RV
1
)(
'
2
'
1   .         (S7) 
Since the expression levels of transporters (e.g. P-glycoprotein) in the ROI may be different 
from those in the reference region, the rate constant governing the transport of tracer across 
the blood brain barrier in the reference region is indicated as '1K .  
NSV  may be expressed as: 
P
FT
FTNDNS
C
C
k
K
VVV 
2
'
1¨           (S8) 
4. Manuscripts 
 
 
322 
At equilibrium state, and if no active transport takes place ( ppFT CfC  ), the volume of 
distribution of non-specifically bound drug in relation to the free plasma concentration can be 
inferred from the rate constants and pf such that: 
11
'
2
'
1
, 
kf
K
f
V
f
V
V
pp
ND
p
NS
FNS          (S9) 
Equation S9 equals equation. 2 in the main manuscript. From equation S5 it becomes obvious 
that the signal reflecting receptor binding will be lowered by non-specific binding, which is 
embraced in the term FNSV , . An estimate of FNSV , in vitro may be obtained by assessment of 
the brain tissue/water distribution coefficients available through LIMBA.  
 
 
 
Figure S1   Classical three-compartmental model used to quantify PET data. pC  is the total 
concentration of tracer in plasma, NDC  is the sum of free and non-specifically bound tracer (non-
displceable concentration), and SC is the concentration of tracer specifically bound to the target site in 
the region of interest. 1K  (
'
1K ) and 2k denote the rate constants for the transfer from plasma into and 
out of the brain, respectively, and 3k  and 4k  describe association and dissociation to and from the 
receptors, respectively. 
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Structures not provided at the moment.  
 
Figure S2   Structures of the radioligands tested with in vitro autoradiography (unlabeled form).  
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Figure S3   Structures of the PET tracers characterized in vivo (literature data) 
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5  Summary 
PET has found ever growing interest in the pharmaceutical industry as a non-invasive 
imaging modality with great potential to accelerate the development of novel therapeutics, 
particularly of CNS-active drugs [1]. However, the availability of innovative PET tracers for 
imaging the brain is currently the limiting factor to exploit the full potential of PET for the 
drug discovery and development process [2]. Many potential radioligands fail due to an 
imbalance between specific binding at the target site and NSB to non-target proteins and lipid 
membranes [3]. Since NSB reduces the sensitivity of PET to the specific binding, 
radioligands showing extensive NSB are unlikely to be successful, particularly in 
combination with low receptor density and/or low receptor affinity. Estimating the extent of 
NSB at an early stage in the PET tracer development process is therefore highly desirable and 
was the main purpose of the thesis. Specifically, we explored whether compounds with 
unfavorably high NSB can be identified prior to radioactive labeling and with reduced animal 
testing as compared to yet existing methods (autoradiography, equilibrium dialysis). 
In pursuit of our aim, we have evaluated the predictive power of three membrane-mimicking 
systems and their corresponding miniaturized assays (in brackets), namely i) octanol 
(CAMDIS), ii) phospholipids dissolved in dodecane (PAMPA), and iii) brain homogenate 
prepared in dodecane (LIMBA).  
It was essential to translate the measurement of each surrogate parameter into a miniaturized 
format (if not yet available) in order to be in line with our ambition for higher-throughput and 
minimal consumption of samples, reagents and animal tissue. At the beginning of this thesis, 
only PAMPA was already established as a screening method [4] while CAMDIS and LIMBA 
have been developed and validated as entirely new assays. However, also PAMPA required 
the optimization of experimental conditions in terms of compatibility with mass spectrometry 
and lipid as well as buffer composition.  
In the following, we summarize the major contributions of this thesis pertaining to the 
development and optimization of the individual assays. The thorough validation of the assays 
was the precondition for evaluating the assays with respect to their ability to predict NSB.  
As a strategy to identify the model system which yields the most reliable NSB - estimates, we 
first evaluated the simplest artificial membrane-mimicking system, namely octanol. However, 
our data indicated that octanol (CAMDIS) is only a poor surrogate for NSB which brought us 
to the next more complex artificial membrane-mimicking system, namely the PAMPA 
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barrier. Since the predictive power of the membrane fraction was still unsatisfactory, we 
tested whether the use of brain homogenate (LIMBA) provides more reliable NSB - estimates 
which could justify using animal tissue over artificial membrane-mimicking systems. The 
abovementioned order of increasing complexity is maintained in the following summary of 
our research.  
5.1 CAMDIS - Development of a Novel Assay for the Measurement of Octanol/Water 
Distribution Coefficients 
 
Related Manuscripts:  
 
Manuscript 1 Carrier Mediated Distribution System (CAMDIS): A Novel Approach 
for the Measurement of Octanol/Water Distribution Coefficients 
Manuscript 2 The Impact of Drug Adsorption on the Accuracy of LogDoct 
Manuscript 3 Drug Adsorption to Teflon and Excipient-Aided Drug Recovery 
 
It is worth to recall that octanol/water distribution coefficients ( octDlog ) have already been 
used for NSB prediction, albeit with varying success depending on the structural similarity of 
the test compounds [3]. The major advantage of octDlog  is certainly the fact that many 
laboratories routinely measure this key physicochemical parameter, e.g. for the prediction of 
a drug candidate’s ADMETox profile [5]. Provided that the octDlog  yields reliable NSB-
estimates, the characterization of potential PET tracers could thus be implemented in the 
available screening platforms without the need for additional facilities.  
However, the value of octDlog  for the prediction of tissue binding was ambiguous due to i) 
the small datasets characterized hitherto and ii) the reliance on indirect lipophilicity data 
derived from reversed phase chromatography [6]. On the one hand, there was a broad 
consensus that tissue binding and lipophilicity ( octDlog ) are unrelated except for compounds 
within a given structural family [3]. On the other hand, remarkably good correlations between 
tissue binding and calculated octanol/water partition coefficient ( octPc log ) have been 
reported, yet an evaluation on the basis of measured octPlog  data was missing [7].  The lack of 
directly measured lipohilicity data is supposedly a consequence of several difficulties 
encountered with the traditional shake flask technique, i.e. high consumption of reagents in 
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addition to tedious, time-consuming and error-prone phase separation associated with a low 
throughput.  
One of the original contributions of this work is a novel miniaturized octDlog  assay 
(CAMDIS) in which the drawbacks of the traditional shake flask technique have been 
overcome. We could demonstrate that a filter support for octanol facilitates the phase 
separation and thus considerably reduces the net manpower hours required for the assessment 
of octDlog   
The concern as to whether adsorption to the filter-supported interface disturbs the accuracy of 
octDlog was addressed in manuscript 1 along with the question under which experimental 
conditions adsorption does not significantly compromise the accuracy of octDlog . Our data 
indicated that amphiphilic, cationic compounds adsorb at the octanol/water interface 
irrespective of whether or not a filter support is used. While the filter matrix is inert to 
adsorption, the spreading of octanol across the filter area increases the extent of interfacial 
drug enrichment, simply by enlarging the boundary surface between octanol and water. We 
could demonstrate that the interface effect does not manifest itself as experimental artifact, 
except for the rare case that several unfavourable conditions coincide, namely i) the presence 
of a positive charge, and ii) low lipophilicity of the test compound, iii) low volume of octanol 
and iv) low drug concentrations. Under these conditions, few drug molecules enter the 
octanol phase, and, in turn, drug adsorption to the octanol/water interface cannot be 
neglected. The related overestimation of  octDlog  could be counteracted by an appropriate 
choice of experimental conditions (total drug concentration: 100μM, volume of octanol 
depending on the octDlog range) and a clear definition of the applicable octDlog  range 
(- 0.5 - maximal 4.2).  
In miniaturized octDlog  assays it is also important to consider that the surface formed between 
the well plate and the aqueous phase is much more prominent as compared to large scale 
experiments.  Whether and to what extent adsorption to the assay construct (Teflon) affects 
the accuracy of octDlog  was studied in manuscript 2 along with the problem of drug 
aggregation / precipitation as a potential source of experimental artifact. We could 
demonstrate that the compounds which are most susceptible to adsorption (lipophilic, high 
molecular weight compounds) are not the compounds for which a major error in octDlog  
occurs: The reason is that the distribution of lipophilic drugs into octanol (non-saturable) 
outweighs the adsorption to the well plate (saturable) and the associated violation of the mass 
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balance equation. Exceptions are lipophilic and sparingly soluble drugs (e.g. paclitaxel) 
which precipitate during the time course of the experiment giving rise to erroneously low 
octDlog  values. The same trend towards an underestimation of octDlog  was observed for drugs 
which have a high tendency for adsorption despite being hydrophilic. The latter pattern is 
typical for large and coplanar compounds carrying many hydrogen-bond donors and forming 
multilayers presumably by stacking interactions. While adsorption-related artifacts for the 
hydrophilic compounds could be counteracted by increasing the volume of octanol (or the 
drug concentration), this is not a viable option for the lipophilic, sparingly soluble drugs. 
Under these conditions hardly any drug would be left in the aqueous phase and the limits of 
detection would soon be reached.  
These considerations raised the question of another strategy for correcting erroneous octDlog  
values. The most obvious possibility was the recovery of drug residing at the Teflon surface, 
however, this required an excipient which is both effective and compatible with the method 
used for detecting the analyte, i.e. HPLC-ESI/MS. In this regard it is important to note that 
excipients may disturb the concentration analysis with ESI/MS by suppressing the ionization 
efficiency of the analyte of interest (matrix effect) [8]. Previous studies on excipient-aided 
drug recovery have focused on case studies or small datasets, however, since structurally 
diverse compounds are encountered in screening assays such as CAMDIS, strategies are 
required that work for most and at best all types of analytes. Moreover, and contrary to our 
results, Teflon is often considered as inert to adsorption and accordingly no efforts have been 
made before towards recovery of adsorbed drugs by means of excipient. Therefore, we 
studied the sorption of a set of structurally diverse compounds to a Teflon well plate, 
followed by the study of excipient-aided drug recovery. The test dataset (n=24) covered a 
wide physicochemical property space and included acidic, basic, neutral and zwitterionic 
compounds. Various classes of excipients were investigated, namely i) detergents of different 
charge states (sodium dodecyl sulfate [SDS], CTAB [cetyltrimethylammonium bromide], 
Polyoxyethylene lauryl ether [Brij 35], Na· 3-[(3-Cholamidopropyl) dimethylammonio]-1-
propanesulfonate [CHAPS], taurocholic acid) ii) organic solvents (DMSO, 2-propanol, 
acetonitrile) and iii) 2,6-di-O-methyl-β-cyclodextrin. We could demonstrate that micellar 
concentrations of SDS most effectively reversed the adsorption of drugs, more precisely the 
adsorption of cationic drugs. This indicates that not only solubilization but also charge effects 
play a major role for drug recovery. Our data suggests that electrostatic repulsion between 
SDS enriched at the Teflon surface and SDS incorporated in the drug-loaded micelles (net 
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negatively charged) facilitates desorption. However, since SDS and all other excipients 
except 2-propanol disturbed the concentration analysis in ESI/MS, we recommend using SDS 
for data analysis with UV and 2-propanol whenever MS compatibility is required. Except for 
doxorubicin, 2-propanol could completely recover all compounds and therefore we consider 
the solvent a good compromise between efficiency and compatibility with mass spectrometry.  
Accordingly, 2-propanol was used in pursuit of our goal to improve the accuracy of the 
CAMDIS - octDlog values which were affected by drug precipitation and/or adsorption to the 
well plate (manuscript 2). At the example of paclitaxel we demonstrated that the corrected 
CAMDIS - octDlog  value was indeed in better agreement with the gold standard value 
obtained from a traditional shake flask experiment (1L glass flask). The remaining slight 
discrepancy may be explained by the presence of drug aggregates in CAMDIS and the 
supposedly different distribution coefficient as compared to the drug monomer.  The example 
shows that 2-propanol may be used for recovering a drug and correcting the mass balance 
equation, however, it cannot correct for changes in the distribution behavior of a compound 
due to formation of aggregates. 
With the optimized experimental conditions and the knowledge gained from the adsorption 
studies, we validated CAMDIS on an extended 52 compound dataset with known shake flask 
octDlog values (manuscript 1). Excellent agreement of the CAMDIS- octDlog  values with the 
shake flask data (gold standard) was obtained (r
2
 = 0.996, standard error of estimate, 
SEE = 0.111), and therefore we propose CAMDIS as a high throughput alternative to the 
traditional shake flask technique. This enabled the rapid and accurate characterization of a 
larger set of compounds and in turn a higher level of statistical certainty with respect to the 
prediction of NSB (see below). 
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5.2 PAMPA - Optimization towards MS Compatibility, Study on the PAMPA 
Membrane Structure 
 
Related Manuscripts:  
 
Manuscript 4 Evaluation and Management of Excipient-Related Matrix Effects in 
HPLC-ESI/MS Analysis of PAMPA-Permeability 
Manuscript 5 
31
P and 
1
H-NMR Studies on the Molecular Organization of Lipids in the 
PAMPA Permeation Barrier 
  
PAMPA is a well - established primary screen for passive permeability [9], however, the 
permeation barrier has only been used as a means to regulate permeability
7
 [10]. As an 
original contribution, we studied whether the fraction of drug retained in the PAMPA 
membrane can be used for estimating the non-specific binding of drugs in brain. We started 
our study with the experimental conditions applied in Roche (pH 6.5; membrane: 10% egg 
lecithin in dodecane) and optimized them in the course of this thesis. The optimization 
concerned two aspects, namely i) the use of HPLC-ESI/MS as a more sensitive and specific 
detection method as compared to UV and ii) the search for a chemical composition 
(membrane, donor, acceptor) that is better predictive for brain tissue binding.   
With respect to the first aspect, we investigated whether the excipients used in PAMPA cause 
matrix effects in ESI/MS, and if so, how it is feasible to avoid or correct associated artifacts. 
We focused on glycocholic acid (GCA) because it is used as a solubilizer in the Roche 
PAMPA setup and is as such of direct interest for our research project. Since matrix-related 
excipients effects are a matter of general concern, we also studied excipients which have been 
applied in PAMPA as model formulation agents, namely hydroxypropyl--cyclodextrin 
(HP -  - CD), propylene glycol (PG) and N-methyl-2-pyrrolidone (NMP) [11]. Finally, the 
simulated gastrointestinal fluid in the fasted state (FaSSIF) and in the fed state (FeSSIF), 
respectively, were included in our study due to their relevance for predicting food-induced 
changes in permeability and solubility [12]. As revealed by surface activity measurements, 
                                                          
7
 An exception is the method proposed by Faller et al. for deriving octanol/water partition coefficients from 
apparent permeability values.  However, the Faller approach suffers from reduced accuracy in the octPlog  range 
0 - 2, requires knowledge of the apK  and is an indirect method. Moreover, the authors have applied octanol as 
the permeation barrier rather than a mixture of phospholipids in an organic solvent. 
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matrix effects were most pronounced for excipients favoring the air-water interface (GCA, 
the FaSSIF/FeSSIF media), and/or forming multiply-charged ions (HP -  - CD). PG caused 
the least matrix effects which moreover only became evident for hydrophilic compounds 
coeluting with PG close to the solvent front. The non-uniform presence of ion-suppressing 
excipients in the PAMPA sandwich resulted in erroneous concentration measurements and 
accordingly in invalid estimates of permeability and membrane retention. To obtain accurate 
results, the excipient concentrations in the donor and acceptor compartment should be 
adjusted to the same level prior to injecting aliquots of each compartment into the HPLC-MS 
system. If the purpose of the excipient was only to increase a compound’s solubility, 
replacement of the frequently used GCA by PG is suggested. Provided that the sensitivity of 
the mass spectrometer is sufficiently high for detecting sparingly soluble analytes, it is also 
feasible to perform PAMPA measurements without the aid of a solubilizer. As will be 
outlined below, the presence of GCA resulted in very poor NSB predictions and highly 
variable data than in its absence, and therefore we abstained from applying solubilizers. The 
second aspect, the optimization of the chemical composition towards better capability to 
predict tissue binding, will be summarized in chapter 5.3 in the framework of a comparative 
evaluation of all assays. At this point we would like to remind that each model including 
PAMPA can never be more than an approximation to the reality (i.e. non-specific tissue 
binding in living animals and humans). In order to assess the scope and the limitations of 
model it is of utmost importance to understand its structure and the properties associated with 
it. At the beginning of this thesis, the PAMPA membrane was a black box and all previous 
attempts to shed light in it, e.g. by means of fluorescence anisotropy measurements, had 
failed [13]. As a novel approach to resolving the question, we applied different nuclear 
magnetic resonance (NMR) techniques which are well established in classical membrane 
science [14]. In contrast to the nature of a classical membrane (phospholipid-water 
dispersion), the PAMPA barrier is formed from a phospholipid - dodecane mixture
8
 which is 
immobilized on a filter that is dipped into an aqueous phase. By means of 
31
P-NMR, we 
could demonstrate that the lipids in the PAMPA barrier are organized in an ‘isotropic’ phase 
contradicting speculations as to the presence of micro-bilayers and hexagonal phases. Pulsed 
field gradient NMR (PFGNMR) [15] experiments further revealed that the ‘isotropic’ motion 
corresponds to the diffusion of small aggregates which have a diameter in the order of 
d = 4 - 7 nm. In addition to the NMR studies, the distribution coefficients of diverse drugs 
                                                          
8
 Roche setup: 9% egg lecithin (m/v) and 0.45 % cholesterol (m/v) dissolved in dodecane 
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between the PAMPA-lipid solution and buffer, PAMPADlog  (pH7.4), were measured in order to 
link the structure of the PAMPA barrier with its function. The binding of cationic 
amphiphilic drugs to the PAMPA barrier strongly increased with a rise from 0 to 1% egg 
lecithin in dodecane indicating a change in the binding mechanism. The results from both 
series of experiments could most likely be explained by the presence of reverse micelles 
which act as a carrier rather than as a barrier particularly for cationic amphiphilic compounds. 
This distinguishes PAMPA from biological membranes. The size cutoff, arising from 
attenuated insertion into densely packed biological membranes [16], was not observed in 
PAMPA and therefore we recommend considering effective PAMPA permeability values for 
bulky compounds as possibly too optimistic. 
 
5.3 LIMBA - Development of a Novel Assay for the Measurement of Brain 
Tissue/Water Distribution Coefficients, Comparative Evaluation of CAMDIS, 
PAMPA and LIMBA  
 
Related Manuscripts:  
 
Manuscript 6 Evaluation of a Novel Lipid Membrane Binding Assay (LIMBA) for the 
Assessment of Brain Tissue Binding 
 
5.3.1 Development and Validation of LIMBA  
So far, we have summarized the optimization of miniaturized in vitro assays which rely on 
artificial membrane-mimicking models (i.e. octanol and the PAMPA membrane) and whose 
ability to predict brain tissue binding was supposed to be tested (see below). We are aware of 
the fact that membrane models are always oversimplifications of the in vivo situation (see 
above) and it goes without saying that making brain tissue itself the test system of interest is 
the closest approximation thereof. Accordingly, the unbound fraction of drug in brain 
homogenate ( brainuf , ) measured by equilibrium dialysis is considered a reliable surrogate for 
brain tissue binding [17]. However, the high consumption of animal tissue hampers the 
throughput of the assay and limits its application for routine screening purposes. We therefore 
developed a novel assay (LIMBA = Lipid Membrane Binding Assay) in which the advantage 
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of the equilibrium dialysis technique, i.e. the close resemblance to the in vivo situation, is 
combined with the high throughput and low reagent consumption of CAMDIS. The 
conceptual idea of LIMBA is borrowed from CAMDIS and involves the measurement of 
drug distribution in a 2-phase system (tissue surrogate and water) and the use of a filter to 
facilitate the phase separation. The two systems differ in the nature of the tissue surrogate, 
namely octanol in CAMDIS and brain homogenized in dodecane in LIMBA. 
Homogenization of the tissue was mandatory since automation requires the supply of brain 
tissue in the form of an easily dispensable liquid. Although it would be clearly preferable to 
use aqueous buffer as dispersing agent (like in equilibrium dialysis), a long chain organic 
solvent (dodecane) was necessary to avoid mutual mixing of the two phases. The 
miniaturized format of LIMBA allows working with minute amounts of brain tissue which is 
particularly suitable for the characterization of compounds with extensive tissue binding. 
Notably these are the compounds which should be identified prior to radioactive labeling 
since they are unlikely to be successfully applied in PET.  
At the example of 126 structurally diverse drugs, we could demonstrate that the brain 
tissue/water distribution coefficients ( brainDlog ) available through LIMBA are in good 
agreement with brainuf ,  values available through equilibrium dialysis. Exceptions are anionic 
and zwitterionic compounds for which the extent of tissue binding was underestimated by 
LIMBA, possibly due to electrostatic repulsion at the negatively polarized filter support. 
However, cationic and non-ionic compound predominate in most drug discovery programs 
including the development of PET tracers. The good agreement between brainDlog  (LIMBA) 
and brainuf ,  for this majority of compounds demonstrates that preparing tissue homogenate in 
dodecane (instead of aqueous buffer) does not change the ranking between the two tissue 
binding scales, with respect to the chemical space investigated. In this regard, it is important 
to note that large and hydrophobic drugs for which non-specific binding to Teflon has been 
predicted as > 5% (manuscript 2) was excluded from the dataset to avoid artifacts (drug 
recovery by addition of 2 - propanol was not established yet at the time of the assay 
development). We could show by means of 
31
P-NMR that dodecane disrupts the phospholipid 
bilayer of undisrupted brain tissue in favor of an isotropic phase (not further specified). A 
deviation from the good agreement between LIMBA and the equilibrium dialysis technique 
for larger compounds is thus expected since it is well known that the insertion into densely 
packed bilayers requires more energy than the insertion into a more unordered structure. 
Nevertheless, good agreement between LIMBA and the equilibrium dialysis method was 
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obtained (r
2 
= 0.74 (n = 73 drugs of the 126 compound dataset, for exclusion criteria see 
manuscript 6), r
2 
= 0.91 for a high quality dataset). 
It is important to note that the experience gained from CAMDIS in terms of management of 
adsorption - related artifacts was applied in LIMBA in order to aid the selection of optimized 
experimental conditions and the interpretation of outliers (compounds for which 
adsorption - related artifacts and drug precipitation are likely or have been observed were 
excluded from the validation dataset.).  
5.3.2 Comparative Evaluation of CAMDIS, PAMPA and LIMBA  
So far, we have summarized i) the development of CAMDIS, ii) the optimization of PAMPA 
with respect to the compatibility with mass spectrometry and iii) the development and 
validation of LIMBA. We have analyzed and eliminated potential artifacts and indicated for 
which compounds the assays are applicable. These investigations are the necessary 
precondition for answering the key question as to which assay should be used for predicting 
the NSB of potential PET tracers in brain.  For obvious ethical reason it would be preferable 
to rely on artificial surrogate systems, i.e. either octanol (CAMDIS) or phospholipids 
dissolved in dodecane (PAMPA). But we also raised the question whether the predictive 
power of LIMBA is considerably better as compared to CAMDIS and PAMPA - which may 
justify the use of minute amounts of animal tissue. 
For validation purposes, we compared the octDlog  , PAMPADlog and  brainDlog  values obtained 
from CAMDIS, PAMPA and LIMBA, respectively with the brainuf ,  values (= industrial gold 
standard) available through equilibrium dialysis.  
The poor correlation between octDlog  (pH 7.4) and brainuf ,  confirms what has been observed 
before by other authors on much smaller datasets, the weakness of octDlog for predicting 
tissue binding [6]. Nevertheless, it is interesting to note that the measured octanol/water 
partition coefficient of the unionized drug ( Plog
9
) was in much better agreement with the 
brainuf ,  data as compared to octDlog . This has also been recognized before but only on the 
basis of calculated Plog values [7]. Using the fraction of drug retained in the PAMPA 
membrane (expressed as PAMPADlog ), the prediction of brainuf ,  was better reliable as compared 
to CAMDIS (r
2
(PAMPA) = 0.61 vs. r
2
(CAMDIS) = 0.23), provided that the assay was 
                                                          
9
 Measured Plog  values were calculated from measured octDlog  ( pH 7.4 ) values and the measured 
apK using the Henderson - Hasselbalch equation. The transformation is not applicable to zwitter-ionic 
compounds which were therefore excluded from the dataset.  
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conducted under optimized experimental conditions (brain polar lipids (BPL), pH 7.4, no 
solubilizers). In contrast, the PAMPA method as used in Roche was unsuitable to predict 
tissue binding (r
2 
= 0.38). However, tissue binding as determined by means of equilibrium 
dialysis ( brainuf , ) was best described by the brain tissue/water distribution coefficients 
( brainDlog ) available through LIMBA (r
2 
= 0.74 (n=73, see above). Table 1 summarizes the 
comparative evaluation of the in vitro assays. 
 
Table 1   Overview of assays investigated. 
Assay Surrogate 
system for 
tissue binding  
Predictive 
ability for NSB 
(n=73)
b
 
Applicability range Demand for 
brain tissue 
Model 
system 
CAMDIS 
(novel 
assay) 
Octanol Poor  
(r
2
=0.23, 
octDlog (pH 7.4)) 
Non-ionic 
compounds 
None Reverse 
octanol 
micelles 
PAMPA 
(optimized 
assay) 
BPL-dodecane 
mixture, no 
excipients
a
 
Good  
(r
2
=0.61)  
Non-ionic and 
cationic compounds 
None Reverse 
phospholipid 
micelles 
LIMBA 
(novel 
assay) 
Brain 
homogenized in 
dodecane  
Very good 
(r
2
=0.74) 
Non-ionic and 
cationic compounds 
Low Bilayer and 
isotropic 
phase 
Equilibrium 
dialysis 
(established) 
Brain 
homogenized in 
buffer 
Gold standard All charge classes High Bilayer  
a
The standard Roche PAMPA setup (egg lecithin in dodecane, presence of glycocholic acid in the donor, 
pH 6.5) was inappropriate (correlation statistics with the dialysate method: r
2
=0.375). 
b
statistics for all charge 
classes and based on the subset of compounds which could be measured with LIMBA. 
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5.4 NSB in Autoradiography and in PET 
 
Related Manuscripts:  
 
Manuscript 7 Label-Free Assay for the Assessment of Non-specific Binding of 
Positron Emission Tomography Tracer Candidates 
 
5.4.1 NSB Asessment with LIMBA  
Hitherto, the predictive power of CAMDIS, PAMPA and LIMBA has been tested by 
comparison with the equilibrium dialysis method. The strategy has been pursued because a 
high number of compounds had been characterized with the dialysis method and the 
interpretation of the data was not complicated by active transport mechanisms (the goal was 
to develop an assay for the assessment of passive tissue binding). This enabled an 
unambiguous comparison of the assays and a high statistical certainty level (n=126 
compounds). However, the brain homogenate used in equilibrium dialysis is also just an in 
vitro surrogate for intact brain tissue which could differ by e.g. the packing density of the 
lipids.  
Therefore, our next objective was to test whether the assay which was in best agreement with 
equilibrium dialysis, namely LIMBA, is also predictive for the binding of drugs and PET 
tracers to undisrupted brain tissue. To this purpose, brainDlog values available through LIMBA 
were compared with i) NSB quantified with in vitro autoradiography (30 marketed and 
proprietary compounds, in-house data) and ii) estimates of the volume of distribution of non-
specifically bound drug characterized with PET (10 marketed tracers, in vivo literature data). 
Moreover, we compared the predictive power of brainDlog  (LIMBA) with that of the 
traditional lipophilicity parameter, i.e. octDlog . The in vitro autoradiography data was used 
for validation purposes since a larger number of compounds was available than from PET 
(literature data) - which we considered beneficial for the explanatory power of a prediction 
model. Moreover, it was advantageous that in vitro autoradiographs are not confounded by 
active transport mechanisms at the blood brain barrier since brain slices rather than intact 
brain imbedded in adjacent compartments were used. In contrast, the volume of distribution 
obtained from in vivo PET is a more complex parameter and e.g. efflux transport at the BBB 
may complicate the unambiguous data interpretation. Our data showed that the brain 
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tissue/water distribution coefficients ( brainDlog ) available through LIMBA are more predictive 
for NSB (in vitro autoradiography data) than octDlog  (r
2
 (LIMBA) = 0.87 - 0.91 depending on 
the assay protocol, see below). The analysis further showed that the time brain slices were 
exposed to a washing solution after incubation with tracer matters for the determination of 
NSB.  A clear trend towards lower binding at longer washing times was observed. Therefore 
correlations between in vitro assays (LIMBA,CAMDIS) and NSB have to be performed on 
the basis of the same assay protocol and washing procedure in autoradiography. Regarding 
the in vivo PET data, LIMBA was suitable to predict the NSB for tracers which are 
considered non-Pgp substrates.  
5.4.2 Identification of PET Tracer Candidates with a High Probability of Attrition 
So far, we have shown that the extent of NSB of potential PET tracers can be predicted with 
LIMBA, which works with the unlabeled compound and which requires considerably reduced 
animal testing as compared to other assays (equilibrium dialysis, autoradiography). However, 
NSB in the reference region should not be contemplated in isolation from total binding (TB) 
in the region of interest. The ratio between both (i.e. TB/NSB) determines the image quality 
and therefore the likely development success or failure of a potential PET tracer (see 
introduction). It was stressed that PET tracer candidates with low TB/NSB ratios are unlikely 
to be successful [3].  
We could show that a plot of TB/NSB vs. NSB can be used as classification map for the 
identification of inappropriate PET tracer candidates: None of the compound tested with NSB 
> 3 fmol/mg protein reached a TB/NSB ratio > 5. The key question was whether the 
compounds with inappropriately high NSB can also be identified by using the brainDlog  value 
available through LIMBA. Provided that the brain slices in autoradiography were exposed for 
maximal 4 min to the washing solutions, LIMBA was indeed suitable to identify the 
problematic compounds. This means that compounds with undesirably high NSB and a low 
probability of a sufficient TB/NSB ratio can be identified without the need for 
autoradiography and prior to radioactive labelling.  
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5.5 Conclusions 
In conclusion, we have shown that the NSB of potential PET tracers in brain can be estimated 
with a novel miniaturized in vitro assay, LIMBA, which requires only minute amounts of 
brain homogenate prepared in dodecane (1.2 μL). Neither octanol nor the phospholipid-
dodecane mixture used in PAMPA could mimic the binding of drugs to brain tissue with the 
same accuracy. In comparison to the equilibrium dialysis technique, the consumption of 
animal tissue could be considerably reduced and therefore we recommend favouring LIMBA 
when brain tissue binding data is requested. Since LIMBA works with unlabelled 
compounds, PET tracers with inappropriately high NSB can be identified prior to 
resource - intensive autoradiography studies. We have developed LIMBA as a semi-
automated screening assay which requires similar efforts in terms of time and technical 
facilities as compared to other physicochemical screening assays. The implementation of 
LIMBA in the existent platforms for eADME screening experiments is therefore viable 
without much additional expenditures. LIMBA may accelerate the selection of PET tracers 
with appropriate NSB characteristics and the rejection of compounds with undesirable high 
background noise (= NSB). This may enhance the confidence in the likely development 
success of a PET tracer and reduce the attrition rate in the late and more costly stages. The 
availability of innovative PET tracers for studying the functioning of brain may ultimately 
advance the expansion of PET for the drug discovery process in pursuit of a higher efficiency 
and lower attrition rate.  
5.6 Limitations and Outlook into Future Research 
In the course of this thesis, the ability of LIMBA to estimate the NSB of drugs and PET 
tracers in tissue has been demonstrated at the example of brain tissue, however, it would also 
be of great value to test the applicability of LIMBA to other tissues. The sum of all 
tissue/water distribution coefficients could be utilized to calculate a drug’s volume of 
distribution, one of the key pharmacokinetic parameters required for rational dosing selection 
[18]. Moreover, tissue/water distribution coefficients available through LIMBA could be used 
to parameterize physiologically-based pharmacokinetic (PBPK) models which are frequently 
applied to predict a test compound’s pharmacokinetic profile in different animal species [19]. 
Until now, drug tissue distribution is predicted by mechanistic equations integrating 
compound lipophilicity (octanol/water or oil/water distribution coefficients), the binding of 
compound to proteins and phospholipids and the levels of protein, lipids and water in plasma 
and tissue [20]. As will be demonstrated in an additional manuscript (unpublished results, the 
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work is not included in the thesis), LIMBA yields more reliable estimates for brain tissue 
binding as compared to the mechanisms-based model implemented in Gastroplus®
10
. The 
inferior predictive power may be attributed to the fact that the models rely on the assumption 
that the properties of phospholipids can be resembled by a mixture water and octanol, which 
is a severe oversimplification of the reality.  
Even though LIMBA enables the assessment of NSB at considerably reduced amounts of 
brain tissue, artificial membrane mimicking systems would still be preferable. Hitherto we 
have only compared egg lecithin and porcine lipids, but it would also be interesting to 
perform a design of experiments with phospholipid mixtures of different charge state and 
chain length, to simulate the lipid composition of human brain and other tissues. Rather than 
relying on the PAMPA setup, we recommend using the assay construct of CAMDIS and 
LIMBA since the latter is specifically designed to measure distribution coefficients. It should 
be mentioned that measuring permeability and membrane retention at the same time is an 
advantage of PAMPA but also complicates the analysis of the data:  We could demonstrate 
that PAMPA lipid/water distribution coefficients are concentration dependent owing to 
charge repulsion and probably saturation at the interfaces. The presence of two liquid-water 
interfaces in PAMPA enhances the concentration dependency and the difficulty to correct the 
effect by the choice of appropriate experimental conditions. The determination of membrane 
binding constants would then require concentration dependent measurements and an 
interpretation of the obtained binding isotherms by means of the Gouy-Chapman theory [21].  
Finally, we would like to stress that NSB should not be considered as an isolated parameter. 
Other factors such as permeability across the blood brain barrier, receptor density and target 
affinity are equally important for the success of an imaging agent [22]. Recently, a bio-
mathematical modelling approach has been successfully applied to predict a PET tracer’s 
image quality by integrating the properties of both the drug and of the biological system into 
a prediction model [23]. An important input parameter was the unbound fraction of tracer in 
brain which had been measured with the equilibrium dialysis technique but which could be 
assessed by using LIMBA with less brain tissue.  
 
 
 
                                                          
10
 Test date: June 2012. The Rodgers model was tested at the example of the 126-compound used also for the 
validation of LIMBA. The brainuf ,  values obtained from equilibrium dialysis were considered the gold standard. 
Model input parameters: measured octDlog  values.  
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